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Look at the patient lying alone in bed  
What a pathetic picture he makes.  
The blood clotting in his veins.  
The lime draining from his bones.  
The scybola stacking up in his colon.  
The flesh rotting from his seat.  
The urine leaking from his distended bladder  
and the spirit evaporating from his soul.  
Teach us to live that  
we may dread unnecessary time in bed.  
Get people up and we may save  
patients from an early grave. 
 
Dr. Richard Asher, 1942 
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Skeletal muscle mass is of great importance for overall health and well-being. Well 
known is the relevance of muscle tissue quantity to muscle strength, functional capacity 
and physical performance. However, the critical role of skeletal muscle mass in the 
metabolism of the macronutrients carbohydrate, fat, and protein is often underappre-
ciated. Numerous situations, such as the recovery from illness or rehabilitation after 
injury, can necessitate a period of physical inactivity in otherwise healthy individuals. 
This muscle disuse is initiated to enhance the recovery process but is accompanied by 
muscle loss, termed muscle atrophy [1-3]. Muscle atrophy contributes to numerous 
negative health consequences including a loss of functional capacity and muscle 
strength [4-6], the development of insulin resistance [7, 8], a decline in basal metabolic 
rate [9, 10], and the accrual of body fat [11, 12]. For these reasons, it is important to 
develop interventional strategies to attenuate atrophy of disused muscle. The present 
thesis will focus on experimentally induced muscle disuse and the underlying physiolog-
ical mechanisms involved in muscle disuse atrophy. Particular emphasis will be placed 
on discussing potential nutritional or exercise-mimicking interventional strategies to 
reduce the loss of muscle mass during muscle disuse. 
Models of muscle disuse atrophy 
Muscle disuse is generally studied in healthy humans with various lab-based models. 
Models of local inactivity that have been used include arm or leg immobilization [3]. 
When the effect of whole-body disuse is to be assessed, researchers can choose for a 
head-down tilted bed rest setting, where volunteers are placed in a -6 degrees head-
down position to mimic microgravity [11]. Alternatively, a more clinically relevant bed 
rest setting can be inferred, during which volunteers are allowed to sit semi-upright, 
mimicking hospitalization [13]. While these approaches do not induce the contraindica-
tions associated with injury or illness, they provide a more controlled setting in which 
the impact of disuse per se can be examined. The current thesis will focus on results 
from leg immobilization and ‘hospitalization’ bed rest, as they are regarded as the most 
clinically relevant situations of experimental muscle disuse. 
Leg immobilization is a model of local inactivity, induced by a leg cast or removable 
brace, which isolates muscle disuse in a single muscle or muscle group while the contra-
lateral leg serves as a control. This model is of great practical value as participants are 
able to carry out their activities of daily life to a certain extent and maintain their habit-
ual dietary intake. Due to the absence of systemic factors that could potentially influ-
ence muscle atrophy, leg immobilization represents a suitable model to study muscle 
loss caused by isolated disuse per se. In contrast, with the use of the bed rest model, 
muscle loss is possibly influenced by systemic factors that are activated due to whole-
body disuse. Examples of processes that possibly impact on muscle atrophy during bed 
rest are increased systemic inflammation [14, 15], microvascular dysfunction [16], im-
pairments in whole-body insulin sensitivity [8], and unfavourable hormonal changes [17, 
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18], which all potentially contribute to a higher metabolic stress response. Whereas 
these factors influence muscle loss and consequently make it impossible to study the 
impact of disuse alone, the experimental bed rest model represents a more clinically 
relevant model as it directly translates to the hospitalized patient who is bedridden in 
an attempt to facilitate recovery. An experimental consideration of the bed rest model 
is that the decline in energy expenditure during whole-body inactivity [19] requires 
nutritional modification away from an individual’s habitual diet [20, 21]. 
Due to the presence (during bed rest) or absence (during leg immobilization) of sys-
temic factors that possibly modulate muscle atrophy, one can expect differences in the 
quantity of muscle loss such that bedridden participants will lose more muscle mass 
than immobilized individuals. Indeed, estimations based on previous studies show an 
approximate 0.5% daily decline in local muscle mass during limb immobilization, where-
as an estimated 0.6% daily decrease in whole-body muscle mass is observed with bed 
rest (Figure 1; [3]). In contrast, previous work, comparing results from separate studies, 
has suggested that more muscle is lost with immobilization than with bed rest [22]. 
However, to date, no direct comparisons between both experimental models have been 
made.  
 
 
Figure 1 | Relationship between the duration of muscle disuse and the subsequent rate of muscle atrophy. The 
rate of muscle atrophy is expressed as percentage of muscle lost per day. Reproduced with permission [3]. 
 
Although researchers have attempted to extrapolate the impact of leg immobilization to 
a whole-body level, this extrapolation is difficult as different muscle groups show differ-
ent rates of muscle (fibre) atrophy [23]. When choosing a model to study the impact of 
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muscle disuse, all characteristics of the different models should be kept in mind in order 
to select the appropriate model to answer the specific research question. 
Regulation of muscle protein turnover during disuse 
Skeletal muscle proteins are constantly built up and broken down to maintain a 
good quality of skeletal muscle tissue. On a daily basis, this turnover of muscle proteins 
is approximately 1-2%. The processes of muscle protein synthesis and muscle protein 
breakdown determine net muscle protein balance, and therefore dictate the quantity of 
muscle mass in an individual. When both processes are in equilibrium, the quantity of 
muscle mass will remain constant (Figure 2A). 
 
 
Figure 2 | Schematic representation of the processes of muscle protein synthesis (MPS, line) and muscle 
protein breakdown (MPB, dotted line). A: Normal state, in which both processes are in equilibrium and the 
net gain and loss of muscle protein are equal, resulting in muscle mass maintenance. B: During muscle disuse, 
the anabolic response to protein feeding is decreased while muscle protein breakdown is not significantly 
altered, resulting in a net loss of muscle protein. Adapted from [24].  
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Both muscle protein synthesis and muscle protein breakdown rates can be strongly 
modulated by food ingestion [25-27]. In a normal, rested individual in a postabsorptive 
state, whole-body net protein balance is negative [28-30]. Conversely, after food inges-
tion, muscle protein synthesis is stimulated and muscle protein breakdown is de-
creased, resulting in a net positive protein balance [28, 30, 31]. However, during a peri-
od of muscle disuse, there must be a (temporary) shift towards a more negative muscle 
protein balance, resulting in the net breakdown of muscle proteins. This change in pro-
tein net balance must occur due to a decline in muscle protein synthesis, an increase in 
muscle protein breakdown, or a combination of both. 
Declines in basal (postabsorptive) muscle protein synthesis rates following a period 
of disuse have been shown multiple times. A 25-50% decrease in basal muscle protein 
synthesis rates has been reported following both leg immobilization [5, 32-34] and bed 
rest [11, 35-38] in young, healthy volunteers. Given the magnitude of the decline in 
muscle protein synthesis following muscle disuse, multiple research groups have sug-
gested that muscle protein breakdown could not have changed substantially, thereby 
ruling out a major role for changes in muscle protein breakdown in the development of 
muscle disuse atrophy [3, 5, 11, 24, 39, 40]. Measuring muscle protein breakdown in 
vivo in humans is technically challenging and rates of muscle protein breakdown are 
therefore relatively sparsely reported. Two studies have reported no changes in muscle 
protein breakdown rates following several weeks of bed rest [11, 37]. Conversely, sev-
eral studies using static markers of muscle protein breakdown suggest a rise in muscle 
protein breakdown immediately following the onset of muscle disuse [32, 41, 42]. Taken 
together, the current literature suggests that muscle disuse atrophy occurs due to a 
decline in basal muscle protein synthesis rates, accompanied by a concomitant decline 
in muscle protein breakdown [40]. Evidence suggests that muscle protein breakdown 
could be upregulated in the first few days of muscle disuse [40], however, this should be 
confirmed by in vivo human intervention studies using methods to directly measure 
muscle protein breakdown rates. 
Muscle mass maintenance is influenced by basal muscle protein synthesis as well as 
by the postprandial muscle protein synthetic response to feeding [30]. More recent 
work has provided evidence to show that disuse reduces the sensitivity of skeletal mus-
cle tissue to the anabolic properties of amino acid or protein administration. Specifical-
ly, an attenuated rise in whole-body protein synthesis following food intake was ob-
served in bed-rested individuals when compared to an ambulatory group [43, 44]. In 
concurrence, 1-2 weeks of disuse reduced the postprandial muscle protein synthetic 
response to both amino acid infusion [34] and essential amino acid ingestion [45]. In 
agreement, we have shown comparable declines in postprandial muscle protein synthe-
sis rates after ingestion of a bolus of intact protein following 14 days of leg immobiliza-
tion [46]. These results imply that a blunted muscle protein synthetic response follow-
ing dietary protein ingestion, also termed ‘anabolic resistance’, plays an important role 
in the muscle atrophy that is observed during disuse (Figure 2B). Whether or not post-
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prandial muscle protein breakdown rates are also affected following muscle disuse, and 
therefore contribute to the observed muscle loss, remains to be established. 
Postprandial protein handling and the subsequent muscle protein synthetic re-
sponse are regulated on various levels [47, 48]. Their regulation ranges from protein 
digestion and amino acid absorption [49], the insulin-stimulated (postprandial) increase 
in muscle tissue perfusion [50, 51], the uptake of amino acids in skeletal muscle [52], 
intramyofibrillar anabolic signalling [53, 54], to the increase in muscle protein synthesis 
rate and inhibition of muscle protein breakdown [55]. Many of these factors may be 
affected during a period of disuse, resulting in altered rates of postabsorptive as well as 
postprandial muscle protein synthesis and breakdown. Muscle disuse, and particularly 
(head-down tilt) bed rest, may also modulate the digestion and absorption of ingested 
foods [11, 56]. Additionally, physical inactivity could lead to impairments in insulin-
mediated tissue perfusion, as has been demonstrated in older men presenting anabolic 
resistance [50]. This would impair amino acid delivery to the muscle and attenuate the 
postprandial rise in muscle protein synthesis rates. Other researchers pointed out that 
amino acid uptake in muscle may also be affected by an attenuated postprandial rise in 
amino acid transporter protein content following a period of bed rest [45]. Currently, 
the contribution of these individual factors to disuse-associated anabolic resistance 
remains to be elucidated. However, irrespective of where anabolic resistance actually 
resides, it is clear that interventional strategies to preserve muscle mass during disuse 
should aim to increase both postabsorptive muscle protein synthesis rates as well as 
improve the muscle protein synthetic response to feeding. 
Interventions to prevent muscle loss during disuse 
The two key anabolic stimuli for skeletal muscle tissue are muscle contraction [57] and 
food intake [30]. Indeed, re-introduction of some level of physical activity can already 
preserve skeletal muscle mass during a period of disuse [58, 59]. However, in some 
cases an increase in physical activity is simply not realistic due to limb immobilization or 
general weakness. In those cases, neuromuscular electrical stimulation (NMES) can be 
used as an exercise mimetic by evoking muscle contractions. By means of placing one or 
more electrodes on the skin and applying an electric current, the muscle contracts in-
voluntarily. Previous work from our group showed that NMES can be applied to increase 
postabsorptive muscle protein synthesis rates in vivo in humans [60]. Although previous 
studies have successfully applied NMES in prolonged models of disuse atrophy [33], it is 
currently unclear if NMES can preserve muscle mass during short periods of muscle 
disuse. Aside from physical activity, dietary protein consumption has been shown essen-
tial to maintain skeletal muscle mass in a disuse setting [3]. In the past, high-dose essen-
tial amino acid supplementation has been shown to attenuate the loss of muscle mass 
during prolonged bed rest in young [13, 61, 62] and older [38] individuals. However, it 
remains to be established whether an increase in dietary protein consumption can alle-
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viate muscle mass losses in the older population. Furthermore, the synergy between 
physical activity and food intake in driving postprandial muscle protein synthesis [63-67] 
indicates that interventional strategies should combine the benefits of exercise or exer-
cise mimetics with the anabolic properties of amino acid or protein feeding to prevent 
or attenuate muscle disuse atrophy.  
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T H E S I S  O U T L I N E  
This thesis describes a collection of studies that characterize the impact of short-term 
muscle disuse on muscle mass and function, and examine the efficacy of various inter-
ventional strategies to attenuate the loss of muscle mass and strength. We start by 
assessing the impact of short-term disuse, which plays an important role in the loss of 
muscle mass and strength with ageing, termed sarcopenia. Chapter 2 compares the 
impact of 5 versus 14 days of leg immobilization on muscle mass and strength in young, 
healthy males, and shows that merely 5 days of muscle disuse already leads to a sub-
stantial decline in both muscle mass and strength. Therefore, in Chapter 3 we describe a 
study where we applied such a short period of disuse to assess its impact on postab-
sorptive and postprandial muscle protein synthesis rates. The subsequent chapters 
investigate various interventional strategies to prevent the loss of muscle mass and 
strength during short-term disuse. We start off by examining whether NMES can be 
used as an exercise mimetic to attenuate muscle loss during leg immobilization (Chapter 
4). We also assessed the efficacy of NMES in a clinical model of critically ill, comatose 
patients, who are suffering from severe muscle wasting (Chapter 5). We demonstrate 
that NMES can prevent muscle atrophy in a setting of one-legged knee immobilization 
as well as prevent muscle wasting in comatose patients. Chapter 6 describes the efficacy 
of a nutritional intervention to attenuate the decline in muscle mass and strength dur-
ing a short period of leg immobilization in older men. Subsequently, we combined both 
nutritional and exercise (mimetic) stimuli in two parallel studies (Chapter 7 and 8). Chap-
ter 7 describes a study assessing the surplus effect of NMES prior to ingestion of a meal-
like amount of protein on muscle protein accretion in active, older individuals. To trans-
late these findings to a more clinically relevant setting, the combined impact of NMES 
and protein ingestion was tested in in a group of healthy older men during a day of bed 
rest (Chapter 8). Chapter 9 discusses the differences between the two most widely used 
experimental models of muscle disuse (i.e. bed rest and immobilization). Though muscle 
atrophy seems comparable between both models, bed rest is shown to have substantial 
impact on metabolic health. Chapter 10 describes the last study in this thesis where we 
assessed the impact of one week of bed rest on both muscle mass and metabolic 
health. Finally, in Chapter 11, the outcomes of Chapters 2 through 10 are discussed and 
a general conclusion is provided. Additionally, the implications of this thesis are dis-
cussed and directions for future research are formulated. As such, this thesis forms an 
overview of interventional strategies that can attenuate muscle loss during disuse, and 
provides targets for future research to prevent and treat muscle disuse atrophy. 
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A B S T R A C T  
Background The impact of disuse on the loss of skeletal muscle mass and strength 
has been well documented. Given that most studies have investigated 
muscle atrophy after more than 2 weeks of disuse, few data are avail-
able on the impact of shorter periods of disuse. We assessed the im-
pact of 5 and 14 days of disuse on skeletal muscle mass, strength and 
associated intramuscular molecular signaling responses. 
Methods Twenty-four healthy, young (23±1 y) males were subjected to either 5 
(n=12) or 14 (n=12) days of one-legged knee immobilization using a 
full leg cast. Before and immediately after the immobilization period, 
quadriceps muscle cross-sectional area (CSA), leg lean mass and mus-
cle strength were assessed, and biopsies were collected from the 
vastus lateralis. 
Results Quadriceps muscle CSA declined from baseline by 3.5±0.5 (P<0.0001) 
and 8.4±2.8% (P<0.0001), leg lean mass was reduced by 1.4±0.7 
(P=0.07) and 3.1±0.7% (P<0.01), and strength decreased by 9.0±2.3 
(P<0.0001) and 22.9±2.6% (P<0.0001) following 5 and 14 days of im-
mobilization, respectively. Muscle myostatin mRNA expression dou-
bled following immobilization (P<0.05) in both groups, while the myo-
statin precursor isoform protein content decreased after 14 days only 
(P<0.05). Muscle MAFBx mRNA expression increased from baseline by 
a similar magnitude following either 5 or 14 days of disuse, whereas 
MuRF1 mRNA expression had increased significantly only after 5 days. 
Conclusion We conclude that even short periods of muscle disuse can cause sub-
stantial loss of skeletal muscle mass and strength, and are accompa-
nied by an early catabolic molecular signaling response.  
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I N T R O D U C T I O N  
The recovery from illness or injury often requires otherwise healthy humans to undergo 
a period of muscle disuse (e.g. bed rest or limb immobilization). A major consequence 
of disuse is skeletal muscle atrophy [1-3]. The ensuing impairments in muscle function 
[1-5], metabolic rate [6, 7] and insulin sensitivity [8], and accrual of body fat mass [9-11] 
following two or more weeks of muscle disuse have been well documented.  
Studies investigating muscle disuse atrophy generally employ relatively long experi-
mental periods, ranging from two to as long as 17 weeks of bed rest or limb immobiliza-
tion [2, 5, 12, 13]. However, over the last decade, efforts have been made within 
healthcare systems to reduce the duration of bed rest/immobilization that patients 
endure due to illness or injury. At present, the average length of hospitalization for 
elderly patients admitted with acute illness is only 5-6 days [14]. Moreover, periods of 
illness and minor injury that do not require hospitalization but necessitate inactive re-
covery at home generally last only a few days. Recent work has reported that limb im-
mobilization for only four days already causes a decline in functional strength in older 
adults [15, 16]. However, currently, no data exist on the impact of such short periods of 
disuse (i.e. <7 days) on skeletal muscle mass. Such information is of important clinical 
relevance since it has been hypothesized that successive bouts of muscle loss during 
short periods of disuse accumulate throughout the lifespan and may be responsible for 
much of the loss of muscle mass typically observed in the ageing population [17-19]. 
Accordingly, we hypothesize that even short periods of muscle disuse can lead to sub-
stantial loss of muscle tissue. Therefore, in the present study, we compared the impact 
of a short (i.e. 5 days) versus more prolonged (i.e. 14 days) period of immobilization on 
skeletal muscle mass and functional strength. 
Skeletal muscle atrophy during more prolonged disuse (i.e. >10 days) is attributed to 
declines in both the rate of postabsorptive and postprandial muscle protein synthesis, 
without any apparent changes in muscle protein breakdown rates [2, 10, 17, 20]. We 
[17, 18], and others [15, 21-23], have argued that elevated muscle protein breakdown 
may also contribute to muscle loss during the first few days of disuse. Myostatin has 
been demonstrated to be a key negative regulator of muscle mass in animals [24, 25] 
and humans [26]. Aside from its documented role in the regulation of muscle protein 
synthesis [27] and myogenesis [28, 29], myostatin has also been suggested as a regula-
tor of muscle protein breakdown [30]. Therefore, in the present study, we also assessed 
the impact of 5 and 14 days of limb immobilization on the skeletal muscle mRNA and 
protein expression of myostatin and associated genes.  
In the present study we selected 24 healthy, young men who were subjected to ei-
ther 5 (n=12) or 14 (n=12) days of one-legged knee immobilization. Skeletal muscle 
mass and function were assessed before and after immobilization, and muscle biopsies 
were collected to assess the associated molecular signaling responses. This is the first 
study to report substantial muscle atrophy after merely 5 days of muscle disuse in vivo 
in humans. 
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M E T H O D S  
Subjects 
Twenty-four healthy, young (23±1 y) men volunteered to participate in the present 
study. All subjects were fully informed of the nature and possible risks of the experi-
mental procedures, before their written informed consent was obtained. Subjects were 
screened to exclude any person with lower limb and/or back injuries sustained within a 
year prior to beginning the study, a (family) history of thrombosis/cardiovascular dis-
ease, use of anti-coagulants, musculoskeletal/orthopaedic/haemostatic disorders, or 
participation in any regular resistance training program within 6 months of beginning 
the study. During screening, all subjects were instructed and familiarized with safe lift-
ing technique for the leg extension exercise. Maximum strength was assessed using the 
multiple repetitions testing procedure [31] for each leg separately. The study was ap-
proved by the Medical Ethics Committee of the Maastricht University Medical Centre, 
Maastricht, the Netherlands. The present study is part of a greater project investigating 
muscle disuse atrophy in humans. 
Experimental design 
In the present study a parallel design was applied with a subject cohort being assigned 
to an experimental treatment in which subjects underwent either 5 or 14 days of one-
legged knee immobilization by means of a full leg cast. Before and after the immobiliza-
tion period, computed tomography (CT) scans, dual-energy x-ray absorptiometry (DXA) 
scans and 1 repetition max (1RM) tests were performed to determine changes in mus-
cle mass and strength, and muscle biopsies were collected to assess changes in muscle 
fibre characteristics and the mRNA and protein expression of key genes associated with 
the regulation of muscle mass. 
Diet and physical activity  
All subjects received the same standardized meal the evening prior to the experimental 
test days (33±2 kJ·kg body weight-1, providing 44 energy% (En%) carbohydrate, 22 En% 
protein, and 34 En% fat). All volunteers were instructed to refrain from strenuous phys-
ical activity, avoid alcohol intake and to keep their diet as constant as possible for 2 days 
prior to the experimental test day. 
Experimental visits 
Subjects participated in two identical experimental test days, before and immediately 
after the immobilization period. Approximately two days prior to the immobilization 
period, subjects participated in the first test day. During the visit, subjects arrived at the 
laboratory at 08.00 h in the fasted state and body weight was measured with a digital 
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balance with an accuracy of 0.1 kg (SECA GmbH, Hamburg, Germany). Thereafter, a sin-
gle slice CT-scan (Philips Brilliance 64, Philips Medical Systems, Best, the Netherlands) 
was performed to assess upper leg muscle cross-sectional area (CSA). The scanning char-
acteristics were as follows: 120 kV, 300 mA, rotation time of 0.75 s, and a field of view of 
500 mm. With subjects lying supine with their legs extended and feet secured, a 3 mm 
thick axial image was taken 15 cm proximal to the top of the patella. The precise scan 
position was marked with semi-permanent ink for the duration of the experimental pro-
tocol to ensure accurate repeat measurements. Muscle area of the right leg was selected 
between 0 and 100 Hounsfield units [32], after which the quadriceps muscle was select-
ed by manual tracing using ImageJ software (version 1.45d, National Institute of Health, 
Maryland, USA) [32, 33]. After CT scanning, body composition (fat, fat-free mass and 
bone mineral content) was determined by DXA scan (Hologic Inc., Bedford, USA). Lean 
mass and percent body fat were determined on a whole-body level and for specific re-
gions (e.g. legs). Thereafter, a muscle biopsy was collected from the vastus lateralis mus-
cle of the leg identified as the leg to become immobilized (or the previously immobilized 
leg in the case of the second visit). Muscle biopsy samples were obtained from the mid-
dle region of the vastus lateralis, ~1-3 cm below the level that the CT scan was per-
formed, and ~3 cm below entry through the fascia, by using the percutaneous needle 
biopsy technique [34]. Muscle samples were dissected carefully and freed from any visi-
ble non-muscle material and were immediately frozen in liquid nitrogen and stored at -
80°C until further analysis. Thereafter, subjects single leg one repetition maximum (1-
RM) was assessed [35]. After warming up, the load was set at 97.5% of the estimated 1-
RM from the screening visit, and increased after each successful lift until failure. Three 
min rest periods were allowed between lifts. A repetition was considered valid when the 
subject used proper form and was able to complete the entire lift in a controlled manner 
without assistance. Finally, subjects were instructed on, and familiarized with, the use of 
crutches. On the day of cast removal, all measures of muscle mass and strength were 
repeated in the same manner, and a muscle biopsy was collected prior to any weight 
bearing activity from a site ~2 cm from the position of the first biopsy. 
Limb immobilization 
Approximately 48 h after the first test day, subjects reported at 8.00 h at the Casting 
Room at Maastricht University Medical Centre, to have a full leg cast fitted. The applica-
tion of the cast signified the first day of either the 5 (n=12) or 14 (n=12) day immobiliza-
tion period. The circular leg cast extended from 10 cm above the ankle to approximately 
25 cm above the patella. The knee was casted at a 30o angle of flexion to prevent sub-
jects performing any weight bearing activities with the casted leg. Subjects were pro-
vided with crutches for proper ambulation. All subjects were instructed to perform a 
series of simple ankle exercises (i.e. plantar and dorsal flexion, and circular movements 
of the entire foot) to keep the calf muscle pump activated in the immobilized leg, 
 26 | CHAPTER 2 
thereby minimizing the risk of developing deep vein thrombosis. Subjects remained in 
the cast for the duration of the period but those in the group immobilized for 14 days 
were required to visit the Casting Room after 7 days to have the cast tightened. At the 
end of the immobilization period, subjects were collected from their home by car, and 
brought into the laboratory for the second test day at 08.00 h. Prior to the start of the 
second test day, subjects visited the Casting Room to have the cast removed. Thereaf-
ter, subjects were taken by wheelchair to the laboratory so the muscle biopsies could 
be collected prior to any weight bearing exercise being performed. Following biopsy 
collection, subjects were able to bear weight on the immobilized leg for approximately 
1-2 h prior to strength testing to minimize deficits due to initial joint stiffness.  
Immunohistochemistry 
Frozen muscle biopsies were cut into 5 µm thick cryosections using a cryostat at -20°C, 
and thaw mounted on uncoated pre-cleaned glass slides. Samples from pre and post 
immobilization were mounted together on the same glass slide. Care was taken to 
properly align the samples for cross-sectional fibre analyses. Muscle biopsies were 
stained for muscle fibre typing (FT). First antibodies were directed against laminin (poly-
clonal rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and myo-
sin heavy chain (MHC)-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, 
Iowa City, IA). Appropriate secondary antibodies were applied: goat anti-rabbit IgG 
AlexaFluor647 and goat anti-mouse IgM AlexaFluor555 (dilution 1:400 and 1:500, re-
spectively; Molecular Probes, Invitrogen, Breda, the Netherlands). All primary and sec-
ondary antibodies were diluted in 0.1% Bovine Serum Albumin (BSA) in 0.1% Tween- 
phosphate-buffered saline (PBS). All incubations took place at room temperature, un-
less otherwise stated. Staining procedures were as follows. After fixation (5 minutes 
acetone), slides were air dried and incubated at room temperature for 30 minutes with 
3% BSA in 0.1% Tween-PBS. Slides were then washed (5 minutes PBS). Thereafter, pri-
mary antibodies against laminin and MHC-I were applied for 45 minutes. Slides were 
then washed and incubated with the appropriate secondary antibodies. After a final 
washing step, all slides were mounted with cover glasses using Mowiol (Calbiochem, 
Amsterdam, the Netherlands).  
Images were visualized and automatically captured at 10x magnification with a fluo-
rescent microscope equipped with an automatic stage (IX81 motorized inverted micro-
scope, Olympus, Hamburg, Germany) EXi Aqua CCD camera (QImaging). Micromanager 
1.4 software was used for image acquisition [36]. Quantitative analyses were done using 
Image J software package (version 1.45d, National Institute of Health, [33]). All image 
recordings and analyses were performed by an investigator blinded to subject coding. 
Mean muscle fibre size was calculated for the type I and type II muscle fibres separately. 
As a measure of fibre circularity, form factors were calculated by using the following 
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formula: (4π·CSA)·(perimeter)-2. No differences in fibre circularity were observed over 
time or between groups (data not shown). 
rtPCR 
Total RNA was isolated from 10-20 mg of frozen muscle tissue using TRIzol® Reagent 
(Life Technologies, Invitrogen), according to the manufacturer’s protocol. Total RNA 
quantification was carried out spectrophotometrically at 260 nm (NanoDrop ND-1000 
Spectrophotometer, Thermo Fisher Scientific, USA), and RNA purity was determined as 
the ratio of readings at 260/280 nm. Thereafter, first strand cDNA was synthesized from 
1 µg RNA sample using iScriptTM cDNA synthesis kit (BioRad; cat. 170-8891) in a reac-
tion volume of 20 µL. Taqman PCR was carried out using a 7300 Real Time PCR System 
(AppliedBiosystems, USA), with 2 µL of cDNA, 12.5 µl TaqmanTM master mix, 1.25 µl 
TaqmanTM probe and 9.25 µl H2O in a 25 µL final well volume. Each sample was run in 
duplicate, together with a serial dilution standard curve. The housekeeping gene 18S 
was used as an internal control as this gene has been used previously in similar human 
immobilization studies [12, 37, 38] and was unaffected by immobilization (i.e. mean Ct 
values were unaffected over time during each assay: example Ct values pre and post 
immobilization were 8.99±0.08 and 9.04±0.05; P=0.53, for the 5 day group: 9.46±0.10 
and 9.52±0.12; P=0.56 for the 14 day group). Taqman primer/probe sets were obtained 
from Applied Biosystems (Foster City, USA): myogenin, MyoD, myostatin, MAFBx, 
MuRF1, FOXO1, mTOR, P70S6K, citrate synthase, PGC1α, FAK, PAT1, LAT1 and 18S. The 
thermal cycling conditions used were: 2 min at 50°C, 10 min at 95oC, followed by 40 
cycles at 95°C for 15 s and 60°C for 1 min. Ct values of the target genes were normal-
ized to Ct values of the internal control and final results were calculated as relative 
expression against the standard curve. The Ct values of all genes of interest were always 
within the lower and upper boundaries of the standard curve. 
Western blotting 
A portion of each muscle sample frozen for biochemical analyses was homogenized in 
14 volumes Tris buffer (20 mM Tris-HCL, 5 mM EDTA. 10 mM Na-pyrosphospate, 100 
mM NaF, 2 mM Na3VO4, 1% Nonident P-40; pH 7.4) supplemented with the following 
protease and phosphatase inhibitors: Aprotinin 10 µg·mL-1, Leupeptin 10 µg·mL-1, Ben-
zamidin 3 mM and PMSF 1 mM. After homogenization, each muscle extract was centri-
fuged for 5 min at 10,000g (4°C) and sample buffer was added to the supernatant to 
final concentrations of 60 mM Tris, 5% glycerol, 20 mg·mL-1 SDS, 0.1mM DTT, 20 µg·mL-1 
bromophenol blue. The supernatant was then heated for 5 min at 100°C and immedi-
ately placed on ice. Immediately before analyses, the muscle extraction sample was 
warmed to 50°C and centrifuged for 1 min at 3,000g (RT). Total amount of sample load-
ed on the gel was based on weight (1.0 mg per lane). Protein samples were run on a 
Criterion ‘any kDa’ gel (Biorad Order No. 567-1124) for 10 min at 50 V (constant volt-
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age) and ±90 min at 150 V (constant voltage) and transferred onto a Trans-blot Turbo 
0.2 µm nitrocellulose membrane (Biorad Order No. 170-4159) in 7 min at 2.5A and 25V. 
Specific proteins were detected by overnight incubation at 4°C on a shaker with specific 
antibodies in 50% in PBS Odessey blocking buffer (Li-Cor Biosciences Part No. 927-
40000) after blocking for 60 min at RT in 50% in PBS Odessey blocking buffer. The anti-
bodies used in this study were anti-myostatin (52 and 26 kDa; rabbit polyclonal IgG, 
Santa Cruz, sc-6885-R; dilution 1:500 in 50% Odessey blocking buffer), anti-myoD (37 
kDa; rabbit polyclonal IgG, Santa Cruz, sc-760; dilution 1:1000 in 50% Odessey blocking 
buffer), anti-myogenin (34 kDa; rabbit polyclonal IgG, Santa Cruz, sc-576; dilution 1:500 
in 50% Odessey blocking buffer), and anti α-actin (42 kDa; mouse monoclonal IgM, 
Sigma A2172; dilution 1:10000 in 50% Odessey blocking buffer. Following incubation 
membranes were washed 3 times 10 min in 0.1%PBS-Tween 20 and 1 time 10 min. with 
PBS. Next, samples were incubated (1 h at RT) with Infrared secondary antibodies, don-
key anti-rabbit IRDYE 680 (Li-Cor, Cat. No. 926-32223, dilution 1:10000) and donkey 
anti-mouse IRDYE 800CW (Li-Cor, Cat. No. 926-32212, dilution 1:10000) dissolved in 
50% in PBS Odessey blocking buffer. After a final wash step (3 x 5 min) in 0.1% 
Tween20-PBS and 1 time 10 min. with PBS protein quantification was performed by 
scanning on an Odyssey Infrared Imaging System (LI-COR Biotechnology, Lincoln, NE). 
Values for target proteins were adjusted for total α-actin content as the protein levels 
of this housekeeper were not altered by either 5 (from 20.24±3.06 to 17.30±2.18 arbi-
trary units; P=0.39) or 14 days of immobilization (from 15.69±3.36 to 15.98±3.17 arbi-
trary units; P=0.90). 
Statistics 
All data are expressed as means±SEM. A two-way ANOVA with time (pre and post) and 
treatment (5 and 14 days) as factors was used to compare differences in all time de-
pendent parameters. When a significant main effect was detected, a Bonferoni post-
hoc test was applied to locate these differences. For non-time dependent variables, a 
paired t test was used to compare means. Statistical significance was set at P<0.05. All 
calculations were performed by using GraphPad Prism version 5.0 for Windows, 
GraphPad Software, San Diego California USA.  
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R E S U L T S  
Participants 
Subjects’ characteristics in the 5 day immobilization group (body mass; 76.0±4.2 kg, 
BMI; 22.5±1.2 kg·m-2, body fat; 15.6±1.4%, lean body mass; 60.0±2.7 kg, and blood 
HbA1c; 5.1±0.1%) did not differ from those in the 14 day immobilization group (body 
mass 82.5±3.1 kg, BMI; 25.0±1.1 kg·m-2, body fat; 20.0±2.1%, lean body mass; 63.5±2.7 
kg, and blood HbA1c; 5.7±0.3%). No changes in any of these parameters were observed 
during the experimental periods (data not shown). 
Muscle mass, strength and muscle fibre cross-sectional area 
Measurements of muscle mass and strength are displayed in Figure 1. Quadriceps cross-
sectional area (CSA) determined by CT-scan (A) did not differ between groups at base-
line, but significantly declined by 3.5±0.5% (from 7504±342 to 7238±324 mm2; P<0.001) 
and 8.4±2.8% (from 7666±382 to 7022±375 mm2; P<0.001) following 5 and 14 days of 
immobilization, respectively. A significantly greater amount of muscle mass was lost 
following 14 days when compared with 5 days of immobilization (significant interaction; 
P<0.05). Interestingly, when taking the m rectus femoris as an individual muscle, no 
atrophy was present in either the 5 (from 745±55 to 737±52 mm2; P>0.05) or 14 (from 
598±34 to 659±56 mm2; P>0.05) day groups. Leg lean mass, as determined by DXA (B), 
did not differ between groups at baseline and declined over time in both groups (effect 
of time; P<0.001) by 1.4±0.7 (from 10133±425 to 9986±411 g; P=0.66) and 3.1±0.7% 
(1187±452 to 10841±450 g; P<0.01) following 5 and 14 days of immobilization, respec-
tively. Whole-body lean and fat mass did not change throughout the experiment in 
either group.  
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Figure 1 | Mean (±SEM) percentage loss of quadriceps cross-sectional area (CSA; A), lean leg mass (B) and 
single leg 1 repetition maximum strength (1RM; C) following either 5 (n=12) or 14 days (n=12) of one-legged 
knee immobilization in healthy, young men. Data were analyzed using absolute values pre and post immobili-
zation in both groups with a two-way ANOVA (time x treatment). In case of a significant interaction effect, 
Bonferroni post-hoc tests were applied to locate the individual differences. A: Significant time (P<0.001) and 
interaction (P<0.05) effects. B: Significant time (P<0.001) effect. C: Significant time (P<0.001) and interaction 
(P<0.001) effects. *** P<0.001 compared with pre immobilization. 
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Muscle strength (C) did not did not differ between groups at baseline, but declines of 
9.0±2.3 (from 77.9±3.9 to 71.1±4.1 kg; P<0.001) and 22.9±2.6% (from 73.8±4.2 to 
55.9±3.6 kg; P<0.0001) were observed following 5 and 14 days of immobilization, re-
spectively (effect of time; P<0.001). A significantly greater loss in muscle strength was 
experienced by volunteers following 14 versus 5 days of immobilization (interaction 
effect; P<0.001).  
Type I and II muscle fibre CSA of biopsies collected before and after immobilization 
in both groups are displayed in Figure 2. Type I muscle fibre CSA was significantly great-
er at baseline in the 14 day compared to 5 day immobilization group (P<0.05). Limb 
immobilization resulted in a significant decrease in type I muscle fibre CSA after 14 days 
of immobilization (7±3% decline; P<0.05) but not after 5 days of muscle disuse (pre: 
5259±328 µm2, post: 5404±404 µm2; P>0.05). Type II muscle fibre CSA did not differ 
between groups at baseline (P=0.11) and declined over time in both groups (significant 
effect of time; P<0.05), reaching statistical significance after 14 days of immobilization 
only (7735±463 to 6619±311 µm2; 13±4% decline; P<0.05).  
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Figure 2 | Mean (±SEM) type I (A) and type II (B) muscle fibre cross-sectional area (CSA) before (pre) and after 
(post) either 5 (n=12) or 14 days (n=12) of one-legged knee immobilization in healthy, young men. Data were 
analyzed using with a two-way ANOVA (time x treatment). In case of a significant main effect, Bonferroni post-
hoc tests were applied to locate the individual differences. A: Significant treatment (P<0.01) effect. B: Signifi-
cant time (P<0.01) effect. * P<0.05 compared with corresponding pre immobilization values. 
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At baseline, muscle fibre type composition showed 43±3 and 57±3% type I and II muscle 
fibre, respectively, in the 5 day group, and 35±3 and 65±3%, respectively, in the 14 day 
group. No differences were observed between groups. There was a significant time 
effect (P<0.01) for a greater type I muscle fibre proportion following immobilization 
with 10±7 (P=0.10) and 26±12% (P<0.05) more type I muscle fibres following 5 and 14 
days of immobilization, respectively. 
Skeletal muscle mRNA expression and protein content 
0
1
2
3
*
Myostatin
**A
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.5
1.0
1.5
2.0
2.5
*
B Myostatin
Pr
ot
ein
 co
nt
en
t (
AU
)
0
5
10
15
** *
C Myogenin
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.2
0.4
0.6
0.8
***
D Myogenin
Pr
ot
ein
 co
nt
en
t (
AU
)
0
5
10
15
20 MyoDE
 Pre Post  Pre Post
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.1
0.2
0.3
0.4
14 days
 5 days
 Pre Post  Pre Post
F MyoD
Pr
ot
ein
 co
nt
en
t (
AU
)
0.0
0.2
0.4
0.6
0.8
 
Figure 3 | Skeletal muscle mRNA expression and protein content of myostatin (A and B, respectively), myogen-
in (C and D, respectively) and myoD (E and F, respectively) before (Pre) and after (Post) either 5 (n=12) or 14 
days (n=12) of one-legged knee immobilization in healthy, young men. Figure B represents the 52 (main) and 
26 kDa (inset) isoforms of myostatin. Data were analyzed with a two-way ANOVA (time x treatment). In case 
of a significant main effect, Bonferroni post-hoc tests were applied to locate the individual differences. A: 
Significant time (P<0.001) and treatment (P<0.05) effects. B: Significant interaction (P<0.05) effect. C: Signifi-
cant time (P<0.001) effect. D: Significant time (P<0.001) and interaction (P<0.01) effects. E: Significant treat-
ment (P<0.05) effect. F: No significant effects were detected. *P<0.05, **P<0.01 and ***P<0.001 compared 
with corresponding Pre value. 
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Figure 3 depicts the skeletal muscle mRNA expression and protein content of myostatin, 
myogenin, and MyoD. Muscle myostatin mRNA expression (A) increased significantly by 
68 and 54% after 5 (P<0.05) or 14 (P<0.01) days of immobilization, respectively. While 
myostatin (52 kDa isoform) protein content (B) remained unaltered in the 5 day group, 
14 days of limb immobilization led to a 32% reduction (P<0.05). No significant differ-
ences were observed between groups or over time in muscle protein content of the 26 
kDa isoform of myostatin (B; inset). Muscle myogenin mRNA expression (C) increased 
significantly by 96 and 64% following 5 (P<0.01) or 14 (P<0.05) days of immobilization, 
respectively. However, the muscle protein content of myogenin (D) increased only in 
the 14 day group by 51% (P<0.001) and did not change in the 5 day group. Muscle my-
oD mRNA expression (E) and protein content (F) did not differ between groups and 
seemed to remain unaffected by either duration of immobilization. 
The skeletal muscle mRNA expression data for selected genes implicated in the 
regulation of muscle mass, amino acid metabolism or oxidative metabolism are dis-
played in Figure 4. Muscle MAFBx mRNA expression (A) increased by 48 and 40% follow-
ing 5 (P<0.01) or 14 (P<0.05) days of immobilization, respectively, while muscle MuRF1 
(B) mRNA expression increased (56%) only in the 5 day group. Muscle mRNA expression 
of FOXO1 (C), mTOR (D), LAT1/SLC (F), PAT1 (G) and FAK (J) were not altered by either 
duration of immobilization. Muscle mRNA expression of P70S6K (E) increased modestly 
(18%; P<0.05) following 5 but not 14 days of immobilization. PGC1α (H) and citrate 
synthase (I) muscle mRNA expression declined by 73 (P<0.01) and 33% (P<0.01) in the 5 
day group, and 72 (P<0.01) and 31% (P<0.01) in the 14 day group, both respectively.  
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Figure 4 | Skeletal muscle mRNA expression of MAFBx (A), MuRF1 (B), FOXO1 (C), mTOR (D), P70S6K (E), 
LAT1/SLC (F), PAT1 (G), PGC1α (H), citrate synthase (I) and FAK (J) before (Pre) and after (Post) either 5 
(n=12) or 14 days (n=12) of one-legged knee immobilization in healthy, young men. Data were analyzed 
with a two-way ANOVA (time x treatment). In case of a significant main effect, Bonferroni post-hoc tests 
were applied to locate the individual differences. A: Significant time (P<0.001) effect. B: Significant 
treatment (P<0.01) effect. C: No significant effects. D: No significant effects. E: Significant time (P<0.05) 
effect. F: No significant effects. G: No significant effects. H: Significant time (P<0.001) effect. I: Significant 
time (P<0.001) effect. J: Significant time (P<0.05) effect. * P<0.05, ** P<0.01 and *** P<0.001 compared 
with corresponding Pre value. 
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D I S C U S S I O N  
The principal novel finding of the present study is that skeletal muscle mass already 
declines substantially after only 5 days of limb immobilization. Moreover, we provide 
evidence for a divergent molecular signaling response within skeletal muscle tissue 
regarding the expression of myostatin and components of the ubiquitin-proteasome 
pathway during the early (5 days) compared with the later stages (14 days) of muscle 
disuse. These findings underline the clinical relevance of striving to prevent or minimize 
muscle loss even during short periods of bed rest or immobilization due to illness or 
injury.  
The multitude of negative consequences that are brought about by the loss of skele-
tal muscle tissue following a period of bed rest or limb immobilization [17] make muscle 
disuse atrophy an important area for scientific research and clinical evaluation. Previous 
studies have demonstrated that muscle loss during limb immobilization generally occurs 
at a rate of 0.5-0.6% per day [17]. In keeping with this, in the present study, we report 
that 14 days of limb immobilization led to an ~8.5% loss of quadriceps cross-sectional 
area (CSA; Figure 1A), representing ~350 g lean tissue lost (Figure 1B). This considerable 
muscle atrophy was accompanied by a ~25% loss of muscle strength (Figure 1C) follow-
ing 14 days of immobilization, underlining the detrimental impact of prolonged disuse 
on functional capacity. On a muscle fibre level, we report that 14 days of immobilization 
led to a clear atrophy of both type I and type II muscle fibres (Figure 2), with the latter 
being quantitatively most affected. These findings are in line with previous studies 
demonstrating disuse atrophy in both fibre types [39-42], with type II muscle fibres 
being the most susceptible [42].  
Innovations within healthcare systems have reduced the duration that patients’ typ-
ically remain hospitalized, such that 5-6 days is now the average stay for an elderly 
person admitted with acute illness [14]. However, to what extent such a short period of 
disuse may impact upon skeletal muscle mass has not yet been evaluated. This is the 
first study to show that only 5 days of limb immobilization already induces a 3.5% de-
cline in quadriceps muscle CSA in vivo in humans (Figure 1A). We assessed muscle mass 
of the quadriceps as an entire unit due its important role in numerous daily functions. 
However, it is also true that the 3.5% observable atrophy may represent an underesti-
mate of the muscles more specific to knee extension, since the m. rectus femoris did 
not atrophy in either group. The lack of atrophy in this specific muscle likely relates to 
its contribution to hip extension which may have still occurred to a certain extent during 
the immobilization period. Regardless, the decline in muscle CSA was accompanied by 
our observation of as much as ~150 g lean mass lost from a single leg after merely 5 
days of disuse (Figure 1B). Our data are in line with a previous short-term disuse study 
which reported a 3% loss of thigh muscle mass assessed by MRI after 7 days of bed rest 
in young men [43]. We were unable to detect any significant changes in muscle fibre 
size from the collected muscle biopsies following 5 days of immobilization. This is not 
 Short-term muscle disuse atrophy | 37 
surprising given the considerable inter- and intra- subject variation in muscle fibre size 
[44]. In fact, decreases in muscle mass likely need to exceed ~6% before specific muscle 
fibre atrophy can be detected using immunohistochemistry in combination with fluo-
rescence microscopy [44]. It should be noted that a recent study was able to show an 
~8 and 12% decline in type I and II muscle fibre CSA, respectively, following only 4 days 
of immobilization [15]. The reason(s) for the apparent discrepancy between this and the 
present study is unclear, but could relate to a differing immobilization protocol (knee 
brace vs. casting) or less variability in the data. Importantly, the loss of muscle mass 
following 5 days of immobilization led to an even greater (relative) decline in leg muscle 
strength of ~9% (Figure 1C), suggesting that already compromised patients could easily 
fall below a critical threshold with respect to carrying out normal daily activities follow-
ing only a few days of illness or injury. A striking observation of the present study was 
that a substantial amount of the atrophy and loss of strength observed after 14 days 
was already present after only 5 days of limb immobilization. Since losses of strength 
over a more prolonged period seem mostly attributable to continued loss of muscle 
mass [45], this underlines the importance of intervening as early as possible when a 
period of disuse is unavoidable.  
While muscle atrophy during prolonged disuse is generally attributed to declines in 
muscle protein synthesis rates [2, 10, 17, 46], evidence also suggests that a rapid in-
crease in muscle protein breakdown during the first few days of disuse may also con-
tribute to overall muscle loss [17, 18, 37, 38, 47, 48]. Myostatin, a proposed ‘master’ 
negative regulator of skeletal muscle mass in animals [24, 25] and humans [26], acts via 
the inhibition of mammalian target of rapamycin (mTOR) muscle protein synthesis sig-
naling [27] and by initiating muscle protein breakdown through the ubiquitin pro-
teasome system [30]. Consistent with previous animal [49] and human [12, 37, 50] 
disuse studies, we report a clear up-regulation of myostatin gene expression in re-
sponse to 5 and 14 days of limb immobilization (Figure 3). In parallel, we observed a 
profound increase in gene expression of the two primary ubiquitin ligases, MAFBx and 
MuRF1 [51], after 5 days of immobilization, which became less striking after 14 days 
(Figure 4). These data extend on previous findings [20, 37, 38, 47, 52] by suggesting that 
an early and transient increase in ubiquitin-proteasome mediated muscle protein 
breakdown, possibly mediated via increased myostatin transcription, contributes to 
muscle disuse atrophy during the first few days of disuse. In support, it has previously 
been shown that anti-body directed inhibition of endogenous myostatin is capable of 
attenuating muscle atrophy in the short- but not long-term phase of hind-limb unload-
ing in rodents [49]. However, it should be noted that we were unable to demonstrate 
that increased myostatin transcription led to the successful translation of either the (52 
kD) precursor or purported biologically active (26 kD) isoforms of the protein. Clearly 
more research is warranted to directly assess muscle protein breakdown rates in com-
bination with myostatin signaling during (short-term) disuse. Such information will allow 
us to better define their contribution to muscle disuse atrophy, and assess whether 
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myostatin [53] and/or proteasome inhibition [54] are viable future targets for attenuat-
ing muscle disuse atrophy in humans. 
Myostatin also plays a key role in myogenesis through the inhibition of the myogenic 
regulatory factors, most notably myogenin and MyoD [28, 29, 55]. Here, we provide 
novel evidence that the up-regulation of myostatin transcription does not translate into 
increased protein levels during limb immobilization. In fact, after 14 days of limb immo-
bilization, myostatin protein content (52 kD isoform) had significantly declined by 32% 
(Figure 3). We extend on previous work with the observation that myogenin mRNA 
expression, considered mandatory for satellite cell differentiation and therefore myo-
genesis, increased after 5 and 14 days of immobilization, which translated into greater 
protein content after 14 days of immobilization (Figure 3). The present findings imply 
that prolonged disuse down-regulates myostatin at the functional level (i.e. protein) and 
thereby facilitates the successful translation of myogenin, possibly in anticipation of a 
forthcoming anabolic stimulus (i.e. re-ambulation). Therefore, it could be speculated 
that the regulation of myogenesis/satellite cells via myostatin and the myogenic regula-
tory factors may be of more physiological relevance in the regeneration of muscle mass 
(rather than in muscle atrophy) following more prolonged periods of disuse. As such, a 
disuse induced ‘priming’ of the myogenic machinery for an anabolic stimulus may ex-
plain the rapid rate of muscle growth generally observed in healthy individuals recover-
ing from disuse atrophy [12, 56]. This has important clinical relevance when considering 
the design of rehabilitative programs to improve muscle mass and function following 
disuse in various populations. 
Concerning our measures of gene expression, an interesting consideration is the im-
pact of disuse on total ribosome content and RNA abundance. It has been shown that 
limb disuse [57] and denervation [58] can result in a reduction in both de novo riboso-
mal RNA synthesis and global (ribosomal) RNA content. Though we did not make these 
measurements in the present study, we did not observe any differences in total RNA 
quality obtained from samples pre and post immobilization, nor did we see any changes 
over time in our housekeeping gene (18S). Moreover, any such changes in global RNA 
abundance would only make the elevated expression of the muscle atrogenes, myo-
statin, and myogenic regulatory factors all the more striking. 
The present study illustrates the impact of only a few days of disuse on skeletal 
muscle mass and strength. Extending on this, we also report a decline in citrate syn-
thase and PGC1α gene expression after only 5 days of immobilization (Figure 4), sug-
gesting that a decline in oxidative capacity and/or insulin sensitivity may also occur after 
only a few days of disuse. Thus, in clinically compromised populations (e.g. hospitalized 
elderly, critically ill, hip-fracture or acute illness patients), just a few days of bed rest or 
immobilization can likely already compromise functional capacity and metabolic health. 
Such patient groups are particularly vulnerable to atrophy during disuse since the pres-
ence of illness related stress responses are known to accelerate muscle loss during 
disuse [59, 60]. Furthermore, short successive periods of muscle disuse atrophy 
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throughout the lifespan will contribute significantly to the age-related loss of muscle 
mass and strength, and muscle quality [17-19, 61]. Together with the observation that 
we seem to lose our ability to regain lost muscle tissue as we age [42], these data sup-
port the concept that successive short periods of bed rest or immobilization throughout 
the lifespan can contribute substantially to the development of sarcopenia and decline 
in metabolic health. As a whole, our data underline the importance of understanding 
the response to muscle disuse, both in terms of molecular signaling as well as physiolog-
ical/functional changes, if we are to develop effective nutritional, exercise and/or 
pharmacological interventions aimed at attenuating muscle disuse atrophy during short 
periods of bed rest or immobilization.  
In conclusion, limb immobilization leads to a rapid loss of skeletal muscle mass and 
strength, with substantial atrophy already occurring during the first 5 days of muscle 
disuse. These data imply that successive short periods of muscle disuse, due to illness or 
injury, can be of important clinical relevance and, therefore, effective interventional 
strategies should be designed to prevent muscle atrophy during such short periods of 
muscle disuse. 
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A B S T R A C T  
Background Disuse leads to rapid loss of skeletal muscle mass and function. It has 
been hypothesized that short, successive periods of muscle disuse 
throughout the lifespan play an important role in the development of 
sarcopenia. The physiological mechanisms underlying short-term 
muscle disuse atrophy remain to be elucidated. We assessed the im-
pact of five days of muscle disuse on postabsorptive and postprandial 
myofibrillar protein synthesis rates in humans. 
Methods Twelve healthy, young (22±1 y) men underwent a five day period of 
one-legged knee immobilization (full leg cast). Quadriceps cross-
sectional area (CSA) of both legs was assessed before and after immo-
bilization. Continuous infusions of L-[ring-2H5]-phenylalanine and L-[1-
13C]-leucine were combined with the ingestion of a 25 g bolus of in-
trinsically L-[1-13C]-phenylalanine and L-[1-13C]-leucine labelled dietary 
protein to assess myofibrillar muscle protein fractional synthetic rates 
(FSRs) in the immobilized and non-immobilized control leg. 
Results  Immobilization led to a 3.9±0.6% decrease in quadriceps muscle CSA 
of the immobilized leg. Based on the L-[ring-2H5]-phenylalanine tracer, 
immobilization reduced postabsorptive myofibrillar protein synthesis 
rates by 41±13% (0.015±0.002 vs 0.032±0.005%.h-1; P<0.01) and post-
prandial myofibrillar protein synthesis rates by 53±4% (0.020±0.002 vs 
0.044±0.003%.h-1; P<0.01). Comparable results were found using the 
L-[1-13C]-leucine tracer. Following protein ingestion, myofibrillar pro-
tein-bound L-[1-13C]-phenylalanine enrichments were 53±18% lower 
in the immobilized compared with the control leg (0.007±0.002 and 
0.015±0.002 MPE, respectively; P<0.05). 
Conclusion We conclude that five days of muscle disuse substantially lowers post-
absorptive myofibrillar protein synthesis rates and induces anabolic 
resistance to protein ingestion.  
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I N T R O D U C T I O N  
In otherwise healthy humans, the recovery from injury or illness often mandates a peri-
od of local (e.g. limb immobilization) or whole-body (e.g. bed rest) muscle disuse. It has 
long been recognized that a prolonged period of disuse (i.e. > 10 days) leads to rapid 
skeletal muscle atrophy [1-3]. The resulting negative health consequences that accom-
pany prolonged muscle disuse atrophy, such as a reduction in functional capacity [1, 2], 
insulin sensitivity [4] and basal metabolic rate [5], have been well documented. As such, 
muscle disuse atrophy is of great clinical relevance and therefore represents an im-
portant area for scientific investigation. 
Although a single bout of prolonged disuse provides an acute metabolic and func-
tional challenge to any individual, perhaps of more long-term relevance is the preva-
lence of (multiple) shorter periods of disuse that occur throughout the lifespan. For 
example, the average length of hospitalization for elderly patients admitted with acute 
illness is 5-6 days [6] and most periods of illness and injury that require home-based 
recovery/reduced physical activity generally last less than one week. We [7, 8], and 
others [9, 10] have hypothesized that the accumulation of such short periods of disuse 
over the lifespan represents an important factor in the development of age-related 
sarcopenia. In support, we recently reported that even a period of muscle disuse lasting 
only five days already leads to substantial losses of skeletal muscle mass and functional 
strength in young [7] and older [11] subjects.  
Mechanistically, any sizeable loss of skeletal muscle mass must be underpinned by a 
persistent imbalance between muscle protein synthesis and breakdown rates. A body of 
early muscle atrophy studies performed in animal models comprehensively demon-
strated that a decline in muscle protein synthesis rates was a key factor responsible for 
disuse atrophy [e.g. 12, 13, 14]. Critically, however, no data are currently available as-
sessing in vivo muscle protein turnover rates during a period of short-term disuse (i.e. 
<10 days) in humans. Accordingly, the physiological mechanisms underlying skeletal 
muscle atrophy during short-term disuse in humans remain to be elucidated. Previous 
human studies, applying more prolonged periods of disuse, suggests that declines in the 
fasting muscle protein synthesis rates [2, 15, 16] and/or a reduced responsiveness to 
the anabolic properties of amino acids/food intake [16-18] are important factors re-
sponsible for disuse atrophy. In the present study, we applied specifically produced 
intrinsically L-[1-13C]-phenylalanine and L-[1-13C]-leucine labelled dietary protein com-
bined with continuous intravenous L-[ring-2H5]-phenylalanine and L-[1-13C]-leucine 
infusions [19] to assess both postabsorptive and postprandial muscle protein synthesis 
rates as well as the metabolic fate of ingested protein following 5 days of leg immobili-
zation in 12 healthy young men.  
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M E T H O D S  
Subjects 
Twelve healthy, young (22±1 y) men volunteered to participate in the present study. 
Subjects’ characteristics are presented in Table 1. 
 
Table 1 | Subjects’ characteristics (n=12) 
Age (y) 22±1 
Body mass (kg) 82.5±2.7 
BMI (kg.m-²) 24.6±0.7 
Body fat (% of body mass) 19.4 ±1.2 
Lean body mass (kg) 63.5±1.6 
Average leg lean mass (kg) 10.9±0.4 
HbA1c (%) 5.0±0.1 
Values represent means±SEM. HbA1c: glycosylated haemoglobin.  
 
All subjects were fully informed of the nature and possible risks of the experimental 
procedures, before providing written informed consent. Subjects were screened to 
exclude any person with lower limb and/or back injuries sustained within a year prior to 
the study, a (family) history of thrombosis/cardiovascular disease, use of anti-
coagulants, musculoskeletal/orthopaedic/haemostatic disorders, or participation in any 
regular resistance training program within 6 months prior to the study. During screen-
ing, body composition (fat, fat-free mass and bone mineral content) were determined 
by dual-energy x-ray absorptiometry (DXA) scan (Hologic Inc., Discovery A, QDR series, 
Bedford, USA). Whole-body and regional lean mass and percent body fat were deter-
mined using the software package Apex version 2.3 (Hologic, Bedford, USA). The study 
was approved by the Medical Ethics Committee of the Maastricht University Medical 
Centre, Maastricht, the Netherlands in accordance with the guidelines set out in the 
Declaration of Helsinki. 
Experimental design 
Subjects participated in a single stable isotope tracer infusion experimental visit imme-
diately following a five day period of one-legged knee immobilization by means of a full 
leg cast. During the experimental visit, continuous intravenous infusions of L-[ring-2H5]-
phenylalanine and L-[1-13C]-leucine were combined with the ingestion of 25 g intrinsi-
cally L-[1-13C]-phenylalanine and L-[1-13C]-leucine labelled dietary protein. Throughout 
the experimental visit, multiple blood samples were drawn and muscle samples were 
obtained from both legs in a previously validated, comprehensive approach to deter-
mine muscle protein metabolism [19]. This design allowed us to simultaneously assess 
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postabsorptive and postprandial muscle protein synthesis rates, and the metabolic fate 
of the ingested protein, in the immobilized and non-immobilized control leg. 
Pre-testing 
Two days prior to the immobilization period, subjects participated in a single pre-testing 
session to assess skeletal muscle mass of the legs. Subjects arrived at the laboratory at 
08.00 h and body weight was measured with a digital balance with an accuracy of 0.1 kg 
(SECA GmbH, Hamburg, Germany). Thereafter, a single slice CT-scan (Philips Brilliance 64, 
Philips Medical Systems, Best, the Netherlands) was performed to assess upper leg mus-
cle cross-sectional area (CSA). The scanning characteristics were as follows: 120 kV, 300 
mA, rotation time of 0.75 s, and a field of view of 500 mm. With subjects lying supine 
with their legs extended and feet secured, a 3 mm thick axial image was taken 15 cm 
proximal to the top of the patella. The precise scan position was marked with semi-
permanent ink for the duration of the experimental protocol to ensure accurate repeat 
measurements. Muscle area of the legs was selected between 0 and 100 Hounsfield 
units [20], after which the quadriceps muscle was selected by manual tracing using Im-
ageJ software (version 1.45d, National Institute of Health, Maryland, USA) [21-23]. Next, 
the leg to be immobilized was selected at random (counterbalanced for left and right 
legs) and subjects were instructed on, and familiarized with, the use of crutches (casting 
described below). On the morning of the experimental test day (i.e. the end of the im-
mobilization period) the cast removal was immediately followed by a second CT scan. 
Limb immobilization 
Two days following pre-testing, subjects attended the Casting Room at Maastricht Uni-
versity Medical Centre at 08.00 h to have a full leg cast fitted to induce one-legged knee 
immobilization. First, a high moisture zinc paste bandage (Varicex®T, Lohmann & 
Rauscher, Germany) was placed around the calf to prevent the cast dropping, and a 
foam ankle band was applied (Collar ‘n’ Cuff TM, Mölnlycke Health Care, Gothenburg, 
Sweden) to avoid pressure from the cast on the ankle joint. Thereafter, cotton padding 
was applied to the leg for skin protection (Cellona®, Lohmann & Rauscher,Neuwied, 
Germany) and a fibreglass and polyurethane resin lightweight cast (Delta-Lite®, BSN 
Medical, Germany) was fitted to the leg. The circular leg cast extended from 10 cm 
above the ankle to approximately 25 cm above the patella. The knee was casted at a 30o 
angle of flexion to prevent subjects performing any weight bearing on the casted limb. 
Subjects were provided with crutches for proper ambulation. Throughout the immobili-
zation period, subjects were instructed to perform a series of daily simple ankle exercis-
es (i.e. plantar and dorsal flexion, and circular movements of the entire foot) to keep 
the calf muscle pump activated in the immobilized leg, thereby minimizing the risk of 
developing a deep vein thrombosis. Prior to the start of the stable isotope infusion visit, 
subjects visited the Casting Room to have the cast removed and had a second CT scan 
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performed as described above. Following cast removal, subjects were exclusively trans-
ported by wheelchair to prevent any weight bearing on the immobilized leg. 
Diet and physical activity  
All subjects received the same standardized meal the evening prior to the stable isotope 
infusion experimental visits (33±2 kJ.kg-1 body weight, providing 44 energy% (En%) car-
bohydrate, 22 En% protein, and 34 En% fat). All volunteers were instructed to refrain 
from alcohol intake and to keep their diet as constant as possible for the duration of the 
immobilization period. 
Experimental visits 
On the morning following the 5 day immobilization period (i.e. day 6) subjects arrived at 
the laboratory by taxi at 08:00 h for a stable isotope infusion experiment. Following cast 
removal and CT-scanning (described above), a polytetrafluoroethylene catheter was 
inserted into an antecubital vein for stable-isotope infusion. A second catheter was 
inserted into a heated dorsal hand vein of the contralateral arm after which the hand 
was placed in a hot box (60°C) for arterialized blood sampling [24]. After a basal blood 
sample was collected (t = -240 min), the plasma phenylalanine and leucine pools were 
primed with a single intravenous dose (2.0 µmol.kg-1 L-[ring-2H5]-phenylalanine; 4.0 
µmol.kg-1 L-[1-13C]-leucine), after which continuous L-[ring-2H5]-phenylalanine (0.06 
µmol.kg-1.min-1) and L-[1-13C]-leucine (0.10 µmol.kg-1.min-1) infusions were started. After 
the subjects rested in a semi-supine position for 120 min, a second blood sample was 
drawn and muscle biopsies were collected from the vastus lateralis muscle of both legs 
(t = -120 min). This signified the beginning of a 2 h period for the determination of post-
absorptive muscle protein synthesis rates during which blood samples were collected 
every 30 min (i.e. t = -90, -60, -30 and 0 min). At t = 0 min, muscle biopsies were again 
collected from the vastus lateralis muscle of both legs. Immediately after these biop-
sies, subjects ingested a single bolus of 25 g intrinsically L-[1-13C]-phenylalanine and L-
[1-13C]-leucine-labelled whey protein dissolved in 350 mL vanilla flavored water signify-
ing the beginning of a 4 h period for the determination of postprandial muscle protein 
synthesis rates. We have previously shown [19] that the above described use of doubly 
labelled milk protein allows the measurement of postprandial muscle protein synthesis 
rates without the disturbance of steady state tracer conditions, with the concomitant 
determination of de novo muscle protein accretion from the ingested protein source 
(for full details of the approach please refer to [19]). 
Following protein ingestion, subjects rested in a semi-supine position for another 
240 min, during which arterialized blood samples were collected at regular intervals (t = 
30, 60, 90, 120, 180 and 240 min) after which final muscle biopsies were collected from 
both legs (t = 240 min) marking the end of the infusion period.  
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Blood samples were collected into EDTA-containing tubes and centrifuged at 3500g 
for 10 min at 4oC. Aliquots of plasma were frozen in liquid nitrogen and stored at -80°C. 
The muscle biopsy samples were all taken from separate incisions and in different direc-
tions, at least 2 cm apart. Muscle biopsy samples were obtained from the middle region 
of the vastus lateralis, ~15 cm above the patella and ~3 cm below entry through the 
fascia, using the percutaneous needle biopsy technique [25]. Muscle samples were 
dissected carefully and freed from any visible non-muscle material and were immedi-
ately frozen in liquid nitrogen and stored at -80°C until further analysis.  
Production of intrinsically labelled protein 
Intrinsically L-[1-13C]-phenylalanine and L-[1-13C]-leucine milk protein was obtained by a 
constant infusion of L-[1-13C]-phenylalanine (455 µmol·min-1) and L-[1-13C]-leucine (200 
µmol·min-1) maintained for 96 h in a lactating dairy cow [26-28]. The milk was collected, 
processed, and fractionated into the whey protein concentrate as previously described 
[27]. The L-[1-13C]-phenylalanine and L-[1-13C]-leucine enrichments in whey protein 
were measured by gas chromatography-combustion-isotope ratio mass spectrometry 
(GC-C-IRMS; MAT 252, Finnigan, Breman, Germany) and averaged 38.7 MPE and 9.3 
MPE, respectively. The proteins met all chemical and bacteriologic specifications for 
human consumption. 
Plasma analyses  
Plasma glucose and insulin concentrations were analyzed using commercially available 
kits (Glucose HK CP, ABX Diagnostics, ref. A11A01667, Montpellier, France and Milli-
pore, ref. HI-14K, Billerica, USA, respectively). Plasma amino acid concentrations and 
enrichments were determined by GCMS analysis (Agilent 7890A GC/5975C; MSD, Little 
Falls, DE, USA). Specifically, internal standards of [U-13C6]-leucine and [U-13C915N]-
phenylalanine, and [U-13C915N]-tyrosine were added to the samples. The plasma was 
deproteinised on ice with 10 mg of dry 5-sulfosalicylic acid. Free amino acids were puri-
fied using cation exchange chromatography (AG 50W-X8 resin; Bio-Rad Laboratories, 
Hercules, CA, USA). The free amino acids were converted to their t-butyldimethylsilyl 
(TBDMS) derivative before analysis by GCMS. The amino acid concentrations were de-
termined using electron impact ionization by monitoring ions at mass/charge (m/z) 302 
and 308 for unlabelled and [U-13C6]-leucine respectively, 336 and 346 for unlabelled and 
[U-13C915N]-phenylalanine respectively, and 466 and 476 for unlabelled and [U-13C915N]-
tyrosine respectively. The plasma free L-[ring-2H5]-phenylalanine enrichments were 
measured from the m/z ratios at 336 (m+0) and 341 (m+5), with m+0 representing the 
lowest molecular weight of the ion. For L-[1-13C]-phenylalanine, m/z 336 (m+0) and 337 
(m+1) were monitored. For L-[1-13C]-leucine, m/z 302 (m+0) and 303 (m+1) were moni-
tored. Standard regression curves were applied in all isotopic enrichment analyses to 
assess linearity of the mass spectrometer and to control for the stable isotope effects 
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that occur during analysis. Phenylalanine and leucine enrichments were corrected for 
the presence of both the 13C and 2H isotopes.  
Muscle tracer analyses  
Myofibrillar protein enriched fractions were extracted from 50 mg of wet muscle tissue 
by hand-homogenizing on ice using a Teflon pestle in a standard extraction buffer (7.5 
μl·mg-1) [29]. The samples were spun at 1500g for 10 min at 4°C. The resultant superna-
tants that contained the sarcoplasmic proteins were removed. The remaining myofibril-
lar and collagen pellet were washed with 500 µl of extraction buffer and spun at 700 ×g 
for 10 min at 4°C. The myofibrillar proteins were solubilized by adding 1.5 mL of 0.3 м 
NaOH and heating at 50°C for 30 min with vortex mixing every 10 min. Samples were 
centrifuged at 10000g for 5 min at 4°C, the supernatant containing the myofibrillar-
enriched fraction was collected and the collagen pellet was discarded. Myofibrillar pro-
teins were precipitated by the addition of 1 mL of 1 м PCA and spinning at 700g for 10 
min at 4°C. The myofibrillar enriched proteins were washed twice with 70% ethanol. 
Amino acids were liberated by the addition of 2 mL of 6 м HCL and heating at 110°C for 
24 h. The hydrolysed myofibrillar protein fraction was dried under a nitrogen stream 
while being heated to 120°C and, subsequently, dissolved in a 25% acetic acid solution 
and passed over a Dowex exchange resin (AG 50W-X8, 100 – 200 mesh hydrogen form; 
Biorad, Hercules, CA, USA). The free amino acids were eluted with 2 м NH4OH, dried, 
and the purified amino acids were derivatised into MTBSTFA-phenylethylamines [30, 
31] to measure the L-[ring-2H5]-phenylalanine labelling using GCMS analysis as de-
scribed previously [32]. Separate aliquots of the purified amino acids were converted to 
their N(O,S)-ethoxycarbonyl ethyl esters derivatives to determine the L-[1-13C]-
phenylalanine and L-[1-13C]-leucine labelling of the myofibrillar proteins by gas chroma-
tography combustion-isotope ratio mass spectrometry analysis (GC-C-IRMS; Trace GC 
Ultra, IRMS model MAT 253, Thermo Scientific, Breman, Germany). The derivatised 
amino acids were separated on a 30m×0.25mm×0.25µm DB-5 column (temperature 
program: 120°C for 10 min; 3°C·min−1 ramp to 200°C; 30°C·min−1 ramp to 300°C; hold 
for 5 min) prior to combustion. Standard regression curves were applied from a series 
of known standard enrichment values against the measured values to assess the lineari-
ty of the mass spectrometer and to account for any isotope fractionation that may have 
occurred during the analysis. In addition, western blot homogenates (see below) were 
used to determine the muscle intracellular free amino acid pool tracer enrichments 
using methods described previously [19]. 
mRNA analyses 
Total RNA was isolated from 10-20 mg of frozen muscle tissue using TRIzol® Reagent 
(Life Technologies, Invitrogen), according to the manufacturer’s protocol. Total RNA 
quantification was carried out spectrophotometrically at 260 nm (NanoDrop ND-1000 
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Spectrophotometer, Thermo Fisher Scientific, USA), and RNA purity was determined as 
the ratio of readings at 260/280 nm. Thereafter, first strand cDNA was synthesized from 
1 µg RNA sample using iScriptTM cDNA synthesis kit (BioRad; cat. 170-8891). Taqman 
PCR was carried out using a 7300 Real Time PCR System (AppliedBiosystems, USA), with 
2 µL of cDNA, 12.5 µl TaqmanTM master mix, 1.25 µl TaqmanTM probe and 9.25 µl H2O in 
a 25 µL final well volume. Each sample was run in duplicate, together with a serial dilu-
tion standard curve. The housekeeping gene 18S was used as an internal control as this 
gene was unaffected by immobilization (mean Ct values were unaffected over time; 
data not shown) and has been used previously in similar studies [7, 33, 34]. Taqman 
primer/probe sets were obtained from Applied Biosystems (Foster City, USA): LAT1, 
PAT1, SNAT2, CD98, MAFBx, MuRF1, FOXO1, IL-6, TNFα and 18S. The thermal cycling 
conditions used were: 2 min at 50oC, 10 min at 95°C, followed by 40 cycles at 95°C for 
15 s and 60°C for 1 min. Ct values of the target genes were normalized to Ct values of 
the internal control and final results were calculated as relative expression against the 
standard curve. To avoid redundancy, mRNA data in the fasted state are only presented 
in the second fasting biopsy.  
Western blotting 
A portion of each muscle sample frozen for biochemical analyses was homogenized in 7 
volumes Tris buffer (20 mM Tris-HCL, 5 mM EDTA. 10 mM Na-pyrosphospate, 100 mM 
NaF, 2 mM Na3VO4, 1% Nonident P-40; pH 7.4) supplemented with the following prote-
ase and phosphatase inhibitors: Aprotinin 10 µg·mL-1, Leupeptin 10 µg·mL-1, Benzamidin 
3 mM and PMSF 1 mM. After homogenization, each muscle extract was centrifuged for 
10 min at 10,000g (4°C) and sample buffer was added to the supernatant to final concen-
trations of 60 mM Tris, 10% glycerol, 20 mg·mL-1 SDS, 0.1 mM DTT, 20 µg·mL-1 bromo-
phenol blue. The supernatant was then heated for 5 min at 100°C and immediately 
placed on ice. Immediately before analyses, the muscle extraction sample was warmed 
to 50°C and centrifuged for 1 min at 13,000g (RT). Total amount of sample loaded on the 
gel was based on weight (1.0 mg per lane). With the exception of mTOR, protein samples 
were run on a Criterion Precast TGX 4-20% gel (Biorad Order No. 567-1094) for 10 min at 
50 V (constant voltage) and ±90 min at 150 V (constant voltage) and transferred onto a 
Trans-blot Turbo 0.2 µm nitrocellulose membrane (Biorad Order No. 170-4159) in 7 min 
at 2.5 A and 25 V. mTOR proteins were run and blotted under the same conditions but 
on a Criterion Precast XT 3-8% Tris-acetate gel (Biorad order No. 345-0130). Specific 
proteins were detected by overnight incubation at 4°C on a shaker with specific antibod-
ies in 50% in PBS Odyssey blocking buffer (Li-Cor Biosciences Part No. 927-40000) after 
blocking for 60 min at RT in 50% in PBS Odyssey blocking buffer. Polyclonal primary 
phospho-specific antibodies [α-tubulin (52 kDa; dilution 1:10 000, rabbit monoclonal IgG; 
Cell Signaling Tecnhologies, Beverly, MA, USA; Order No. 2125), anti-phospho-mTOR 
(Ser2448), anti-phospho-S6K1 (Thr389), anti-phospho-S6 (Ser235/Ser236), anti-phospho-4E-
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BP1 (Thr37/46), anti-mTOR, anti-S6K1, anti-RS6 and anti-4E-BP1 were purchased from Cell 
Signaling Technologies. Following incubation, membranes were washed 3 times 10 min 
in 0.1% PBS-Tween 20 and once for 10 min in PBS. Next, samples were incubated on a 
shaker (1 h at RT) with Infrared secondary antibodies, donkey anti-rabbit IRDYE 800 
(Rockland, Cat. No. 611-732-127, dilution 1:10000) and donkey anti-mouse IRDYE 800CW 
(Li-Cor, Cat. No. 626-32212, dilution 1:10000) dissolved in 50% PBS Odyssey blocking 
buffer. After a final wash step (3 x 10 min) in 0.1% Tween20-PBS and once 10 min in PBS, 
protein quantification was performed by scanning on an Odyssey Infrared Imaging Sys-
tem (LI-COR Biotechnology, Lincoln, NE) with local background subtraction and intensity 
of the bands expressed as arbitrary units. α-Tubulin was used to standardize for the 
amount of protein loaded. Phosphorylation status as a proxy of activation of the signaling 
proteins was expressed relative to the total amount of each protein. 
Calculations 
The fractional synthetic rates (FSRs) of the myofibrillar proteins were calculated using 
the standard precursor-product equation: 
 
FSR (%·h-1) = ∆Ep / [ Eprecursor × t ] × 100 
 
where ∆Ep is the change in phenylalanine or leucine labelling between two muscle 
biopsies, Eprecursor is the average labelling over time curve (AUC) of the plasma precursor 
pool; and t indicates the tracer incorporation time (hours) between two muscle biop-
sies.  
Statistics 
All data are expressed as means±SEM. A one-way ANOVA was used to assess changes 
over time in plasma glucose, insulin and amino acid concentrations. A two-way repeat-
ed measures ANOVA with time (pre and post) and leg (immobilized and non-
immobilized) as within-subjects factors was used to compare differences in quadriceps 
CSA. A two-way repeated measures ANOVA with time (fasting and fed) and leg (immobi-
lized and non-immobilized) as within-subjects factors was used to compare differences 
in L-[1-13C]-leucine and L-[ring-2H5]-phenylalanine myofibrillar protein-bound enrich-
ments and FSR and all mRNA and protein expression data. Myofibrillar protein-bound L-
[1-13C]-phenylalanine enrichments and FSR were compared using paired t-tests. For all 
ANOVA analyses, when a significant time*leg interaction was detected, a Bonferoni 
post-hoc test was applied to locate the individual differences. Statistical significance was 
set at P<0.05. All calculations were performed by using GraphPad Prism version 5.0 
(GraphPad Software, San Diego, CA, USA). 
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R E S U L T S  
Muscle mass 
Muscle quadriceps cross-sectional area (CSA) determined by CT-scan of the mid-thigh is 
displayed in Figure 1. 
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Figure 1 | Mean (±SEM) quadriceps cross-sectional area (CSA) before (Pre) and after (Post) 5 days of one-
legged knee immobilization in the immobilized (IMMOB) and non-immobilized control (CON) legs of healthy, 
young men (n=12). Data were analyzed with a two-way repeated measures ANOVA (time x leg) with Bonfer-
roni post-hoc tests to locate differences: Significant time (P<0.05) and interaction (P<0.01) effects, *P<0.05
compared with corresponding Pre value.  
 
Quadriceps CSA did not differ between legs at baseline and remained unchanged 
throughout the experiment in the non-immobilized leg (from 8039±326 to 8181±313 
mm2; P=0.24). However, five days of immobilization resulted in a 3.9±0.6% decrease in 
quadriceps muscle CSA of the immobilized leg (from 8208±312 to 7876±285 mm2; 
P<0.0001). 
Plasma analyses 
Plasma glucose concentrations declined over time (P<0.001) during the experimental 
visit (not shown). Plasma insulin concentrations (Figure 2A) showed a rapid and brief 
increase following protein ingestion up to ~23 mU.L-1 after 30 min, before returning to 
baseline levels after 90 min (time effect; P<0.001). Plasma phenylalanine (Figure 2B), 
leucine (Figure 2C) and tyrosine (Figure 2D) concentrations increased (all P<0.0001) 
following protein ingestion and remained above basal levels for 90-180 min. The time 
course of plasma L-[ring-2H5]-phenylalanine (E), L-[1-13C]-leucine (F) and L-[1-13C]-
phenylalanine (G) enrichments are also illustrated in Figure 2. 
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Figure 2 | Mean (±SEM) plasma insulin (A), phenylalanine (B), leucine (C) and tyrosine (D) concentrations, and 
mean (±SEM) plasma L-[ring-2H5]-phenylalanine (E), L-[1-13C]-leucine (F) and L-[1-13C]-phenylalanine (G) en-
richments across time (x axis; minutes) before and following ingestion of 25 g protein (at t = 0 min) after 5 
days of one-legged knee immobilization in healthy, young men (n=12). Data were analyzed with a one-way 
repeated measures ANOVA with Bonferonni post hoc tests applied to locate differences: A, B, C, D, E, F and G
all showed significant time effects (P<0.001) and * indicates values significantly different compared to ‘t = 0’.  
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During the postabsorptive period, plasma L-[ring-2H5]-phenylalanine and L-[1-13C]-leu-
cine remained in steady-state at ~7 and ~6 MPE, respectively. Following protein inges-
tion (at t = 0 min), plasma L-[ring-2H5]-phenylalanine enrichments decreased for 90 min 
before returning to fasting, steady-state levels (P<0.0001), while plasma L-[1-13C]-
leucine enrichments increased and remained at a steady state of ~8 MPE throughout 
the entire postprandial period (P<0.0001). Following protein ingestion, plasma L-[1-13C]-
phenylalanine enrichments increased rapidly to ~14 MPE after 30 min and remained 
elevated for 180 min into the postprandial period (P<0.0001). These higher plasma 
enrichments of L-[1-13C]-phenylalanine compared with L-[1-13C]-leucine following pro-
tein ingestion reflects the greater enrichment of the L-[1-13C]-phenylalanine tracer in 
the intrinsically labelled protein. The greater rise in plasma leucine concentrations com-
pared with phenylalanine is due to the higher leucine content (compared with phenylal-
anine) in whey protein.  
Skeletal muscle tracer analyses 
Based on the L-[ring-2H5]-phenylalanine tracer and the plasma enrichment as the pre-
cursor pool, postabsorptive and postprandial myofibrillar FSRs were 41±13% 
(0.015±0.002 vs 0.032±0.005%.h-1; P<0.01) and 53±4% (0.020±0.002 vs 0.044±0.003%.h-
1; P<0.01) lower, respectively, in the immobilized compared with the control leg. Protein 
ingestion increased myofibrillar FSR in both legs (P<0.05), and when comparing delta 
change a trend was observed for a lower increase in the immobilized leg (P=0.12). Indi-
vidual postabsorptive and postprandial myofibrillar FSRs based on the L-[ring-2H5]-
phenylalanine tracer and plasma precursor are illustrated in Figure 3. 
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Figure 3 | Individual subjects’ postabsorptive (A) and postprandial (B) fractional myofibrillar protein synthesis
rates (FSR) calculated from L-[ring-2H5]-phenylalanine following 5 days of one-legged knee immobilization in 
the immobilized (IMMOB) and non-immobilized control (CON) legs of healthy, young men (n=12). Data were 
analyzed with a two-way repeated measures ANOVA and significant main effects of protein ingestion (P<0.05) 
and immobilization (P<0.001) were detected (for interaction P=0.16). 
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Similar results were observed when the intracellular L-[ring-2H5]-phenylalanine enrich-
ments were used as the precursor pool, with postabsorptive and postprandial myofibril-
lar FSRs being 30±19% (0.026±0.004 vs 0.051±0.008%.h-1; P<0.01) and 48±4% 
(0.032±0.003 vs 0.062±0.005%.h-1; P<0.01) lower, respectively, in the immobilized com-
pared with the control leg. Postprandial FSR calculations using L-[ring-2H5]-
phenylalanine required the use of a modestly disturbed precursor pool (Figure 2E). 
However, comparable postabsorptive and postprandial myofibrillar FSRs were observed 
when using the L-[1-13C]-leucine tracer which, following a readjustment in enrichments 
levels during the transition from fasted to fed, presented a steady state plasma precur-
sor pool in both conditions (Figure 2F). Specifically, postabsorptive (0.011±0.012 vs 
0.036±0.011%.h-1; P<0.01) and postprandial (0.023±0.003 vs 0.055±0.007%.h-1; P<0.01) 
myofibrillar FSRs were lower in the immobilized compared to control leg, respectively. 
Moreover, similar results were observed when the intracellular L-[1-13C]-leucine en-
richments were used as the precursor pool, with postabsorptive (0.018±0.004 vs 
0.053±0.015%.h-1; P<0.01) and postprandial (0.044±0.007 vs 0.102±0.014%.h-1; P<0.01) 
myofibrillar FSRs being lower in the immobilized compared with control leg, respective-
ly. Following protein ingestion, the increase in myofibrillar protein-bound L-[1-13C]-
phenylalanine enrichments were 53±18% lower in the immobilized compared with the 
control leg (0.007±0.002 and 0.015±0.002 MPE, respectively; P<0.05; Figure 4). 
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Figure 4 | Delta myofibrillar protein enrichment of L-[1-13C]-phenylalanine 4 h after the ingestion of 25 g
intrinsically L-[1-13C]-phenylalanine labelled protein following 5 days of one-legged knee immobilization in the 
immobilized (IMMOB) and non-immobilized control (CON) legs of healthy, young men (n=12). Data were 
analyzed with a paired t-test. * P<0.05 compared with CON.  
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mRNA and cell signaling analyses 
The skeletal muscle mRNA expression of genes implicated in the regulation of intracellu-
lar amino acid transport are presented in Figure 5. 
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Figure 5 | Skeletal muscle mRNA expression of LAT1 (A), PAT1 (B), SNAT2 (C) and CD98 (D) in the fasted and 
fed (4 h following ingestion of 25 g protein) state following 5 days of one-legged knee immobilization in the 
immobilized (IMMOB) and non-immobilized control (CON) legs of healthy, young men (n=12). Data were 
analyzed with two-way repeated measures ANOVAs. A: Significant main effect of protein ingestion (P<0.05). B: 
No significant effects. C: No significant effects. D: Significant main effect of protein ingestion (P<0.05). *P<0.05 
compared with corresponding fasted value.  
 
Muscle LAT1 mRNA expression (A) increased with protein ingestion (P<0.05) in both legs 
(by 87 and 57% for control and immobilized leg, respectively) with no effect of immobi-
lization. PAT1 (B) and SNAT2 (C) were not affected by protein ingestion or immobiliza-
tion. Muscle CD98 mRNA expression (D) increased with protein ingestion (P<0.05) in 
both legs (by 20 and 26% for control and immobilized leg, respectively) with no effect of 
immobilization. Muscle mRNA expression of genes involved in muscle protein break-
down and inflammation are shown in Figure 6. 
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Figure 6 | Skeletal muscle mRNA expression of MAFBx (A), MuRF1 (B), FOXO1 (C), TNFα (D) and IL-6 (E) in the 
fasted and fed (4 h following ingestion of 25 g protein) state following 5 days of one-legged knee immobiliza-
tion in the immobilized (IMMOB) and non-immobilized control (CON) legs of healthy, young men (n=12). Data 
were analyzed with two-way repeated measures ANOVAs. A: Significant main effect of immobilization
(P<0.05). B: Significant main effect of immobilization (P<0.01). C: Significant main effect of immobilization
(P<0.01). D: No significant effects. E: Significant main effect of protein ingestion (P<0.05). † P<0.05 compared 
with corresponding CON values. * P<0.05 compared with corresponding fasted value. 
 
Muscle MAFBx (A), MuRF1 (B) and FOXO1 (C) mRNA expression were all greater in the 
immobilized compared with control leg (all P<0.05) but were not affected by protein 
ingestion. Muscle TNFα mRNA expression was not affected by protein ingestion or im-
mobilization and muscle IL-6 mRNA expression increased with protein ingestion 
(P<0.05) but was not changed with immobilization. Figure 7 depicts the muscle phos-
phorylation status (presented as a ratio of phosphorylated to total protein) of key pro-
teins involved in the initiation of muscle protein synthesis. 
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Figure 7 | Muscle phosphorylation status (presented as a ratio of phosphorylated to total protein) of mTOR
(A) S6K (B), RS6 (C) and 4-EBP1 (D) in the fasted and fed (4 h following ingestion of 25 g protein) state follow-
ing 5 days of one-legged knee immobilization in the immobilized (IMMOB) and non-immobilized control (CON) 
legs of healthy, young men (n=12). Data were analyzed with two-way repeated measures ANOVAs. A: Signifi-
cant interaction effect (P<0.01). B: No significant effects. C: Significant main effect of feeding (P<0.01). D: 
Significant interaction effect (P<0.01). † P<0.05 compared with corresponding CON values. * P<0.05 com-
pared with corresponding fasted value.  
 
Protein ingestion increased the phosphorylation status of RS6 (C) in both legs (time 
effect; P<0.01) and a similar trend (P=0.14) was also observed for S6K1 (B). There was 
an interaction effect for mTOR (A) and 4-EBP1 (D) (both P<0.05) such that the immobi-
lized leg in the fed state showed lower phosphorylation status when compared with the 
corresponding control leg or fasted value. 
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D I S C U S S I O N  
The present study demonstrates that the loss of quadriceps muscle mass observed 
during merely five days of muscle disuse can be attributed to a decline in basal myofi-
brillar protein synthesis rates and a reduced capacity of skeletal muscle tissue to utilize 
dietary protein derived amino acids for de novo myofibrillar protein synthesis in healthy 
males.  
The present study demonstrates that the (~4%) loss of quadriceps cross-sectional 
area induced by 5 days of muscle disuse (Figure 1) is accompanied by an approximate 
halving of postabsorptive myofibrillar protein synthesis rates when compared with the 
non-immobilized, control leg (Figure 3). This striking decrease was comparable irrespec-
tive of whether the incorporation of L-[ring-2H5]-phenylalanine or L-[1-13C]-leucine was 
used to calculate myofibrillar protein synthesis rates. Our data demonstrate that the 
decline in basal muscle protein synthetic rate that occurs during more prolonged im-
mobilization and bed rest studies [2, 15, 16] occurs much more rapidly than previously 
thought. Extending on this, we report that the reduced capacity to synthesize muscle 
proteins in the postabsorptive state is pronounced in the contractile myofibrillar pro-
teins. Therefore, reduced basal myofibrillar protein synthesis rates can, at least in part, 
explain the considerable loss of muscle mass and function that rapidly occurs during 
only a few days of muscle disuse. As such, increasing basal myofibrillar protein synthesis 
rates should form a key therapeutic target for effective interventional strategies aiming 
to preserve muscle mass. 
Skeletal muscle is maintained by the successive daily stimulation of muscle protein 
synthesis rates following food intake [35]. Previous studies, employing more prolonged 
disuse protocols, have suggested that a reduced responsiveness to the anabolic proper-
ties of amino acids may develop with prolonged disuse [16-18]. However, determining 
muscle protein synthesis rates in response to the ingestion of a bolus of dietary protein 
has its technical difficulties. The measurement of fractional muscle protein synthesis 
rate requires precursor pool enrichments to remain in a relative steady state between 
serial muscle biopsy collections. However, the ingestion of a meal-like bolus of dietary 
protein disturbs tracer steady state by diluting the precursor pool. Previous workers 
have attempted to obviate this problem by co-ingesting free labelled amino acids [36], 
ingesting small repeated boluses of protein [37], or simply by making non-steady state 
calculations [18]. All these approaches have their specific methodological limitations 
when assessing postprandial muscle protein synthesis rates following ingestion of a 
single bolus of dietary protein [19]. Recently, we produced milk proteins intrinsically 
labelled with high L-[1-13C]-phenylalanine enrichment levels (>30 MPE) and lower levels 
of L-[1-13C]-leucine (~8-10 MPE). The high enrichment L-[1-13C]-phenylalanine levels 
allow us to directly assess the use of dietary protein derived phenylalanine for de novo 
muscle protein synthesis, whereas the lower L-[1-13C]-leucine enrichment allows us to 
match the plasma L-[1-13C]-leucine precursor pool enrichment during a primed constant 
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intravenous L-[1-13C]-leucine infusion. Using this approach, we have previously meas-
ured postprandial muscle protein synthesis rates under both steady and non-steady-
state precursor pool conditions as well as assessing the metabolic fate of the ingested 
protein derived amino acids [19]. Here, we show that protein ingestion increased mus-
cle protein synthesis rates above basal, postabsorptive values in the control leg 
(0.032±0.005 vs 0.044±0.003; Figure 3). Despite a rise in circulating plasma insulin and 
leucine concentrations known to be sufficient to support maximal protein anabolism 
(Figure 2) [38-40], postprandial myofibrillar protein synthesis rates were >50% lower in 
the previously immobilized leg when compared with the control leg (Figure 3). The low-
er postprandial muscle protein synthetic rates in the immobilized leg were observed 
independent of which tracer was used to calculate FSR. It should be noted, however, 
that protein ingestion did still increase FSR in both legs and the delta increase in FSR 
only tended to be lower in the immobilized leg. This suggests that the absolute rate of 
FSR was more affected than the relative FSR response to food ingestion. However, the 
postprandial incorporation of dietary protein derived L-[1-13C]-phenylalanine in myofi-
brillar protein was more than 50% lower in the immobilized versus control leg (Figure 5), 
supporting the concept that the anabolic response to feeding per se is diminished. Con-
sequently, a few days of disuse is followed by rapid onset of anabolic resistance of mus-
cle tissue to dietary protein ingestion, resulting in reduced postprandial myofibrillar 
protein accretion. It is therefore of important clinical relevance to evaluate strategies 
that can overcome disuse induced anabolic resistance and preserve muscle mass during 
short periods of muscle disuse. Effective strategies could include changing the amount 
[41, 42], type [43-46] or timing [47] of dietary protein administration, or applying mi-
metics for physical activity such as neuromuscular electrical stimulation [48, 49] to at-
tenuate muscle disuse atrophy [50]. The fact that disused muscle is still responsive to 
protein ingestion implies that interventional strategies aiming to preserve muscle mass 
during a period of disuse should minimize time spent in the postabsorptive state. 
Although anabolic resistance has now been reported in a variety of situations, the 
underlying mechanism(s) are poorly understood. Impairments could conceivably reside 
systemically (e.g. protein digestion and/or absorption [15, 43], or the postprandial hor-
monal response and subsequent microvascular perfusion [51, 52]) or locally at the mus-
cle tissue level (e.g. muscle amino acid uptake [53] and/or intramuscular signaling [54, 
55]). We have previously provided evidence to suggest that the responsible mecha-
nisms for disuse induced anabolic resistance are intracellular [18]. Intracellular muscle 
amino acid transport requires the presence of specific amino acid transporter proteins. 
Several of these amino acid transporters, including L-type amino acid transporter 1 
(LAT1), sodium coupled neutral amino acid transporter 2 (SNAT2) and CD98/SLC3A2 
(CD98), reside on the cell membrane, and are thought to work in concert to regulate 
intracellular amino acid flux. Proton assisted amino acid transporter (PAT1) is found in 
the lysosomal membrane and is thought to be instrumental in exporting amino acids 
from the lysosomal lumen into the cytosol. LAT1, SNAT2, CD98 and PAT1 mRNA and/or 
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protein expression have all been shown to increase and coincide with a rise in muscle 
protein synthesis following essential amino acid ingestion and/or a single bout of re-
sistance-type exercise [53, 56, 57]. Interestingly, the increased expression of LAT1 and 
SNAT2 following essential amino acid ingestion was shown to be blunted following 7 
days of bed rest [17]. Taken together, these data have led to the hypothesis that the 
amino acid transporter expression response to increased amino acid availability may 
regulate postprandial muscle protein synthesis [53, 58]. In the present study, we ob-
served no differences in amino acid transporter expression levels between the immobi-
lized and control leg (Figure 5). Our data confirm the responsiveness of amino acid 
transporter expression following protein ingestion but do not support the hypothesis 
that changes in amino acid transporter expression may be responsible for the local 
muscle disuse induced anabolic resistance. However, it should be acknowledged that 
we only present gene expression of these transporters, and this may not necessarily 
reflect their protein content and/or cellular location and involvement in amino acid 
transport.  
Postprandial stimulation of muscle protein synthesis rates is initiated by a phos-
phorylation cascade where mammalian target of rapamycin (mTOR) and its downstream 
targets P70S6 protein kinase (P70S6K/S6K1), ribosomal protein S6 (RS6) and eukaryotic 
translation initiation factor 4E binding protein 1 (4E-BP1) are of central importance [59, 
60]. Consistent with previous studies [e.g. 17, 61] we report that the ingestion of pro-
tein led to a modest general increase in the phosphorylation of these anabolic signaling 
proteins (Figure 7). Interestingly, immobilization significantly impaired postprandial 
activation of mTOR and its downstream target 4E-BP1 such that they actually decreased 
following protein ingestion; whereas P70S6K and its subsequent activation of S6K1 did 
not seem to be affected. Both the lack of robust feeding induced increases in phosphor-
ylation of these proteins in the control leg, as well as the decrease in phosphorylation in 
the immobilized leg may be explained by our study design which allowed the determi-
nation of anabolic signaling at a single postprandial time-point, 4 h following protein 
ingestion. Due to its role in initiating the translation process, peak stimulation of this 
signaling cascade generally occurs 1-2 h following protein ingestion [57, 61-63] and 
begins to subside thereafter [57, 61-63]. It may be speculated, therefore, that peak 
stimulation was missed and we are observing the residual activation of these anabolic 
proteins in the control leg, and the reduced phosphorylation in the disused leg repre-
sents a reduced transduction of the anabolic signal through mTOR/4E-BP1, impairing 
the assembly of the active eIF4F complex and/or via the suppression of translation initi-
ation [59]. Consistent with these findings, we have recently observed that lipid induced 
anabolic resistance is also characterized by an impairment of postprandial 4E-BP1 acti-
vation [64]. Collectively, our data point to an intracellular signaling defect that likely 
underpins anabolic resistance under diverse circumstances. Future work aiming to elu-
cidate the intracellular impairments underlying disuse induced anabolic resistance 
would likely require earlier and more frequent biopsy points to capture rapid, transient 
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changes and determine a detailed time-course of intracellular responses to protein 
ingestion following disuse. Moreover, employing dynamic measures of intracellular 
amino acid flux are required to discriminate between anabolic signaling defects per se 
and simply a reduced amino acid supply to the intracellular signaling pathways following 
disuse. A final interesting consideration in light of our cell signaling data is the inclusion 
of younger subjects. Using a retrospective, database analysis, it has recently been 
shown that ageing is associated with a hyperphosphorylation of mTOR in the fasted 
state [65]. Moreover, it has also been reported that mTOR/P70S6K responsiveness to 
protein ingestion may be enhanced in older muscle [66], despite a reduced muscle 
protein synthetic response. These findings suggest a reduced efficiency of older muscle 
in terms of signal transduction or, at least, an altered dynamic relationship between cell 
signaling and muscle protein synthesis. In the same way, it could also be speculated that 
disuse may also alter the efficiency and/or kinetics or feeding induced mTOR activation, 
underlining the importance of conducting future time course based studies. Conse-
quently, understanding the relationship between the relevant signaling pathways and 
muscle protein synthesis in disused young and older muscle remains an important fu-
ture research direction. 
Aside from changes in muscle protein synthesis, we assessed the gene expression of 
two primary ubiquitin ligases, Muscle Atrophy F-Box/atrogin-1 (MAFbx) and Muscle-
Specific RING-finger protein 1 (MuRF1), and their key transcription factor, fork head box 
protein 01 (FOXO1) [67, 68] to obtain insight into possible changes in muscle protein 
breakdown. In keeping with our previous work [7, 11], the expression of these genes 
were markedly elevated in the immobilized compared with the control leg (Figure 6). 
These data are consistent with previous assertions that a rapid and transient rise in 
muscle protein breakdown may contribute to muscle disuse atrophy [3, 69-71], though 
it should be noted that these static molecular data cannot be considered as conclusive 
evidence for alterations in muscle protein breakdown. Indeed, recent reports have 
suggested that MuRF1 may also have a pivotal role in inhibiting muscle protein synthet-
ic pathways [72] and thus could have contributed to the observed anabolic resistance. 
Although it has been suggested that a rapid rise in muscle protein breakdown at the 
onset of disuse may be provoked by a pro-inflammatory state [73, 74], we failed to 
detect any evidence of increased inflammation in the immobilized muscle tissue as 
indicated by IL-6 and TNFα gene expression (Figure 6). Irrespective of leg, protein inges-
tion resulted in a robust increase in IL-6 gene expression which likely reflects the shift in 
energy and substrate metabolism in the transition to the postprandial state, processes 
within which IL-6 plays a metabolic role [75, 76]. 
In conclusion, the present study demonstrates that a decline in postabsorptive myo-
fibrillar protein synthesis rates and an impaired capacity to utilize dietary protein de-
rived amino acids for de novo myofibrillar protein synthesis are key factors underlying 
short-term skeletal muscle disuse atrophy. Given the proposed role of muscle disuse in 
the development of age-related sarcopenia, it is critical that strategies aimed at stimu-
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lating muscle protein synthesis rates and/or overcoming anabolic resistance should be 
developed and applied as early as possible in an effort to preserve skeletal muscle mass 
and function. 
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A B S T R A C T  
Background Short periods of muscle disuse, due to illness or injury, result in sub-
stantial skeletal muscle atrophy. Recently we have shown that a single 
session of neuromuscular electrical stimulation (NMES) increases 
muscle protein synthesis rates. 
Aim  To investigate the capacity for daily NMES to attenuate muscle atro-
phy during short-term muscle disuse. 
Methods Twenty-four healthy, young (23±1 y) males participated in the present 
study. Volunteers were subjected to 5 days of one-legged knee immo-
bilization with (NMES; n=12) or without (CON; n=12) supervised NMES 
sessions (40 min sessions, twice daily). Two days prior to and immedi-
ately after the immobilization period, CT-scans and single leg one-
Repetition Maximum (1RM) strength tests were performed to assess 
quadriceps muscle cross-sectional area (CSA) and leg muscle strength, 
respectively. Furthermore, muscle biopsies were taken to assess mus-
cle fibre CSA, satellite cell content and mRNA and protein expression 
of selected genes. 
Results  In CON, immobilization reduced quadriceps CSA by 3.5±0.5% 
(P<0.0001) and muscle strength by 9±2% (P<0.05). In contrast, no sig-
nificant muscle loss was detected following immobilization in NMES 
although strength declined by 7±3% (P<0.05). Muscle MAFbx and 
MuRF1 mRNA expression increased following immobilization in CON 
(P<0.001 and P=0.07, respectively) whereas levels either declined 
(P<0.01) or did not change in NMES, respectively. Immobilization led 
to an increase in muscle myostatin mRNA expression in CON (P<0.05) 
but remained unchanged in NMES. 
Conclusion During short-term disuse, NMES represents an effective interventional 
strategy to prevent the loss of muscle mass, but it does not allow 
preservation of muscle strength. NMES during disuse may be of im-
portant clinical relevance in both health and disease. 
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I N T R O D U C T I O N  
Situations such as the recovery from illness or injury require otherwise healthy individu-
als to undergo short periods of bed rest or limb immobilization. Under these circum-
stances there is a rapid loss of skeletal muscle mass [1-3] that leads to reduced func-
tional capacity [1-4], loss of muscle strength [5], impaired insulin sensitivity [6], a de-
cline in basal metabolic rate [7, 8], and a concomitant increase in body fat mass [9-11]. 
As a consequence, the extent of disuse atrophy that occurs due to illness or injury has 
previously been identified as an important predictor of the duration of hospitalization 
and subsequent rehabilitation [12]. 
During periods of disuse, muscle atrophy occurs as a consequence of an imbalance 
between muscle protein synthesis and breakdown rates. Previous studies, employing 
either 10-14 days of bed rest [10, 13] or 2-6 weeks of limb immobilization [2, 14-16] as 
models of disuse, have demonstrated impairments in both fasting and postprandial 
muscle protein synthesis rates without any discernible changes in muscle protein 
breakdown [13, 17]. Maintaining a certain minimal level of physical activity during peri-
ods of muscle disuse can offset such impairments in postabsorptive or postprandial 
muscle protein synthesis rates [11, 18] and, as such, attenuate muscle tissue loss [19, 
20]. Unfortunately, in many clinical situations physical activity is temporarily not feasible 
or simply impossible and, thus, surrogates should be sought to alleviate muscle disuse 
atrophy. 
Neuromuscular electrical stimulation (NMES) offers an attractive alternative way to 
allow muscle contraction, thereby acting as a surrogate for habitual physical activity 
during periods of muscle disuse due to illness or injury. Recently, we applied contempo-
rary stable isotope methodology with repeated muscle biopsy sampling to demonstrate 
that a single session of NMES increases muscle protein synthesis rates for several hours 
in vivo in men [21]. Moreover, self-administered NMES has previously been shown to 
maintain muscle protein synthesis rates during long-term recovery from tibia fracture 
[14], and clinically applied NMES has shown beneficial effects on skeletal muscle func-
tion in patients recovering from surgery [22, 23] or suffering from severe cardiac com-
plications [24, 25]. However, to date, the capacity of supervised NMES as an interven-
tional strategy to counteract the loss of muscle mass and strength during a short period 
of disuse remains to be established. This may be of important clinical relevance as the 
loss of muscle mass and strength during short periods of bed rest or immobilization 
following illness or injury are believed to delay subsequent recovery and likely contrib-
ute substantially to the loss of muscle mass with ageing [26, 27]. 
In the present study we investigate the efficacy of NMES as a means to attenuate 
skeletal muscle disuse atrophy. We hypothesized that a twice daily supervised NMES 
program could preserve skeletal muscle mass and attenuate the loss of muscle strength 
during a 5 day period of leg immobilization. We assessed changes in muscle mass fol-
lowing 5 days of one-legged knee immobilization using a full leg cast in 24 healthy 
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young men with or without twice daily supervised NMES sessions. Muscle mass was 
assessed at a limb level using CT and DXA scans, whereas muscle biopsies were ob-
tained prior to and immediately after immobilization to assess changes in muscle fibre 
type characteristics and relevant myocellular signalling.  
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M E T H O D S  
Subjects 
A total of 24 healthy young males (age: 23±1 y; body mass: 76±2 kg; body mass index 
[BMI] 22±1 kg·m-2) were included in the present study which was approved by the Med-
ical Ethical Committee of the Maastricht University Medical Centre in accordance with 
the Declaration of Helsinki. Prior to the study, subjects completed a routine medical 
screening and general health questionnaire to ensure their suitability to take part. Ex-
clusion criteria were: BMI below 18.5 or above 30 kg·m-2; any back, knee or shoulder 
complaints which may interfere with the use of crutches; type 2 diabetes mellitus (de-
termined by HbA1c-values >7.0%); any family history of thrombosis; and/or severe car-
diac problems. Furthermore, subjects who had performed structured and prolonged 
resistance type exercise training during the 6 months prior to the study were also ex-
cluded. All subjects were informed of the nature and possible risks of the experimental 
procedures, before their written informed consent was obtained. During screening, an 
estimation of one-Repetition Maximum (1RM) single leg knee extension strength (Tech-
nogym, Rotterdam, the Netherlands) was made using the multiple repetitions testing 
procedure [28].  
 
 
Figure 1 | Schematic representation of the experimental protocol. NMES = Neuromuscular electrical stimula-
tion  
 
  
Time (days) 0 1 2 3 4 5-1-2
One-legged knee immobilization
Muscle biopsy + 
blood sample
CT + DXA scan
1RM
CON group
NMES group
= NMES session
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Study design 
After inclusion, subjects were randomly allocated into either the control (CON; n=12) or 
the neuromuscular electrical stimulation (NMES; n=12) group. The experimental proto-
col is depicted in Figure 1. Both groups underwent a 5 day period of muscle disuse in-
duced via one-legged knee immobilization by way of a full leg cast, either with (NMES 
group) or without (CON group) NMES performed twice daily under supervision at home. 
The leg to be immobilized was randomized and counter-balanced between left and 
right. On two separate test days, 48 h before and immediately after the immobilization 
period, single slice computed tomography (CT) scans were performed at the mid-thigh 
of both legs, whole-body dual energy x-ray absorptiometry (DXA) scans were taken, leg 
volume was measured by anthropometry [29], a single muscle biopsy and venous blood 
sample were collected, and one-legged knee extension strength (1RM) was assessed. 
Muscle mass and function 
Forty eight h prior to, and immediately after the immobilization period, subjects visited 
the laboratory in the fasted state for 2 identical test days (i.e. test days 1 and 2). During 
the test days, several measurements of muscle mass and function were performed. 
First, anatomical cross-sectional area (CSA) of the quadriceps muscle and whole thigh 
were assessed via a single slice CT scan (Philips Brilliance 64, Philips Medical Systems, 
Best, the Netherlands). The scanning characteristics were as follows: 120 kV, 300 mA, 
rotation time of 0.75 s, and a field of view of 500 mm. While the subjects were lying 
supine, legs extended and their feet secured, a 3 mm thick axial image was taken 15 cm 
proximal to the top of the patella. On test day 1, the precise scanning position was 
marked with semi-permanent ink for replication on test day 2. CT-scans were analysed 
for the CSA of the whole thigh muscle as well as the quadriceps by manual tracing using 
ImageJ software (version 1.46d, National Institute of Health, Maryland, USA)[30]. 
Thereafter, body composition and bone mineral content were measured via DXA-scan 
(Hologic, Discovery A, QDR Series, Bedford, MA, USA). Whole-body and regional lean 
mass were determined using the system’s software package Apex version 2.3. Leg vol-
ume of both legs was also assessed by anthropometry as described previously [29]. 
Maximal calf circumference of both legs was measured as part of the measurements to 
determine leg volume. Maximum strength was evaluated for each leg separately by 
one-Repetition Maximum (1RM) strength tests on a leg extension machine (Technogym, 
Rotterdam, the Netherlands). The estimations obtained during the screening visit were 
used to determine 1RM as described previously [31]. 
Blood and muscle sampling 
During test day 1, fasting venous blood samples were collected to determine basal 
plasma glucose and insulin concentrations. Blood (10 mL) was collected into EDTA-
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containing tubes and directly centrifuged at 1,000g for 10 min at 4°C. Aliquots of plas-
ma were immediately frozen in liquid nitrogen and stored at -80°C until further analysis. 
Plasma glucose concentrations (Glucose HK CP, ABX Diagnostics, ref. A11A01667, 
Montpellier, France) were analysed with a COBAS FARA semi-automatic analyser 
(Roche, Basel, Switzerland). Plasma insulin concentrations were determined by radio-
immunoassay (Millipore, ref. HI-14K, Billerica, MA, USA). Additionally, during test day 1 
and 2, a single muscle biopsy sample was collected from the leg previously selected for 
immobilization. After local anaesthesia was induced, percutaneous needle biopsy sam-
ples were collected from the vastus lateralis muscle, approximately 15 cm above the 
patella [32]. Any visible non-muscle tissue was removed immediately, and part of the 
biopsy sample was embedded in Tissue-Tec (Sakura Finetek, Zoeterwoude, the Nether-
lands) before being frozen in liquid nitrogen-cooled isopentane, while another part was 
immediately frozen in liquid nitrogen. Muscle samples were subsequently stored at -
80°C until further analyses. 
Leg immobilization 
Forty eight h following test day 1, a full leg cast (randomized and counterbalanced for 
left and right legs) was applied in the plaster room of the Academic Hospital in Maas-
tricht at 8:00 on the first day of the immobilization period. The leg cast extended from 
~5 cm above the ankle until ~25 cm above the patella (i.e. approximately halfway up the 
upper leg). The cast was set so the knee joint was placed at a ~30 degree angle of flex-
ion to prevent subjects from performing weight-bearing activities with the casted leg. 
The immobilization period always comprised 3 week days and 2 weekend days. Addi-
tionally, for subjects assigned to the NMES group, placement of the electrodes for 
NMES was determined prior to fitting the cast (described below) and a small ‘window’ 
(a rectangle of approximately 12 × 6 cm) was cut in the cast ~5 cm above the knee. 
Following the removal of this window, the section of cast was placed back from where it 
was removed and bandaged firmly in place. Subjects were given crutches and instructed 
on their correct usage before being provided with transportation home. Application of 
the cast signified the beginning of the immobilization period which continued for 5 d, 
after which the cast was removed at 8.00 at the plaster room immediately prior to per-
forming test day 2. 
Neuromuscular electrical stimulation 
For subjects allocated to the NMES group, two NMES sessions were performed each 
day at the subjects’ home for the duration of the 5 day immobilization period (i.e. 10 
sessions in total). Neuromuscular electrical stimulation sessions were performed in the 
morning (7.00-12.00) and afternoon (13.00-18.00), with a minimum of 4 h between 
sessions. During each session, with the subject lying supine with a pillow placed under 
the knee to obviate the flexion angle, the window was removed from the cast and elec-
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trodes were placed on the distal part at the muscle belly of the m. rectus femoris and 
the m. vastus lateralis, and at the inguinal area of both muscles. The position of the 
electrodes was re-marked each day with semi-permanent ink to ensure that location of 
the electrodes was not altered between sessions. 
Stimulation was provided by an Enraf Nonius TensMed S84 stimulation device (Enraf 
Nonius, Rotterdam, the Netherlands) and 4, 2 mm-thick, self-adhesive electrodes (50 x 
50 mm; Enraf Nonius), discharging biphasic symmetric rectangular-wave pulses. The 
NMES protocol consisted of a warm-up phase (5 min, 5 Hz, 250 µs), a stimulation period 
(30 min, 100 Hz, 400 µs, 5 s on (0.75 s rise, 3.5 s contraction, 0.75 s fall) and 10 s off), 
and a cooling-down phase (5 min, 5 Hz, 250 µs). Subjects set the intensity of the stimu-
lation to a level at which full contractions of m. quadriceps femoris were visible and 
palpable, and the heel began to slightly lift. This protocol was based on our previous 
work [21] demonstrating an acute increase in muscle protein synthesis following a sin-
gle bout of NMES and selected due to previous work using high-frequency (>60 Hz), 
high pulse duration (>250 µs) NMES [33, 34]. Researchers encouraged subjects to in-
crease the intensity of the stimulation during each subsequent session to provide a 
‘progressive’ stimulus. 
Dietary intake 
On the evening prior to both test days subjects received a standardized meal containing 
2900 kJ providing 51 Energy% (En%) as carbohydrate, 32 En% as fat, and 17 En% as 
protein. Subjects completed weighted dietary intake records for the 5 day duration of 
the immobilization period as well as on a separate consecutive 5 day occasion before 
the immobilization period. The same 5 days of the week were selected for both record-
ing periods. Dietary intake records were analysed with DieetInzicht software, based on 
NEVO table 2011. 
Muscle analyses 
The portion of the muscle biopsies frozen and mounted in Tissue-Tek was cut into 5µm 
thick cryosections using a cryostat at -20°C. Pre and post samples from one control and 
one NMES subject were mounted together on uncoated, pre-cleaned glass slides. Care 
was taken to correctly align the samples for cross-sectional fibre analyses. Muscle biop-
sies were stained for muscle fibre typing (FT) and satellite cell (SC) content as described 
in detail previously [35]. In short, slides were incubated with primary antibodies directed 
against myosin heavy chain (MHC)-I (A4.840, dilution 1:25; Developmental Studies Hy-
bridoma Bank, Iowa City, IA), laminin (polyclonal rabbit anti-laminin, dilution 1:50; Sigma, 
Zwijndrecht, the Netherlands) and CD56 (dilution 1:40; BD Biosciences, San Jose, CA). 
The following appropriate secondary antibodies were applied: goat anti-mouse IgM 
AlexaFluor555, goat anti-rabbit IgG AlexaFluor647, and Streptavidin Alexa 488 (dilution 
1:500, 1:400, and 1:200, respectively; Molecular Probes, Invitrogen, Breda, the Nether-
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lands). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, 0.238 µM; Molecu-
lar Probes). Images were captured at 10x magnification with a fluorescent microscope 
equipped with an automatic stage, and analysed using ImageJ software (version 1.46r, 
National Institute of Health [30]). Mean numbers of 184±17 and 220±22 muscle fibres 
were analysed in the biopsy samples collected pre and post immobilization, respectively. 
The portion of the muscle biopsy sample immediately frozen in liquid nitrogen was 
used to determine mRNA and protein expression of several target genes as described 
previously [36]. In short, total RNA was isolated from 10-20 mg of frozen muscle tissue, 
which was then quantified spectrophotometrically. Thereafter, RNA purity was deter-
mined and cDNA synthesis was performed, and Taqman PCR was carried out as report-
ed previously using 18S as a housekeeping gene [37]. Taqman primer/probe sets were 
obtained from Applied Biosystems (Foster City, USA) for the following genes of interest: 
mammalian target of rapamycin (mTOR), P70S6 kinase (P70S6K), myogenic factor 4 
(myogenin), MyoD, myostatin, Atrogen-1/Muscle Atrophy F-box (MAFbx), Muscle RING-
finger protein-1 (MuRF1), Forkhead box protein O1 (FOXO1), Focal Adhesion Kinase 
(FAK), large neutral amino acid transporter 1 (LAT1) and Proton-coupled amino acid 
transporter 1 (PAT1). Ct values of the target genes were normalized to Ct values of the 
internal control 18S, and final results were calculated as relative expression against the 
standard curve. 
Muscle samples (∼40 mg) for Western blotting analyses were analysed as described 
previously [37]. The antibodies used in this study were anti Myostatin (52 kDa; dilution 
1:500; rabbit polyclonal IgG; Santa Cruz sc-6885-R), anti MyoD (37 kDa; dilution 1:1000; 
rabbit polyclonal IgG; Santa Cruz sc-760), anti Myogenin (34 kDa; dilution 1:500; rabbit 
polyclonal IgG; Santa Cruz sc-576) and anti α-actin (42 kDa; dilution 1:160.000, mouse 
monoclonal IgM; Sigma A2172). 
Statistics 
All data are expressed as means±standard error of the mean (SEM). Baseline character-
istics between groups were compared by means of an independent samples t-test. Pre- 
versus post-intervention data were analysed using repeated-measures ANOVA with 
time (pre vs post) as within-subjects factor and treatment (CON vs NMES) as between-
subjects factor. Pearson’s Correlation Coefficient was used to test for significant correla-
tions. For the muscle fibre analysis, fibre type (type I vs type II) was added to the re-
peated-measures ANOVA as a within-subjects factor. In case of a significant interaction, 
paired t tests were performed to determine time effects within groups or within type I 
or II fibres and independent t tests for group differences in the pre- and post-
intervention values. Statistical significance was set at P<0.05. All calculations were per-
formed using SPSS version 20.0 (Chicago, IL, USA).  
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R E S U L T S  
Subjects 
Subjects’ characteristics are provided in Table 1. No differences between the control 
(CON) and neuromuscular electrical stimulation (NMES) group were observed for any of 
the parameters. 
 
Table 1 | Subjects’ characteristics 
 CON (n=12) NMES (n=12) 
Age (y) 22 ± 1 23 ± 1 
Body mass (kg) 74.4 ± 3.5 77.7 ± 2.2 
Height (m) 1.84 ± 0.03 1.84 ± 0.02 
BMI (kg·m-2) 21.9 ± 1.0 23.1 ± 0.7 
Leg volume (L) 8.23 ± 0.50 8.15 ± 0.30 
Glucose (mmol·L-1) 5.01 ± 0.11 5.08 ± 0.07 
Insulin (mU·L-1) 8.77 ± 0.70 8.93 ± 1.01 
HOMA-index 1.97 ± 0.18 2.03 ± 0.26 
Glycated haemoglobin (%) 5.1 ± 0.1 5.4 ± 0.1 
Values are means±SEM. Abbreviations: BMI, Body Mass Index; HOMA-index, Homeostatic Model Assessment 
Index [38]. 
Dietary intake 
During the 5 days of immobilization the daily energy intake averaged 8.5±0.7 and 
8.7±0.6 MJ·day-1 in the CON and NMES group, respectively, with average daily protein 
intakes of 1.01±0.04 and 1.00±0.08 g·kg body weight-1·day-1. For both energy intake and 
protein intake, no significant interaction effects were found. 
Neuromuscular electrical stimulation 
The intensity of the NMES intervention for subjects in the NMES group averaged 
20.8±1.6 mA during the first session and was progressively increased to 42.2±3.7 mA in 
the final session. The average NMES intensity across all sessions and all subjects was 
30.6±2.2 mA. 
Muscle mass  
For quadriceps muscle CSA, a significant time*treatment interaction was observed in 
the immobilized leg (Figure 2; P<0.001). Quadriceps CSA in the CON group had de-
creased by 3.5±0.5% (from 7504±342 to 7238±324 mm2; P<0.001), whereas in the 
NMES group no significant decrease in quadriceps CSA was detected (from 7740±259 to 
 NMES prevents short-term muscle disuse atrophy | 81 
7675±254 mm2: P=0.07). In agreement, a significant time*treatment interaction 
(P<0.001) was also observed for changes in CSA of the whole-thigh muscle, which 
showed a 3.7±0.6% decrease in the CON group (P<0.001), with no changes in the NMES 
group (-0.5±0.4%: P=0.192). In the non-immobilized leg, quadriceps and thigh muscle 
CSA did not show any changes following 5 days of immobilization in both the CON and 
NMES group. 
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Figure 2 | Cross-sectional area (CSA) of m. quadriceps femoris in the CON and NMES group, before and after 5 
days of one-legged knee immobilization, as measured by single-slice CT scan. Data were analysed with a 
Repeated Measures ANOVA, and demonstrated a significant time*treatment interaction (P=0.001). Data are 
expressed as means±SEM. * P<0.05; significantly different when compared with pre-immobilization values. 
 
In line with the data on muscle CSA, a significant time*treatment interaction was ob-
served for leg lean mass (P<0.05). Subjects in the CON group lost on average 147±72 g 
of muscle tissue in the immobilized leg, representing 1.4±0.7% loss of leg muscle tissue 
(P=0.066). In contrast, the NMES group showed an increase of 209±82 g (1.9±0.7%) in 
the immobilized leg after 5 days of immobilization (P<0.05). No changes over time in leg 
lean mass were detected in the non-immobilized leg of subjects in the CON and NMES 
group (P>0.05). 
For leg volume and calf circumference, no changes over time (time effect, P>0.05) 
or between groups (interaction effect, P>0.05) were observed. 
Scatter plots for correlations between NMES intensity and key outcome measures 
are presented as supplemental information in Figure 5. No significant correlations were 
found between the NMES intensity and delta quadriceps CSA (Figure 5A), delta muscle 
strength (Figure 5B), and delta leg lean mass (Figure 5C), respectively. 
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Muscle strength 
For muscle strength, a significant main effect of time (P=0.001) was detected in the 
immobilized leg such that one-legged 1RM declined by 9.0±2.2% (from 77.9±3.9 to 
71.1±4.1 kg) and 6.5±3.2% (from 78.3±4.5 to 72.9±4.4 kg) in the CON and NMES groups, 
respectively, with no differences between groups. Muscle strength in the non-
immobilized leg increased in both groups (time effect, P<0.05); from 78.8±4.4 to 
81.5±4.9 kg in the CON group and from 76.9±3.1 to 81.9±3.4 kg in the NMES group. 
 
Table 2 | Muscle fibre characteristics 
  CON NMES 
 Fibre type Pre Post Pre Post 
Muscle fibre CSA (µm2) I 5259 ± 328 5378 ± 392 5676 ± 424 5493 ± 430 
 II 6680 ± 328 * 6316 ± 441 5885 ± 426 6412 ± 586 † 
% Fibre (number) I 43 ± 3 45 ± 4 52 ± 3 46 ± 3 
 II 57 ± 3 * 55 ± 4 48 ± 3 54 ± 3 
Nuclei per fibre I 2.8 ± 0.2 2.9 ± 0.2 2.9 ± 0.2 2.7 ± 0.2 
 II 3.3 ± 0.1 3.3 ± 0.2 2.9 ± 0.2 2.9 ± 0.2 
Myonuclear domain (µm2) I 1910 ± 57 1848 ± 68 1944 ± 87 1997 ± 63 
 II 2057 ± 103 * 1935 ± 79 2004 ± 89 2233 ± 83 # 
Number of SCs per fibre I 0.090 ± 0.007 0.109 ± 0.009 0.115 ± 0.011 0.106 ± 0.010 
 II 0.072 ± 0.006 0.075 ± 0.007 0.075 ± 0.011 * 0.060 ± 0.007 
Number of SCs per mm2 I 17.3 ± 0.3 20.8 ± 1.7 20.8 ± 2.0 19.2 ± 1.4 
 II 11.5 ± 1.4 * 12.5 ± 1.6 12.5 ± 1.4 * 9.6 ± 1.0 
SCs per myonuclei (%) I 3.3 ± 0.2 3.8 ± 0.3 4.0 ± 0.4 3.8 ± 0.3 
 II 2.2 ± 0.2 * 2.4 ± 0.3 2.5 ± 0.3 * 2.1 ± 0.2 
Data represent means±SEM. Abbreviations: CSA, cross-sectional area; SC, satellite cell; SCs per myonuclei (%), 
the number of SCs as a percentage of the total number of myonuclei (i.e. number of myonuclei + number of 
SCs). * Significantly different from type I fibre value (P<0.05). † Signiﬁcantly diﬀerent from pre value in NMES 
group. # Significantly different from CON post-immobilization value (P<0.05) 
Muscle fibre characteristics 
Muscle fibre characteristics are displayed in Table 2. Before the intervention, no signifi-
cant difference was observed in type I and type II muscle fibre CSA between groups. A 
significant time*treatment*fibre type interaction was observed for muscle fibre CSA 
(P<0.001). Separate analyses showed no significant change in both type I and type II 
muscle fibre CSA in the CON group after immobilization. In contrast, we observed a 
significant increase in type II muscle fibre CSA in the NMES group over time (from 5885 
± 426 to 6412 ± 586 µm2; P<0.05), whereas in type I fibres no time effect was observed 
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(P>0.05). Fibre distribution showed no differences at baseline between groups, and did 
not change over time in both groups (P>0.05). 
For myonuclear domain size, a significant time*treatment*fibre type interaction was 
observed (P<0.05) and an overall effect of fibre type (P<0.001), with larger myonuclear 
domain sizes in type II vs. type I fibres in both the CON and NMES group. No changes in 
type I myonuclear domain size were found (P>0.05), while a significant time*treatment 
interaction was observed in type II fibres (P<0.05) caused by a greater myonuclear do-
main in the NMES vs. CON group after immobilization. At baseline, no differences in SC 
content were observed between groups (P>0.05). In addition, no changes over time 
were found for type I and type II SC content expressed per muscle fibre, per millimetre 
squared, or as a percentage of the total number of myonuclei (P>0.05 for all three pa-
rameters). 
mRNA and protein expression 
Figure 3 and 4 display the relative expression in skeletal muscle mRNA of selected genes 
of interest in the CON and NMES group, two days prior to and immediately following 5 
days of one-legged knee-immobilization. No differences in mRNA expression of selected 
genes were observed between CON and NMES at baseline. For muscle myostatin mRNA 
expression, a significant time*treatment interaction was observed (Figure 3A; P<0.05). 
Separate analysis showed a 68% increase following immobilization in the CON group 
(P<0.05), whereas a trend for a decline was observed in the NMES group (P=0.075). For 
muscle mRNA expression of MyoD (Figure 3C) and myogenin (Figure 3E) a significant 
increase was observed over time (P<0.05 and P<0.01, respectively), with no differences 
between groups.  
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Figure 3 | Skeletal muscle mRNA expression of myostatin, MyoD and myogenin in the CON and NMES group 
before and after 5 days of one-legged knee immobilization. Data were analysed with a Repeated Measures 
ANOVA, and expressed as means±SEM. * P<0.05; significantly different when compared with pre-
immobilization values. 
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Figure 4 | Skeletal muscle mRNA expression of selected genes of interest in the CON and NMES group before 
and after 5 days of one-legged knee immobilization. Data were analysed with a Repeated Measures ANOVA. * 
P<0.05; significantly different when compared with pre-immobilization values. Data are expressed as 
means±SEM. Abbreviations: MAFbx, Muscle Atrophy F-box; MuRF1, Muscle RING-finger protein-1; FOXO1, 
Forkhead box protein O1; FAK, Focal Adhesion Kinase; LAT1, large neutral amino acid transporter 1; PAT1, 
Proton-coupled amino acid transporter 1. 
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A significant time*treatment interaction was observed for the mRNA expression of 
muscle MAFbx (Figure 4A; P<0.001) and MuRF1 (Figure 4B; P<0.05). MAFBx mRNA ex-
pression was upregulated in the CON group (48%; P<0.001), whereas in the NMES 
group a decline was observed (35%, P<0.05). MuRF1 mRNA expression tended to in-
crease in the CON group (56%, P=0.066), while no change over time was observed in 
the NMES group (P>0.05). No significant changes occurred over time or between groups 
in the muscle mRNA expression of FOXO1 (Figure 4C), mTOR (Figure 4E) or FAK (Figure 
4D). A significant time*treatment interaction was observed for the muscle mRNA ex-
pression of P70S6K (Figure 4F; P<0.05), with an 18% upregulation following immobiliza-
tion in the CON group (P<0.01), whereas no change was observed in the NMES group 
(P>0.05). Muscle mRNA expression of the amino acid transporters LAT1/SLC (Figure 4G) 
and PAT1 (Figure 4H) had significantly increased following immobilization (both P<0.05), 
with no differences between groups. 
Protein expression of myostatin, myoD and myogenin are presented in Figure 3. For 
both myostatin and MyoD, no changes in protein expression were observed (both 
P>0.05). Myogenin protein expression tended to increase following immobilization 
(P=0.054) with no differences between groups (P=0.122 for time*treatment interaction). 
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D I S C U S S I O N  
In the present study, we demonstrated that neuromuscular electrical stimulation 
(NMES) prevented skeletal muscle atrophy to occur during 5 days of one-legged knee 
immobilization. However, NMES could not rescue the loss of muscle strength during this 
short period of disuse. Moreover, we report that the molecular changes associated with 
muscle disuse atrophy can largely be prevented by the daily application of NMES. 
Skeletal muscle disuse leads to a loss of muscle mass and strength and is accompa-
nied by numerous negative health consequences [1-4, 6-11]. Based on previous studies, 
the rate of muscle loss during experimental lower limb immobilization is approximately 
0.5% per day [27, 39]. However, this loss does not appear to be linear with higher rates 
of muscle loss occurring during the first few days of disuse [40]. In the present study we 
report that merely 5 days of one-legged knee immobilization significantly decreased 
quadriceps muscle cross-sectional area by 3.5% in a group of healthy young males (Fig-
ure 2; CON group), representing ~150 g of muscle tissue lost from the immobilized leg. 
When translating our observations of muscle loss in a single limb to a whole-body level, 
assuming that 60% of whole-body muscle loss occurs in the lower limbs, patients could 
lose as much as 1 kg of muscle tissue during 5 days of bed rest [5, 41]. This is consistent 
with previous studies investigating the impact of 10 days of bed rest [13, 41]. Further-
more, the 5 days of leg immobilization also resulted in a substantial 9.0±2.2% decline in 
leg strength. Clearly, these data demonstrate the impact of short periods of muscle 
disuse on muscle mass and strength and underline the clinical relevance to develop 
effective interventional strategies to attenuate muscle disuse atrophy and associated 
negative health consequences. 
The use of NMES has been proposed as an interventional strategy to alleviate mus-
cle loss in a variety of clinical conditions [14, 22-25]. Recently, we showed that a single 
NMES session stimulates muscle protein synthesis in vivo in men [21]. In the current 
study, we investigated whether the application of daily NMES could attenuate the loss 
of muscle mass during a short period of muscle disuse. Strikingly, the application of 
supervised NMES performed twice daily on the immobilized leg entirely prevented any 
disuse atrophy (Figure 2), with no measurable loss of muscle observed in the NMES 
group (-0.8±0.4%; P>0.05). Given the inherent variability of the measurement of muscle 
fibre size [42], we were unable to detect specific muscle fibre atrophy following only 5 
days of disuse in the control group (Table 2). However, we did detect a small but signifi-
cant increase in type II muscle fibre size following immobilization in the group receiving 
NMES. These data suggest that high-frequency NMES may exert its protective effect on 
skeletal muscle disuse atrophy predominantly through the recruitment of type II muscle 
fibres. This is of significant relevance as muscle loss due to more prolonged disuse [43, 
44] and/or ageing [45, 46] has been attributed to specific type II muscle fibre atrophy 
[42]. It is important to view the present data in the context of the potential clinical ben-
efits of applying NMES to preserve muscle mass during relatively short periods of mus-
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cle disuse. Previously, NMES has generally been applied during rehabilitation [47, 48], 
when muscle mass has already been lost and has to be regained. However, in the pre-
sent study we clearly demonstrate the relevance of applying NMES during a period of 
disuse or bed rest to prevent muscle tissue loss. 
Muscle disuse atrophy is generally accompanied by a substantial decline in muscle 
strength and impairments in functional capacity [1-3]. Previous studies performing one-
legged knee immobilization have reported a decline in muscle strength ranging from 0.4 
[49] to 4.2% per day [50] with an average muscle strength loss of ~1.3% per day [27]. In 
the present study, we report that 5 days of limb immobilization resulted in a 9.0% loss 
of leg muscle strength (representing an average daily loss of 1.8% per day). Consistent 
with earlier reports [4, 50, 51], we show a greater relative decline in muscle strength 
when compared to the loss of muscle mass. This is in agreement with previous sugges-
tions that neuromuscular deconditioning during the early stages of training or disuse is 
mainly responsible for the rapid changes in muscle strength [52, 53]. This also explains 
why the decline in muscle strength in the control group was only partially rescued with 
NMES (-6.5±3.2%). We speculate that the application of NMES will likely further attenu-
ate muscle strength loss during more prolonged periods of muscle disuse, when muscle 
mass loss becomes the key determinant of the decline in muscle strength. In agree-
ment, previous work assessing the impact of prolonged NMES training has been shown 
to effectively increase muscle strength in healthy young subjects [33, 34], in CHD pa-
tients [54] and in patients suffering from septic shock [55]. 
Aside from assessing the impact of NMES on muscle mass and strength during a pe-
riod of disuse, we also investigated some of the myocellular mechanisms that may be 
responsible for the NMES mediated prevention of muscle mass loss during immobiliza-
tion. Skeletal muscle satellite cells (SCs) are essential for repair, maintenance and 
growth of myofibres [56-58]. Moreover, we have previously reported that type II fibre 
specific atrophy associated with ageing [59] and spinal cord injury [60] is also accompa-
nied by a decline in SC content in these fibres. In the present study, we hypothesized 
that a better maintenance of muscle SC content in the NMES group contributes to the 
preservation of muscle mass. However, short-term immobilization did not alter SC con-
tent in either type I or II fibres in either the control or NMES group (Table 2). As such, 
the present data suggest that changes in SC content are not instrumental in the early 
development of disuse atrophy, nor the NMES mediated prevention of muscle loss. 
However, it cannot be ruled out that the rate of SC proliferation may be of more rele-
vance during muscle atrophy (or NMES mediated prevention of muscle loss) observed 
over a more prolonged period of disuse [61]. Furthermore, we determined the mRNA 
and protein expression of key signalling proteins thought to be important in the regula-
tion of muscle maintenance. Myostatin is regarded as a negative regulator of muscle 
mass in vivo [62, 63], primarily by inhibiting myogenesis [64, 65] via its inhibitory action 
on the myogenic regulatory factors [66], notably MyoD and myogenin [67, 68]. Con-
sistent with the proposed role of myostatin, we report an increased mRNA expression in 
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the CON group that was prevented in the NMES group (Figure 3). Moreover, the signifi-
cant increase in the mRNA expression of MyoD and myogenin seemed to be larger in 
the NMES group but was observed in both groups, while this did not result in an in-
creased muscle protein expression (Figure 3). Collectively these data are consistent with 
a role for myostatin in the NMES mediated maintenance of muscle mass during disuse. 
Increased rates of muscle protein breakdown have been suggested to play a role in 
short-term (<10 days) muscle disuse atrophy [27, 69]. Muscle protein breakdown in 
humans is thought to be regulated primarily by the ubiquitin-proteasome pathway, with 
key roles for the ubiquitin ligases MAFbx and MuRF1 [70, 71], and their upstream tran-
scription factor FOXO1 [72]. In accordance, in the present study we report that both 
MAFbx and MuRF1 mRNA expression increase with immobilization (Figure 4). Strikingly, 
these effects were prevented in the NMES group, suggesting that NMES may also help 
to preserve muscle mass during disuse by preventing an increase in muscle protein 
breakdown. 
In the present study we applied NMES to the quadriceps only. This muscle group is 
particularly susceptible to muscle loss during whole-body disuse [5] and is functionally 
important to allow proper performance of daily living activities. From a clinical perspec-
tive, it could be speculated that multiple muscle groups should be targeted with NMES 
to ensure muscle mass maintenance during whole-body disuse. Although extending the 
use of NMES to multiple muscle groups could introduce practical constraints (e.g. skin 
irritation, antagonistic contractions, time constraints), optimizing such protocols will 
allow (more) effective clinical use of NMES. Given the role of skeletal muscle mass in 
metabolic homeostasis, muscle preservation during disuse would likely have a positive 
impact on preserving both metabolic health [73] and functional capacity. 
The present study clearly demonstrates that merely a few days of disuse will lead to 
substantial loss of muscle mass and strength. Furthermore, NMES is identified as an 
effective interventional strategy to preserve muscle mass during such short periods of 
disuse. These data are of important clinical relevance as hospitalization following acute 
illness or injury is generally accompanied by a hospital stay of ~6 days [74]. The loss of 
muscle mass and strength during such short (successive) periods of muscle disuse im-
pairs functional capacity and hinders the subsequent rehabilitation upon discharge. In 
fact, it is now much speculated that the development of sarcopenia in the older popula-
tion is, at least partly, attributed to the muscle loss that is experienced during short, 
successive periods of muscle disuse due to illness or injury occurring over the latter 2-3 
decades of our lifespan [26, 40]. The use of NMES could also be of particular relevance 
to other patient groups and populations suffering from muscle atrophy, such as athletes 
recovering from injury [75], mechanically ventilated patients [55], spinal cord injured 
subjects [60], and post-surgery patients [23]. Preventing or attenuating the loss of mus-
cle mass and strength during limb immobilization or bed rest likely minimizes the bur-
den of muscle disuse, shortens hospital stay, and facilitates subsequent rehabilitation in 
both health and disease. 
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In conclusion, NMES represents an effective interventional strategy to prevent the 
loss of muscle mass during short periods of muscle disuse. This is likely attributed to a 
stimulation of muscle protein synthesis and suppression of muscle protein breakdown. 
NMES forms a feasible strategy to prevent muscle loss and support subsequent rehabili-
tation during short periods of muscle disuse due to illness or injury. 
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A B S T R A C T  
Background Fully-sedated patients, being treated in the ICU, experience substan-
tial skeletal muscle loss. Consequently, survival rate is reduced and full 
recovery after awakening is compromised. Neuromuscular electrical 
stimulation (NMES) represents an effective method to stimulate mus-
cle protein synthesis and alleviate muscle disuse atrophy in healthy 
subjects. 
Methods We investigated the efficacy of twice-daily NMES to alleviate muscle 
loss in six fully-sedated ICU patients admitted for acute critical illness 
(n=3 males, n=3 females; age 63±6 y; APACHE II disease severity-
score: 29±2). One leg was subjected to twice-daily NMES of the quad-
riceps muscle for a period of 7±1 d while the other leg acted as non-
stimulated control (CON). Directly before the first and on the morning 
after the final NMES session, quadriceps muscle biopsies were collect-
ed from both legs to assess muscle fibre-type specific cross-sectional 
area (CSA). Furthermore, phosphorylation status of key proteins in-
volved in the regulation of muscle protein synthesis was assessed, and 
mRNA expression of selected genes was measured. 
Results  In the CON leg, type I and type II muscle fibre CSA decreased by 16±9 
and 24±7%, respectively (P<0.05). No muscle atrophy was observed in 
the stimulated leg. NMES increased mTOR phosphorylation by 19% 
when compared to baseline (P<0.05), with no changes in the CON leg. 
Furthermore, mRNA expression of key genes involved in muscle pro-
tein breakdown either declined (FOXO1; P<0.05) or remained un-
changed (MAFBx and MuRF1), with no differences between legs. 
Conclusion In conclusion, NMES represents an effective and feasible intervention-
al strategy to prevent skeletal muscle atrophy in critically ill, comatose 
patients. 
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I N T R O D U C T I O N  
Critically ill patients suffer from extensive muscle wasting, which occurs rapidly at the 
onset of an ICU stay [1-3]. Aside from an increased risk of mortality [4, 5], consequences 
to this muscle loss include muscle weakness, prolonged mechanical ventilation, fatigue, 
decreases in muscle strength, impaired glucose homeostasis and delayed recovery and 
rehabilitation [6-9]. Muscle atrophy in ICU patients exceeds that seen in normal hospi-
talized or bedridden persons [10, 11]. Moreover, ICU patients who are mechanically 
ventilated and deeply sedated are thought to be even more susceptible to muscle wast-
ing and subsequent negative health consequences due to a complete lack of muscle 
contraction. Despite this, no data are currently available concerning muscle fibre atro-
phy in this specific ICU patient subpopulation. 
Early ambulation has been proven a successful rehabilitation strategy in non-
sedated ICU patients in terms of improving functional outcomes and overall prognosis 
[12]. However, in fully-sedated patients, early ambulation is not feasible and, as such, 
alternative strategies should be defined to alleviate muscle wasting. Neuromuscular 
electrical stimulation (NMES) is an effective means to invoke involuntary muscle con-
tractions. Previously, NMES has been shown to attenuate the loss of muscle mass and 
strength experienced by non-sedated ICU patients [13] and healthy individuals subject-
ed to limb immobilization [14]. However, the potential for NMES to rescue muscle mass 
in fully-sedated, comatose ICU patients has not been investigated. In the present study, 
we investigated our hypothesis that daily NMES attenuates skeletal muscle fibre atro-
phy in fully-sedated, comatose ICU patients. Fully-sedated ICU patients, expected to be 
sedated for a minimum of three days, were included in the present study. NMES was 
performed twice-daily on the quadriceps of one leg, whereas the other leg served as a 
sham-treated control. Prior to and immediately after the intervention, plasma samples 
were taken to assess any systemic changes in amino acid availability during the experi-
ment, and muscle biopsies were taken from both legs to assess muscle fibre atrophy 
and myocellular characteristics. Additionally, RT-PCR and Western blotting were per-
formed on collected muscle tissue samples to assess the potential impact of NMES on 
basal mRNA and protein expression levels of key genes involved in the regulation of 
muscle mass maintenance.  
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M E T H O D S  
Patients 
All patients admitted to the Intensive Care Unit (ICU) of Jessa Hospital, Hasselt, Belgium 
between March 2012 and July 2013 were assessed for eligibility for the present study 
(see Supplemental Figure 1). Patients admitted to the ICU were screened by the nursing 
staff, and were excluded if one or more of the following exclusion criteria were met: 
<18 or >80 y old, not expected to undergo complete sedation, suffering from spinal 
cord injury, recent arterial surgery on the legs, local wounds that prohibit the applica-
tion of neuromuscular electrical stimulation (NMES), chronic use of corticosteroids, 
intake of certain antithrombotic drugs, or the presence of an implantable cardioverter-
defibrillator (ICD) and/or pacemaker. Secondly, the expected sedation time was esti-
mated by the responsible physician and patients were excluded if this was <3 days. All 
patients who were excluded based on an expected short sedation time were re-
evaluated after 24 h, and included if the revised expected sedation time was >3 days. 
Participants were accepted into the study after written informed consent was obtained 
from their legal representatives. The study was approved by the Medical Ethical Com-
mittee of the Jessa Hospital in accordance with the Declaration of Helsinki. 
Study design 
An overview of the experimental protocol is depicted in Supplemental Figure 2. Patients 
were included in the study directly after informed consent was obtained from their legal 
representatives, which was generally given within 2.5 days after admission to the ICU 
(depicted in column ‘Time to inclusion’ in Table 1). After this, patient’s legs were ran-
domly assigned as either the control (CON) or stimulated (NMES) leg, counterbalanced 
for left and right legs. Randomization was performed by an independent investigator, 
and treatment allocation was performed by using sequentially labelled envelopes which 
were opened after inclusion of subjects. Baseline measurements were then taken, 
which consisted of assessment of leg circumference (measured at different locations on 
the upper leg), obtaining an arterial blood sample, and obtaining a muscle biopsy from 
both legs. After the pre-measurements, NMES was performed twice-daily on one leg 
(NMES) whereas the other leg served as a control (CON). Post-measurements were 
performed on the final day of sedation, with a minimum study duration of 3 days and a 
maximum of 10 days. The study duration for each patient is depicted in Table 1. Post-
measurements were performed prior to subjects being awake. Standard medical care 
was not altered, and passive mobilization was performed on both legs according to 
standard care procedures. 
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Data collection 
At baseline, data on demographic and clinical characteristics of the patients were ob-
tained, including information necessary to determine the severity of illness. These data 
were scored according to the Acute Physiology and Chronic Health Evaluation II 
(APACHE II) system with higher values indicating more severe illness and more thera-
peutic interventions, respectively [15]. Arterial blood samples were collected from the 
catheter already placed in the arteria radialis. Blood (10 mL) was collected into EDTA-
containing tubes and immediately centrifuged at 1,000g for 10 min at 4°C. Aliquots of 
plasma were directly snap-frozen in liquid nitrogen and stored at -80°C until further 
analysis. Processing and storage of the samples was done by UBiLim (Universitaire Bi-
obank Limburg, Hasselt, Belgium). Plasma amino acid concentrations were measured 
using ultra-performance liquid chromatography tandem mass spectrometry as de-
scribed previously [16], and results are displayed in Supplemental Table 2. 
In addition, during the pre- and post-measurements, a muscle biopsy sample was 
collected from each leg. After injection of local anesthesia, percutaneous needle biopsy 
samples were collected from m. vastus lateralis, approximately 15 cm above the patella 
using the Bergström technique [17].  
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Neuromuscular electrical stimulation 
Neuromuscular electrical stimulation sessions were performed both in the morning 
(11:00 AM) and afternoon (4.30 PM). Four self-adhesive electrodes (2 mm thick, 50 x 50 
mm) were placed on the distal part at the muscle belly of the m. rectus femoris and the 
m. vastus lateralis, and at the inguinal area of both muscles. The electrodes were con-
nected to an Enraf-Nonius TensMed S84 stimulation device (Enraf-Nonius, Rotterdam, 
the Netherlands), discharging biphasic symmetric rectangular-wave pulses. The position 
of the electrodes was re-marked daily with a semi-permanent marker to maintain the 
same location of stimulation for each session. The NMES protocol was composed of a 
warm-up phase (5 min, 5 Hz, 250 µs), a stimulation period (30 min, 100 Hz, 400 µs, 5 s 
on (0.75 s rise, 3.5 s contraction, 0.75 s fall) and 10 s off), and a cooling-down phase (5 
min, 5 Hz, 250 µs). The intensity of the stimulation was set to a level at which full con-
tractions of m. quadriceps femoris were both visible and palpable. The intensity was 
raised approximately every 3 min when a full muscle contraction was no longer 
achieved with the current intensity. This protocol was based on our previous work 
showing increased rates of muscle protein synthesis after a single bout of NMES [18], 
and applied on the immobilized leg of healthy young adults [14]. During the NMES ses-
sions, four electrodes and compatible cables were also applied to the control leg to 
standardize all procedures (representing a sham treatment). 
Dietary intake 
When patients were hemodynamically stable, enteral feeding was started according to 
routine guidelines of the ICU at Jessa Hospital as early as possible. Patients were fed 
Nutrison Multi Fibre (containing 420 kJ, 16 En% protein, 49 En% carbohydrates, and 35 
En% fat per 100 mL). Generally, patients were fed maximally 80 mL per hour with short 
intervals during which nutritional supply was paused. Gastric emptying was determined 
by the nursing staff, and food administration was altered accordingly. Nutritional support 
was not modulated and was applied according to the standard medical care in this ICU. 
Muscle analyses 
Muscle samples were freed from any visible non-muscle tissue and separated into dif-
ferent sections; the first part (~30 mg) was imbedded in Tissue-Tek (Sakura Finetek, 
Zoeterwoude, the Netherlands), frozen on liquid nitrogen cooled isopentane and used 
to determine muscle fibre-type specific cross-sectional area (CSA) and satellite cell con-
tent as done previously [19]. The second part (~15 mg) was snap frozen in liquid nitro-
gen and used for real time-PCR analysis to determine mRNA expression of selected 
genes as described before [14, 20], and compared with mRNA expression of n=6 
healthy, age- and gender-matched controls. The third part (~40 mg) was snap frozen in 
liquid nitrogen for Western Blot analysis to determine the total content and phosphory-
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lation status of several key proteins of interest as described previously [18]. All muscle 
analyses were performed by an investigator blinded to treatment. 
Statistics 
Based on data from previous studies in healthy subjects in our laboratory [14,21], we 
calculated that 8 patients would be required to detect a 8% difference in muscle fibre 
CSA between CON and NMES over 7 days (using an α level of 0.05 and a β level of 0.10). 
All data presented are expressed as means±SEM. Baseline differences between legs 
were compared with a paired samples t-test. Pre- and post-intervention data were 
analyzed using repeated measures analysis of variance (ANOVA) with time (pre vs post) 
and treatment (CON vs NMES) as factors. Fibre type (type I vs type II) was added as a 
third within-subjects factor when analyzing all muscle fibre characteristics. In case of 
significant interaction (time x treatment), paired-samples t-tests were performed to 
determine time effects within the CON and NMES leg separately. Alternatively, when a 
time x treatment effect was observed for muscle fibre characteristics, a 2-way ANOVA 
was performed for the CON and NMES leg separately, with time and treatment as fac-
tors. For the mRNA analyses, differences between patients and healthy controls were 
tested by means of an independent samples t-test between the mean value of the CON 
and NMES leg in patients and the values observed in healthy controls. Statistical anal-
yses were performed using the SPSS version 20.0 software package (SPSS Inc., Chicago, 
IL, USA), with P<0.05 as the value for statistical significance. 
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R E S U L T S  
Patients 
Between March 2012 and July 2013, 9 patients were included in the present study. Two 
patients awoke after <3 study days and one patient died. Therefore, the presented 
results represent data collected from 6 patients. Clinical characteristics of the included 
patients are listed in Table 1. Energy intake per day averaged 5.31±0.56 MJ, with a mean 
protein intake of 0.56±0.06 g·kg body weight-1·day-1. 
Neuromuscular electrical stimulation 
Within 5 min of the start of the actual 30 min stimulation period, a full muscle contrac-
tion was achieved. The intensity of the NMES intervention for subjects averaged 29.9 mA 
during the first session and was progressively increased to 32.3 mA in the final session.  
Muscle fibre characteristics 
Figure 1 illustrates the delta change in muscle fibre cross-sectional area (CSA) in both 
the NMES and CON legs throughout the study.  
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Figure 1 | Changes in muscle fibre cross-sectional area (CSA) in the control (CON) and stimulated (NMES) leg 
of sedated patients, after 7±1 days of twice-daily NMES. A significant interaction effect (P<0.05) was ob-
served, and a time effect in the CON leg (P<0.05). * Significantly different from zero (P<0.05). 
 
Table 2 details skeletal muscle fibre type specific characteristics at baseline and follow-
ing 7±1 d of full sedation in both legs. In the CON leg, a significant decline of 16±9% and 
24±7% was observed in type I and II muscle fibre CSA, respectively (time effect; P<0.05). 
In contrast, the NMES leg showed no atrophy in either type I or II muscle fibres (time x 
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treatment interaction effect; P<0.05). Muscle fibre type distribution showed an overall 
significant time x treatment interaction effect (see Table 2; P<0.05), with a shift from 
type I towards type II fibres in the CON leg, and a shift towards more type I fibres in the 
NMES leg. At baseline, satellite cell content was greater in type I vs type II muscle fibres 
(expressed per muscle fibre, per millimeter squared, and as a percentage of total myo-
nuclei). No differences in muscle fibre type specific myonuclear content, myonuclear 
domain size or satellite cell content were observed between legs or over time. 
 
Table 2 | Muscle fibre characteristics 
  CON NMES 
 Fibre type Pre Post Pre Post 
Muscle fibre CSA (µm2) I 4560 ± 261 3879 ± 484 * 4414 ± 441 4512 ± 550 
 II 3412 ± 530 2647 ± 512 * 3168 ± 607 3246 ± 590 
% Fibre I 53 ± 8 † 45 ± 5 † 42 ± 6 † 46 ± 6 † 
 II 47 ± 8 † 55 ± 5 † 58 ± 6 † 54 ± 6 † 
% Fibre area I 59 ± 9 56 ± 8 51 ± 8 55 ± 7 
 II 41 ± 9 44 ± 8 49 ± 8 45 ± 7 
Nuclei per fibre I 2.4 ± 0.1 2.5 ± 0.2 2.3 ± 0.2 2.6 ± 0.2 
 II 2.1 ± 0.2 # 2.1 ± 0.2 # 1.9 ± 0.2 # 2.3 ± 0.3 # 
Myonuclear domain (µm2) I 1853 ± 69 1574 ± 183 1931 ± 110 1760 ± 142 
 II 1573 ± 162 # 1255 ± 203 # 1618 ± 153 # 1452 ± 220 # 
Number of SCs per fibre I 0.083 ± 0.014 0.085 ± 0.012 0.075 ± 0.006 0.092 ± 0.006 
 II 0.061 ± 0.015 # 0.049 ± 0.013 # 0.048 ± 0.008 # 0.055 ± 0.009 # 
Number of SCs per mm2 I 18.8 ± 2.9 22.7 ± 2.7 17.6 ± 1.7 22.1 ± 4.1 
 II 18.6 ± 2.9 # 17.8 ± 2.0 # 17.0 ± 3.9 # 19.8 ± 4.6 # 
SCs/myonuclei (%) I 3.4 ± 0.5 3.5 ± 0.4 3.4 ± 0.4 3.7 ± 0.4 
 II 2.7 ± 0.4 # 2.3 ± 0.5 # 2.5 ± 0.3 # 2.5 ± 0.3 # 
Data represent means±SEM. Abbreviations: SC, satellite cell; SCs/myonuclei (%), the number of SCs as a 
percentage of the total number of myonuclei (i.e. number of myonuclei + number of SCs). * Significantly 
different from pre-intervention value (P<0.05). # Significantly different from type I fibre value (P<0.05). † 
Significant treatment*time*fibre type interaction effect (P<0.05) 
mRNA expression 
Figure 2 displays the relative muscle mRNA expression of key genes involved in the 
regulation of muscle protein synthesis and breakdown in the CON and NMES leg before 
and after the intervention, as well as for a group of healthy, age- and gender-matched 
controls.  
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Figure 2 | Skeletal muscle mRNA expression of genes of interest. Abbreviations: FOXO1, Forkhead box protein 
O1; MAFbx, Muscle Atrophy F-box; MuRF1, Muscle RING-finger protein-1; mTOR, mammalian target of ra-
pamycin; P70S6K, P70S6 kinase. * Significantly different from patients at baseline (P<0.05). # Significantly 
different from pre-value (P<0.05). 
 
At baseline, mRNA expression did not differ between NMES and CON legs. However, 
MAFBx, MuRF1, FOXO1, mTOR and P70S6K were all more highly expressed in the pa-
tients compared with healthy controls (P<0.01). There was a significant time effect 
(P<0.05) such that FOXO1 and P70S6K expression decreased during the period of seda-
tion, with no differences between legs. Expression levels for all other genes did not 
reveal any interaction or time effects. The mRNA expression of additional genes in-
volved in the regulation of myogenesis, oxidative metabolism, mechano-sensing and 
cellular amino acid transport are presented in Supplemental Figure 3. 
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Signaling proteins 
The skeletal muscle content and phosphorylation status of key proteins involved in the 
regulation of muscle protein synthesis are displayed in Figure 3.  
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Figure 3 | Skeletal muscle protein expression of Akt, mTOR and P70S6K in the control (CON) and stimulated
(NMES) leg, before (white bars) and after (black bars) 7±1 days of twice-daily NMES. Left graphs: total 
protein expression, right graphs: phosphorylated/total expression. Abbreviations: mTOR, mammalian target
of rapamycin; P70S6K, P70S6 kinase. * Significantly different from pre-intervention values (P<0.05). 
 
Neither total protein content, nor phosphorylation status of Akt was affected by time or 
the intervention (both P>0.05). Whereas muscle mTOR content was unaffected by time 
or treatment, a significant time x treatment interaction effect (P<0.05) was found for 
the phosphorylation status of mTOR. mTOR phosphorylation increased by as much as 
19±5% in the NMES leg (P<0.05), with no changes in the CON leg (P>0.05). Muscle 
P70S6K total protein content decreased following the intervention in both legs (time 
effect, P<0.05), without changes in phosphorylation status (P>0.05). 
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D I S C U S S I O N  
In the present study, we demonstrate for the first time that fully-sedated patients expe-
rience substantial type I and type II muscle fibre atrophy during a ~7 d stay in the ICU. 
Daily application of neuromuscular electrical stimulation (NMES) effectively prevents 
skeletal muscle fibre atrophy, offering an effective and feasible interventional strategy 
to alleviate muscle wasting in comatose ICU patients. 
General admission to the ICU has been shown to cause substantial muscle wasting 
[22] with a decline in type I and type II muscle fibre cross-sectional area of 3 and 4% per 
day, respectively [2]. In keeping with this, we show a 2.8 and 4.4% decline in muscle 
fibre size in type I and II muscle fibres, respectively, in fully-sedated patients (i.e. no 
possibility of voluntary muscle contraction) during on average 7 days in the ICU (Figure 
1). By way of comparison, muscle atrophy brought about by disuse only in healthy hu-
mans (i.e. limb immobilization) leads to a 0.5 and 0.9% per day decline in type I and II 
muscle fibre cross-sectional area (CSA), respectively [21]. This implies that the mecha-
nisms responsible for muscle wasting in the ICU are not simply attributed to disuse. One 
possible contributing factor could be inadequate nutritional status. Sufficient dietary 
protein is considered a key factor in the maintenance of muscle mass [23-25], and pre-
vious research has shown that sufficient protein intake is associated with reduced mor-
tality rates in critically ill patients [26, 27]. In the current study, patients received 
0.56±0.06 g protein·kg body weight-1·day-1, which is below the current guidelines of 1.3-
2.0 g protein·kg body weight-1·day-1 recommended during critical illness [28, 29], and 
has likely contributed to the extensive level of muscle wasting. In support, plasma ami-
no acid concentrations in our patients declined throughout the sedated state (Supple-
mental Table 2). In agreement, previous work has reported declines in circulating amino 
acid concentrations during critical illness [30]. Such a decline in circulating amino acid 
concentrations likely reduces amino acid uptake in muscle [31] and, as such, could 
modulate the efficacy of NMES as a means to stimulate muscle protein synthesis rates. 
From a mechanistic viewpoint, disuse atrophy has been primarily attributed to de-
clines in muscle protein synthesis rates [20, 32-34]. However, it has been suggested that 
in various conditions associated with rapid muscle wasting a multitude of other factors 
(e.g. increased inflammation, higher metabolic stress responses etc.) may stimulate 
muscle proteolysis, driving much of the muscle loss [35]. In line with this, we see evi-
dence of the severely metabolically compromised condition of our patients as demon-
strated by numerous clinical chemistry indictors obtained throughout the study (e.g. 
high white blood cell counts and C-reactive protein (CRP) concentrations; Supplemental 
Table 1). In keeping with this, molecular markers that have been used as a proxy for 
changes in muscle protein breakdown rate were elevated upon admission to the ICU, 
when compared with a group of healthy subjects (i.e. MAFBx, MuRF1 and FOXO1; Figure 
2). The subsequent decline in the expression levels of these genes suggest a decline in 
muscle protein turnover during hospital stay but expression levels remained elevated 
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when compared to healthy controls. This is not unexpected given the metabolic stress 
response upon ICU admission [36]. In contrast to previous work investigating the impact 
of NMES on an immobilized leg [14], we observed no significant differences in the ex-
pression levels of various genes between the stimulated and unstimulated leg in this 
comatose ICU setting. The absence of such differences may be attributed to various 
factors, but underline our understanding that changes in the expression and phosphory-
lation levels of various genes being used as a proxy for changes in muscle protein 
breakdown and synthesis do not necessarily represent changes in muscle protein 
breakdown and synthesis rates and do not necessarily translate to a net increase or 
decrease in muscle mass [37]. Taken together, the present data highlight the need for 
immediate and effective intervention at the onset of ICU admission to stimulate muscle 
protein synthesis and inhibit proteolysis, thereby preventing or attenuating extensive 
muscle wasting. An interesting observation in the stimulated leg was that NMES re-
versed the decline in phosphorylation status of mTOR (Figure 3D), which seems to be in 
line with previous work showing that NMES increases muscle protein synthesis rates 
[18]. 
Daily application of NMES has been shown to prevent muscle atrophy in healthy 
subjects during a week of leg immobilization [14]. Moreover, clinical trials have demon-
strated beneficial effects of NMES on muscle function in various bed-rested popula-
tions, including patients suffering from COPD [38, 39] and sepsis [40, 41]. The current 
study demonstrates, for the first time, that NMES is capable of preventing muscle wast-
ing in fully-sedated patients during 7 days in the ICU (with a +7±12% change in mixed 
muscle fibre CSA in the stimulated leg compared with a -21±8% decline in mixed muscle 
fibre CSA in the control leg; Figure 1). The prevention of muscle atrophy in these indi-
viduals can have profound clinical implications. For instance, maintaining muscle mass 
during critical illness has been shown to reduce mortality rates [4, 5]. Additionally, since 
muscle mass is vital for functional capacity [42], metabolic homeostasis [9], and im-
mune function [43], maintaining muscle mass during an ICU stay is essential to allow 
proper recovery during rehabilitation. As such, preventing muscle wasting is imperative 
for promoting quality of life after hospital discharge and reducing the likelihood of re-
hospitalization. NMES in fully-sedated patients can be easily applied by nursing staff, is 
relatively cheap and does not seem to cause any adverse effects on vital parameters 
during or after the sessions [44]. Some difficulties applying NMES in ICU patients have 
been reported previously and are likely due to increased skin/soft tissue impedance 
and/or edema [13]. Despite experiencing similar problems in the present study, all 
NMES sessions could be successfully performed without any adverse effects. Taken 
together, our data demonstrate that NMES is practical and feasible as a countermeas-
ure for muscle wasting in clinically compromised ICU patients. Future studies should 
address whether these findings would translate into longer-term benefits such as in-
creased survival rates, reduced hospitalization length of stay and/or improved rehabili-
tation outcomes. 
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C O N C L U S I O N  
NMES represents an effective and feasible interventional strategy to prevent skeletal 
muscle wasting in critically ill, comatose patients. 
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Supplemental Figure 1 | Patient flow 
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Supplemental Figure 2 | Overview of the experimental protocol. Upper part: Overview of the study, in which
fully-sedated patients were subjected to minimally 3 days and maximally 10 days of NMES. Post-intervention 
measurements were performed prior to patient awakening. Lower part: detailed overview of each study day.
‘…’ represents the duration between ICU admission and obtaining informed consent from the patient’s legal 
representatives (i.e. on average 2.5 days). 
Leg circumference measurements 
In the morning of day 1, circumference of the legs was measured using a tape measure 
at 5, 10 and 20 cm proximal to the top of the patella. The positions of leg circumference 
measurements were marked with semi-permanent ink to ensure the exact same meas-
uring position during the post-measurements. 
Muscle analysis 
The part of the muscle sample that was mounted and frozen in Tissue-Tek (Sakura 
Finetek, Zoeterwoude, the Netherlands) was cut into 5µm thick cryosections using a 
cryostat at -20°C. Pre- and post-intervention samples of the NMES and CON leg of each 
subject were mounted together on uncoated, pre-cleaned glass slides, while care was 
taken to properly align the samples for cross-sectional fibre analyses. Stainings were 
performed to measure muscle fibre typing (FT) and satellite cell (SC) content. To do this, 
slides were incubated with primary antibodies directed against myosin heavy chain 
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(MHC)-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA), 
laminin (polyclonal rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Nether-
lands) and Pax7 (neat; cell supernatant from cells obtained from the Developmental 
Studies Hybridoma Bank, Iowa City, IA, USA). Pax7 has been extensively used in the 
determination of SC content in human skeletal muscle by us [1] and others [2]. After 
washing, the appropriate secondary antibodies were applied: goat anti-rabbit IgG 
AlexaFluor647, goat anti-mouse IgM AlexaFluor555, and Streptavidin Alexa 488 (dilution 
1:400, 1:500, and 1:200, respectively; Molecular Probes, Invitrogen, Breda, the Nether-
lands). Myonuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, 0.238 µM; 
Molecular Probes). Both primary and secondary antibodies were diluted in 0.1% Bovine 
Serum Albumin (BSA) in 0.1% Tween- phosphate-buffered saline (PBS). All incubation 
steps were performed at room temperature. Staining of the muscle tissue was done as 
follows. After fixation in acetone for 5 min, slides were air dried and incubated with 3% 
BSA in 0.1% Tween-PBS for 30 min. Slides were washed in PBS for 5 min, and incubated 
with Pax7 for 2 h. Thereafter, slides were washed (standard washing protocol: 5 min 
0.1% Tween-PBS, 2x5 min PBS) and incubated with goat anti-mouse Biotin (dilution 
1:133, Vector Laboratories, Inc., Burlingame, CA, USA) for 60 min, washed again, and 
incubated with Streptavidin for 60 min. After washing, primary antibodies against lam-
inin and MHC-I were applied for 45 min. Slides were then washed and incubated with 
the appropriate secondary antibodies, diluted together with DAPI. After a last washing 
step, slides were mounted with cover glasses Mowiol (Calbiochem, Amsterdam, the 
Netherlands). Staining procedures resulted in images with nuclei stained in blue, Pax7 in 
green, MHC-I in red, and laminin in far-red. Images were visualized and automatically 
captured at 10x magnification with a fluorescent microscope equipped with an auto-
matic stage (IX81 motorized inverted microscope, Olympus, Hamburg, Germany) and 
EXi Aqua CCD camera (QImaging, Surrey, BC, Canada). Image acquisition was done by 
Micromanager 1.4 software [3], and images were analyzed with Image J software pack-
age (version 1.46r, National Institute of Health [4]). Recording and analyzing of the im-
ages was done by an investigator blinded to subject coding. As a measure of fibre circu-
larity, form factors were calculated by using the following formula: 
(4π·CSA)·(perimeter)-2. No differences in fibre circularity were observed between legs or 
between pre- and post-intervention samples. Mean numbers of 257±33 and 238±23 
muscle fibres were analyzed in the pre- and post-intervention samples, respectively. 
The part of the muscle sample that was frozen in liquid nitrogen was used to deter-
mine mRNA and protein expression of several genes of interest. Frozen muscle (10-20 
mg) was used for mRNA isolation using Tri Reagent (Sigma-Aldrich, St. Louis, MO, USA), 
according to the manufacturer’s protocol. Quantification of total RNA was carried out 
spectrophotometrically at 260 nm using the NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific, Madison, WI, USA), and RNA purity was determined as the 
ratio of readings at 260/280 nm. Thereafter, first strand cDNA was synthesized from 1 
μg RNA sample using random primers (Promega, Madison, WI, USA) and PowerScript 
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Reverse Transcriptase (Applied Biosystems, Foster City, CA, USA). Taqman PCR was 
carried out using an ABI Prism 7000 sequence detector (Applied Biosystems, USA), with 
2 μL of cDNA, 18 μl·L-1 of each primer, 5 μl·L-1 probe, and Universal Taqman 2 × PCR 
mastermix (Eurogentec S.A., Seraing, Belgium) in a 25 μL final volume. Each sample was 
run in duplicate, in duplex reactions. A separate standard curve was included for each 
gene, with serial dilutions of cDNA synthesized in parallel with the study samples. 18S 
was selected as a housekeeping gene to be used as an internal control, as we have used 
it previously and have shown that it does not change with muscle disuse [5, 6], i.e. 
mean Ct values did not change over time in either leg (data not shown). Taqman pri-
mer/probe sets (Applied Biosystems) were obtained for the following genes of interest: 
mammalian target of rapamycin (mTOR), P70S6 kinase (P70S6K), myogenic factor 4 
(myogenin), MyoD, myostatin, Atrogin-1/Muscle Atrophy F-box (MAFbx), Muscle RING-
finger protein-1 (MuRF1), Forkhead box protein O1 (FOXO1), Focal Adhesion Kinase 
(FAK), large neutral amino acid transporter (LAT1) and Proton-coupled amino acid 
transporter 1 (PAT1). All genes of interest were labelled with the fluorescent reporter 
FAM. Thermal cycling was performed using the following conditions: 2 min at 50°C, 10 
min at 95oC, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Ct values of the 
genes of interest were normalized to Ct values of 18S, and these values were calculated 
as relative expression against the standard curve. Muscle samples from age- and sex-
matched healthy controls were analyzed to compare pre-intervention values of the 
patients in the study to healthy volunteers. 
Muscle homogenates for Western blotting analysis were made using ~40 mg of 
muscle tissue in 7x volumes Tris buffer (20 mM Tris-HCL, 5 mM EDTA. 10 mM Na-
pyrosphospate, 100 mM NaF, 2 mM Na3VO4, 1% Nonident P-40; pH 7.4) supplemented 
with the following protease and phosphatase inhibitors: Aprotinin 10 µg·mL-1, Leupeptin 
10 µg·mL-1, Benzamidin 3 mM and PMSF 1 mM. Muscle samples were centrifuged for 10 
min at 10,000 g (4°C), where after sample buffer (final concentration: 60 mM Tris, 5% 
glycerol, 20 mg·mL-1 SDS, 0.1mM DTT, 20 µg·mL-1 bromophenolblue) was added to the 
supernatant. The solution was then boiled for 5 min at 100°C, after which the samples 
were put on ice. Directly before the commencement of the analyses, the extraction 
sample was warmed to 50°C and centrifuged for 1 min at 1,000 g at room temperature. 
Each lane on the gel was loaded with a total of 50 μg muscle sample. Protein samples 
(for (p)Akt, (p)P70S6K and α-actin quantification) were run on a Criterion ‘any kDa’ gel 
(Biorad Order No. 567-1124) for 10 min at 50 V (constant voltage) and ±90 min at 150 V 
(constant voltage) and transferred onto a Trans-blot Turbo 0.2 µm nitrocellulose mem-
brane (Biorad Order No. 170-4159) in 7 min at 2.5A and 25V. For (p)mTOR protein a 
Tris-acetate gel was used (Biorad Order nr. 345-0129), and the gel was transferred onto 
a Trans-blot Turbo 0.2 µm nitrocellulose membrane (Biorad Order No. 170-4159) in 10 
min at 1.3A and 25V. Specific proteins were detected by overnight incubation at 4°C on 
a shaker with specific antibodies in 50% PBS/Odyssey blocking buffer (Li-Cor Biosciences 
Part No. 927-40000) after blocking for 60 min at RT in 50% PBS/Odyssey blocking buffer. 
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Antibodies that were used in this study were anti-Akt (60 kDa; dilution 1:1000, #9272 
Cell Signaling) and anti-phospho-Akt (Ser473; 60 kDa, dilution 1:1000, #9271 Cell Signal-
ling), anti-mTOR (289 kDa; dilution 1:1000, #2972 Cell Signalling) and anti-phospho-
mTOR (Ser2448; 289 kDa, dilution 1:1000, #2971 Cell Signalling), anti-P70S6K (70 kDa; 
dilution 1:1000, #9202 Cell Signalling), anti-phospho P70S6K (Thr389; 70kDa, dilution 
1:1000, #9206 Cell Signalling) and anti α-actin (42 kDa; dilution 1:100.000, mouse mon-
oclonal IgM, Sigma A2172). After incubation, membranes were washed 3 x 10 min in 
0.1% PBS-Tween and 1 x 10 min with PBS. Samples were incubated for 1 h at room 
temperature with the following secondary antibodies: donkey anti-rabbit IRDYE 680 (Li-
Cor, Cat. No. 926-32223, dilution 1:10000) and donkey anti-mouse IRDYE 800CW (Li-
Cor, Cat. No. 926-32212, dilution 1:10000) dissolved in 50% PBS Odyssey blocking buff-
er. After the last washing step (3 x 5 min in 0.1% Tween20-PBS and 1 x 10 min with PBS), 
protein quantification was performed by scanning on an Odyssey Infrared Imaging Sys-
tem (LI-COR Biotechnology, Lincoln, NE, USA). 
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Laboratory results 
Supplemental Table1 | Average laboratory values during the study period 
 Value Reference value 
White blood cell count (*109·L-1) 15.9 ± 2.5 4.5 – 11.0 
Lymphocytes (*109·L-1) 0.8 ± 0.1 1.01 – 3.38 
Monocytes (*109·L-1) 0.90 ± 0.30 < 0.82 
CRP (mg·dL-1) 9.1 ± 2.3 < 0.5 
Ureum (mg·dL-1) 74.6 ± 10.9 17-43 
Creatinine (mg·dL-1) 0.9 ± 0.1 0.51 – 0.95 
Total plasma protein (g·dL-1) 5.7 ± 0.2 6.6 – 8.3 
Albumin (g·dL-1) 2.8 ± 0.1 3.5 – 5.2 
CRP = C-reactive protein 
Plasma amino acid concentrations 
Plasma concentrations of the measured amino acids are displayed in Supplemental 
Table 2. Following the intervention, significant decreases in the concentrations of ala-
nine, histidine and phenylalanine were observed (all P<0.05), whereas for leucine a 
trend for a decline was seen (P=0.065). 
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Supplemental Table 2 | Plasma AA concentrations 
 Pre Post 
α-aminobutyric acid  47 ± 10 29 ± 4 
Alanine 369 ± 50 241 ± 31 * 
Arginine 66 ± 16 47 ± 8 
Asparagine 63 ± 10 44 ± 5 
Aspartic acid 4 ± 1 6 ± 2 
Citrulline 18 ± 3 23 ± 4 
Cysteine 40 ± 11 48 ± 9 
Glutamic acid 46 ± 15 73 ± 20 
Glutamine 470 ± 59 430 ± 70 
Glycine 263 ± 67 189 ± 24 
Histidine 81 ± 4 55 ± 6 * 
Isoleucine 77 ± 6 60 ± 7 
Leucine 158 ± 9 111 ± 14 
Lysine 218 ± 38 145 ± 19 
Methionine 40 ± 6 28 ± 5 
Ornithine 90 ± 18 78 ± 11 
Phenylalanine 99 ± 10 71 ± 8 * 
Proline 161 ± 21 158 33 
Serine 85 ± 14 69 ± 9 
Taurine 42 ± 12 45 ± 8 
Threonine 139 ± 28 91 ± 16 
Tryptophan 34 ± 7 31 ± 6 
Tyrosine 77 ± 13 61 ± 8 
Valine 283 ± 22 222 ± 24 
Data are presented as means±SEM.* Significantly different from pre-value (P<0.05). All values are presented 
as μmol·L-1. 
Leg circumference 
No baseline differences in leg circumference between NMES and CON legs were ob-
served, and no effect of time or treatment occurred (both interaction and time effect 
P>0.05). 
mRNA analysis 
For myostatin (Supplemental Figure 3A), myoD (Supplemental Figure 3B), and myogenin 
(Supplemental Figure 3C), no differences were observed when compared with healthy 
controls and no interaction effect was found for the CON and NMES leg (all P>0.05). FAK 
(Supplemental Figure 3D) was higher in patients than in healthy controls (P<0.05), but 
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was not changed over time or between legs (P>0.05). For both PGC-1α (Supplemental 
Figure 3E) and citrate synthase (Supplemental Figure 3F) no differences between healthy 
controls and patients were observed (both P<0.05). Although not significantly (P>0.05), 
PGC-1α tended to decrease over time in both legs. Citrate synthase showed a significant 
time*treatment interaction (P<0.05); when both legs were tested separately with a 
paired-samples t-test a trend for a decline in the CON leg (P=0.059) was observed, while 
in the NMES leg no decrease was observed (P>0.05). The amino acid transporters LAT1 
(Supplemental Figure 3G) and PAT1 (Supplemental Figure 3H) were not different (LAT1) 
or significantly higher (PAT1; P<0.01) in patients compared with healthy controls, 
whereas over time no changes were observed in either gene (both P>0.05). 
  
 NMES prevents muscle atrophy during critical illness | 121 
0
1
2
3
4
MyostatinA
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.2
0.4
0.6
0.8
1.0
MyoDB PrePost
0
1
2
3
4
MyogeninC
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.5
1.0
1.5
2.0
FAK
*
D
0.0
0.5
1.0
1.5
2.0
PGC-1αE
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.5
1.0
1.5
2.0
2.5
Citrate synthase #F
Healthy CON NMES
0.0
0.5
1.0
1.5
2.0
LAT1/SLCG
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
Healthy CON NMES
0
1
2
3
*
PAT1H
 
Supplemental Figure 3 | Skeletal muscle mRNA expression of genes of interest in the CON and NMES leg of
fully-sedated ICU patients (right part of the figure) versus healthy controls (left column), before (white bars) 
and after (black bars) 7±1 days of twice-daily NMES. Abbreviations: FAK, Focal Adhesion Kinase; LAT1, Large
Neutral Amino Acid Transporter 1; PAT1, Proton-coupled amino acid transporter 1; PGC-1α, Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha. * Significantly different from the mean pre-
intervention value of the CON and NMES legs. # Significant interaction effect (P<0.05). 
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A B S T R A C T  
Background Short successive periods of muscle disuse, due to injury or illness, can 
contribute significantly to the loss of muscle mass with ageing (sarco-
penia). It has been suggested that increasing the protein content of 
the diet may be an effective dietary strategy to attenuate muscle dis-
use atrophy. We hypothesized that protein supplementation twice-
daily would preserve muscle mass during a short period of limb im-
mobilization. 
Methods Twenty-three healthy, elderly (69±1 y) males were subjected to 5 days 
of one-legged knee immobilization by means of a full leg cast with 
(PRO group; n=11) or without (CON group; n=12) administration of a 
dietary protein supplement (20.7 g protein, 9.3 g carbohydrate, and 
3.0 g fat) twice daily. Two days prior to and immediately after the im-
mobilization period, single slice CT-scans of the quadriceps and single 
leg 1-Repetition Maximum (1RM) strength tests were performed to 
assess muscle cross-sectional area (CSA) and leg muscle strength, re-
spectively. Additionally, muscle biopsies were collected to assess mus-
cle fibre characteristics, and mRNA and protein expression of selected 
genes. 
Results  Immobilization decreased quadriceps CSA by 1.5±0.7% (P<0.05) and 
2.0±0.6% (P<0.05), and muscle strength by 8.3±3.3% (P<0.05) and 
9.3±1.6% (P<0.05) in the CON and PRO groups, respectively; without 
differences between groups. Skeletal muscle myostatin, myogenin, 
and MuRF1 mRNA expression increased following immobilization in 
both groups (P<0.05), while muscle MAFbx mRNA expression in-
creased in the PRO group only (P<0.05). 
Conclusion In conclusion, dietary protein supplementation (~20 g twice daily) 
does not attenuate muscle loss during short-term muscle disuse in 
healthy older men. Clinical trial registration: NCT01588808 
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I N T R O D U C T I O N  
A period of prolonged (i.e. several weeks) muscle disuse, due to illness or injury, can 
lead to substantial loss of skeletal muscle mass and strength in otherwise healthy indi-
viduals. The resulting negative health consequences, such as impaired functional capaci-
ty [1-3], decreased muscle strength [4], the onset of insulin resistance [5], and a decline 
in basal metabolic rate [6, 7], are of particular concern to elderly individuals, who are 
already functionally and/or metabolically compromised. Recently, we [8, 9] as well as 
others [10] have shown that even a few days of disuse can already lead to significant 
losses of muscle mass and strength in young and old men. These findings are of particu-
lar clinical relevance as hospitalization of elderly due to acute illness generally results in 
an average 5-7 day hospital stay [11]. It has been hypothesized that such short succes-
sive periods of muscle disuse occurring throughout the lifespan may be instrumental in 
the progressive loss of muscle mass that occurs with ageing [12, 13]. 
Any substantial loss of skeletal muscle mass due to muscle disuse must be attributed 
to a chronic imbalance between muscle protein synthesis and breakdown rates. A de-
cline in basal (postabsorptive) muscle protein synthesis rates has been reported follow-
ing both bed rest [14-16] as well as limb immobilization [17-19]. Furthermore, recent 
work from our laboratory [20] as well as others [17, 21, 22] has shown that the muscle 
protein synthetic response to protein or amino acid administration becomes blunted 
following a period of disuse. Additionally, there is some indirect evidence that increases 
in muscle protein breakdown rates occur during the initial first few days of muscle dis-
use only [23-25]. As such, it is now widely thought that declines in both postabsorptive 
and postprandial muscle protein synthesis rates play the major causal role in the loss of 
muscle mass during a period of disuse [26, 27]. Dietary protein intake stimulates muscle 
protein synthesis rates and inhibits muscle protein breakdown, and thereby allows net 
muscle protein accretion [28]. Accordingly, it has been speculated that maintaining or 
even increasing dietary protein intake can attenuate muscle loss during a period of 
disuse [12, 27]. In support, intervention studies have shown high-dose, essential amino 
acid supplementation to attenuate muscle loss during prolonged bed rest in young [29-
31] and elderly individuals [32]. However, the potential for a practical dietary protein 
feeding strategy to alleviate muscle loss during short-term disuse in the elderly popula-
tion remains to be investigated. 
In the present study, we investigated our hypothesis that dietary protein supple-
mentation attenuates muscle loss during a short period of muscle disuse in older men. 
To test this hypothesis, 23 healthy elderly men were selected to participate in a study 
during which they were subjected to 5 days of one-legged knee immobilization with or 
without dietary protein supplementation (~20 g protein twice daily). Muscle mass and 
strength were assessed prior to and immediately after immobilization, and muscle biop-
sy samples were collected to assess muscle fibre characteristics and associated myocel-
lular signaling. 
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Subjects 
Twenty-three healthy elderly men (mean age 69±1 y) were included in the present 
study. Prior to inclusion, a general health questionnaire was filled in by the subjects and 
a routine medical screening was completed to exclude individuals with BMI below 18.5 
or above 30 kg·m-2; any back, knee or shoulder complaints that could interfere with the 
use of crutches; a (family) history of thrombosis; type 2 diabetes mellitus (determined 
by HbA1c values >7.0%); severe cardiac problems; or a history of performing prolonged 
resistance-type exercise in the six months preceding the start of the study. All subjects 
were informed on the nature and risks of the experiment before written informed con-
sent was obtained. The present study was approved by the Medical Ethical Committee 
of Maastricht University Medical Centre in accordance with the Declaration of Helsinki. 
Experimental outline 
An overview of the experimental protocol is depicted in Figure 1. 
 
Figure 1 | Outline of the experimental protocol. Two groups of healthy elderly males were included to under-
go 5 days of one-legged knee-immobilization, with (PRO; n=11) or without (CON; n=12) protein supplementa-
tion (~20 g protein twice daily). 
 
After inclusion into the study, subjects were randomly allocated to either the control 
(CON, n=12) or the protein (PRO, n=11) group. Both groups were subjected to five days 
 
Time (days) 0 1 2 3 4 5-1-2
One-legged knee immobilization
Muscle biopsy + 
blood sample
CT + DXA scan
1-RM
CON group
PRO group
= Protein drink
Test day 1 Test day 2
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of muscle disuse induced by way of a full leg cast. The immobilized leg was randomly 
allocated and counter-balanced between left and right. Two days prior to casting and 
directly after cast removal, a series of measurements was performed. Single slice com-
puted tomography (CT) scans were performed at the mid-thigh of both legs, whole-
body dual energy x-ray absorptiometry (DXA) scans were taken, a single muscle biopsy 
from the immobilized leg and venous blood sample were collected, and one-legged 
knee extension strength (1RM, one-Repetition Maximum) was assessed for both legs. 
Muscle mass and function tests 
Forty eight hours prior to, and directly after the casting period, subjects visited the 
laboratory for two identical test days (i.e. test days 1 and 2). During these test days, 
multiple measurements of muscle mass and function were performed. Firstly, the ana-
tomical cross-sectional area (CSA) of m. quadriceps femoris and whole thigh were as-
sessed via a single slice computed tomography (CT) scan (Philips Brilliance 64, Philips 
Medical Systems, Best, The Netherlands) as done before [8]. With subjects placed in a 
supine position, their legs extended and their feet secured, a 3 mm thick axial image 
was taken 15 cm proximal to the top of the patella. On test day 1 the exact scanning 
position was marked with semi-permanent ink for replication on test day 2. ImageJ 
software (version 1.46r, National Institute of Health, Bethesda, MD, USA) was used to 
analyze CT scan images for the cross-sectional area of all thigh muscles as well as the 
quadriceps muscle separately. Secondly, a DXA scan (Hologic, Discovery A, QDR Series, 
Bedford, MA, USA) was used to determine body composition and bone mineral content. 
Leg lean mass was determined using the system’s software package Apex version 2.3. 
Maximal muscle strength was determined for each leg individually by 1RM strength 
tests on a leg extension machine (Technogym, Rotterdam, the Netherlands) as done 
before [8, 33]. 
Blood and muscle sampling 
Fasting venous blood samples were collected for determination of basal plasma glucose 
and insulin concentrations on test day 1 and 2. Blood (10 mL) was collected in EDTA-
containing tubes and immediately centrifuged at 1,000g for 10 min at 4°C. Aliquots of 
plasma were snap frozen in liquid nitrogen and stored at -80°C until further analysis. 
Plasma glucose, free fatty acids, and triglyceride concentrations were analyzed with a 
ABX Pentra 400 analyzer (Horiba Diagnostics, Montpellier, France) with test kits from 
ABX Diagnostics (Montpellier, France), whereas plasma insulin concentrations were 
determined by radioimmunoassay (Millipore, ref. HI-14K , Billerica, MA, USA). Plasma 
amino acid concentrations were measured using ultra-performance liquid chromatog-
raphy tandem mass spectrometry as described previously [34]. 
Muscle biopsies were taken from m. vastus lateralis of the immobilized leg prior to 
casting and immediately after cast removal, prior to performing any weight bearing 
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activities. Biopsies were taken at the same time (08.30 AM) in the morning after an 
overnight fast and the same standardized meal was provided the evening prior to mus-
cle biopsy collection. Percutaneous muscle biopsies were taken from m. vastus lateralis 
with the Bergstrom technique, approximately 15 cm above the patella. The collected 
muscle was freed from any visible non-muscle tissue, processed immediately, and 
stored at -80°C until further analysis. 
Leg immobilization 
Two days after performing test day 1, at 8:00 in the morning, a full leg cast (randomized 
and counterbalanced for left and right leg) was applied in the casting room of the Aca-
demic Hospital in Maastricht. This marked the start of the 5 day immobilization period 
that always contained 3 week days and 2 weekend days. The cast extended from ~5 cm 
above the ankle until ~25 cm above the patella. A ~30 degree angle of flexion of the 
knee joint was established in order to prevent subjects from performing weight-bearing 
activities with the immobilized leg. Subjects received crutches and were instructed on 
the correct usage before being provided with transportation home. The cast was re-
moved at 8:00 on the morning of test day 2, after exactly 5 days of immobilization. 
Protein supplementation 
Subjects were randomly allocated to the group receiving a high whey protein leucine-
enriched oral nutritional supplement (PRO) or the control group receiving no supple-
ment (CON). Subjects allocated to the PRO group consumed the first drink in the labora-
tory on the morning of casting and were instructed to consume one drink directly after 
breakfast and one drink immediately prior to sleep on each day during immobilization 
(i.e. twice-daily, 10 drinks in total). Each drink provided 635 kJ, 21 g protein, 9 g carbo-
hydrates, 3 g fat, and a mixture of vitamins, minerals and fibres. Supplemental Table 1 
depicts the composition of the study product. 
Dietary intake 
Standardized meals, containing 2.9 MJ and providing 51 Energy% (En%) as carbohy-
drate, 32 En% as fat, and 17 En% as protein, were consumed on the evening prior to 
both test days. Weighted dietary intake records were completed by the subjects for the 
5 day duration of the immobilization period as well as on a separate consecutive 5 day 
occasion either before or after (randomly allocated to avoid recording bias) the immobi-
lization period. The same 5 days of the week were selected for both recording periods. 
DieetInzicht software [35], based on the NEVO table 2011, was used to analyze dietary 
intake records. 
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Muscle analysis 
Muscle samples were freed from any visible non-muscle tissue and separated into two 
sections. The first part (~30 mg) was imbedded in Tissue-Tek (Sakura Finetek, Zoeter-
woude, the Netherlands), frozen on liquid nitrogen cooled isopentane and used to de-
termine muscle fibre-type specific cross-sectional area (CSA) and satellite cell content as 
done previously [8]. The second part (~15 mg) was snap frozen in liquid nitrogen and 
used for real time-PCR analysis to determine mRNA expression of selected genes as 
described before [8, 20]. A detailed overview of the muscle analyses is presented in the 
supplemental material. 
Statistics 
All data are expressed as means±SEM. Baseline values between groups were compared 
by means of an independent samples t-test. Pre- versus post-immobilization data were 
analyzed using Repeated Measures ANOVA with treatment (CON vs PRO) as between-
subjects factor and time (pre- vs post-immobilization) as within-subjects factor. Fibre 
type (type I vs type II) was added to the test as a within-subjects factor when perform-
ing the statistical analyses for the muscle data. In case of a significant main effect, 
paired-samples t tests were executed to determine time effects within treatment 
groups or within fibre types, and independent-samples t tests were performed to de-
termine group differences in pre- and post-immobilization values. When a significant 
main effect was detected, Bonferroni’s post hoc test was applied to locate the differ-
ences. A P-value of <0.05 was used to determine statistical significance. All data were 
analyzed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).  
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Subjects 
Subjects’ characteristics are provided in Table 1. No baseline differences between the 
control (CON) and protein (PRO) groups were observed for age, height, weight, BMI, 
glucose, insulin, HOMA, or HbA1c levels at baseline. Glucose, insulin, and HOMA were 
measured pre- and post-intervention, and did not change over time in either group. 
 
Table 1 | Subjects’ characteristics of healthy older men in the control (CON) and protein supplemented (PRO) 
groups 
 CON (n=12) PRO (n=11) 
Age (y) 70 ± 1 68 ± 1 
Body mass (kg) 82.9 ± 3.0 79.6 ± 2.4 
Height (m) 1.74 ± 0.02 1.74 ± 0.02 
BMI (kg·m-2) 27.3 ± 0.6 26.4 ± 0.8 
Leg volume (L) 7.96 ± 0.28 7.90 ± 0.35 
Plasma glucose (mmol·L-1) 5.6 ± 0.1 5.7 ± 0.1 
Plasma insulin (uU·mL-1) 11.7 ± 1.4 9.9 ± 1.0 
Glycated hemoglobin (%) 5.4 ± 0.1 5.7 ± 0.1 
HOMA-index 3.0 ± 0.4 2.6 ± 0.3 
Glycated hemoglobin (mmol·mol-1) 35.9 ± 1.2 38.4 ± 1.3 
Values are means±SEM. Abbreviations: HOMA-index, Homeostatic Model Assessment Index. No differences 
were observed between groups (P>0.05 for all variables). 
Muscle mass and strength 
Quadriceps muscle cross-sectional area (CSA) is displayed in Figure 2A. At baseline, no 
differences were observed in quadriceps or whole leg muscle CSA between groups 
(P>0.05 for both parameters). Five days of immobilization caused significant muscle 
atrophy of the quadriceps (time effect, P<0.001; see Figure 2A) and the whole leg (time 
effect, P<0.05; from 13.3±5.4 to 13.2±5.3 cm2 (-0.7±0.6%) in CON and from 12.6±4.2 to 
12.4±4.6 cm2 (-1.6±0.6%) in PRO) with no differences between groups (P-
interaction>0.05 for both parameters). Immobilization did not affect whole-body or leg 
lean mass in either group (data not shown; both P>0.05). Leg muscle strength data are 
presented in Figure 2B. Maximal leg muscle strength had decreased following immobili-
zation in the CON and PRO group (time effect, P<0.001), with no differences between 
groups (P-interaction>0.05). 
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Figure 2 | A Cross-sectional area (CSA) of m. quadriceps femoris in healthy elderly participants in the CON 
(n=12) and PRO (n=11) groups, measured by single-slice CT scan 48h prior to and immediately following 5
days of leg immobilization. B Leg muscle strength as measured by 1RM, in both the CON and PRO group. Data
are expressed as means±SEM. *P<0.05; significantly different when compared with pre-immobilization values. 
Dietary intake 
Table 2 shows data for subjects’ habitual diet for 5 days under free living conditions and 
during the 5 day immobilization period. No differences in habitual diet were observed 
between groups (all measured parameters P>0.05). Habitual diet did not change due to 
immobilization in the CON group (P>0.05), whereas in the PRO group, twice-daily inges-
tion of the protein drink significantly increased protein intake (expressed as g·day-1, g·kg 
body weight-1·day-1, and En%) compared with baseline (P<0.05) and the CON group 
(P<0.05). Habitual protein intake averaged 1.1 g·kg body weight-1·day-1 and was in-
creased to 1.6 g·kg body weight-1·day-1 during the immobilization period in the PRO 
group. Energy intake in the PRO group was maintained during immobilization; a relative-
ly higher amount of energy was received from protein, at the expense of energy from 
fat (P<0.05). 
 
132 | CHAPTER 6 
Table 2 | Dietary intake of healthy elderly subjects under free-living conditions and during a 5-day period of 
leg immobilization, with (PRO) or without (CON) supplementation. 
 CON (n=12) PRO (n=11) 
 Free living Immobilization Free living Immobilization 
Energy intake (MJ · day-1) 8.82 ± 0.62 9.03 ± 0.46 8.73 ± 0.54 9.50 ± 0.49 
Protein intake (g · day-1) 85 ± 9 86 ± 4 90 ± 4 125 ± 6 * 
Protein (g·kg body weight-1·day-1) 1.04 ± 0.12 1.05 ± 0.06 1.14 ± 0.07 1.60 ± 0.11 * 
Protein (En%) 16.7 ± 1.2 16.4 ± 0.7 18.0 ± 0.9 22.9 ± 1.0 * 
Fat (En%) 31.6 ± 1.3 32.9 ± 2.3 29.5 ± 1.8 25.8 ± 1.2 * 
Carbohydrate (En%) 51.7 ± 2.0 50.6 ± 2.1 52.5 ± 2.1 51.3 ± 1.5 
Data represent means±SEM. Data in the PRO group are expressed including twice-daily intake of the protein 
supplement. * Significantly different from free living value (P<0.05) 
Plasma analyses 
Plasma amino acid concentrations (Supplemental Table 2) were increased in both 
groups for alanine, cysteine, phenylalanine, threonine, and tryptophan (all P<0.05). For 
valine (P-interaction<0.05), an increase following immobilization was observed in the 
PRO group only (P<0.05). All other measured amino acids were not changed following 
immobilization (all P>0.05). Immobilization, with or without protein supplementation, 
did not influence plasma free fatty acid (CON: from 384±33 to 354±33 μmol·L-1; PRO: 
from 446±48 to 404±46 μmol·L-1) or triglyceride (CON: from 1190±210 to 1270±92 
μmol·L-1; PRO: from 968±88 to 1110±118 μmol·L-1) concentrations (both P>0.05). 
Muscle fibre characteristics 
Muscle fibre characteristics are displayed in Table 3. At baseline, no differences be-
tween groups were observed for any of the variables. No measurable decline in muscle 
fibre CSA was observed following immobilization in either group (P>0.05). Although no 
changes in myonuclear content were observed following immobilization (P>0.05), myo-
nuclear domain size decreased in both fibre types in both CON and PRO (time effect, 
P<0.05). At baseline, satellite cell (SC) content expressed per muscle fibre, per millime-
tre squared, and as a percentage of the total number of myonuclei was higher in type I 
compared with type II fibres (P<0.05 for all three parameters). No changes over time or 
differences between groups were observed (P>0.05). 
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Table 3 | Muscle fibre characteristics of healthy elderly individuals before (pre) and after (post) 5 days of leg 
immobilization, with (PRO) or without (CON) supplementation. 
  CON (n=12) PRO (n=11) 
 Fibre type Pre Post Pre Post 
Muscle fibre CSA (µm2) I 5654 ± 391 5037 ± 487 5646 ± 469 5370 ± 379 
 II 5592 ± 564 5000 ± 525 5131 ± 390 5027 ± 356 
Fibre (%) I 49 ± 3 44 ± 3 48 ± 5 48 ± 5 
 II 51 ± 3 56 ± 3 52 ± 5 52 ± 5 
Fibre (area%) I 50 ± 4 45 ± 3 51 ± 5 49 ± 6 
 II 50 ± 4 55 ± 3 49 ± 5 51 ± 6 
Nuclei (n/fibre) I 2.8 ± 0.1 2.9 ± 0.3 2.8 ± 0.2 2.9 ± 0.2 
 II 2.8 ± 0.1 2.8 ± 0.2 2.8 ± 0.2 2.8 ± 0.2 
Myonuclear domain (µm2) I 2026 ± 86 1716 ± 106 * 2035 ± 89 1914 ± 97 * 
 II 2072 ± 112 1770 ± 126 * 1843 ± 111 1791 ± 112 * 
SC (n/fibre) I 0.101 ± 0.014 0.091 ± 0.013 0.099 ± 0.010 0.099 ± 0.007 
 II 0.056 ± 0.008 # 0.055 ± 0.009 # 0.062 ± 0.006 # 0.060 ± 0.006 # 
SC (n/mm2) I 18.1 ± 2.5 18.0 ± 2.3 17.7 ± 2.1 19.1 ± 1.6 
 II 10.1 ± 1.5 # 10.3 ± 1.4 # 11.8 ± 1.1 # 12.7 ± 1.6 # 
SC (n/myonuclei, %) I 3.6 ± 0.4 3.3 ± 0.5 3.7 ± 0.5 3.6 ± 0.3 
 II 1.9 ± 0.2 # 2.0 ± 0.3 # 2.2 ± 0.2 # 2.2 ± 0.2 # 
Data represent means±SEM. Abbreviations: CSA, cross-sectional area; SC, satellite cell; SC, n/myonuclei (%), 
the number of SCs as a percentage of the total number of myonuclei (i.e. number of myonuclei + number of 
SCs). # Significantly different from values in type I fibre (P<0.05). * Significantly different from pre-
immobilization values (P<0.05) 
mRNA expression 
Figure 3 and Supplemental Figure 1 display the skeletal muscle mRNA expression of the 
selected genes of interest. Muscle mRNA expression of myostatin (Figure 3A) and my-
ogenin (Figure 3C) increased following immobilization in both groups (P<0.05), whereas 
myoD (Figure 3B) tended towards an increase in both groups (P=0.07). MAFBx mRNA 
expression (Figure 3D) showed a significant time*treatment interaction (P<0.05) with a 
significant increase only detected in the PRO group (P<0.05) following immobilization. 
Muscle MuRF1 mRNA (Figure 3E) significantly increased in both groups (time effect, 
P<0.01). There was a trend for an interaction effect (P=0.07) such that MuRF1 mRNA 
expression was increased to a greater extent in PRO (P<0.05) compared with CON 
(P>0.05). For the mRNA expression of both amino acid transporters LAT1 (Supplemental 
Figure 1D) and PAT1 (Supplemental Figure 1E), a significant time effect was found 
(P<0.01 for both genes) such that expression was upregulated following immobilization 
in both groups. All other genes showed no significant changes between or within 
groups. 
134 | CHAPTER 6 
0.0
0.5
1.0
1.5
2.0
2.5
MyostatinA
*
*
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0.0
0.5
1.0
1.5
MyoDB PrePost
0.0
0.5
1.0
1.5
MyogeninC * *
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0
1
2
3
4
5
*
D MAFBx
CON PRO
0.0
0.5
1.0
1.5
2.0
*
*
E MuRF1
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
CON PRO
0
1
2
3
4
5
FOXO1F
 
Figure 3 | Skeletal muscle mRNA expression of selected genes involved in myogenesis (A-B-C) and muscle 
proteolysis (D-E-F), measured 48 h prior to and immediately following 5 days of one-legged knee immobiliza-
tion in healthy elderly men in the CON (n=12) and PRO (n=11) group. *P<0.05; significantly different when 
compared with pre-immobilization values. Data are expressed as means±SEM. Abbreviations: MAFBx, Muscle 
Atrophy F-box; MuRF1, Muscle RING-finger protein-1; FOXO1, Forkhead box protein O1. 
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D I S C U S S I O N  
In the present study, we demonstrate that merely 5 days of one-legged knee immobili-
zation leads to substantial skeletal muscle mass and strength loss in healthy, elderly 
men. Increasing dietary protein intake by supplementing ~20 g protein twice-daily did 
not attenuate the loss of muscle mass or strength during 5 days of muscle disuse in 
older males. 
A period of prolonged muscle disuse and the associated muscle atrophy causes nu-
merous negative health consequences [1, 2, 4, 6], and the occurrence of successive 
periods of muscle disuse likely represents a key factor responsible for the loss of muscle 
mass during the later decades of our lifespan [13]. In the present study, we report that 
only 5 days of muscle disuse already leads to substantial loss of muscle mass (-
1.5±0.7%; Figure 2A) and strength (-8.3±3.3%; Figure 2B) in older individuals. These data 
are in line with recent data from our group in which we observed similar muscle mass 
and strength losses in younger individuals [8]. Furthermore, Suetta et al. reported signif-
icant muscle fibre atrophy after 4 days of immobilization in both young and older indi-
viduals [10]. The rapid muscle atrophy observed in our older subjects after merely 5 
days of leg immobilization is of important clinical significance, as successive short peri-
ods of muscle disuse due to illness or injury are highly prevalent during the later stages 
of our lifespan [36]. In line, the average length of hospitalization for elderly patients 
admitted with acute illness is 5–7 days [11]. The observed muscle loss is of particular 
relevance as the older population has difficulty to regain skeletal muscle mass and 
strength following a period of disuse [37]. Even when applying rehabilitative resistance-
type exercise training after a period of disuse, muscle mass does not seem to be re-
stored after 4 weeks of intense supervised training [37]. For these reasons, it is present-
ly believed that the impact of short successive episodes of muscle disuse may be of key 
relevance in the development of sarcopenia [13]. 
Practical and effective interventional strategies are needed to prevent or attenuate 
muscle mass and strength loss during short periods of muscle disuse in healthy elderly 
as well as more clinically compromised subpopulations. It has been proposed that simp-
ly increasing the protein content of the diet may alleviate the loss of muscle tissue dur-
ing a period of disuse [12, 27]. Indeed, studies focusing on mimicking prolonged hospi-
talization (i.e. >2-3 weeks bed rest under tightly controlled dietary conditions) have 
shown that supplementation with high doses of crystalline essential amino acids (~50 g, 
equivalent to ~100-150 g intact protein) attenuates the loss of muscle mass [29-31]. 
Given the clinical relevance of short, successive periods of muscle disuse, we assessed 
the efficacy of a more practical and feasible dietary strategy to attenuate muscle loss 
during a short period of limb immobilization under free living conditions. Increasing 
dietary protein intake from 1.1 to 1.6 g·kg body weight-1·day-1 did not rescue the loss of 
muscle mass or strength observed during a 5 day period of leg immobilization (Figure 2). 
The apparent discrepancy between the outcome of the present study and previous 
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work in prolonged bed rest studies may be attributed to differences in protein intake in 
the control group. In the present study the control group retained normal habitual en-
ergy and protein intake (1.1 g·kg body weight-1·day-1) whereas the protein group re-
ceived additional supplementation (1.6 g·kg body weight-1·day-1). In contrast, in previous 
bed rest studies that show benefits of amino acid supplementation on muscle mass 
maintenance, the control groups generally consumed dietary protein at a level no high-
er than 0.8 g·kg body weight-1·day-1 [29-31]. Consequently, we speculate that maintain-
ing dietary protein intake is required to prevent muscle loss during disuse, but that 
increasing dietary protein intake above habitual levels does not further alleviate muscle 
loss during disuse [38, 39]. This would be of particular relevance in institutionalized or 
hospitalized elderly who are unable to maintain habitual dietary protein consumption 
during more prolonged periods of muscle disuse due to illness or injury. Additional 
considerations of the present nutritional intervention include the type and timing of 
protein administered. We selected whey protein in the present study as we have previ-
ously shown it leads to greater postprandial muscle protein accretion compared with 
casein protein in healthy elderly men [40]. We chose to supplement volunteers at 
breakfast time since we have previously shown that community dwelling elderly indi-
viduals generally consume inadequate amounts of protein at breakfast [41]. Specifically, 
the supplement was consumed directly after breakfast to avoid volunteers compensat-
ing for the supplement by consuming less breakfast and therefore ensuring adequate 
protein was consumed. This was achieved given that the PRO group consumed (36±2 g 
at this meal compared to the CON group who only consumed 13±1 g, the latter being an 
amount insufficient to properly stimulate muscle protein synthesis rates [42]. We opted 
to deliver the second supplement immediately prior to sleep, since we have recently 
shown that such a strategy effectively stimulates overnight muscle protein synthesis 
rates [43]. However, it is also true that these beneficial effects on nocturnal muscle 
protein synthesis were obtained with the ingestion (or intragastric administration) of 
large amounts of casein protein, to ensure a more sustained hyperaminoacidemia 
throughout the night [44]. Accordingly, it could be speculated that future nutritional 
strategies aimed at attenuating muscle disuse atrophy may wish to consider incorporat-
ing large boluses of casein as a pre-bedtime meal. In contrast, it could also be hypothe-
sized that ingestion of a large bolus of dietary protein prior to sleep increases both 
muscle protein synthesis and breakdown rates, without net muscle protein accretion 
[45]. Though previous work has shown improvements in overnight whole-body protein 
balance following protein administration in healthy older men [43] and in young adults 
during overnight recovery from exercise [46], we cannot exclude that such improve-
ments in overnight protein balance may not occur in a setting of muscle disuse.  
Besides assessing the impact of protein supplementation on muscle mass and 
strength during short-term disuse, we wished to gain insight into the underlying my-
ocellular mechanisms involved in muscle disuse atrophy and/or muscle mass mainte-
nance. Muscle loss during short-term muscle disuse is thought to be, at least partly, 
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mediated by accelerated rates of muscle protein breakdown [13]. Myostatin is known 
as a negative regulator of muscle growth in vivo [47], and acts through multiple path-
ways including the stimulation of muscle protein breakdown [48]. Consistent with this 
role, we observed increases in myostatin mRNA expression (Figure 3) and in markers of 
muscle protein breakdown (i.e. increased gene expression of MAFBx and MuRF1; Figure 
3). This is in line with previous findings [10] and our own work in young men [8, 9], and 
supportive of a role for muscle protein breakdown in short-term muscle atrophy, possi-
bly mediated through increased myostatin transcription. Given the lack of effect of 
protein supplementation on muscle mass in the present study, it is not surprising that 
we observed no attenuation of the rise in myostatin and markers of proteolysis. In fact, 
we actually observed that MAFBx and MuRF1 gene expression increased to a greater 
extent in the PRO group (Figure 3), supporting the idea that increasing dietary protein 
intake beyond the habitual dietary protein intake level may strongly stimulate overall 
protein turnover rates. 
Myostatin is also reported to regulate muscle size by acting via the inhibition of my-
ogenesis through its inhibitory action on the myogenic regulatory factors [49]. However, 
in line with our previous work [8, 50], we report that the disuse-induced increase in 
myostatin expression does not coincide with impaired expression of the myogenic regu-
latory factors (i.e. MyoD and myogenin, Figure 3). Moreover, no alterations in muscle 
satellite cell content were observed, suggesting that the mechanisms underlying short-
term disuse atrophy do not require alterations in myogenesis or satellite cell content. 
Recent data have suggested that the expression of specific amino acid transporters 
within skeletal muscle provide a site of regulation for muscle protein synthesis [51]. As 
such, we analyzed the gene expression of Large Neutral Amino Acid Transporter 1 
(LAT1/SLC) and Proton-coupled amino acid transporter 1 (PAT1) which are thought to 
be the key transporters facilitating intramuscular transport of BCAAs particularly in 
response to nutrition [52]. Interestingly, LAT1 and PAT1 mRNA expression (Supple-
mental Figure 1) increased following immobilization in both groups, possibly indicating a 
compensatory mechanism by which atrophying muscle attempts to ‘scavenge’ circulat-
ing amino acids as a substrate for muscle protein synthesis. 
In the present study we show that protein supplementation on top of a diet contain-
ing ample protein (1.1 g·kg body weight-1·day-1) does not alleviate muscle loss during 
short-term single leg disuse. This shows that besides maintaining dietary protein intake, 
other strategies are warranted to help maintain muscle mass. Where possible, perform-
ing some degree of exercise should be considered during disuse [39]. In conditions 
where exercise is not feasible due to injury or illness, low-volume physical activity [53] 
or even exercise surrogates [8] could be suggested. Furthermore, other nutritional 
compounds, such as creatine or omega-3 fatty acids, may support muscle maintenance 
during disuse [27]. An often under-appreciated consideration is how dietary strategies 
could support rehabilitation following a period of disuse. This area has been compara-
tively under studied [54-57] but, given the opportunity to combine nutrition with re-
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ambulation and/or physical exercise, future research should address how dietary pro-
tein and/or other nutritional strategies could best be used to facilitate the rapid and 
complete restoration of muscle mass following a period of disuse.  
In short, we conclude that short-term muscle disuse results in a substantial decline 
in both muscle mass and strength in older individuals. Increasing dietary protein intake 
during short-term muscle disuse on top of a diet providing >1.0 g·kg body weight-1·day-1 
does not alleviate muscle disuse atrophy in healthy, elderly men. 
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Supplemental Table 1 | Composition of the study product 
Component Unit PRO 
Energy kcal / kJ 150 / 635 
     Protein % 55 
     Carbohydrates % 25 
     Fat % 18 
     Fibre % 2 
Protein   
     Total g 20.7 
     Total EAA g 10.6 
     Total leucine g 2.8 
     Total phenylalanine g 0.6 
Carbohydrates   
     Total g 9.4 
     Sugars g 4.2 
Fat   
     Total g 3.0 
     Saturated g 0.8 
Fibre   
     Total g 1.3 
     Soluble g 1.3 
Minerals   
     Sodium mg 150 
     Potassium mg 279 
     Chloride mg 70 
     Calcium mg 500 
     Phosphorus mg 250 
     Magnesium mg 37 
Trace elements   
     Iron mg 2.4 
     Zinc mg 2.2 
     Copper μg 270 
     Manganese mg 0.50 
     Fluoride mg 0.15 
     Molybdenum μg 15 
     Selenium μg 15 
     Chromium μg 7.5 
     Iodine μg 20 
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Component Unit PRO 
Vitamins   
     Vitamin A μg-RE 152 
     Cholecalciferol μg 20 
     Vitamin E mg α-TE 7.5 
     Phylloquinone μg 12 
     Thiamin mg 0.23 
     Riboflavin mg 0.25 
     Niacin mg NE 8.8 
     Pantothenic acid mg 0.81 
     Vitamin B6 mg 0.76 
     Folic acid μg 203 
     Vitamin B12 μg 3.0 
     Biotin μg 6.1 
     Vitamin C μg 32 
Extra additions   
     Carotenoids mg 0.30 
     Choline mg 56 
Data are presented as mean values, n=23.  Abbreviations used: EAA, essential amino acid; NE, niacin equiva-
lents; RE, retinol equivalents; α-TE, α-tocopherol equivalents. 
Muscle analyses 
Muscle samples that were mounted and frozen in Tissue-Tek were cut into 5µm thick 
cryosections using a cryostat at -20°C. Samples were carefully aligned for cross-sectional 
fibre analyses. Pre and post immobilization samples from one PRO and one CON subject 
were mounted together on uncoated, pre-cleaned glass slides. All biopsies were stained 
for muscle fibre type (FT) and satellite cell (SC) content. At the start of the staining pro-
cedure, glass slides were incubated with primary antibodies against myosin heavy chain 
(MHC)-I (A4.840, dilution 1:25, Developmental Studies Hybridoma Bank, Iowa City, IA), 
laminin (polyclonal rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Nether-
lands) and CD56 (dilution 1:40; BD Biosciences, San Jose, CA). CD56 has been used in 
previous research by ourselves [1-3] and others [4] for determination of SC content in 
human skeletal muscle. After washing, slides were incubated with the appropriate sec-
ondary antibodies: goat anti-rabbit IgG AlexaFluor647, goat anti-mouse IgM AlexaFlu-
or555, and Streptavidin Alexa 488 (dilution 1:400, 1:500, and 1:200, respectively; Mo-
lecular Probes, Invitrogen, Breda, the Netherlands). Nuclei were stained with 4,6-
diamidino-2-phenylindole (DAPI, 0.238 µM; Molecular Probes). All incubations steps 
were done at room temperature. Both primary and secondary antibodies were diluted 
in 0.1% Bovine Serum Albumin (BSA) in 0.1% Tween- phosphate-buffered saline (PBS). 
The staining procedure was done as follows. After slides were fixated in acetone for 5 
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min, slides were air dried and incubated for 30 min with 3% BSA in 0.1% Tween-PBS. 
After a 5 min washing step with PBS, slides were incubated with CD56 in 0.1% BSA in 
0.1% Tween-PBS for 2 h. Afterwards slides were washed (standard washing protocol: 5 
min 0.1% Tween-PBS, 2 x 5 min PBS) and incubated with goat anti-mouse Biotin (dilu-
tion 1:133, Vector Laboratories, Inc., Burlingame, CA) for 60 min. After washing, slides 
were incubated with Steptavidin for 30 min. Thereafter, slides were washed and incu-
bated with primary antibodies against MHC-1 and laminin for 30 min. Slides were 
washed and the appropriate secondary antibodies were applied, diluted together with 
DAPI. After a final washing step, all slides were mounted with cover glasses using 
Mowiol (Calbiochem, Amsterdam, the Netherlands). Staining procedures resulted in 
nuclei stained in blue, CD56 in green, MHC-I in red, and laminin in far-red. Images were 
visualized and automatically captured at 10x magnification with a fluorescent micro-
scope equipped with an automatic stage (IX81 motorised inverted microscope, Olym-
pus, Hamburg, Germany) and EXi Aqua CCD camera (QImaging, Surrey, BC, Canada). 
Image acquisition was performed by Micro-Manager 1.4 software as done before [5]. 
Analysis of the recorded images was performed by an investigator blinded to subject 
coding. To assess fibre circularity, form factors were calculated by using the following 
formula: (4π·CSA)·(perimeter)-2. Fibre circularity did not change over time or between 
groups. Mean numbers of 148±12 and 151±12 fibres were analyzed in pre- and post-
immobilization samples, respectively. 
The part of the muscle that was directly frozen in liquid nitrogen was used to deter-
mine mRNA expression of several genes of interest. Total RNA was isolated by using Tri 
Reagent (Sigma-Aldrich) on 10-20 mg of frozen muscle, according to the manufacturer’s 
protocol. Quantification of total RNA was carried out spectrophotometrically at 260 nm 
(NanoDrop ND-1000 Spectrophotometer, Thermo Fisher Scientific, USA), and RNA puri-
ty was determined as the ratio of readings at 260/280 nm. Subsequently, first strand 
cDNA was synthesized from 1 μg RNA sample using random primers (Promega) and 
PowerScript Reverse Transcriptase (AppliedBiosystems, USA). Taqman PCR was carried 
out using an ABI Prism 7000 sequence detector (AppliedBiosystems, USA), with 2 μL of 
cDNA, 18 μl·L-1 of each primer, 5 μl·L-1 probe, and Universal Taqman 2 × PCR mastermix 
(Eurogentec) in a final volume of 25 μL. Each sample was run in duplicate, in duplex 
reactions, with a separate standard curve included for each gene (serial dilutions of 
cDNA synthesized in parallel with the study sample). 18S was used as a housekeeping 
gene as an internal control, and similarly to previous human immobilization studies [6, 
7] it seemed unaffected by treatment (i.e. mean Ct values did not change over time in 
each of the intervention groups; data not shown). Taqman primer/probe sets (Applied 
Biosystems, Foster City, USA) were obtained for the following genes of interest: mam-
malian target of rapamycin (mTOR), P70S6 kinase (P70S6K), myogenic factor 4 (myogen-
in), MyoD, myostatin, Atrogin-1/Muscle Atrophy F-box (MAFbx), Muscle RING-finger 
protein-1 (MuRF1), Forkhead box protein O1 (FOXO1), Focal Adhesion Kinase (FAK), 
large neutral amino acid transporter 1 (LAT1) and Proton-coupled amino acid trans-
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porter 1 (PAT1). All genes of interest were labelled with the fluorescent reporter FAM. 
The thermal cycling conditions used were: 2 min at 50°C, 10 min at 95°C, followed by 40 
cycles at 95°C for 15 s and 60°C for 1 min. Ct values of the genes of interest were nor-
malized to Ct values of the housekeeping gene, and final results were calculated as 
relative expression against the standard curve. 
 
Supplemental Table 2 | Plasma amino acid concentrations measured 48 h prior to and immediately following 5 
days of one-legged knee immobilization in healthy elderly men with (PRO; n=11) or without (CON; n=12) 
twice-daily protein supplementation. 
 CON (n=12) PRO (n=11) 
 Pre Post Pre Post 
 μmol·L-1 μmol·L-1 μmol·L-1 μmol·L-1 
α-aminobutyric acid  30 ± 4 25 ± 2 27 ± 2 30 ± 4 
Alanine 393 ± 36 485 ± 36 * 379 ±25 423 ± 22 * 
Arginine 88 ± 5 90 ± 4 84 ± 3 81 ± 4 
Asparagine 47 ± 2 47 ± 2 45 ± 2 45 ± 2 
Aspartic acid 5 ± 1 5 ± 1 4 ± 1 4 ± 1 
Citrulline 39 ± 3 36 ± 2 35 ± 1 38 ± 3 
Cysteine 42 ± 3 46 ± 2 * 44 ± 2 50 ± 2 * 
Glutamic acid 69 ± 10 68 ± 7 58 ± 9 59 ± 9 
Glutamine 605 ± 29 622 ± 27 575 ± 39 540 ± 31 
Glycine 217 ± 11 237 ± 12 204 ± 10 194 ± 13 
Histidine 86 ± 5 86 ± 2 83 ± 4 84 ± 3 
Isoleucine 70 ± 5 73 ± 4 66 ± 4 76 ± 8 
Leucine 138 ± 8 137 ± 5 128 ± 7 154 ± 16 
Lysine 190 ± 10 191 ± 7 177 ± 9 212 ± 14 
Methionine 28 ± 2 29 ± 1 27 ± 1 30 ± 2 
Ornithine 60 ± 4 62 ± 3 58 ± 4 60 ± 4 
Phenylalanine 59 ± 3 60 ± 2 * 56 ± 3 64 ± 2 * 
Proline 218 ± 27 223 ± 22 169 ± 14 192 ± 12 
Serine 90 ± 6 93 ± 5 85 ± 5 89 ± 7 
Taurine 81 ± 8 89 ± 6 96 ± 10 82 ± 7 
Threonine 129 ± 7 135 ± 8 * 120 ± 7 154 ± 15 * 
Tryptophan 56 ± 4 59 ± 3 * 53 ± 3 62 ± 4 * 
Tyrosine 67 ± 4 69 ± 3 65 ± 4 71 ± 3 
Valine 261 ± 17 259 ± 9 240 ± 12 288 ± 19 * 
Data are presented as means±SEM, n=23. * Significantly different from pre-immobilization value (P<0.05). 
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No significant time*treatment nor time effects were found for mTOR (Supplemental 
Figure 1A), P706SK (Supplemental Figure 1B), and FAK (Supplemental Figure 1C: all 
P>0.05).  
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Supplemental Figure 1 | mRNA expression of anabolic genes of interest in the CON (n=12) and PRO (n=11) 
group 48 h prior to and immediately following 5 days of leg immobilization. *P<0.05; significantly different 
when compared with pre-immobilization values. Data are expressed as means±SEM, n=23. Abbreviations: 
FAK, Focal Adhesion Kinase; LAT1, large neutral amino acid transporter; mTOR, mammalian target of rapamy-
cin; PAT1, proton-coupled amino acid transporter 1; P70S6K, P70S6 kinase. 
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Background The loss of muscle mass and strength that occurs with ageing, termed 
sarcopenia, has been (at least partly) attributed to an impaired muscle 
protein synthetic response to food intake. We previously showed that 
neuromuscular electrical stimulation (NMES) can stimulate fasting 
muscle protein synthesis rates and prevent muscle atrophy during 
disuse. We hypothesized that NMES prior to protein ingestion would 
increase postprandial muscle protein accretion. 
Methods Eighteen healthy, elderly (69±1 y) males participated in this study. 
After performing a 70 min unilateral NMES protocol, subjects ingested 
20 g intrinsically L-[1-13C]-phenylalanine-labelled casein. Plasma sam-
ples and muscle biopsies were collected to assess postprandial mixed 
muscle and myofibrillar protein accretion, as well as associated my-
ocellular signaling, during a 4 hour postprandial period in both the 
control (CON) and stimulated (NMES) leg. 
Results  Protein ingestion resulted in rapid increases in both plasma phenylal-
anine concentrations and L-[1-13C]-phenylalanine enrichments, which 
remained elevated during the entire 4 h postprandial period (P<0.05). 
Mixed muscle protein-bound L-[1-13C]-phenylalanine enrichments sig-
nificantly increased over time following protein ingestion, with no dif-
ferences between the CON (0.0164±0.0019 MPE) and NMES 
(0.0164±0.0019 MPE) leg (P>0.05). In agreement, no differences were 
observed in the postprandial rise in myofibrillar protein-bound L-[1-
13C]-phenylalanine enrichments between the CON and NMES legs 
(0.0115±0.0014 vs 0.0133±0.0013 MPE, respectively; P>0.05). Signifi-
cant increases in mTOR and P70S6K phosphorylation status were ob-
served in the NMES stimulated leg only (P<0.05). 
Conclusion A single session of NMES prior to food intake does not augment post-
prandial muscle protein accretion in healthy, older men. 
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I N T R O D U C T I O N  
Ageing is accompanied by declines in skeletal muscle mass and strength, termed sarco-
penia [1]. A less than optimal diet and sedentary lifestyle are factors contributing to 
sarcopenia [1, 2]. However, the underlying mechanisms remain to be elucidated. From a 
physiological perspective, any loss of muscle mass must be attributed to an imbalance 
between muscle protein synthesis and breakdown rates. Research has generally 
demonstrated that basal (i.e. postabsorptive) muscle protein synthesis [3-6] and break-
down [7, 8] rates do not change with advancing age. As such, research has since fo-
cused on the impact of ageing on the anabolic response to food intake. Recent work has 
shown that the skeletal muscle protein synthetic response to dietary protein ingestion is 
impaired in older individuals [4, 6, 9]. This ‘anabolic resistance’ to food intake is now 
regarded as a key factor in the etiology of sarcopenia [6, 10]. Accordingly, we [3, 11, 12] 
and many others [4, 13-15] have begun to investigate ways to overcome anabolic re-
sistance in older individuals in an effort to develop more effective strategies to attenu-
ate age-related muscle loss and support healthy ageing. 
One strategy that has been shown to be effective to increase the postprandial muscle 
protein synthetic response to feeding is physical activity performed prior to food inges-
tion [16-20]. By combining the ingestion of a meal-like bolus (i.e. 20 g) of intrinsically 
labelled milk protein with the continuous infusion of stable isotope-labelled amino acids, 
we were able to show that a single bout of physical activity performed prior to protein 
ingestion augments the postprandial use of dietary protein derived amino acid for de 
novo muscle protein synthesis [16]. However, some conditions do not allow an increase 
in physical activity level. For example, acute periods of illness or injury necessitate short 
periods of bed rest or limb immobilization. Such successive short periods of local or 
whole-body muscle disuse increase anabolic resistance to feeding and contribute to the 
development of sarcopenia during the lifespan [21, 22]. Therefore, alternative strategies 
to maximize the postprandial muscle protein synthetic response to food ingestion are 
warranted in both health and disease. 
In situations where physical activity levels are reduced, neuromuscular electrical 
stimulation (NMES) may be used as an alternative means to elicit muscle contraction. We 
have previously shown that NMES increases (fasting) muscle protein synthesis rates [23], 
and can be applied effectively to prevent muscle atrophy during short periods of muscle 
disuse in young men [24] as well as critically ill patients [25]. In the present study, we 
hypothesized that a single bout of NMES improves postprandial protein accretion by 
increasing the postprandial use of dietary protein derived amino acids for de novo mus-
cle protein synthesis in older adults. To test this hypothesis, we selected 18 healthy older 
males who were subjected to 70 min of unilateral NMES followed by the ingestion of 20 
g intrinsically L-[1-13C]-phenylalanine-labelled casein protein. This was combined with 
regular blood and muscle tissue sampling to assess postprandial protein accretion and 
underlying myocellular signaling in both the stimulated and non-stimulated leg. 
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Subjects 
Eighteen healthy, elderly men (age 69±1 y) were selected to participate in the present 
study. Subjects were excluded if one of the following criteria were met: BMI below 18.5 
or above 30 kg·m-2, type 2 diabetes mellitus, use of non-steroidal anti-inflammatory 
drugs, presence of a pacemaker or implantable cardioverter defibrillator, or having 
participated in any regular resistance-type exercise program within 6 months prior to 
the study. Subjects’ characteristics are displayed in Table 1. All subjects were informed 
on the nature and risks of the study before written informed consent was obtained. The 
study was approved by the Medical Ethical Committee of the Maastricht University 
Medical Centre in accordance with the Declaration of Helsinki. 
 
Table 1 | Subjects’ characteristics 
Age (y) 69 ± 1 
Weight (kg) 83.4 ± 2.2 
BMI (kg·m-2) 26.5 ± 0.6 
Body fat (% body weight) 22.0 ± 1.0 
Lean body mass (kg) 62.5 ± 1.5 
Leg lean mass (kg) 10.0 ± 0.3 
Quadriceps CSA (mm2)* 7151 ± 266 
Leg volume (L) 8.4 ± 0.2 
Basal plasma glucose (mmol·L-1) 5.7 ± 0.1 
Basal plasma insulin (mU·L-1) 10.2 ± 1.0 
HbA1c (%) 5.4 ± 0.1 
OGIS (mL·min-1·m-2) 433 ± 9 
Values represent means±SEM. BMI, body mass index; CSA, cross-sectional area; HbA1c, glycosylated hemo-
globin; OGIS, oral glucose insulin sensitivity. * Data from n=10 participants 
Pretesting 
All subjects filled out a health questionnaire and completed a routine medical screening 
before inclusion into the study. During this visit, an Oral Glucose Tolerance Test (OGTT) 
was performed in a fasted state [26] to test for type 2 diabetes mellitus, and height and 
weight were measured. A second visit was performed to assess body composition via 
whole-body dual energy x-ray absorptiometry (DXA) and single-slice computed tomog-
raphy (CT) of m. quadriceps femoris, at 15 cm above the patella. Also during this visit, 
subjects were familiarized with the NMES protocol to be used in the experimental visit 
(see below for details). 
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Diet and physical activity prior to testing 
The evening prior to the test day, subjects consumed a standardized meal containing 
2900 kJ providing 51 energy% (En%) as carbohydrate, 32 En% as fat, and 17 En% as 
protein. All subjects received instructions to refrain from any sort of heavy physical 
activity and to keep their diet as constant as possible during the 48 h prior to the test 
day.  
Experimental protocol 
An overview of the experimental protocol is depicted in Figure 1. 
 
Figure 1 | Outline of the experimental protocol. Eighteen healthy, older men ingested a protein drink contain-
ing 20 g casein following unilateral NMES (neuromuscular electrical stimulation). 
 
After an overnight fast, subjects arrived at the laboratory at 8:00 AM for a single test 
day. While resting in a supine position on a bed, a catheter was placed in a heated dor-
sal hand vein and placed in a hot box at 60°C for arterialized venous blood sampling 
[94]. After collection of a basal arterialized blood sample at t = -210 min, a blood sample 
was collected 120 min (t = -90 min) after the baseline sample. After this, an NMES pro-
tocol (see below for details) was started at t = -70 min. After terminating the NMES 
session at t = 0 min, a blood sample was taken, and muscle biopsies were collected from 
both the stimulated (NMES) and the non-stimulated (CON) leg within approximately 5 
min after the end of the NMES protocol. Subjects then received a test drink containing 
20 g intrinsically L-[1-13C]-phenylalanine-labelled protein. The consumption of this drink 
signified the beginning of a 4 h postprandial period. Arterialized blood samples were 
subsequently collected every 60 min with the final sample being taken at t = 240 min. At 
the same time (at t = 240 min), muscle biopsy samples were taken from both the NMES 
and CON leg. 
Arterialized venous blood samples were collected into pre-cooled EDTA-containing 
tubes and centrifuged at 1000g for 10 min at 4°C. Aliquots of plasma were snap frozen 
in liquid nitrogen and stored at -80°C until further analysis. Muscle biopsy samples were 
collected from the middle region of m. vastus lateralis, ~15 cm above the patella [28]. 
-210 -120 -60 0 60 120 180 240Time (min)
CON leg
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Blood draw
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Any visible non-muscle tissue was removed, and the muscle sample was frozen in liquid 
nitrogen. Subsequently, samples were stored at -80°C until further analysis. 
Neuromuscular electrical stimulation 
After inclusion, one of the subjects’ legs was randomly allocated to receive 70 min of 
NMES during the experimental visit. Prior to the NMES session, subjects were placed in 
a supine position with a pillow underneath both knees to instigate light knee flexion. 
Four self-adhesive electrodes (50 x 50 mm; Enraf-Nonius, Rotterdam, the Netherlands) 
were placed on the distal part at the muscle belly of the m. rectus femoris and the m. 
vastus lateralis, and at the inguinal area of both muscles of both legs. The electrodes 
were connected to an Enraf-Nonius TensMed S84 stimulation device, discharging bipha-
sic symmetric rectangular-wave pulses. However, NMES was only applied to one leg 
(NMES) while the other leg served as a sham-treated control (CON). The 70-min proto-
col consisted of a warm-up phase (5 min, 5 Hz, 250 μs), a stimulation period (60 min, 
100 Hz, 400 μs, 5 s on (0.75 s rise, 3.5 s contraction, 0.75 s fall) and 10 s off), and a cool-
ing-down phase (5 min, 5 Hz, 250 μs). This protocol was selected as we previously 
demonstrated it is effective in preventing muscle atrophy during short-term disuse in 
young men [24] and critically ill patients [25]. Subjects were encouraged to continuously 
adjust the intensity of the stimulation to the level where a full contraction of m. quadri-
ceps femoris was both visible and palpable, with the heel slightly being lifted from the 
bed. The NMES protocol was completed by all subjects. The maximal intensity of the 70 
min NMES session averaged 35.9±2.7 mA, whereas the average intensity across all sub-
jects and sessions averaged 26.1±1.5 mA. 
Preparation of intrinsically labelled protein 
Intrinsically L-[1-13C]-phenylalanine-labelled micellar casein protein was obtained by 
infusing a Holstein cow with large quantities of L-[1-13C]-phenylalanine, collecting milk, 
and purifying the casein fraction as described previously [29]. The average L-[1-13C]-
phenylalanine enrichment was 38.7 mole percent excess (MPE). All subjects received a 
drink with 20 g casein in a total volume of 350 mL, flavored with vanilla flavor. 
Plasma analyses 
Plasma glucose and insulin concentrations were analyzed by Dr. Stein und Kollegen 
Laboratories (Mönchengladbach, Germany) using commercially available kits (GLUC3, 
Roche, Ref: 05168791 190, and Immunologic, Roche, Ref: 12017547 122, respectively). 
Plasma amino acid concentrations and enrichments were determined by GC-MS (Ag-
ilent 7890A GC/5975C; MSD, Little Falls, DE, USA). Plasma phenylalanine was converted 
to its tert-butyl dimethylsilyl (TBDMS) derivative before analysis by GC-MS by using 
electron impact ionization by monitoring ions at mass/charge (m/z) 336 and 337 for 
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unlabelled and L-[1-13C]-labelled phenylalanine, respectively [12]. Standard regression 
curves were applied from a series of known standard enrichment values against the 
measured values to assess the linearity of the mass spectrometer and to account for 
any isotope fractionation which may have occurred during the analysis. Phenylalanine 
enrichments were corrected for the presence of the 13C isotopes. 
Muscle tissue analyses 
Mixed muscle protein-bound enrichments were determined in a piece of wet muscle 
(~45 mg) as described previously [3]. Briefly, muscle was freeze-dried, and collagen, 
blood and other visible non-muscle material was removed under a dissecting micro-
scope. After homogenizing and incubating samples in ice-cold 2% perchloric acid (PCA), 
samples were centrifuged. The supernatant was collected for determination of L-[1-
13C]-phenylalanine enrichments in the muscle free amino acid pool using GC-MS analy-
sis [12]. The mixed muscle protein pellet washed, hydrolyzed overnight, and dried under 
a nitrogen stream. Next, free amino acids were dissolved in 50% acetic acid solution and 
passed over cation exchange AG 50W0X8 resin columns. To determine the L-[1-13C]-
phenylalanine enrichment, the purified amino acids were derivatized into their N(O,S)-
ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate (ECF), and then meas-
ured by GC-C-IRMS (MAT 253; Thermo Scientific, Bremen, Germany) using a DB5-MS-
column (no. 122122-5532; Agilent J+W, USA), GC Isolink, and monitoring ion masses 44, 
45, and 46. By establishing the relation between the enrichment of a series of L-[1-13C]-
phenylalanine standards of variable enrichments and the enrichments of the N(O,S)-
ethoxycarbonyl ethyl esters of these standards, the mixed muscle protein-bound en-
richment of phenylalanine was determined. 
Myofibrillar protein enriched fractions were extracted from wet muscle tissue as de-
scribed elsewhere [30]. In short, ~50 mg wet muscle tissue was manually homogenized 
on ice using a Teflon pestle in a standard extraction buffer, after which the samples 
were centrifuged and the supernatants containing sarcoplasmic proteins were re-
moved. In an additional step, the myofibrillar fraction-containing supernatant was col-
lected and the collagen pellet was removed. The remaining myofibrillar fraction was 
purified and hydrolyzed, such that the free amino acids remained and could be dried 
under a nitrogen stream. The enrichment of the derivative was measured by GC-C-IRMS 
by using a DB5-MS-column (no. 122-5532; Agilent J+W, USA), GC Isolink, and monitoring 
of ion masses 44, 45, and 46. By establishing the relationship between the enrichment 
of a series of L-[1-13C]-phenylalanine standards of variable enrichment, the myofibrillar 
protein-bound enrichment of phenylalanine was determined. Standard regression 
curves were applied to assess the linearity of the mass spectrometer and to control for 
the loss of tracer. Muscle protein deposition from the ingested casein over the 4 h 
postprandial period was expressed as the relative increase of L-[1-13C]-phenylalanine 
enrichment in muscle tissue. 
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Western blot analyses were performed as described previously [25]. In short, ~30 mg 
muscle tissue was homogenized and protein quantification was performed. After protein 
quantification, the gels were transferred onto a nitrocellulose membrane. Specific pro-
teins were detected by overnight incubation with the following antibodies: anti-mTOR 
(289 kDa; dilution 1:1000, #2972 Cell Signaling, Danvers, MA, USA) and anti-phospho-
mTOR (Ser2448; 289 kDa, dilution 1:1000, #2971 Cell Signaling), anti-P70S6K (70 kDa; 
dilution 1:1000, #9202 Cell Signaling) and anti-phospho P70S6K (Thr389; 70 kDa, dilution 
1:1000, #9206 Cell Signaling), anti-RS6 (32 kDa; dilution 1:1000; #2217 Cell Signaling) and 
anti-phospho-RS6 (Ser235/Ser236, 32 kDa; dilution 1:1000; #4856 Cell Signaling) and anti α-
tubulin (52 kDa; dilution 1:1000; #2125 Cell Signaling). The complementary secondary 
antibodies applied were IRDye 680 donkey anti-rabbit (Cat. No. 926-32223, dilution 
1:10000, Li-Cor, Lincoln, NE, USA) and IRDye 800CW donkey anti-mouse (Cat. No. 926-
32212, dilution 1:10000, Li-Cor). Protein quantification was performed by scanning on an 
Odyssey Infrared Imaging System (LI-COR Biotechnology, Lincoln, NE, USA). 
Statistics 
All data are expressed as means±SEM. Differences in baseline leg values (i.e. left vs 
right) were determined using a paired samples t-test. A one-way repeated measures 
analysis of variance (ANOVA) with time as within-subjects factor was used to analyze 
effects in plasma concentrations and enrichments. Differences in protein-bound L-[1-
13C]-phenylalanine enrichments between legs after 4 h incorporation were analyzed 
using a paired-samples t-test. When a significant main effect was detected, Bonferroni’s 
post hoc test was applied to locate the differences. Statistical analyses were performed 
using the SPSS version 22.0 software package (SPSS Inc., Chicago, IL, USA), with statisti-
cal significance set at P<0.05.  
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R E S U L T S  
Plasma analyses 
For plasma glucose and insulin concentrations, depicted in Figure 2, a significant time 
effect was observed (both P<0.001). 
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Figure 2 | Means±SEM plasma glucose (A) and insulin (B) concentrations prior to and following ingestion of 20
g casein. The gray bar represents a 70 min NMES protocol. Data were analyzed with one-way repeated 
measures ANOVA with time as within-subjects factor. A significant time effect (P<0.001) was found for both 
glucose and insulin. * Significantly different from t = 0 min (P<0.05). 
 
During the postprandial period, plasma glucose and insulin concentrations averaged 
5.6±0.1 mmol·L-1 and 7.5±0.8 mU·L-1, respectively. Figure 3 displays plasma concentra-
tions of phenylalanine (A), tyrosine (B), and leucine (C). At the start of the experiment, 
fasting plasma phenylalanine, tyrosine, and leucine concentrations averaged 54±1, 62±2 
and 128±5 μM, respectively. Following the ingestion of 20 g casein, at t = 0 min, concen-
trations of these three amino acids increased rapidly (time effect; P<0.001) and re-
mained elevated until the end of the experiment. 
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Figure 3 | Means±SEM plasma phenylalanine (A), tyrosine (B), and leucine (C) concentrations during the 
fasting period (t = -210 until 0 min) and following the ingestion of 20 g casein. The gray bar represents the 70
min NMES protocol. Data were analyzed with one-way repeated measures ANOVA with time as within-
subjects factor. For all amino acids, significant time effects were observed (all P<0.001). * Significantly differ-
ent from t = 0 min (P<0.05). 
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Figure 4 depicts plasma enrichments of L-[1-13C]-phenylalanine. After ingestion of the 
protein beverage, plasma L-[1-13C]-phenylalanine enrichments increased (P<0.001), and 
remained elevated throughout the 4 h postprandial period. 
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Figure 4 | Plasma L-[1-13C]-phenylalanine enrichments. The 70 min NMES protocol is visualized by the grey
bar. Values are expressed as means±SEM. Data were analyzed with one-way repeated measures ANOVA with 
time as within-subjects factor. A significant time effect was found (P<0.001). * Significantly different from t = 
0 min (P<0.05). 
 
Muscle tracer analyses 
Muscle free L-[1-13C]-phenylalanine enrichments averaged 4.1±0.2 and 4.1±0.2 MPE at 
4 h after protein ingestion in the CON and NMES leg, respectively, which did not differ 
(P>0.05). Figure 5A depicts mixed muscle L-[1-13C]-phenylalanine enrichments following 
ingestion of 20 g casein in the CON and NMES leg. Four hours after the ingestion of 20 g 
casein protein, mixed muscle L-[1-13C]-phenylalanine enrichments did not differ be-
tween legs: 0.0164±0.0019 and 0.0164±0.0019 MPE in the CON and NMES leg, respec-
tively (P>0.05). L-[1-13C]-phenylalanine enrichments of the intracellular free amino acid 
pool were 4.074±0.183 and 4.115±0.163 MPE in the CON and NMES leg, respectively 
(P>0.05). 
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Figure 5 | Individual subjects’ mixed muscle (A) and myofibrillar protein-bound (B) L-[1-13C]-phenylalanine 
enrichments (MPE) over a 4 h period following ingestion of 20 g casein, in the CON and NMES leg. Data are
presented as means±SEM. 
 
Myofibrillar protein-bound L-[1-13C]-phenylalanine enrichments are presented in Figure 
5B. Ingestion of 20 g casein resulted in an increase in L-[1-13C]-phenylalanine enrich-
ments up to 0.0115±0.0014 and 0.0133±0.0013 MPE in the CON and NMES leg, respec-
tively (P>0.05).  
Signaling proteins 
The muscle phosphorylation status of selected proteins involved in the regulation of 
muscle protein synthesis is displayed in Figure 6. 
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Figure 6 | Skeletal muscle phosphorylation status (expressed as means±SEM) of selected proteins in the
control (CON) and stimulated (NMES) leg. Muscle samples were taken directly after (t = 0 min) ingestion of 20 
g casein protein, and 4 h thereafter (t = 240 min). * Significantly different from t = 0 min. # Significantly differ-
ent from CON. Abbreviations: mTOR, mammalian target of rapamycin; P70S6K, P70S6 kinase; RS6, ribosomal
protein S6. 
 
Data are expressed as the ratios between the phosphorylated protein and the total 
protein content. Directly after cessation of the NMES, for P70S6K, a higher phosphoryla-
tion status was observed in the NMES leg when compared to the CON leg (P<0.05, Fig-
ure 6B). Following protein ingestion, the phosphorylation status of mTOR (Figure 6A) 
significantly increased over time in the NMES leg only (interaction effect; P<0.05). No 
changes in the phosphorylation status of P70S6K were observed after protein ingestion 
between legs or over time. Despite a significant interaction effect for RS6 (Figure 6C; 
P<0.01), no changes over time were found in the CON and NMES legs. 
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D I S C U S S I O N  
In the present study we show that neuromuscular electrical stimulation (NMES) prior to 
protein ingestion does not augment the use of dietary protein derived amino acids for 
de novo muscle protein accretion in healthy, older males. Nevertheless, we observed 
significant increases in mTOR and P70S6K phosphorylation in muscle following the bout 
of NMES. 
Ageing is accompanied by declines in skeletal muscle mass and strength, called sar-
copenia [1]. Previous research has shown that the older population possesses a blunted 
skeletal muscle protein synthetic response to food intake, termed ‘anabolic resistance’ 
[4, 6, 9]. This anabolic resistance is now believed to represent a key factor in the etiolo-
gy of sarcopenia [6, 10]. In the current study, intake of a meal-like amount of 20 g in-
trinsically labelled casein led to a rapid increase in plasma amino acid concentrations 
(Figure 3), which was accompanied by an increase in plasma L-[1-13C]-phenylalanine 
enrichment that remained elevated for the entire 4 h postprandial period (Figure 4). 
This demonstrates a clear amino acid signal to stimulate anabolism as well as a tracer 
precursor allowing the determination of postprandial muscle protein accretion. Indeed, 
these dietary protein derived amino acids were rapidly used for de novo muscle protein 
synthesis, as evidenced by the ~0.016 MPE increase in muscle protein-bound L-[1-13C]-
phenylalanine in mixed muscle tissue and ~0.012 MPE in the myofibrillar fraction of the 
muscle tissue obtained in the control leg 4 h after protein ingestion (Figure 5). The use 
of intrinsically L-[1-13C]-phenylalanine labelled protein allows us to assess the percent-
age of the ingested protein that was released into the circulation and used for de novo 
muscle protein synthesis [31]. Based on the assumption that L-[1-13C]-phenylalanine 
enrichments in m. vastus lateralis would be representative of most other muscle 
groups, we calculated that a total of 0.037±0.004 g L-[1-13C]-phenylalanine had been 
incorporated in all appendicular lean tissue during the entire 4 h postprandial period. 
This translates to 2.0±0.2 g muscle protein, and equals 9.9±1.2% of the ingested dietary 
protein derived amino acids that were incorporated in de novo muscle protein. These 
data are in line with our recent calculations [31] and demonstrate the possibilities of 
using intrinsically labelled protein to demonstrate the metabolic fate of dietary protein 
derived amino acid in vivo in humans [29]. 
Physical activity performed prior to food intake has been shown to further increase 
postprandial muscle protein synthesis compared with food intake alone [16-20], and to 
augment the use of protein derived amino acids for de novo muscle protein synthesis 
[16]. Currently, it remains unknown to what extent the stimulating properties of physi-
cal activity are attributed to its impact on skeletal muscle perfusion or whether the 
effects are predominantly intramuscular. As maintaining or increasing physical activity 
can be compromised in various clinical and non-clinical settings, exercise mimetics such 
as NMES may be used to evoke involuntary contractions to reintroduce some level of 
physical activity. Indeed, previous work from our group has shown that local NMES can 
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increase postabsorptive muscle protein synthesis rates by as much as 27% when com-
pared to the non-stimulated, control leg [23]. To date, no studies have assessed the 
impact of NMES on the postprandial muscle protein synthetic response to feeding. In 
the current study, we assessed postprandial protein accretion following ingestion of a 
single bolus of intrinsically labelled protein in an electrically stimulated (NMES) and a 
non-stimulated, control leg. Despite the 70 min of neuromuscular electrical stimulation 
prior to protein ingestion we observed no differences in the muscle free L-[1-13C]-
phenylalanine enrichments or the deposition of dietary protein derived amino acids into 
de novo muscle protein between both legs (0.0164±0.0019 vs 0.0164±0.0019 MPE and 
0.0115±0.0014 vs 0.0133±0.0013 MPE for the increase in L-[1-13C]-phenylalanine en-
richment in mixed muscle protein and myofibrillar protein, respectively; Figure 5). Clear-
ly, a single session of NMES prior to protein ingestion was not sufficient to modulate the 
metabolic fate of the dietary protein derived amino acids and did not augment post-
prandial protein deposition in the stimulated leg of these healthy, older males. 
The postprandial stimulation of muscle protein synthesis is initiated by a phosphory-
lation cascade in which mammalian target of rapamycin (mTOR) and its downstream 
effectors P70S6 kinase (P70S6K) and ribosomal protein S6 (RS6) are key players [32, 33]. 
This pathway is not only activated by protein intake, but also by physical activity (as 
reviewed in [34]). Here we show that protein ingestion did not lead to changes in activa-
tion of mTOR, P70S6K, and RS6 in the control leg (Figure 6). This is not surprising con-
sidering our low dose of protein administered [35] as well as previous work showing the 
peak of this translation initiation process to generally occur 1-2 h following protein 
ingestion, and to subside thereafter [36-38]. Of course, the timing of our muscle biopsy 
collection that was chosen to optimally measure muscle protein-bound enrichments 
was likely not optimal for the detection of changes in anabolic signaling, which had 
probably subsided by then. However, we observed an early increase in the phosphoryla-
tion of P70S6K immediately following NMES (Figure 6). This is in agreement with our 
previous work demonstrating that an acute bout of NMES stimulates muscle protein 
synthesis in the postabsorptive state, possibly via a similar rise in P70S6K signaling [23], 
but is rather contradictory to previous studies showing an increase in P70S6K to occur 
only several hours after the cessation of exercise [36, 38]. Furthermore, we observed a 
significant increase in mTOR activation 4 h after NMES (Figure 6). This is in line with 
previous data showing greater mTOR phosphorylation at 4 h after NMES [23] and 3 h 
postexercise [39] in older individuals. Clearly, the NMES did induce an anabolic stimulus, 
but this did not seem strong enough to augment the postprandial muscle protein syn-
thetic response to feeding. 
Previously, we have shown that muscle loss during disuse can be prevented by the 
application of NMES in both young males during short-term immobilization [24] as well 
as in critically ill patients in a comatose state [25]. This has been, at least partly, at-
tributed to the increase in basal muscle protein synthesis rate that can be observed 
after performing a single session of NMES [23]. In the present study, we assessed 
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whether NMES augmenting the muscle protein synthetic response to feeding may go 
some way to explaining the beneficial effect on muscle retention during disuse. In con-
trast to our hypothesis, we failed to detect a stimulatory effect of NMES on postprandial 
muscle protein accretion. This implies that NMES may particularly impact upon basal 
protein synthesis rates, as opposed to postprandial protein handling, in healthy older 
men. Although muscle disuse is associated with anabolic resistance to food intake [38, 
40, 41], based on the present data it could be suggested that the observed efficacy of 
NMES to prevent disuse atrophy is primarily attained in the basal state [40, 42, 43]. 
Though our results demonstrate that NMES does not affect postprandial protein han-
dling in healthy, active individuals, we cannot exclude that NMES may modulate post-
prandial protein handling in a more clinically compromised state, where anabolic sensi-
tivity to food intake is further reduced [37, 38, 40, 41] or in fact under situations where 
larger amounts, or more anabolic dietary proteins are provided to older subjects. Obvi-
ously, the efficacy of NMES combined with nutritional support may be of particular 
relevance for older hospitalized patients, who are losing muscle partially due to low 
dietary protein intake [44-46]. Furthermore, it should be noted that we assessed the 
effect of a single bout of NMES only, and we cannot rule out any synergistic effects of 
multiple, repetitive NMES sessions performed over time. 
In conclusion, a single session of NMES prior to protein ingestion does not augment 
postprandial muscle protein accretion in healthy, older males. 
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A B S T R A C T  
Background Short periods of skeletal muscle disuse, due to illness or injury, result 
in substantial skeletal muscle atrophy. Recently, we showed that both 
neuromuscular electrical stimulation (NMES) as well as dietary protein 
ingestion prior to sleep represent effective strategies to stimulate 
muscle protein synthesis rates. In this study we test our hypothesis 
that NMES can augment the impact of protein ingestion prior to sleep 
to stimulate overnight muscle protein accretion. 
Methods Twenty healthy, elderly (69±1 y) males were subjected to 24 h of bed 
rest, starting at 8:00 AM. In the evening, subjects were subjected to a 
70 min one-legged NMES protocol, while the other leg served as non-
stimulated control (CON). Immediately following NMES, a drink con-
taining 40 g intrinsically L-[1-13C]-phenylalanine labelled protein was 
ingested prior to sleep. Repeated blood samples were taken through-
out the night, and muscle biopsies were obtained from both legs in 
the evening and on the following morning (8 h after protein ingestion) 
to assess dietary protein derived L-[1-13C]-phenylalanine enrichment 
in myofibrillar protein. 
Results  Plasma phenylalanine concentrations and L-[1-13C]-phenylalanine 
enrichments increased significantly following protein ingestion and 
remained elevated for up to 6 hours (P<0.05). During overnight sleep, 
myofibrillar protein-bound L-[1-13C]-phenylalanine enrichments in-
creased to a greater extent in the stimulated compared with the con-
trol leg (0.0344±0.0019 vs 0.0297±0.0016 MPE, respectively; P<0.01), 
representing 18±% greater incorporation in the NMES leg. 
Conclusion The combined application of NMES with protein feeding prior to sleep 
increases overnight muscle protein accretion in elderly men. 
  
 NMES and postprandial muscle protein accretion | 171 
I N T R O D U C T I O N  
Ageing is associated with a progressive loss of skeletal muscle mass, often referred to as 
sarcopenia [1]. The loss of muscle mass reduces strength, impairs functional capacity, 
and increases the risk of developing chronic metabolic diseases [2]. Sarcopenia is facili-
tated by a combination of factors, which include a reduced sensitivity to anabolic stimuli 
[3, 4], a less than optimal diet [5], and a more sedentary lifestyle [5]. It has recently 
been suggested that short successive periods of reduced physical activity, due to illness 
or injury, may form a key factor responsible for the progressive loss of muscle tissue in 
the older population [6]. To attenuate muscle loss during such short periods of bed rest 
in the elderly population, various interventional strategies have been suggested [7]. 
The ingestion of dietary protein directly stimulates muscle protein synthesis [8]. 
Aeging is associated with an impaired muscle protein synthetic response to feeding, 
previously coined ‘anabolic resistance’ [9]. Numerous research groups are now looking 
for effective dietary strategies to compensate for this anabolic resistance by increasing 
the amount of dietary protein ingested [10], changing the protein source applied [11, 
12], co-ingesting additional free leucine [13, 14] and altering the timing of protein in-
gestion [15]. Rather than improving the muscle protein synthetic response to the inges-
tion of a single meal, we investigated the possibility of increasing overnight muscle 
protein accretion by dietary protein administration prior to and/or during sleep [16, 17]. 
Our work shows that protein ingestion prior to sleep may represent an effective strate-
gy to stimulate overnight muscle protein synthesis, thereby providing a practical strate-
gy to attenuate muscle loss during periods characterized by anabolic resistance. 
Physical activity is severely restricted during a period of bed rest due to illness or in-
jury. The loss of physical activity reduces the muscle protein synthetic response to pro-
tein feeding [18, 19]. Neuromuscular electrical stimulation (NMES) represents an exer-
cise mimetic to allow muscle contractions to occur and may be used to attenuate disuse 
related anabolic resistance. In agreement, a single session of NMES has been shown to 
increase muscle protein synthesis rates [20]. Furthermore, NMES has been applied 
successfully to prevent muscle atrophy during 5 days of limb immobilization [21]. We 
hypothesize that NMES can further stimulate the muscle protein synthetic response to 
protein feeding, resulting in greater postprandial muscle protein accretion. 
We hypothesized that combining NMES with dietary protein feeding prior to sleep 
could further stimulate overnight muscle protein accretion. If supported, the combined 
application of NMES and protein feeding prior to sleep may be used to attenuate mus-
cle loss during short periods of hospitalization in a compromised elderly population. To 
test our hypothesis, we performed unilateral NMES in the evening after a day of bed 
rest in 20 healthy elderly males. Subjects ingested specifically produced intrinsically L-
[1-13C]-phenylalanine labelled protein [8] to assess overnight muscle protein accretion. 
By taking blood samples throughout the night and muscle biopsies before and after 
sleep from both legs we assessed overnight muscle protein accretion in the stimulated 
172 | CHAPTER 8 
and non-stimulated leg. This is the first study to show that the combined application of 
NMES and protein feeding prior to sleep stimulates overnight muscle protein accretion, 
thereby providing a novel interventional strategy to prevent or attenuate muscle loss 
during short periods of hospitalization in older subjects. 
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M E T H O D S  
Subjects 
Twenty healthy, elderly males (age: 69±1 y) were included in the present study that was 
approved by the Medical Ethical Committee of the Maastricht University Medical Cen-
tre in accordance with the Declaration of Helsinki. Prior to the study, subjects complet-
ed a routine medical screening and general health questionnaire to ensure their suita-
bility to participate. Exclusion criteria were: BMI below 18.5 or above 30 kg·m2, type 2 
diabetes mellitus (determined by oral glucose tolerance testing), severe cardiac prob-
lems, and implantation of a pacemaker and/or implantable cardioverter-defibrillator 
(ICD). Furthermore, subjects who had performed structured and prolonged resistance 
type exercise training during the 6 months prior to the study were excluded. All subjects 
were informed of the nature and possible risks of the experimental procedures, before 
their written informed consent was obtained. 
Pretesting 
Following an overnight fast, the subjects arrived at the laboratory at 8.00 AM in the 
morning of the day of pretesting by car or public transportation. A catheter (Baxter BV, 
Utrecht, the Netherlands) was inserted into an antecubital vein for venous blood sam-
pling. All participants performed an oral glucose tolerance test before inclusion in the 
study. Plasma glucose concentrations were measured to determine oral glucose toler-
ance and/or the presence of type 2 diabetes according to 2006 American Diabetes As-
sociation guidelines [22]. Leg volume was measured by anthropometry as described by 
Jones and Pearson [23]. Directly after the oral glucose tolerance test, body weight, body 
composition, and bone mineral content were measured with Dual Energy X-Ray Absorp-
tiometry (DXA; Lunar Prodigy Advance; GE Health Care, Madison, WI, USA). The sys-
tem’s software package (en-CORE 2005, version 9.15.00) was used to determine whole-
body and regional lean and fat mass. Finally, all subjects performed a short session of 
neuromuscular electrical stimulation (NMES) to familiarize them with the intervention 
and to determine the required stimulation intensity for full muscle contractions during 
testing. 
Diet and physical activity prior and during testing 
All volunteers were instructed to refrain from any vigorous physical activity and to keep 
their diet as constant as possible 3 days prior to the trial. On the day of the experiment, 
subjects consumed a standardized breakfast, mid-morning snack, lunch, mid-afternoon 
snack, and dinner while being in the hospital. The standardized diet (3 meals and 2 
snacks) provided 7.7 MJ, with 60% energy (En%) provided by carbohydrate, 22 En% 
provided by fat, and 18 En% provided by protein. Total protein intake averaged 
1.35±0.02 g·kg body weight -1 during the test day. 
174 | CHAPTER 8 
Study protocol 
After inclusion, one of the subjects’ legs was randomly allocated to receive neuromus-
cular electrical stimulation (NMES), while the other leg served as a (non-stimulated) 
control (CON) leg. The experimental protocol is depicted in Figure 1. 
 
 
Figure 1 | Outline of the experimental protocol. NMES, neuromuscular electrical stimulation. 
 
At 8.00 AM, following an overnight fast, subjects arrived at the laboratory where a first 
blood sample was obtained by venipuncture to determine fasting plasma glucose and 
insulin levels. During the rest of the day, subjects remained in a supine position in their 
hospital bed. At 7:30 PM, A Teflon catheter was inserted in a dorsal hand vein for blood 
sampling and a first blood sample (8 mL) was drawn at 8:00 PM. At night, a 30 cm ex-
tension line was connected to the cannula to allow overnight blood sampling without 
waking the subjects. A 70 min NMES protocol was performed at 9:30 PM. Immediately 
following the NMES, a muscle biopsy was collected from the vastus lateralis muscle (t = 
0 h) from both legs (NMES and CON). Directly after the biopsy procedure, subjects re-
ceived the test drink, consisting of 40 g intrinsically L-[1-13C]-phenylalanine labelled 
casein protein dissolved in a total volume of 450 mL. After consuming the test drink, 
subjects prepared to go to sleep. Blood samples (8 mL) were collected at t = 0, ½, 1, 2, 
4, 6 and 8 h after protein feeding. The next morning, directly after waking up, muscle 
biopsies from both legs were taken from a new incision, proximal from the first incision, 
at t = 8 h after protein feeding. 
Venous blood samples were collected into EDTA-containing tubes and centrifuged at 
1000g for 10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen and stored at 
−80°C unƟl further analysis. Muscle biopsy samples were obtained from the middle 
region of the vastus lateralis muscle, 15 cm above the patella and ~3 cm below entry 
through the fascia using the percutaneous needle biopsy technique [24]. Muscle biopsy 
samples were carefully dissected and freed from any visible non-muscle material and 
then immediately frozen in liquid nitrogen and stored at −80°C unƟl further analysis. 
Time
NMES
23:00 1:00 3:00 5:00 7:0021:008:00
CON leg
NMES leg
Blood draw
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Neuromuscular electrical stimulation 
All subjects performed a single session of neuromuscular electrical stimulation (NMES) 
and a simultaneous sham session (CON) at the opposite leg at 9:30 PM. During this 
session, subjects were lying supine and electrodes were placed on the distal part at the 
muscle belly of the m. rectus femoris and the m. vastus lateralis, and at the inguinal 
area of both muscles. Stimulation was provided by an Enraf-Nonius TensMed S84 stimu-
lation device (Enraf-Nonius, Rotterdam, the Netherlands) and four, 2 mm-thick, self-
adhesive electrodes (50 x 50 mm), discharging biphasic symmetric rectangular-wave 
pulses. The NMES protocol comprised of a warm-up phase (5 min, 5 Hz, 250 µs), a stim-
ulation phase (60 min, 100 Hz, 400 µs, 5 s on (0.75 s rise, 3.5 s contraction, 0.75 s fall) 
and 10 s off), and a cooling-down phase (5 min, 5 Hz, 250 µs). Subjects set the intensity 
of the stimulation to a level at which full contractions of m. quadriceps femoris were 
both visible and palpable, and the heel began to slightly lift. This protocol was based on 
our previous work [25] demonstrating an increase in muscle protein synthesis during a 6 
h period following a single bout of NMES. The same protocol was also used in a previous 
study showing that high-frequency (>60 Hz), high pulse duration (>250 µs) NMES is 
effective in preventing muscle atrophy during short-term muscle disuse [21]. Subjects 
were encouraged to increase the intensity of the stimulation during the entire session 
to provide a ‘progressive’ stimulus. The maximal intensity of the 70 min NMES session 
averaged 36.2±1.8 mA, whereas the average intensity across all sessions and all subjects 
was 27.3±1.3 mA. All subjects completed the NMES protocol. 
Intrinsically labelled protein 
 Intrinsically L-[1-13C]-phenylalanine-labelled casein protein was obtained by infusing a 
Holstein cow with large quantities of L-[1-13C]-phenylalanine, collecting milk, and purify-
ing the casein fraction as described previously [26]. The L-[1-13C]-phenylalanine enrich-
ment in the casein fraction averaged 35.8 mole percent excess (MPE). The casein pro-
tein met all chemical and bacteriological specifications for human consumption. Sub-
jects received a total beverage volume of 450 mL, which provided 40 g casein protein. 
Drinks were flavored by adding 2 mL vanilla flavor (Givaudan, Naarden, the Nether-
lands) per L beverage. 
Plasma analyses 
Plasma glucose (Uni Kit III, 07367204, Roche, Basel, Switzerland) concentrations were 
analyzed with the COBAS-FARA semi-automatic analyzer (Roche). Insulin was analyzed 
by radio-immunoassay (Insulin RIA kit, LINCO Research Inc., St. Charles, MO, USA). 
Plasma amino acid concentrations and enrichments were determined by GC-MS (Ag-
ilent 7890A GC/5975C; MSD, Little Falls, DE, USA). Specifically, internal standards of [U-
13C6]-leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-tyrosine were added to the 
samples. The plasma was deproteinized on ice with dry 5-sulfosalicylic acid. Free amino 
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acids were purified using cation exchange AG 50W-X8 resin (mesh size: 100-200, ionic 
form: hydrogen (Bio-Rad Laboratories, Hercules, CA, USA)) columns. The free amino 
acids were converted to their tert-butyl dimethylsilyl (TBDMS) derivative before analysis 
by GC-MS. The amino acid concentrations were determined using electron impact ioni-
zation by monitoring ions at mass/charge (m/z) 302 and 308 for unlabelled and [U-13C6]-
leucine respectively, 336 and 346 for unlabelled and [U-13C915N]-phenylalanine, respec-
tively. For L-[1-13C]-phenylalanine, m/z 336 (m+0) and 337 (m+1) were monitored. 
Standard regression curves were applied from a series of known standard enrichment 
values against the measured values to assess the linearity of the mass spectrometer and 
to account for any isotope fractionation that may have occurred during the analysis. 
Phenylalanine enrichments were corrected for the presence of the 13C isotopes. Stand-
ard regression curves were applied in all isotopic enrichment analyses to assess the 
linearity of the mass spectrometer and to control for the loss of tracer. Enrichments 
(MPE) were corrected for the natural abundance of 13C phenylalanine [27]. 
Muscle analyses 
Myofibrillar protein enriched fractions were extracted from wet muscle tissue as de-
scribed previously [28]. In short, ~50 mg wet muscle tissue was manually homogenized 
on ice using a Teflon pestle in a standard extraction buffer, after which the samples 
were centrifuged and the supernatants containing sarcoplasmic proteins were re-
moved. In an additional step, the collagen-containing supernatant was removed. The 
remaining myofibrillar fraction was purified and hydrolyzed, such that the free amino 
acids remained and could be dried. The enrichment of the derivative was measured by 
GC-C-IRMS (MAT 253; Thermo Scientific, Bremen, Germany) by using a DB5DB5-MS-
column (no. 122122-5532; Agilent J+W, USA), GC Isolink, and monitoring of ion masses 
44, 45 and 46. By establishing the relationship between the enrichment of a series of L-
[1-13C]-phenylalanine standards of variable enrichment, the myofibrillar protein-bound 
enrichment of phenylalanine was determined. Standard regression curves were applied 
to assess the linearity of the mass spectrometer and to control for the loss of tracer. 
Muscle protein deposition from the ingested casein over the 8 h postprandial period 
was expressed in the relative increase of L-[1-13C]-phenylalanine enrichment in muscle 
tissue. 
Statistics 
All data are expressed as means±SEM. Differences in baseline leg values (i.e. NMES vs 
CON) were determined using a paired, two-tailed Student’s t-Test. Differences in pro-
tein-bound L-[1-13C]-phenylalanine enrichments and FSR between the NMES and CON 
legs after 8 h incorporation were analyzed using a paired-samples t-test. In case of a 
significant effect, a post hoc test with Bonferroni correction was used to locate signifi-
cant differences. Statistical significance was set at P<0.05. All calculations were per-
formed by using the SPSS statistics 22 software package (SPSS Inc., Chicago, IL, USA). 
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R E S U L T S  
Plasma analyses 
Plasma insulin concentrations are presented in Figure 2. Provision of intrinsically la-
belled casein resulted in a small but significant increase in circulating plasma insulin 
concentrations (time effect; P<0.001). Plasma insulin concentrations averaged 20.6±2.4 
mU·L-1 during the overnight period, and reached peak values of 34.7±5.9 mU·L-1 (P<0.01 
versus t = 0). 
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Figure 2 | Plasma insulin concentrations, expressed as means±SEM. Data were analyzed with repeated
measures ANOVA. Plasma insulin: time effect, P<0.001. 
 
Plasma glucose concentrations declined following protein ingestion (time effect; 
P<0.001), and became significantly different from baseline values from t = 2 h onwards 
(P<0.05). Overnight plasma glucose concentrations averaged 5.6±0.1 mmol·L-1. Figure 3 
depicts plasma leucine and phenylalanine concentrations during the overnight period. 
At the start of the experiment, fasting plasma leucine and phenylalanine concentrations 
averaged 133±4 and 57±1 μM, respectively. In the evening, prior to ingestion of the 
protein drink, concentrations averaged 138±7 and 64±1 μM, respectively. Directly after 
protein ingestion (∼10:30 PM), plasma leucine and phenylalanine concentrations in-
creased rapidly (time effects; P<0.001), and remained elevated throughout most of the 
night. Peak plasma leucine (284±11 μM) and phenylalanine (89±3 μM) concentrations 
were reached at 182±19 and 155±25 min after protein ingestion, respectively. 
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Figure 3 | Plasma leucine (A) and phenylalanine (B) concentrations. Values are expressed as means±SEM. Data
were analyzed with repeated measures ANOVA. Plasma leucine: time effect, P<0.001; plasma phenylalanine: 
time effect, P<0.001; *Significantly different from baseline value. 
Stable isotope tracer analyses 
Plasma L-[1-13C]-phenylalanine enrichments over time are presented in Figure 4. Plasma 
L-[1-13C]-phenylalanine enrichments increased rapidly after ingestion of the intrinsically 
L-[1-13C]-phenylalanine labelled casein protein, with plasma L-[1-13C]-phenylalanine 
enrichment levels reaching peak values of 12.2±0.5 MPE at 174±16 min after protein 
consumption. Plasma L-[1-13C]-phenylalanine enrichments remained significantly ele-
vated for the remaining night (time effect; P<0.001). 
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Figure 4 | Plasma L-[1-13C]-phenylalanine enrichments. Values are expressed as means±SEM. Data were
analyzed with repeated measures ANOVA. Plasma phenylalanine: time effect, P<0.001; *Significantly different 
from baseline values. 
 
Myofibrillar muscle protein-bound L-[1-13C]-phenylalanine enrichments are presented in 
Figure 5. Muscle tissue analyses were performed on muscle biopsy samples collected 
before, and 8 h after ingestion of the intrinsically L-[1-13C]-phenylalanine labelled ca-
sein. After the 8 h overnight period, L-[1-13C]-phenylalanine enrichments had increased 
up to 0.0297±0.0016 MPE in the CON leg and 0.0344±0.0019 MPE in the NMES leg, 
(P<0.01), representing 18±6% greater enrichments in the NMES leg compared with the 
CON leg. 
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Figure 5 | Muscle tissue L-[1-13C]-phenylalanine enrichments. Values are expressed as means±SEM. Data were
analyzed with a paired student’s t-test. *Significantly different from the control leg (P<0.01). 
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D I S C U S S I O N  
The present study demonstrates for the first time that ingestion of 40 g casein protein 
prior to sleep leads to overnight de novo myofibrillar protein accretion in healthy, elder-
ly men after a day of bed rest. The overnight accretion of newly formed muscle protein 
was augmented when neuromuscular electrical stimulation (NMES) was applied prior to 
protein ingestion. 
Short periods of bed rest or immobilization due to injury or illness lead to substantial 
loss of skeletal muscle mass and strength [29-32]. The decline in muscle tissue has 
been, at least partly, attributed to a blunted muscle protein synthetic response to food 
ingestion [33]. This so-called anabolic resistance to protein ingestion can be compen-
sated for by changing the dietary protein source [34, 35], the amount of ingested pro-
tein [36-38] and/or the distribution of protein intake throughout the day [39-41]. Re-
cently, we introduced the concept of stimulating overnight muscle protein synthesis by 
providing dietary protein during sleep in older males [16]. Intragastric protein admin-
istration via a nasogastric tube during overnight sleep was followed by proper dietary 
protein digestion and absorption, which increased plasma amino acid availability and 
stimulated de novo muscle protein synthesis in healthy elderly males [16]. In the current 
study, 40 g casein protein was ingested prior to sleep to test the concept of nighttime 
protein feeding in a more practically applicable manner. We show that pre-sleep inges-
tion of intrinsically L-[1-13C]-phenylalanine labelled casein leads to a substantial post-
prandial rise in circulating plasma phenylalanine concentrations (Figure 3) and L-[1-13C]-
phenylalanine enrichments (Figure 4). The increase in plasma L-[1-13C]-labelled phenyl-
alanine clearly demonstrates that protein ingested prior to sleep is followed by proper 
digestion and absorption throughout the remainder of the night. Dietary protein de-
rived amino acids were subsequently used for de novo myofibrillar protein synthesis as 
evidenced by the increase in myofibrillar protein-bound L-[1-13C]-phenylalanine enrich-
ment in both legs in the 8 h following protein ingestion (Figure 5). The results of our 
study are in line with our previous findings and show that protein ingestion prior to 
sleep leads to proper protein digestion, amino acid absorption and net myofibrillar 
protein accretion throughout overnight sleep [16], and demonstrate that protein inges-
tion prior to sleep forms a practical and effective nutritional strategy to stimulate over-
night muscle protein accretion. 
Besides dietary protein ingestion, physical activity is a key anabolic stimulus that is 
required to preserve skeletal muscle mass. In a clinical setting, lack of sufficient physical 
activity causes anabolic resistance [33], resulting in rapid muscle loss [3, 42, 43]. Recent-
ly we introduced NMES as a surrogate for physical activity to increase the sensitivity of 
skeletal muscle tissue to the anabolic properties of protein administration [44] and, as 
such, to attenuate muscle mass loss during a short period of immobilization [21]. We 
hypothesized that NMES performed in the evening sensitizes skeletal muscle tissue to 
the anabolic properties of overnight protein feeding. In the present study, we electrical-
ly stimulated one leg, whereas the other leg was sham stimulated. This means that 
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electrodes and wiring were applied to both legs but only one leg was actually electrically 
stimulated. After protein feeding, the stimulated leg showed an 18±6% greater increase 
in muscle protein-bound L-[1-13C]-phenylalanine enrichment when compared with the 
control leg (0.0344±0.0019 vs 0.0297±0.0016, respectively) assessed over 8 hours of 
subsequent sleep (P<0.01; Figure 5). NMES effectively increased the sensitivity of the 
skeletal muscle tissue to protein feeding with more of the ingested protein being di-
rected towards de novo muscle protein accretion during overnight sleep. 
NMES has been proposed as an interventional strategy that can be used to evoke in-
voluntary muscle contraction during muscle disuse, when individuals experience diffi-
culties performing voluntary muscle contraction. The combined application of NMES 
and protein feeding prior to sleep may be of particular relevance in more clinically com-
promised individuals. An interesting population that could benefit greatly from such an 
intervention are clinically compromised elderly subjects that are hospitalized for a short 
period following a fall and/or a fracture. Most elderly individuals have difficulty regain-
ing skeletal muscle mass after a short period of disuse [45], which impairs rehabilitation 
and contributes greatly to the development of frailty. Therefore, interventional strate-
gies that can preserve skeletal muscle mass during a short period of muscle disuse are 
of paramount importance. From a practical point of view, the use of NMES has been 
shown to be both applicable and feasible during muscle disuse. In all studies performed 
in our laboratory [20, 21], the treatment was well tolerated and no contra-indications or 
side effects were observed. Furthermore, the costs associated with NMES are relatively 
low, and hospital staff can easily apply the technique. Long-term effects of this treat-
ment on muscle mass remain to be investigated, but we expect our results to be appli-
cable for bedridden patients as we have even observed muscle mass preservation fol-
lowing the application of NMES in a setting of accelerated muscle loss in comatose 
patients [46]. 
In conclusion, this is the first study to show that protein ingestion prior to sleep rep-
resents an effective interventional strategy to stimulate overnight skeletal muscle pro-
tein accretion in vivo in healthy, older men. The application of NMES in the evening can 
further augment postprandial muscle protein accretion following protein ingestion prior 
to sleep. The application of NMES combined with protein ingestion prior to sleep repre-
sents a feasible strategy to optimize overnight muscle protein accretion, and may be of 
great clinical benefit to attenuate muscle loss in clinically compromised individuals. 
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A B S T R A C T  
Background Short periods of muscle disuse, caused by injury or illness, result in a 
loss of muscle mass and strength. Muscle disuse can be localized to a 
limb (i.e. leg immobilization due to bone fracture), or may occur on a 
whole-body level (i.e. bed rest during critical illness or following sur-
gery). A direct comparison of the rate of muscle atrophy and loss of 
muscle strength between both conditions is lacking. We tested our 
hypothesis that one week of bed rest leads to greater muscle loss 
when compared with limb immobilization. 
Methods Twenty healthy, young (23±1 y) males were subjected to 7 days of 
either leg immobilization via a full leg cast (n=10), or strict bed rest 
(n=10). Before and immediately after the disuse period, single-slice 
CT-scans and one-Repetition Maximum (1RM) strength tests were 
performed to assess quadriceps cross-sectional area (CSA) and maxi-
mal leg muscle strength, respectively. Additionally, muscle biopsies 
were taken from m. vastus lateralis to assess muscle fibre-type specif-
ic CSA. 
Results  Seven days of muscle disuse resulted in a substantial decline in quad-
riceps CSA in both the limb immobilization (-5.4±1.0%) and bed-rested 
(-3.2±0.9%; P<0.01) group (P<0.001), with no significant differences 
between groups (P>0.05). Maximal leg muscle strength declined by 
6±3% and 8±2%, respectively (P<0.01), with no differences between 
groups (P>0.05). No significant changes in type I and II muscle fibre 
CSA were observed within one week of disuse (P>0.05). 
Conclusion Seven days of muscle disuse following leg immobilization and bed rest 
leads to substantial declines in skeletal muscle mass and strength. Alt-
hough the rate of muscle atrophy does not differ between both mod-
els of disuse, more total lean mass is lost following bed rest compared 
with single leg immobilization. 
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I N T R O D U C T I O N  
An injury or illness often requires a short period of muscle disuse in an otherwise 
healthy person. Such short periods are generally mandated to facilitate recovery, but 
concurrently cause substantial loss of muscle mass and strength [1-3]. Such skeletal 
muscle disuse has been shown to lead to various negative health consequences such as 
an increase in fat mass [4, 5], a decline in basal metabolic rate [6, 7], and the develop-
ment of glucose intolerance and insulin resistance [8, 9]. Preservation of muscle mass 
during short periods of disuse is of important clinical relevance and deserves more fo-
cus in present clinical research. 
Muscle disuse can be localized to a limb, such as seen following arm or leg immobili-
zation after ligament damage or bone fracture. Alternatively, bed rest may be required 
following trauma, surgery, or during (critical) illness. Both limb immobilization [1-3, 10-
13] and bed rest [4, 9, 14-17] have been shown to be accompanied by substantial de-
clines in both muscle mass and strength (as reviewed in [18]). The extent of muscle 
mass and strength loss is likely dependent upon the amount of muscle tissue that is 
subjected to disuse. Whereas muscle loss during limb immobilization can be regarded 
as a direct result of local muscle disuse, bed rest may result in greater muscle loss due 
to the amount of muscle tissue that experiences disuse as well as various systemic fac-
tors (e.g. hormonal changes [9, 19-21], or systemic inflammation [22]) that may in-
crease the rate of muscle atrophy. In the current scientific literature, both models are 
typically applied to investigate the impact of disuse on the loss of muscle mass and 
function. However, whether both models of disuse actually lead to comparable local 
muscle loss remains to be assessed. 
In the present study, we compare the rate of muscle atrophy and loss of muscle 
strength following one week of one-legged knee immobilization versus one week of 
strict bed rest. We hypothesized that the rate of muscle atrophy would be greater dur-
ing bed rest when compared with leg immobilization. To test our hypothesis, we sub-
jected 20 healthy, young males to 7 days of either single leg immobilization or strict bed 
rest. Measures of muscle mass, muscle strength, and muscle fibre type-specific cross-
sectional area were performed to investigate the impact of both models of muscle dis-
use.  
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M E T H O D S  
Participants 
Between September 2013 and April 2015, 20 healthy, young males (age: 23±1 y, BMI 
23.2±0.7 kg·m-2) were included in the present study. These volunteers were part of two 
previous studies (NCT02109380/NCT01894737) which represented part of a larger 
project investigating the role of muscle disuse on muscle mass and function. The cur-
rent article describes a comparison between age- and BMI-matched male participants 
who underwent 7 days of either single leg immobilization or bed rest. Prior to inclusion, 
participants completed a general health questionnaire and routine medical screening to 
ensure their eligibility to participate. Male individuals, 18-35 years old, were excluded if 
they matched one or more of the following exclusion criteria: BMI below 18.5 or above 
30 kg·m-2, a (family) history of thrombosis, diabetes mellitus, and any back, knee or 
shoulder complaints. Furthermore, individuals who underwent surgery or participated 
in progressive resistance training in the past 6 months were excluded from participa-
tion. The present study was approved by the Medical Ethical Committee of Maastricht 
University Medical Centre in accordance with the Declaration of Helsinki. All partici-
pants were informed on the nature and possible risks of the experimental procedures, 
after which written informed consent was obtained. As part of the screening visit, an 
estimation of one-Repetition Maximum (1RM) knee extension strength (Technogym, 
Rotterdam, the Netherlands) was made by using the multiple repetitions testing proce-
dure [23]. 
Experimental outline 
Twenty-four to 48 h prior to, and immediately after the period of disuse, participants 
visited the laboratory in a fasted state for 2 identical test days (i.e. test days 1 and 2) 
during which measures of muscle mass and function were performed. On test day 1, 
firstly, a single-slice CT scan of the upper leg was performed. Next, a muscle biopsy was 
taken from the vastus lateralis muscle. Lastly, a 1RM leg strength test was performed. 
One or two days later, participants returned to the laboratory to start their period of 
muscle disuse (described below). A second test day was performed following 7 days of 
muscle disuse. On that day, the CT scan and muscle biopsy sampling were completed 
before any weight bearing was performed. 
One week of muscle disuse 
Participants were subjected to 7 days of muscle disuse via a leg cast, or by means of strict 
bed rest. Forty-eight h following test day 1, participants in the immobilization group 
reported to the plaster room of the Maastricht University Medical Centre at 8:00 AM on 
the first day of the immobilization period for the application of a full leg cast. The cast 
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extended from halfway up the upper leg (~25 cm above the patella) until ~5 cm above 
the ankle. The cast was applied with the knee joint in an approximate 30 degree angle of 
flexion to prevent participants from performing weight-bearing activities with the immo-
bilized leg. Participants received crutches and were given instructions on their correct 
usage. Application of the cast signified the beginning of the immobilization period, which 
ended following exactly 7 days by cast removal, immediately prior to test day 2. 
Participants who were included in the bed rest group reported to the laboratory on 
the morning after test day 1, to start a 7-day period of strict bed rest at 8:00 AM. From 
that moment on, participants remained in a (semi-) supine position. They were allowed 
to use a pillow and slightly elevate the bed-back to perform their daily activities. All 
hygiene and sanitary activities were done while lying down. The bed rest period ended 
after exactly 7 days, immediately prior to test day 2. 
Muscle mass 
During test days 1 and 2, anatomical cross-section of the quadriceps, hamstring, and 
whole-thigh muscles, as well as leg circumference, were assessed via a single-slice 
Computed Tomography (CT) scan (Philips Brilliance 64, Philips Medical Systems, Best, 
the Netherlands). Images were obtained by using the following scanning characteristics: 
120 kV, 300 mA, rotation time of 0.75 s, and a field of view of 500 mm. While the partic-
ipants were lying supine, legs extended and their feet secured, a 3 mm thick axial image 
was taken 15 cm proximal to the top of the patella. To ensure proper replication of the 
scanning position on test day 2, the precise scanning location was marked with semi-
permanent ink on test day 1. CT-scans were analysed for the CSA of quadriceps, ham-
string, and whole-thigh muscles, as well as leg circumference, by manual tracing using 
ImageJ software version 1.49s (National Institute of Health, Maryland, USA, [24]) using 
0-100 Hounsfield Units for muscle tissue [25]. 
Muscle strength 
Maximum leg strength was evaluated by a 1RM strength test on a leg extension ma-
chine (Technogym). The estimated 1RM values during the screening visit were used to 
determine 1RM as described previously [26]. For the participants in the immobilization 
group, leg strength was measured during a one-legged test with the immobilized leg, 
whereas two-legged 1RM was assessed in the bed rested group. 
Muscle tissue sampling 
During test day 1 and 2, a muscle biopsy was collected from m. vastus lateralis via the 
Bergström technique [27], at approximately 15 cm above the patella. Any visible non-
muscle tissue was removed, and the biopsy was carefully embedded in Tissue Tek (Sa-
kura Finetek, Zoeterwoude, the Netherlands) and frozen in liquid nitrogen-cooled iso-
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pentane. Muscle samples were subsequently stored at -80°C until the analysis were 
performed. 
Dietary intake 
On the evening prior to both test days, participants consumed a controlled meal to 
standardize food intake. During the period of muscle disuse, participants in the immobi-
lization group were instructed to maintain their habitual food intake. Prior to and during 
the immobilization period, participants filled in 3-day dietary records, which were sub-
sequently analysed by Dieetinzicht software (www.dieetinzicht.nl, based on NEVO table 
2011). During the immobilization period, participants reported average energy intakes 
of 8.0 MJ·d-1 and protein intakes of 1.1 g·kg body weight-1·d-1, which was not different 
from their habitual diet (P>0.05). Participants in the bed rest group were fed standard-
ized nutrition for 7 days prior to and during the 7 day bed rest period, based on indirect 
calorimetry measurements for basal metabolic rate and an activity factor of 1.55 and 
1.35, respectively. This resulted in an energy intake of 9.2 MJ·d-1 and protein intake of 
0.98 g·kg body weight-1·d-1 during bed rest. 
Muscle tissue analyses 
In preparation for muscle fibre analyses, a section of muscle mounted and frozen in 
Tissue-Tek was cut into 5µm thick cryosections using a cryostat at -20°C. Pre- and post-
disuse samples of each subject were mounted together on uncoated, pre-cleaned glass 
slides, thereby carefully aligning the samples for cross-sectional fibre analyses. An im-
munohistochemical staining was performed to assess muscle fibre-type specific cross-
sectional area (CSA) as described below. Tissue was fixated in acetone for 5 min, after 
which the slides were air dried and incubated with 3% BSA in 0.1% Tween-PBS for 30 
min. After rinsing with PBS for 5 min, slides were incubated with primary antibodies 
directed against myosin heavy chain (MHC)-I (A4.840, dilution 1:25; DSHB) and laminin 
(polyclonal rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) for 
30 min. Next, slides were washed and the appropriate secondary antibodies were ap-
plied: goat anti-rabbit IgG AlexaFluor647 and goat anti-mouse IgM AlexaFluor555 (dilu-
tion 1:400 and 1:500, respectively; Molecular Probes). Both primary and secondary 
antibodies were diluted in 0.1% Bovine Serum Albumin (BSA) in 0.1% Tween- phos-
phate-buffered saline (PBS). All incubation steps were performed at room temperature. 
After a last washing step, cover glasses were mounted by Mowiol (Calbiochem, Amster-
dam, the Netherlands). As a result of the staining procedure, MHC-I was stained in red 
and laminin in far-red. On the next day, images were visualized and automatically cap-
tured at 10x magnification with a Olympus BX51 fluorescence microscope with custom-
ized spinning disk unit (DSU; Olympus, Zoeterwoude, the Netherlands) with a ultra-high 
sensitivity monochrome electron multiplier CCD camera (1000 x 1000 pixels, C9100-02, 
Hamamatsu Photonics, Hamamatsu City, Japan). Image acquisition was done by Mi-
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cromanager 1.4 software [28], and images were analysed with ImageJ. Recording and 
analysing of the images was performed by an investigator blinded to subject coding. As 
a measure of fibre circularity, form factors were calculated by using the following for-
mula: (4π·CSA)·(perimeter)-2. No difference in fibre circularity was observed between 
pre- and post-disuse samples. On average, 203±24 and 234±33 muscle fibres were ana-
lysed in the pre- and post-disuse samples, respectively. 
Statistics 
All data presented are expressed as means±standard error of the mean (SEM). An inde-
pendent samples t-test was used at baseline to test for differences between groups. 
Pre- versus post-intervention data were analysed using Repeated Measures ANOVA 
with time (pre vs post) as within-subjects factor and treatment (immobilization vs bed 
rest) as between-subjects factor. For muscle fibre-specific analysis, fibre type (type I vs 
type II) was added to the Repeated Measures ANOVA as a within-subjects factor. In case 
of a significant interaction, paired t tests were performed to determine time effects 
within groups or within type I or II fibres, and independent t tests for group differences 
in the pre- and post-intervention values. All statistical analyses were performed using 
SPSS version 22.0 (SPSS Inc., Chicago, IL, USA), and P<0.05 was used to determine statis-
tical significance.  
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R E S U L T S  
Participants 
Participants’ characteristics are displayed in Table 1. No difference between the immo-
bilization and bed rest groups were observed for any of the parameters. 
 
Table 1 | Participants' characteristics 
 Immobilization (n=10) Bed rest (n=10) P-value 
Age (y) 23 ± 1 23 ± 1 0.942 
Body weight (kg) 72.3 ± 4.1 74.9 ± 2.3 0.601 
Height (m) 1.76 ± 0.03 1.81 ± 0.02 0.208 
BMI (kg·m-2) 23.5 ± 1.1 23.0 ± 0.9 0.756 
Values represent means±SEM. BMI, body mass index 
Muscle mass 
Quadriceps cross-sectional area (CSA) declined following 7 days of disuse in both groups 
though no significant interaction based on treatment was observed (Figure 1; time ef-
fect P<0.001, time x treatment interaction P=0.097), such that in the immobilization 
group a 5.4±1.0% decline (from 7646±399 to 7229±373 mm2) was observed and partici-
pants in the bed rest group lost 3.2±0.9% (from 7900±315 to 7664±354 mm2). Whole-
thigh muscle CSA decreased similarly in both groups (mean decline -2.8±0.6%; P<0.001), 
whereas no change in hamstring CSA was observed (P>0.05). Leg circumference de-
clined following the intervention, without differences between groups (mean decrease -
1.1±0.2%, P<0.001). Hounsfield units (HUs) from the whole-thigh muscle increased in 
the bed rest group only (time x treatment interaction; P<0.05), whereas HUs from the 
quadriceps increased similarly in both groups (P<0.01). On a muscle fibre level, no 
changes in muscle fibre CSA of type I (6132±539 to 6290±654 and 6650±725 to 
6218±662 μm2) or II fibres (7561±728 to 7166±714 and 6542±746 to 5982±525 μm2) 
were observed following 7 days of either leg immobilization or bed rest, respectively. 
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Figure 1 | Cross-sectional area of m. quadriceps femoris in the immobilization and bed rest group, before and
after 7 days of muscle disuse, as measured by single-slice CT scan. Values are presented as means±SEM. Data
were analysed with a Repeated Measures ANOVA with treatment and time as factors, and demonstrated a
significant time effect (P<0.001) with no differences between groups (P>0.05). * Significantly different from 
pre 
Muscle strength 
In the immobilization group, one-legged maximal strength declined from 56±5 to 53±5 
kg, representing a 6±3% decline. In the bed rest group, two-legged maximal strength 
decreased from 128±7 to 117±7 kg, which represented an 8±2% decline in leg strength. 
The decline in muscle strength was significant in both groups (time effect, P<0.01), with 
no differences between groups (time x treatment interaction; P=0.522). 
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D I S C U S S I O N  
The current study is the first to directly compare the rate of muscle atrophy and the loss 
of muscle strength following a short period of single leg immobilization versus bed rest. 
We demonstrate that 7 days of leg immobilization and bed rest lead to a 4.3±0.7% de-
cline in muscle mass and a concomitant 7±1% decline in muscle strength. Whereas local 
leg muscle loss did not differ between models, more lean mass was lost following bed 
rest compared with leg immobilization. 
A short period of muscle disuse, which is often necessary for the recovery from inju-
ry or illness, leads to negative health consequences such as the loss of muscle mass and 
strength [1-3], a decline in basal metabolic rate [6, 7], and the development of insulin 
resistance [9]. The two most widely used models to study muscle disuse are bed rest 
and limb immobilization. While both models have been shown to result in substantial 
muscle loss, there are fundamental differences between these experimental settings 
such as the total amount of muscle tissue subjected to disuse, the extent to which free 
movements are possible, and the amount of weight bearing that can be performed. 
Moreover, it is important to acknowledge that in a bed rest setting, systemic factors 
may contribute to greater rates of muscle atrophy [29, 30]. Consequently, we hypothe-
sised that bed rest would elicit a greater local rate of muscle atrophy when compared 
with single leg immobilization. Contrary to our hypothesis, we report an equivalent 
decline in muscle mass following short-term muscle disuse in both models. Irrespective 
of the model, we show that seven days of disuse leads to ~0.6% muscle loss per day 
when assessed at the level of the leg (Figure 1). These data are in line with previous 
work showing an approximate 0.5-0.7% muscle loss per day during muscle disuse (as 
reviewed in [18]). By way of comparison, the ~140 g loss of leg muscle tissue (represent-
ing 3.2% of quadriceps cross-sectional area loss) measured via DXA following bed rest 
translates to ~220 g leg muscle loss (representing 5.4% of quadriceps cross-sectional 
area loss) following leg immobilization (Figure 2). However, due to the obvious involve-
ment of the entire body during bed rest, there is a difference in the absolute amount of 
muscle that is lost after a week of disuse. Therefore, while the relative rate of muscle 
atrophy did not differ between models, the ~1.4 kg muscle loss that was observed fol-
lowing whole-body bed rest evidently exceeds the ~220 g leg muscle loss following limb 
immobilization.  
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Figure 2 | Loss of leg lean mass and total lean mass following 7 days of muscle disuse in a model of leg immo-
bilization versus bed rest. Data on leg lean mass following leg immobilization are extrapolated from muscle
loss measured via quadriceps cross-sectional area (CSA; 5.4±1.0 and 3.2±0.9% decline in quadriceps CSA
following 7 days of leg immobilization and bed rest, respectively) and DXA scans made following 7 days of bed 
rest. 
 
Theoretically, systemic changes associated with whole-body disuse may result in a 
greater degree of muscle loss compared with limb immobilization. Such factors could 
include increased inflammation [22], whole-body insulin resistance [8, 9, 19, 31], or 
increased levels of stress hormones [20, 21]. However, given there is no difference in 
the rate of muscle loss between local leg immobilization and whole-body bed rest, there 
is no reason to suggest that such systemic changes affect muscle loss in a short-term 
bed rest setting, at least in healthy young volunteers. Indeed, previous work has shown 
the absence of systemic alterations, including inflammation [32, 33] and circulating 
stress hormones [34], following short-term bed rest in healthy individuals. Despite the 
potential absence of such changes, it is true that bed rest will have altered several other 
physiological factors such as cardiac output [35], tissue perfusion [36], and whole-body 
and peripheral insulin sensitivity [9, 19, 31]. Since these factors apparently did not 
modulate muscle loss in the present study, our data support the concept that uncom-
plicated disuse is largely a local intracellular process. Of course, more complicated dis-
use experienced during bed rest following major surgery or acute illness may be compli-
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cated by systemic factors and the presence of pharmaceutical treatment. More acceler-
ated muscle atrophy has been observed following bed rest due to critical illness [37, 
38]. Moreover, extreme muscle wasting (i.e. five-fold greater than in uncomplicated 
disuse) has been observed in conditions where a lack of any voluntary motor control is 
evident, such as in fully sedated, comatose patients [39]. Indeed, in such situations large 
increases in C-reactive protein and white blood cells [39, 40] and other inflammatory 
parameters such as IL-6 and TNF-α [41] have been reported. Furthermore, bedridden 
patients are often hyperglycaemic [41] and are treated with a wide range of drugs that 
likely influence metabolism (reviewed in [42]). It is of additional importance to keep in 
mind that in situations of clinical muscle disuse, an individual’s nutritional intake will be 
altered due to decreased energy requirements [43, 44], reduced appetite [45, 46], 
and/or other routes of food administration (e.g. nasogastric or intravenous feeding). In 
such situations, the decrease in energy intake and concomitant reduction in protein 
intake will further accelerate muscle atrophy. These and other factors that potentially 
influence muscle atrophy during both clinical and experimental bed rest are displayed in 
Figure 3. 
 
Figure 3 | Overview of systemic factors that potentially influence muscle atrophy during clinical and experi-
mental bed rest. Factors marked with * are predominantly important in clinical situations of bed rest, whereas
the other factors are relevant in both a clinical and experimental bed rest setting 
 
Although systemic factors clearly play a role in clinically relevant situations of compli-
cated muscle wasting, our data demonstrate that removing the mechanical stimulus 
forms the key factor bringing about muscle atrophy in uncomplicated, ‘healthy’ disuse, 
and that the model applied to induce this is of less relevance. For the proper assess-
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ment of muscle atrophy in short-term disuse studies, irrespective of the disuse model 
used, sensitive measures of muscle mass are clearly warranted. This is evident when 
considering the whole limb muscle atrophy we have observed was not evident on the 
muscle fibre level. While this is likely partially due to the intra- and inter-subject varia-
tion in muscle fibre cross-sectional area [47], the effect of oedema-induced fibre swell-
ing, which is observed with changes in muscle fibre size, should not be disregarded [48]. 
Therefore, for the sensitive measurement of changes in muscle mass, techniques such 
as Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) are preferred. 
Muscle disuse has been shown to induce a substantial decline in muscle strength [1, 
2, 12, 49]. Due to the differences in the amount of movement and degree of weight 
bearing possible, it could be suggested that the loss of muscle strength differs between 
bed rest and immobilization. Specifically, based on separate studies, the loss of muscle 
strength during bed rest appears to be ~0.8% per day, whereas muscle strength de-
creases by ~1-3% per day during lower limb immobilization (reviewed in reference [18]). 
A review by Clark showed corroborative data from separate studies that suggest a more 
pronounced loss of muscle strength with immobilization [50]. In contrast, when we 
directly compared muscle strength loss in the present study, with age-, sex-, and BMI-
matched participants and with the same leg extension machine, we observed no differ-
ences in leg strength loss between the immobilization and bed rest model. Both models 
induced an approximate 7% decline in leg strength following 7 days of disuse (i.e. 1% 
decrease per day), which is in line with previous work from us [10-12] as well as others 
[18, 51]. Our data demonstrate that the neuromuscular component of muscle strength 
loss, generally attributed to a change in motor unit recruitment [52], is not so much 
influenced by the amount of movement possible in both models. This could imply that 
the amount of gravity or weight bearing is a more important factor mediating muscle 
strength loss, rather than the degree of movement possible. 
The current study is the first to directly compare the rate of muscle atrophy and loss 
of muscle strength during short-term leg immobilization versus bed rest. Given the 
magnitude of muscle mass and strength losses, our data underline the clinical relevance 
of preserving muscle mass even during short periods of disuse. From an experimental 
point of view, it could be argued that mechanistic studies aimed at understanding dis-
use atrophy may be better suited to an immobilization model in order to isolate the 
effect of muscle disuse per se, without necessary changes in habitual dietary intake 
and/or systemic adaptations. In contrast, the bed rest model offers a more directly 
relevant model from a clinical perspective as it represents a period of hospitalization 
and its practical implications. An experimental consideration of applying this model is 
the obvious necessity to control an individual’s dietary intake away from their habitual 
diet and with altered energy requirements [53, 54]. Although the rate of muscle atrophy 
at the level of the leg is comparable, care is warranted when extrapolating results on 
muscle loss from leg immobilization to a whole-body level, as different muscle groups 
show different rates of muscle atrophy [49]. Therefore, researchers should carefully 
198 | CHAPTER 9 
consider all influencing factors when choosing the experimental model to address their 
research question. We conclude that short-term muscle disuse leads to substantial 
declines in muscle mass and strength. Though both models result in similar relative 
rates of muscle loss, greater whole-body muscle loss is evident during bed rest. 
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A B S T R A C T  
Background Short (<10 days) periods of muscle disuse, often necessary for recov-
ery from illness or injury, lead to various negative health consequenc-
es. The present study investigated mechanisms underlying disuse-
induced insulin resistance, taking into account muscle atrophy. 
Methods Ten healthy, young males (age: 23±1 y, BMI: 23.0±0.9 kg·m-2) were 
subjected to one week of strict bed rest. Prior to and after bed rest, 
lean body mass (DXA) and quadriceps cross-sectional area (CSA; CT) 
were assessed, and VO2peak and leg strength were determined. 
Whole-body insulin sensitivity was measured using a hyperinsuline-
mic-euglycemic clamp. Additionally, muscle biopsies were collected to 
assess muscle lipid (fraction) content and various markers of mito-
chondrial and vascular content. 
Results  Bed rest resulted in 1.4±0.2 kg lean tissue loss and a 3.2±0.9% decline 
in quadriceps CSA (both P<0.01). VO2peak and 1RM declined by 
6.4±2.3 (P<0.05) and 6.9±1.4% (P<0.01), respectively. Bed rest in-
duced a 29±5% decrease in whole-body insulin sensitivity (P<0.01). 
This was accompanied by a decline in muscle oxidative capacity, with-
out alterations in skeletal muscle lipid content or saturation level, 
markers of oxidative stress, or capillary density. 
Conclusion In conclusion, one week of bed rest substantially reduces skeletal 
muscle mass and lowers whole-body insulin sensitivity, without affect-
ing mechanisms implicated in high-fat diet-induced insulin resistance. 
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I N T R O D U C T I O N  
Recovery from injury or illness generally necessitates a period of bed rest, often as a 
consequence of hospitalization. Prolonged (>10 days) periods of bed rest have been 
shown to induce substantial changes in body composition and are accompanied by 
overall metabolic decline [1, 2]. Though this model of prolonged physical inactivity has 
taught us much about muscle disuse atrophy, it may be of limited clinical relevance to 
most patients who are, on average, hospitalized for less than 7 days [3]. Recent data 
from our laboratory as well as others show that merely a few days of disuse substantial-
ly reduces skeletal muscle mass and strength [2, 4-6]. As a consequence, it has been 
suggested that the accumulation of such short (<10 days), successive periods of bed 
rest or immobilization may largely be responsible for the loss of muscle mass and meta-
bolic decline observed throughout the lifespan [7, 8]. 
Impairments in metabolic health following prolonged disuse have been well de-
scribed and include a decline in glucose tolerance and insulin sensitivity [1, 9], a de-
crease in resting fat oxidation [10], an increase in mitochondrial ROS production [11], 
and a decline in basal metabolic rate [12]. As the decline in metabolic health predispos-
es to greater morbidity and mortality of patients [13], it is of major clinical relevance to 
understand the mechanisms responsible for this decline in metabolic health. Prolonged 
disuse has been associated with substantial loss of muscle mass and/or gain in fat mass 
[2]. Such changes in body composition lower the body’s capacity for blood glucose dis-
posal, and may contribute to the decline in metabolic health. However, changes in body 
composition can only partly explain the observed metabolic decline, as reduced insulin 
sensitivity has been observed during bed rest before measurable changes in body com-
position became apparent [1, 2]. We hypothesize that the substantial muscle atrophy 
caused by short-term bed rest will contribute to, but not fully explain, the vast decline 
in metabolic health. 
One of the key hallmarks of metabolic health is insulin sensitivity. Earlier studies 
have demonstrated that short periods of bed rest impair glucose tolerance and lower 
whole-body and/or peripheral insulin sensitivity [14-18]. The development of insulin 
resistance under conditions of lipid oversupply (e.g. type 2 diabetes mellitus, (high-fat) 
overfeeding) has been associated with lipid deposition in skeletal muscle [19], and, 
more specifically, with an increase in intramuscular lipid intermediates such as diacyl-
glycerols (DAGs), ceramides, and long-chain fatty acyl-CoA, which impair insulin signal-
ing (as reviewed in [20]). Furthermore, both muscle disuse atrophy [21, 22] and the 
development of insulin resistance [23] have also been attributed to a decline in mito-
chondrial content and/or impairments in skeletal muscle mitochondrial function. Addi-
tionally, impairments in micro- and macrovascular function have been linked to periph-
eral insulin resistance [24]. So far, it is unclear which mechanism(s) contribute to the 
proposed development of insulin resistance during short-term bed rest. 
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The objective of the present study was to assess mechanisms that may contribute to 
the development of insulin resistance during short-term muscle disuse, taken into ac-
count the expected muscle atrophy. To achieve this we subjected healthy, young males 
to one week of strict bed rest and used comprehensive measures of muscle mass and 
muscle function in combination with detailed metabolic phenotyping (e.g. whole-body 
insulin sensitivity, substrate metabolism, skeletal muscle lipid content and composition, 
muscle oxidative capacity, and capillary density) to determine their possible contribu-
tion to the development of disuse-induced whole-body insulin resistance. Importantly, 
this was conducted under energy-balanced conditions to eliminate the contribution of 
overfeeding to our results. We hypothesized that bed rest-induced insulin resistance is 
attributed to mechanisms known to induce insulin resistance in chronic metabolic dis-
ease, i.e. ectopic lipid deposition, intramuscular accumulation of lipid intermediates, a 
decline in mitochondrial content, and/or impairment in skeletal muscle capillarization. 
Here we demonstrate that short-term bed rest leads to skeletal muscle atrophy, pro-
nounced whole-body insulin resistance, and a decline in skeletal muscle oxidative ca-
pacity. Strikingly, these effects do not seem to be mediated via mechanisms involved in 
obesity-related insulin resistance such as skeletal muscle lipid accumulation, oxidative 
stress and micro- and/or macrovascular dysfunction.  
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M E T H O D S  
Subjects 
Ten healthy young men (age 23±1 y) were included in the present study. Subjects’ char-
acteristics are presented in Table 1. Prior to inclusion in the study, subjects filled in a 
general health questionnaire and completed a routine medical screening to ensure their 
eligibility to take part in the study. Exclusion criteria were a BMI below 18.5 or above 30 
kg·m-2, a (family) history of thrombosis, type 2 diabetes mellitus (determined by HbA1c 
values >7.0% (53 mmol·mol-1)), and any back, knee or shoulder complaints. Further-
more, subjects who had been involved in structured and prolonged resistance-type 
exercise training during the 6 months prior to the study were also excluded. All subjects 
were informed on the nature and risks of the experiment before written informed con-
sent was obtained. During the screening visit, a fasting blood sample was taken to as-
sess HbA1c, resting energy expenditure was measured with the use of a ventilated 
hood, and a one-Repetition Maximum (1RM) estimation test was performed. The pre-
sent study was approved by the Medical Ethical Committee of Maastricht University 
Medical Centre (registration number 14-3-013) in accordance with the Declaration of 
Helsinki. 
 
Table 1 | Subjects’ characteristics 
Age (y) 23 ± 1 
Body mass (kg) 74.9 ± 2.3 
Height (m) 1.81 ± 0.02 
BMI (kg·m-2) 23.0 ± 0.9 
Fasting glucose (mmol·L-1) 5.7 ± 0.2 
Fasting insulin (mU·L-1) 7.2 ± 1.8 
HbA1c (%) 5.1 ± 0.1 
RMR (MJ·d-1) 7.2 ± 0.2 
BMI, body mass index; HbA1c, glycated haemoglobin; RMR, resting metabolic rate 
Experimental outline 
The experimental protocol is depicted in Supplemental Figure 1. After inclusion into the 
study, subjects visited the university for a pre-testing visit during which the 1RM and 
VO2peak tests were performed. Following this visit, a 7-day period of standardized 
nutrition was started. On day 6 of the controlled diet, a mixed meal tolerance test was 
performed. The day after, on day 7 of the standardized diet and the day prior to bed 
rest, test day 1 was scheduled. During this day a muscle biopsy was taken from the m. 
vastus lateralis, and a hyperinsulinemic-euglycemic clamp, CT- and DXA scans were 
performed. The next morning, subjects arrived at the laboratory to start the bed rest 
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period. The meal tolerance test was repeated on day 6 of bed rest. After exactly seven 
days of bed rest, test day 1 was repeated and subjects were allowed to go home. On the 
next day, subjects returned to the laboratory to repeat the 1RM and VO2peak tests. 
One week of bed rest 
To mimic the effects of a standard hospitalization procedure, subjects underwent a 7-
day period of strict bed rest. On the morning of day 1, subjects reported to the labora-
tory in the fasted state at 8:00. From that moment on, subjects remained in bed. During 
the day, subjects were permitted to use a pillow and elevation of the bed-back to per-
form their daily activities. All hygiene and sanitary activities were performed on the bed. 
Every morning subjects were woken at 8:00 and lights were turned off at 23.00. Partici-
pants were monitored continuously by the research team. 
Dietary intake 
During the screening visit, resting energy expenditure was measured by indirect calo-
rimetry, using an open-circuit ventilated hood system (Omnical, Maastricht University, 
Maastricht, the Netherlands; [25]). For seven days prior to bed rest subjects were given 
standardized food to prepare and consume at home. During the bed rest period itself, 
dietary intake was entirely controlled. During the pre-bed rest period, subjects received 
all food products and prepared the meals at home. In that week, subjects reported to 
the laboratory once or twice to allow adjustments of the diet in response to body 
weight changes (when necessary), to keep body weight stable. During bed rest, energy 
intake was increased when subjects reported being hungry. Energy requirements were 
estimated based on indirect calorimetry data, multiplied by an activity factor (AF) of 
1.55 (prior to bed rest) and 1.35 (during bed rest). Macronutrient composition of the 
diet was identical before and during the bed rest period (Supplemental Table 1). 
Body composition 
During test days 1 and 2 (prior to and immediately after bed rest, respectively), anatom-
ical cross-sectional area (CSA) of the quadriceps muscle, hamstrings and whole thigh 
were assessed via a single slice CT scan (Philips Brilliance 64, Philips Medical Systems, 
Best, the Netherlands). Whilst subjects were lying supine, with their legs extended and 
their feet secured, a 3 mm thick axial image was taken 15 cm proximal to the top of the 
patella. On test day 1, the precise scanning position was marked with semi-permanent 
ink for replication on test day 2. Next, a single slice CT scan at the level of the upper 
border of the L3 vertebra was taken to assess total muscle CSA (i.e. all paraspinal and 
abdominal muscle). For this scan, subjects were lying in a prone position, with their chin 
resting on both hands. The following scanning characteristics were used: 120 kV, 300 
mA, rotation time of 0.75 s, and a field of view of 500x500 mm. CT-scans were analyzed 
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for the CSA of the whole thigh muscle as well as the quadriceps and hamstring muscles, 
and for total muscle CSA at the level of the L3 vertebra by manual tracing using ImageJ 
software (version 1.48t, National Institute of Health, Maryland, USA, [26]). The L3 Skele-
tal Muscle Index (L3 SMI) was calculated by dividing the paraspinal muscle area by 
height squared. Tissue with Hounsfield units (HU) between -29 and +150 HU was se-
lected as muscle tissue. The L3 CT scans were also used to determine intramuscular 
adipose tissue (IMAT), visceral adipose tissue (VAT) and subcutaneous adipose tissue 
(SAT), using SliceOmatic software (version 5.0, Tomovision, Montreal, QC, Canada) as 
described previously [27]. Body composition was measured via DXA (Dual Energy X-Ray 
Absorptiometry; Hologic, Discovery A, QDR Series, Bedford, MA, USA). The system’s 
software package Apex version 2.3 was used to determine whole-body and regional 
lean mass, fat mass and bone mineral content. 
Insulin sensitivity 
On the day prior to bed rest, and directly after one week of bed rest, a hyperinsuline-
mic-euglycemic clamp was performed to assess whole-body insulin sensitivity. At the 
applied level of hyperinsulinemia, hepatic glucose output will be minimal [28, 29]. 
Therefore, the presented whole-body insulin sensitivity data presented here mainly 
reflect peripheral insulin sensitivity. Due to the choices for the setup of this experiment, 
this protocol does not allow assessment of the impact of bed rest on maximal insulin 
responsiveness. Before the start of the experiment, a Teflon cannula was inserted ante-
rogradely in an antecubital vein of the forearm for the infusion of 20% glucose (Baxter 
B.V., Utrecht, the Netherlands) and insulin (40 mU·m-2·min-1; Novorapid, Novo Nordisk 
Farma, Alphen aan den Rijn, the Netherlands). On the contralateral hand, a second 
cannula was inserted into a superficial dorsal hand vein. From this catheter, arterialized 
venous blood was obtained by heating the hand in a hot-box (60°C). A small amount of 
blood was drawn every 5 min throughout the entire 2.5 h clamp to determine glucose 
concentration (ABL800 Flex, Radiometer Medical, Denmark). The amount of glucose 
infused was altered to maintain euglycaemia at 5.0 mmol·L-1. The last 30 min of the 
clamp were used to calculate the mean glucose infusion rate. 
At baseline and during the last 30 min of the clamp, fasting and insulin-stimulated 
energy expenditure and substrate oxidation were assessed by indirect calorimetry using 
an open-circuit ventilated hood system (Omnical, Maastricht University, Maastricht, the 
Netherlands, [25]). From these data, total fat and carbohydrate oxidation rates and 
metabolic flexibility were calculated as described before [30]. To test glucose tolerance 
in a practical manner, a meal tolerance test was performed two days prior to bed rest 
and on day 6 of bed rest at 08:30 as part of the standardized diet. Before and after bed 
rest, subjects received identical test meals which provided 7.6±0.2 kcal·kg body weight-
1, 72±1 g carbohydrate (52±0.4 En%), 19±0.3 g fat (31±0.4 En%) and 24±0.1 g protein 
(17±0.2 En%). While subjects were in an overnight fasted state, an antecubital vein was 
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cannulated to allow repeated blood sampling. Prior to breakfast, and at t = 30, 60, 90 
and 120 min following meal ingestion, a blood sample was collected in a supine position 
to assess plasma glucose and insulin concentrations. The disposition index (DI), as a 
measure of beta cell function, was calculated using the following formula: DI = (I120-
I0/G120-G0) x OGIS. 
Muscle function tests 
Eight or nine days before, and on the day after the 7 day bed rest, an incremental cycle 
ergometer test was performed with 40W increments every 3 min to determine peak 
oxygen uptake (VO2peak). Next, 1RM strength tests on a leg press and leg extension 
device (Technogym, Rotterdam, the Netherlands) were performed to determine maxi-
mal leg strength. The estimations obtained during the screening visit, obtained via the 
multiple repetitions testing procedure [31], were used to determine 1RM as described 
previously [32]. In short, after warming up, the load was set at 90–95% of the estimated 
maximum strength and increased after each successful lift until failure. A 2 min resting 
period was allowed between subsequent attempts. A repetition was deemed valid if the 
participant was able to complete the entire lift in a controlled manner without assis-
tance. Finally, maximal grip strength was determined using a Jamar handheld dyna-
mometer (model BK-7498; Fred Sammons, Inc., Burr Ridge, IL, USA). Three consecutive 
measures were recorded for both hands, and maximal grip strength of both hands was 
averaged to calculate mean maximal grip strength [33]. 
Blood and muscle sampling 
During the meal tolerance tests and on each day of bed rest, blood samples were col-
lected in EDTA-containing tubes and directly centrifuged at 1,000g for 10 min at 4°C. 
Aliquots of plasma were snap frozen in liquid nitrogen and stored at -80°C until further 
analysis. Additionally, before and after bed rest a single muscle biopsy was collected 
from the vastus lateralis muscle. After local anesthesia was induced, a percutaneous 
needle biopsy was taken approximately 15 cm above the patella [34]. Any visible non-
muscle tissue was directly removed, and part of the biopsy sample was embedded in 
Tissue-Tek (4583, Sakura Finetek, Zoeterwoude, the Netherlands) before being frozen in 
liquid nitrogen-cooled isopentane. All remaining muscle tissue was immediately frozen 
in liquid nitrogen. Muscle samples were subsequently stored at -80°C until further anal-
yses. 
Plasma biochemistry 
Plasma glucose and insulin concentrations were analyzed using commercially available 
kits (GLUC3, Roche, Ref: 05168791 190, and Immunologic, Roche, Ref: 12017547 122 
(inter-assay CV 4.9% and intra-assay CV 1.5%), respectively). Plasma free fatty acid con-
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centrations were analyzed with an ABX Pentra 400 analyzer (Horiba Diagnostics, Mont-
pellier, France) with test kits purchased from ABX Diagnostics (Montpellier, France). 
 
Skeletal muscle analyses 
 
Fibre typing 
Muscle biopsies were stained for muscle fibre typing (FT) as described previously [35]. 
The section of the muscle that was mounted and frozen in Tissue-Tek was cut into 5µm 
thick cryosections using a cryostat at -20°C. Pre- and post- bed rest samples of each 
subject were mounted together on uncoated, pre-cleaned glass slides, thereby carefully 
aligning the samples for cross-sectional fibre analyses. Stainings were performed to 
analyze muscle fibre-type specific cross-sectional area (CSA) and intramyocellular tri-
glyceride (IMTG) content. To measure fibre-type specific CSA, slides were incubated 
with primary antibodies directed against myosin heavy chain (MHC)-I (A4.840, dilution 
1:25; DSHB) and laminin (polyclonal rabbit anti-laminin, L9393, dilution 1:50; Sigma-
Aldrich, Zwijndrecht, the Netherlands). After washing, the appropriate secondary anti-
bodies were applied: goat anti-rabbit IgG AlexaFluor647 and goat anti-mouse IgM 
AlexaFluor555 (A-21245 and A-21422; dilution 1:400 and 1:500, respectively; Molecular 
Probes, Invitrogen, Breda, the Netherlands). Myonuclei were stained with 4,6-
diamidino-2-phenylindole (DAPI, D1306, 0.238 µM, Molecular Probes). Both primary 
and secondary antibodies were diluted in 0.1% Bovine Serum Albumin (BSA, A7906, 
Sigma-Aldrich) in 0.1% Tween 20 (P2287, Sigma-Aldrich) dissolved in phosphate-
buffered saline (PBS). Incubation of antibodies was performed at room temperature. 
Skeletal muscle tissue was stained as follows. Tissue was fixated in acetone for 5 min, 
after which the slides were air dried for 15 min and incubated with 3% BSA in 0.1% 
Tween-PBS for 30 min. Slides were then washed (standard washing protocol: 5 min 
0.1% Tween-PBS, 2x5 min PBS) and incubated with the first antibodies for 45 min. After 
washing, slides were incubated with the secondary antibodies, diluted together with 
DAPI, for 45 min. After a last washing step, cover glasses were mounted by Mowiol 
(475904-100GM, Calbiochem, Amsterdam, the Netherlands). As a result of the staining 
procedure, nuclei were stained in blue, MHC-I in red, and laminin in far-red. Images 
were visualized and automatically captured at 10x magnification with a Olympus BX51 
fluorescence microscope with customized spinning disk unit (DSU; Olympus, Zoeter-
woude, the Netherlands) with a ultra-high sensitivity monochrome electron multiplier 
CCD camera (1000 × 1000 pixels, C9100-02, Hamamatsu Photonics, Hamamatsu City, 
Japan). Image acquisition was done by Micromanager 1.4 software [36], and images 
were analyzed with ImageJ. The images were recorded and analyzed by an investigator 
blinded to subject coding. As a measure of fibre circularity, form factors were calculated 
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by using the following formula: (4π·CSA)·(perimeter)-2. On average, 176±31 and 212±60 
muscle fibres were analyzed in the pre- and post-bed rest samples, respectively. 
Capillary density 
An immunohistochemical staining for skeletal muscle capillarization (Figure 6D) was 
performed as described previously [37]. Slides with muscle cryosections of 5 μm were 
taken from the -80°C freezer and thawed for 30 min at room temperature. After fixation 
for 5 min with acetone, samples were air dried again for 15 min. Slides were then incu-
bated for 45 min with CD31 (dilution 1:50; M0823; DAKO, Glostrup, Denmark). Slides 
were then washed (standard washing protocol 3x5 min PBS). After that, a 45 min incu-
bation step with goat anti-mouse biotin (BA-2000, dilution 1:200; Vector Laboratories, 
Burlingame, CA, USA) was started, and a standard wash was performed. Next, slides 
were incubated with Avidin Texas Red (A2006, dilution 1:400, Vector Laboratories), and 
antibodies against MHC-I (A4.840, dilution 1:25, DSHB), and laminin (polyclonal rabbit 
anti-laminin, dilution 1:50, L9393, Sigma-Aldrich) for 45 min and washed. In the final 
incubation step, goat anti-mouse IgM AlexaFluor488 and goat anti-rabbit IgG AlexaFlu-
or350 (A-21042 and A-11046, dilution 1:200 and 1:133, respectively; Molecular Probes) 
were applied for 30 min. After washing, slides were mounted with Mowiol. The staining 
procedure resulted in images with laminin in blue, MHC-I in green, and CD31 in red. 
Images were automatically captured at 10 x magnification with a Olympus BX51 fluores-
cence microscope with customized spinning disk unit (DSU; Olympus) with a ultra-high 
sensitivity monochrome electron multiplier CCD camera (1000 × 1000 pixels, C9100-02, 
Hamamatsu Photonics). Image acquisition was done by Micromanager 1.4 software 
[36], and images were analyzed with ImageJ. The images were recorded and analyzed 
by an investigator blinded to subject coding. In all images, a minimum of 30 fibres were 
counted per fibre type. The number of capillaries was counted, and expressed as capil-
lary-to-fibre ratio and capillary-to-fibre perimeter exchange index (CFPE; number of 
capillaries per 1000 μm perimeter). 
Fibre-type specific lipid content, lipid fractions, and saturation 
An Oil red O (ORO) staining was performed to analyze muscle fibre-type specific IMTG 
content, based on previous work [38]. Freshly cut samples were air dried for 30 min, 
and fixated in 3.7% formaldehyde (1040051000, Merck Millipore, Darmstadt, Germany) 
for 60 min. After rinsing 3x30 sec with Milli-Q, slides were incubated for 5 min in 0.5% 
Triton X-100 (108643, Merck Millipore) in PBS. Slides were then washed for 3x5 min 
with PBS, and incubated for 45 min with primary antibodies against MHC-I (A4.951, 
dilution 1:25, DSHB) and laminin (polyclonal rabbit anti-laminin, dilution 1:50; L9393, 
Sigma-Aldrich) in 0.05% Tween-PBS. After washing (1x5 min 0.05% Tween-PBS, 2x5 min 
PBS) slides were incubated with the appropriate secondary antibodies: goat anti-mouse 
IgG1AlexaFluor488 and goat anti-rabbit IgG AlexaFluor350 (A-21121 and A-11046; dilu-
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tion 1:133 and 1:200, respectively; Molecular Probes, Invitrogen). Slides were then 
washed (1x5 min 0.05% Tween-PBS, 2x5 min PBS) and rinsed for 30 s with Milli-Q, after 
which slides were placed in the ORO solution for 30 min. This solution was made by dis-
solving 250 mg Oil Red O powder (O0625-25G, Sigma-Aldrich) in 50 mL 60% triethyl-
phosphate (538728, Sigma-Aldrich). Of this solution, 48 mL was added to 32 mL of Milli-
Q, which was then filtered using a paper folding filter. After incubation with the ORO 
solution, slides were rinsed with Milli-Q for 3x30 sec, and placed under slow running cold 
tap water, before being mounted with cover glasses and Mowiol. The staining procedure 
resulted in images with laminin in blue, MHC-I in green, and ORO in red. Images were 
semi-automatically captured at 40x magnification with using a Nikon E800 fluorescent 
microscope coupled with a Nikon DS-Fi1c camera (Nikon Instruments, Amsterdam, the 
Netherlands) using the NIS-Elements BR software package version 4.20.01. Analysis of 
the images was done using ImageJ software by an investigator blinded to subject coding. 
No differences in fibre circularity were observed between pre- and post-bed rest sam-
ples. On average, 34±1 muscle fibres were analyzed in both the pre- and post-bed rest 
samples. A representative image of the ORO staining is displayed in Figure 3A. 
To determine intramuscular lipid content and the degree of saturation, ~50 mg wet 
muscle was used as described elsewhere [39]. Total lipid was extracted using chloro-
form-methanol (1:1 vol/vol) and internal standards, and thereafter evaporated under 
nitrogen at 37°C. The extracted lipids were separated into triacylglycerol (TAG), diacyl-
glycerol (DAG), free fatty acids (FFA) and phospholipid (PL) by thin-layer chromatog-
raphy and transferred into separate tubes. After incubation with methanol, pentane 
was added to the samples, which were then vortexed and centrifuged. The pentane 
extracts (upper phase) were isolated and the residues were evaporated under nitrogen 
at 37°C. Finally, the residues were dissolved in iso-octane and FA concentrations in the 
fractions were determined using an analytical gas chromatograph (GC-2010 Plus, Shi-
madzu, Kyoto, Japan). Muscle ceramide content and ceramide fatty acid species were 
analyzed as described previously [40]. 
Enzyme activities 
For mitochondrial enzyme activities, ~10 mg of the muscle was immediately homoge-
nized in 100 vol/wt of a 100 mM potassium phosphate buffer and used for the meas-
urements of maximal β- hydroxyacyl-CoA dehydrogenase (β-HAD) and citrate synthase 
(CS) activities. Total muscle β-HAD activity was measured in TrisHCl buffer (50 mM Tri-
sHCl, 2 mM EDTA, and 250 μM NADH, pH 7.0) and 0.04% Triton-X. The reaction was 
started by adding 100 μM acetoacetyl-CoA, and absorbance was measured at 340 nm 
over a 2 min period (37°C)[41]. The CS activity was assayed spectrophotometrically at 
37°C by measuring the disappearance of NADH at 412 nm [42]. 
214 | CHAPTER 10 
Western Blotting 
Muscle was homogenized as previously described [43], 10 μL of protein was loaded and 
standard SDS-PAGE procedures were followed. Antibodies included total and phosphor-
ylated Akt (Cell Signaling Inc, Danvers, MA, USA), OXPHOS (MitoSciences, Eugene, OR, 
USA), Vascular Endothelial Growth Factor (VEGF), hypoxia inducible factor-1α (HIF-1α), 
endothelial nitric oxide synthase (eNOS), catalase, and SOD2 (all Abcam, Cambridge, 
UK), 4-HNE (Alpha Diagnostics, San Antonio, TX, USA), COXIV (Invitrogen), and α-tubulin 
(Abcam) as a loading control. Protein carbonylation (Oxyblot, Millipore) was determined 
according to manufacturer’s instructions. Ponceau staining was used to confirm equal 
loading for antibodies that required the entire membrane (e.g. 4HNE and protein car-
bonylation). All samples for a given protein were detected on the same membrane 
using chemiluminescence and the FluorChem HD imaging system (Alpha Innotech, San-
ta Clara, CA, USA). 
Statistics 
All data are expressed as means±SEM. Changes over time were analyzed using a paired 
samples Student’s t-test (before vs after bed rest) or a One-Way ANOVA (for daily 
measurements) using a Bonferroni post-hoc test. Muscle characteristics were analyzed 
using a Repeated Measures ANOVA with time (before vs after bed rest) and fibre type 
(type I vs type II) as within-subjects factors. In case of a significant main effect, paired 
samples t tests were performed to assess time effects within fibre types. For the Oil Red 
O analyses, region (SS vs IMF) was added as a within-subjects factor. Statistical signifi-
cance was set at P<0.05. All data were analyzed using SPSS version 22.0 (SPSS Inc., Chi-
cago, IL, USA).  
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R E S U L T S  
Body composition 
Figure 1 displays the effect of short-term bed rest on skeletal muscle mass as assessed 
by DXA (Figure 1A) and CT (Figure 1B). After one week of bed rest, participants lost 
1.4±0.2 kg [range: 0.6 to 2.8 kg] lean tissue mass (Figure 1A; P<0.01), representing a 
2.5±0.4% loss of lean tissue mass. 
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Figure 1 | One week of bed rest leads to a substantial decline in muscle mass. A: Whole-body lean mass 
declined by 1.4±0.2 kg following bed rest. B: Cross-sectional area (CSA) of m. quadriceps femoris declined by 
3.2±0.9%. Data represent mean ± SEM. * Significantly different from pre-bed rest value (P<0.05). 
 
Lean tissue was mainly lost from the trunk (1.0±0.2 kg) and legs (0.28±0.12 kg)(Table 2). 
Fat mass did not change during one-week of bed rest as participants were fed in energy 
balance (-0.2±0.1 kg; P>0.05). A 3.2±0.9% decline in cross-sectional area (CSA) of m. 
quadriceps femoris was observed following bed rest (from 7900±315 to 7664±354 mm2; 
P<0.01, Figure 1B). CSA of the whole thigh muscle had declined by 2.2±1.0% (P<0.05). 
CT scans at the level of the L3 vertebra showed a 1.3±0.4% decline in total muscle CSA 
(P<0.01). As a consequence, the L3 SMI had declined from 51.9±2.5 to 51.1±2.4 cm2 
(P<0.01). Analyses performed with SliceOmatic revealed no changes in intermuscular 
adipose tissue (P>0.05) and visceral adipose tissue (P>0.05). Subcutaneous adipose 
tissue declined from 93±28 to 89±27 mm2 (P<0.01). Following bed rest, non-significant 
declines in type I (from 6650±725 to 6218±662 μm2) and type II muscle fibre CSA (from 
6542±746 to 5982±525 μm2) were observed (P>0.05; Supplemental Table 2). No differ-
ences in fibre circularity were observed between pre- and post-bed rest samples. 
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Table 2 | Body composition 
 Pre Post P-value 
Total mass (kg) 75.3 ± 2.8 73.7 ± 2.9 <0.001 
Total lean mass (kg) 56.2 ± 1.6 54.8 ± 1.7 <0.001 
Lean mass trunk (kg) 27.1 ± 0.8 26.1 ± 0.8 0.001 
Leg lean mass (kg) 9.6 ± 0.3 9.4 ± 0.3 0.042 
Arm lean mass (kg) 3.4 ± 0.2 3.4 ± 0.2 0.183 
ALM (kg) 25.9 ± 0.9 25.6 ± 0.9 0.034 
SMMI (kg·m-2) 7.8 ± 0.2 7.7 ± 0.2 0.026 
Total fat mass (kg) 16.3 ± 2.3 16.1 ± 2.3 0.082 
Fat percentage (%) 21.2 ± 2.3 21.3 ± 2.3 0.403 
BMC (kg) 2.8 ± 0.1 2.7 ± 0.1 0.616 
Values (means±SEM) represent parameters of body composition from n=9 healthy, male volunteers before 
(pre) and after (post) one week of strict bed rest, as measured by DXA. ALM, appendicular lean mass; BMC, 
bone mineral content; SMMI, skeletal muscle mass index 
Insulin sensitivity and glycemic control 
Glucose infusion rate (GIR) during the euglycemic-hyperinsulinemic clamp had declined 
by 29±5% (range: 9-53%; P<0.01) following one week of bed rest (Figure 2A). Adjust-
ment of GIR for total body weight rather than lean body mass yielded similar results (-
29±5%; P<0.01). Postprandial plasma glucose and insulin concentrations observed dur-
ing the meal tolerance tests are displayed in Figure 2C and D. For plasma glucose, the 
area under the curve (AUC) and incremental area under the curve (iAUC) did not differ 
between both tests (both P>0.05). In contrast, plasma insulin concentrations showed a 
significant increase in AUC (from 4963±779 to 6944±513 mU·L-1·min-1; P<0.05) and iAUC 
(from 4213±773 to 5736±430 mU·L-1·min-1; P<0.05) following bed rest. Fasting plasma 
glucose concentrations (Figure 2B) averaged 5.7±0.2 mmol·L-1 prior to bed rest, and did 
not change during the bed rest period (P>0.05). For plasma insulin concentrations (Fig-
ure 2B), a significant time effect (P<0.001) was observed such that fasting insulin con-
centrations had increased from 7.2±1.8 mU·L-1 at baseline to 11.8±1.8 mU·L-1 after one 
week of bed rest. Consequently, the Homeostasis Model Assessment of Insulin Re-
sistance (HOMA-IR) index increased from 1.9±0.5 to 3.1±0.5 from day 1 to 8 (P<0.01). 
The calculated disposition index (DI) was -7043±11949 and 16945±9972 pre- and post-
bed rest, respectively (P>0.05). 
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Figure 2 | Insulin sensitivity and postprandial glycemic control decline following one week of strict bed rest.
Glucose infusion rates (A) declined by 29±5% following bed rest (P<0.01). B: Postabsorptive plasma glucose 
and insulin concentrations on day 1-7 during bed rest. Insulin concentrations increased over time during bed 
rest (P<0.001). Postprandial plasma glucose and insulin concentrations in the meal tolerance tests pre- and 
post-bed rest are depicted in C and D, respectively. For glucose, no changes in iAUC were observed (P>0.05), 
whereas iAUC for insulin were increased following bed rest (P<0.05). Data are shown as means±SEM. 
*Significantly different from pre-bed rest value (P<0.05). 
Energy expenditure and whole-body substrate oxidation 
Resting metabolic rate, as measured by indirect calorimetry, tended to decline from 
1694±47 to 1624±34 kcal·d-1 (-3.8±2.0%, P=0.070) following bed rest. When corrected 
for the total lean tissue mass, no such trend was observed (P>0.05). During both the 
pre- and post-bed rest clamps, energy expenditure was increased during insulin infusion 
(time effect; P<0.01). Stimulation by insulin increased the respiratory quotient from 
0.84±0.01 during the baseline period to 0.93±0.01 during exogenous insulin infusion 
(P<0.001), without differences between pre- and post-bed rest values. Additionally, 
carbohydrate oxidation rates were increased during the pre- and post-bed rest clamp 
(baseline: 0.13±0.01, hyperinsulinemia 0.24±0.01 g·min-1; P<0.001). Fat oxidation rates 
decreased from 0.056±0.007 (baseline) to 0.011±0.005 g·min-1 (insulin) during the pre-
bed rest clamp, and from 0.047±0.004 to 0.014±0.004 g·min-1 during the post-bed rest 
clamp (effect of insulin, P<0.001; trend for time x treatment effect, P=0.065). Total 
protein content and phosphorylation status of both Akt (Ser473) and Akt (Thr308), meas-
ured in fasted biopsies, were not altered following bed rest (P>0.05). 
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Functional outcomes 
A significant decline in 1RM leg press strength, from 211±16 to 196±45 kg (-7±1%; 
P<0.01), was observed following bed rest. Similarly, leg extension strength decreased 
from 128±7 to 117±7 kg (-8±2%; P<0.05). Following bed rest, no changes in hand grip 
strength were observed: grip strength averaged 45±2 kg prior to bed rest and 46±2 kg 
after the 7 day intervention (P>0.05). Results from the cycle ergometer test showed a 
decline in peak oxygen uptake from 3332±200 to 3100±162 mL·min-1, representing a 
6.4±2.3% loss in VO2peak following bed rest (P<0.05) at a maximal workload of 260±16 
vs 246±15 W, respectively (P<0.05). 
Lipid metabolism 
Plasma free fatty acid concentrations (FFAs, Supplemental Figure 2) showed a time ef-
fect (P<0.001) during bed rest. Post-hoc analyses revealed that values on day 7 of bed 
rest were greater than on days 2 through 5 (P<0.05). At baseline, results from the Oil 
Red O staining showed a greater lipid area percentage in type I than type II muscle fi-
bres (P<0.05, Figure 3B), with smaller droplets in type I vs type II fibres in the SS region 
(P<0.05). Following bed rest, no changes in lipid area percentage were observed 
(P>0.05). Droplet size (Figure 3C) changed, such that a significant time x fibre type inter-
action was found (P<0.01). Based on this interaction, we showed greater lipid droplets 
in type I vs type II fibres following bed rest (P<0.01). 
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Figure 3 | Skeletal muscle lipid contents prior to and following one week of bed rest in healthy, young males.
Values represent means± SEM. 3A represents an image of the Oil Red O staining, made by immunofluores-
cence microscopy with a magnification of 40x. I: Oil Red O, II: MHC-I, III: laminin, IV, combined image. The lipid
area percentage is depicted in 3B, and lipid droplet size in 3C. * Significantly different from type I fibres 
(P<0.05). # Significant difference between type I and II post-bed rest values (P<0.05). 
 
Skeletal muscle lipid content of the measured lipid pools did not change with bed rest 
(all P>0.05, Figure 4). In the phospholipid pool, the percentage saturation increased 
(P<0.05; Supplemental Table 3). For the three other pools, the proportion of polyun-
saturated fatty acids (PUFAs) increased or tended to increase. Although contents of 
some specific fatty acid species was altered following bedrest, no changes in total con-
tents of any of the measured lipid pools were observed (Supplemental Table 4). 
220 | CHAPTER 10 
12
:0
14
:0
15
:0
16
:0
16
:1
n-
7
16
:1
n-
7 
TR
17
:0
18
:0
18
:1
 TR
18
:1
n-
7
18
:1
n-
9
18
:2
n-
6
18
:2
n-
6 
TR
18
:2
n-
9
18
:3
n-
3
18
:3
n-
6
18
:4
n-
3
20
:0
20
:1
n-
9
20
:2
n-
6
20
:3
n-
6
20
:3
n-
9
20
:4
n-
6
20
:5
n-
3
21
:0
22
:0
22
:1
n-
9
22
:4
n-
6
22
:5
n-
3
22
:5
n-
6
22
:6
n-
3
23
:0
24
:0
24
:1
n-
9
24
:2
n-
60
50
100
150
200B
M
us
cle
 TA
G
fa
tty
 ac
id 
co
nt
en
t
(%
 of
 pr
e-
be
d r
es
t v
alu
e)
14
:0
15
:0
16
:0
16
:1
n-
7
16
:1
n-
7 T
R
17
:0
18
:0
18
:1
 TR
18
:1
n-
7
18
:1
n-
9
18
:2
n-
6
18
:2
n-
6 T
R
18
:2
n-
9
18
:3
n-
3
18
:3
n-
6
18
:4
n-
3
20
:0
20
:1
n-
9
20
:2
n-
6
20
:3
n-
6
20
:4
n-
6
21
:0
22
:1
n-
9 T
R
22
:2
n-
6
22
:4
n-
6
22
:5
n-
3
22
:5
n-
6
22
:6
n-
3
23
:0
24
:0
24
:1
n-
9
24
:2
n-
60
100
200
300
400D
*
* *
*
*
*
M
us
cle
 D
AG
fat
ty 
ac
id 
co
nt
en
t
(%
 of
 pr
e-
be
d r
es
t v
alu
e)
12
:0
14
:0
15
:0
16
:0
16
:1
n-
7
16
:1
n-
7 T
R
17
:0
18
:0
18
:1
tr
18
:1
n-
7
18
:1
n-
9
18
:2
n-
6
18
:2
n-
6 T
R
18
:2
n-
9
18
:3
n-
3
18
:3
n-
6
18
:4
n-
3
20
:0
20
:1
n-
9
20
:2
n-
6
20
:3
n-
6
20
:3
n-
9
20
:4
n-
6
20
:5
n-
3
22
:0
22
:1
n-
9
22
:1
n-
9 T
R
22
:2
n-
6
22
:4
n-
6
22
:5
n-
3
22
:5
n-
6
22
:6
n-
3
23
:0
24
:0
24
:1
n-
9
24
:2
n-
60
50
100
150
200
250H
*
*
* *
* *
M
us
cle
 PL
fat
ty 
ac
id 
co
nt
en
t
(%
 of
 p
re
-b
ed
 re
st 
va
lue
)
14
:0
15
:0
16
:0
16
:1
n-
7
16
:1
n-
7 T
R
17
:0
18
:0
18
:1
 TR
18
:1
n-
7
18
:1
n-
9
18
:2
n-
6
18
:2
n-
6 T
R
18
:3
n-
3
18
:3
n-
6
20
:0
20
:1
n-
9
20
:2
n-
6
20
:3
n-
6
20
:4
n-
6
21
:0
22
:0
22
:2
n-
6
22
:4
n-
6
22
:5
n-
3
22
:5
n-
6
22
:6
n-
3
23
:0
24
:0
24
:1
n-
9
24
:2
n-
60
200
400
600
800J
* *
* *
*
*
Fatty acid species
M
us
cle
 FF
A
fat
ty 
ac
id 
co
nt
en
t
(%
 of
 pr
e-
be
d r
es
t v
alu
e)
0
50
100
150
200A
M
us
cle
 to
ta
l T
AG
 co
nt
en
t
( μ
m
ol
⋅
g d
ry
 w
eig
ht
-1
)
0
1
2
3
4C
M
us
cle
 to
ta
l D
AG
 co
nt
en
t
( μ
m
ol
⋅
g d
ry
 w
eig
ht
-1
)
0
20
40
60
80
100G
M
us
cle
 to
ta
l P
L c
on
te
nt
( μ
m
ol
⋅
g d
ry
 w
eig
ht
-1
)
Pre Post
0
1
2
3
4
5I
Time
M
us
cle
 to
ta
l F
FA
 co
nt
en
t
( μ
m
ol ⋅
g d
ry
 w
eig
ht
-1
)
14
:0
16
:0
16
:1
n-
7
18
:0
18
:1
n-
9
18
:2
n-
6
18
:3
n-
3
20
:0
20
:4
n-
6
20
:5
n-
3
22
:0
22
:6
n-
3
24
:0
24
:1
n-
90
100
200
300
400F
*Mu
sc
le 
ce
ra
m
ide
fat
ty 
ac
id 
co
nt
en
t
(%
 of
 p
re
-b
ed
 re
st 
va
lue
)
0.0
0.2
0.4
0.6
0.8E
M
us
cle
 to
ta
l c
er
am
ide
 co
nt
en
t
( μ
m
ol
⋅
g d
ry
 w
eig
ht
-1
)
 
Figure 4 | Skeletal muscle total TAG (A), DAG (C), ceramide (E), phospholipid (G), and free fatty acid (I) con-
tent, as well as specific fatty acid species within the different lipid pools. Total content is depicted in the 
panels on the left, and specific fatty acid species are depicted in panels on the right. Values in panel B, D, F, G,
and J are expressed as relative change from pre-bed rest values (indicated by the dotted line). * Significantly
different from pre-bed rest value (P<0.05). 
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Oxidative capacity 
Figure 5 depicts results on various parameters of mitochondrial content. Citrate syn-
thase (CS, 5A) activity decreased by 8±3% following bed rest (P<0.05). Activity of β-HAD 
(5B) tended to decrease by 9±6% (P=0.071). Protein content of the different complexes 
of the OXPHOS system all decreased or tended to decrease, as depicted in 5C. Lipid 
peroxidation, determined by 4-HNE content, did not change following bed rest (5D, 
P>0.05). For protein carbonylation (5E) content, a trend for a decline was observed 
(P=0.075). Both SOD2 (5F) and catalase (5G) protein expression did not change follow-
ing one week of bed rest (P>0.05). 
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Figure 5 | Seven days of strict bed rest leads to a decline in mitochondrial function. Citrate synthase activity 
(CS, A) decreased (P<0.05), whereas β-HAD activity tended (P=0.071) to decrease (B). The protein contents of 
the different complexes of the oxidative phosphorylation are displayed in 5C. Figure 5D-5G depict protein 
expression of 4HNE, protein carbonylation, SOD2 (predicted MW of 27kDa), and catalase (60kDa), respective-
ly. Data represent means±SEM. * Significantly different from pre-bed rest (P<0.05). # Trend for a difference 
from pre-bed rest value (P<0.10). 
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Vascularization 
Seven days of bed rest did not lead to significant changes in VEGF (-13±10%, P>0.05) 
and eNOS (-12±13%, P=0.086) protein expression (Figure 6A+C). For HIF-1α protein 
expression (6B), a 35±11% increase was observed following bed rest (P<0.05). Bed rest 
did not lead to changes in capillary density, or oxidative exchange across the muscle 
bed, as shown by the capillary-to-fibre ratio (6E) and the capillary-to-fibre perimeter 
exchange index (CFPE index; 6F). 
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Figure 6 | Skeletal muscle capillary content is not altered following short-term bed rest. Values are presented 
as means±SEM. No changes in VEGF (Vascular Endothelial Growth Factor, 6A, predicted MW 43kDa) protein 
expression were observed. A significant increase in HIF-1α (Hypoxia-Inducible Factor-1α, 6B, 97kDa) protein 
expression was observed following bed rest. Total eNOS (endothelial nitric oxide synthase, 6C, 133kDa) pro-
tein expression tended to decline following one week of bed rest (P=0.086). 6D represents an immunohisto-
chemical image of the CD31 staining, made by microscopy with a magnification of 20x. I: CD31, II: MHC-I, III: 
laminin, IV, combined image. No changes in capillary-to-fibre ratio (6E) and capillary-to-fibre perimeter ex-
change index (CFPE index; 6F) were observed. * Significantly different from values prior to bed rest (P<0.05). # 
Significantly different from type I fibres (P<0.05). 
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D I S C U S S I O N  
In the present study, we observed that merely one week of bed rest strongly reduced 
muscle mass, strength, and physical performance. Bed rest resulted in the onset of 
severe whole-body insulin resistance and a strong decline in skeletal muscle oxidative 
capacity, both of which occurred in the absence of lipid accumulation or a decline in 
capillary density in skeletal muscle tissue. 
The impact of prolonged bed rest upon skeletal muscle mass and metabolic health 
has been studied extensively [1, 2]. Though the model of prolonged disuse is of substan-
tial scientific importance, it may be of more clinical relevance to study short periods of 
disuse, as patients are typically hospitalized for up to 7 days [3]. Recently, we showed 
that even 5 days of disuse can lead to a ~4% decline in muscle mass and a concomitant 
~9% decline in muscle strength [5]. In keeping with this, in the present study we report 
a 3.2% decline in quadriceps cross-sectional area (CSA) following one week of bed rest 
(Figure 1B)[2]. On a whole-body level, this translated to a 1.4±0.2 kg loss of lean tissue 
(Figure 1A), which is equivalent to ~200 g lean tissue loss per day. In comparison, it took 
a group of healthy, young males 12 weeks of progressive resistance-type exercise train-
ing to gain the equivalent amount of lean tissue (1.7 kg)[44]. Thus, we can lose as much 
muscle in one week of bed rest as we can gain by 12 weeks of intense resistance type 
exercise training. Furthermore, the loss of muscle was accompanied by a substantial 
~8% decline in muscle strength and a ~6% reduction in VO2peak. These findings clearly 
demonstrate that even a short period of disuse has severe consequences for muscle 
mass and physical performance, an effect that is unlikely compensated for during reha-
bilitation. As a consequence, it has been suggested that successive periods of bed rest 
or immobilization may be responsible for the progressive decline in muscle mass 
throughout our lifespan [7, 8]. 
The loss of skeletal muscle mass and/or strength during hospitalization has been 
shown to be predictive of morbidity and mortality [13]. This may be more related to the 
impact of disuse on metabolic health than to the decline in muscle mass per se. There-
fore, in the present study we also aimed to assess the impact of short-term disuse on 
metabolic health. We performed hyperinsulinemic-euglycemic clamps prior to and after 
one week of bed rest to assess whole-body insulin sensitivity, and observed a substan-
tial ~30% decline in glucose disposal (Figure 2A). Under these conditions, hepatic glu-
cose output is strongly diminished and skeletal muscle is responsible for ~85% of glu-
cose disposal [29]. This implies that merely one week of bed rest can lower insulin sensi-
tivity by as much as 30%. These findings are in line with previous studies, demonstrating 
similar declines in whole-body and/or peripheral insulin sensitivity following 7-9 days of 
bed rest [14-16, 18]. This decline in whole-body insulin sensitivity manifested in a great-
er postprandial insulin response required to maintain normoglycaemia following bed 
rest (Figure 2C+D), illustrating the impact of physical inactivity on day to day metabolic 
control. Supporting the concept that profound insulin resistance manifested with bed 
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rest, relatively insensitive population markers such as the HOMA-IR index also increased 
during the intervention. Interestingly, the increase in HOMA-IR over time did not occur 
until 4 days of bed rest and was entirely attributed to an increase in postabsorptive 
insulin concentrations (Figure 2B). Thus, it could be suggested that disuse-induced insu-
lin resistance occurs even more rapidly than one week [9]. Previous work aiming to 
elucidate the impact of bed rest on insulin signaling has shown that bed rest induced 
insulin resistance is accompanied by reductions in the contents and/or activity of key 
proteins regulating glucose uptake and storage in muscle, such as GLUT4, hexokinase 2, 
and glycogen synthase [18]. However, the decline in insulin sensitivity following bed rest 
could not be explained by impaired insulin and AMPK signaling, as Akt and AS160 signal-
ing seemed to remain intact following short-term bed rest [45]. Consequently, other 
mechanisms are likely to be responsible for the development of insulin resistance fol-
lowing short-term bed rest. 
Despite substantial muscle atrophy, a ~3% decline in lean mass likely cannot explain 
the observed ~30% decline in whole-body insulin sensitivity. As such, during short-term 
disuse, other mechanisms must contribute to the development of whole-body insulin 
resistance. Ectopic lipid deposition has often been suggested to lead to the develop-
ment of insulin resistance in situations of lipid oversupply [19]. While previous studies 
have reported increases in intramuscular lipid deposition following prolonged bed rest 
[1], the impact of short-term disuse on skeletal muscle lipid accumulation has been 
comparatively under investigated [46]. In line with our previous findings [46], in the 
current study, we did not detect a measurable increase in type I or II muscle fibre lipid 
content (Figure 3B). We extend on these findings by reporting no increase in subsarco-
lemmal lipid depots, which have been suggested to more specifically contribute to the 
development of insulin resistance [47]. Of course, it could be speculated that an intra-
cellular increase in specific fatty acid intermediates, such as diacylglycerols (DAGs), fatty 
acyl-CoA, ceramides, and/or free fatty acids may be responsible for impairments in 
insulin receptor function and glucose trafficking [20]. Therefore, we also measured 
muscle lipid content of various lipid fractions (Figure 4). In line with our fibre-type spe-
cific data, we did not observe changes in lipid content of the various lipid fractions, 
including DAGs, following one week bed rest. Whereas we did see changes in some 
specific DAG species (Supplemental Table 4), these were not the 18:2 species that have 
been specifically linked to insulin resistance [48]. Whereas previous work has been 
inconclusive about the role for ceramides in the development of insulin resistance [49-
51], we demonstrate no change in total content and only minor changes in specific fatty 
acid species within the ceramide pool following bed rest, thereby likely ruling out a 
mediating role for ceramides in the development of insulin resistance during bed rest. 
Furthermore, the degree of saturation of specifically the DAG pool has been reported to 
be increased in insulin resistant men when compared to control subjects [52]. However, 
we failed to observe any changes in the degree of saturation of the various lipid pools, 
but actually observed a relative increase in polyunsaturated fatty acids (PUFAs, Supple-
mental Table 3) in the different lipid pools. This can potentially be explained by a pref-
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erential oxidation of saturated fatty acids during disuse, which has been suggested 
previously [10]. Collectively, changes in lipid content and/or lipid composition in skeletal 
muscle tissue following bed rest are unlikely to explain the observed development of 
insulin resistance, and therefore other processes must be implicated. 
Mitochondrial dysfunction, and specifically the release of mitochondrial reactive ox-
ygen species (ROS), has been postulated as a key factor in the development of muscle 
disuse atrophy [23] and insulin resistance [53, 54]. Indeed, previous disuse studies have 
demonstrated a decrease in mitochondrial protein content and enzyme activities, the 
onset of mitochondrial respiratory dysfunction, and an increase in ROS emission in situ-
ations of muscle atrophy [11, 22, 55, 56]. In keeping with this, we show a tendency for a 
decline in β-HAD (Figure 4B) and a significant 8% decline in citrate synthase activity 
(Figure 4A), indicative of a decline in mitochondrial content [57]. Similarly, protein con-
tent of all complexes of oxidative phosphorylation (OXPHOS, Figure 4C) decreased with 
bed rest. Given the lack of a fibre type shift away from oxidative fibres (Supplemental 
Table 2) that is normally observed following prolonged bed rest, these changes cannot 
be explained by differences in fibre type distribution. Additionally, it has been suggested 
that short-term bed rest could lead to oxidative stress, which in turn triggers the imbal-
ance between muscle protein synthesis and breakdown [58]. However, we did not find 
increases in either 4-HNE or protein carbonylation suggesting the absence of overt 
oxidative damage. These findings are in contrast to a previous report analyzing markers 
of oxidative damage following a longer period of bed rest [59], suggesting that oxidative 
damage is a consequence of longer periods of bed rest. Given these data, it was not 
surprising that no changes in the antioxidants superoxide dismutase 2 (SOD2) and cata-
lase (Figure 4F+G) were found, as they would usually be increased in the presence of 
oxidative stress. Previous work by Abadi and colleagues [22] indicates that muscle oxi-
dative capacity is impaired following short-term disuse. We extend on these findings by 
confirming actual declines in muscle oxidative capacity following bed rest, and suggest 
that, despite not having measured the GSH:GSSG ratio to assess short-term redox sta-
tus, overt oxidative stress does not seem to play a role in the rapid development of 
insulin resistance during up to one week of bed rest. While time course studies are 
clearly warranted to look at instigating factors of muscle atrophy and the rapid devel-
opment of insulin resistance, our data suggest that impairments in oxidative capacity 
may (partly) contribute to the observed decline in insulin sensitivity during short-term 
bed rest. 
As in vivo peripheral insulin sensitivity can also be modulated by changes in macro- 
and microvascular function [60], we also evaluated the effect of bed rest on various 
angiogenic markers by measuring the expression of vascular endothelial growth factor 
(VEGF) and endothelial nitric oxide synthase (eNOS), as well as hypoxia-inducible factor-
1α (HIF-1α). These data suggest potential early adaptive responses following one week 
of bed rest, as the expression of eNOS tended to decrease while an increase in HIF-1α 
was seen (Figure 5). However, this did not result in actual changes in skeletal muscle 
capillary density as measured by immunohistochemistry. This is in line with previous 
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work showing no changes in capillary density following bed rest [16, 55]. Consequently, 
our data do not provide evidence that a decline in capillary networks contributes to the 
rapid decline in whole-body insulin sensitivity that was observed following one week of 
bed rest. 
The magnitude of changes that we observed following merely one week of bed rest 
underlines the impact of short-term muscle disuse, as this study demonstrates that one 
week of bed rest can result in a similar amount of muscle mass and strength loss as can 
be regained within months of intense rehabilitation [35, 44]. These changes in lean 
mass and muscle strength were observed despite our participants being in energy bal-
ance, suggesting that the impact of bed rest in undernourished individuals will be even 
greater. Next to the decline in muscle mass and function, the observed loss in metabolic 
health during disuse is of paramount importance. By means of comparison, the meas-
ured decline in insulin sensitivity (i.e. ~30%) is similar to the difference between a nor-
mal glucose tolerant individual and a type 2 diabetes patient [52], and is equivalent to a 
decline that is observed following ~30-40 years of ageing [23, 61]. As the decline in 
muscle mass, strength, and peripheral insulin sensitivity have been shown to be good 
proxy markers for patient outcomes following hospitalization [62], our results empha-
size the importance of finding practical and effective interventional strategies that can 
be applied immediately following the onset of muscle disuse. 
We conclude that short-term muscle disuse leads to substantial declines in muscle 
mass and function, and is associated with the development of peripheral insulin re-
sistance and a decrease in skeletal muscle oxidative capacity. Whereas we are still un-
clear on the molecular mechanisms responsible, our findings clearly indicate that intra-
muscular lipid accumulation (implicated in high-fat diet induced insulin resistance), 
impairments in mitochondrial function and changes in capillary density in skeletal mus-
cle tissue cannot be held responsible for the rapid onset of insulin resistance during a 
short period of bed rest. Clearly, early interventions are warranted to prevent or atten-
uate the negative functional and metabolic consequences of short-term bed rest. 
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Supplemental Figure 1 | Schematic outline of the study protocol. CT, Computed Tomography; DXA, Dual 
Energy X-Ray Absorptiometry; 1RM, 1-Repetition Maximum 
 
Supplemental Table 1 | Food intake before and during 7 days of strict bed rest 
 Pre-bed rest Bed rest P-value 
Energy (kcal·d-1) 2589 ± 50 2205 ± 47 <0.001 
Protein (g·kg bw-1·d-1) 1.16 ± 0.02 0.98 ± 0.04 <0.001 
Protein (g·d-1) 88 ± 2 73 ± 1 <0.001 
Fat (g·d-1) 88 ± 2 73 ± 3 0.004 
Carbohydrate (g·d-1) 343 ± 9 297 ± 4 <0.001 
Protein (En%) 14.0 ± 0.3 13.7 ± 0.2 0.354 
Fat (En%) 31.6 ± 0.6 30.7 ± 0.7 0.428 
Carbohydrate (En%) 54.4 ± 0.8 55.6 ± 0.7 0.368 
Values represent means±SEM. Bw, body weight; En%, Energy percentage 
 
232 | CHAPTER 10 
S U P P L E M E N T A L  R E S U L T S  
 
Supplemental Figure 2 | Fasting plasma free fatty acid (FFA) concentration on each day of the bed rest period. 
 
Supplemental Table 2 | Muscle fibre cross-sectional area (CSA), fibre distribution and myonuclear content 
 Fibre type Pre Post P-value 
Muscle fibre CSA (µm2) I 6650 ± 725 6218 ± 662 0.538 
 II 6542 ± 746 5982 ± 525 0.353 
% Fibre (number) I 48 ± 4 40 ± 3 0.102 
% Fibre (area) I 48 ± 5 41 ± 4 0.215 
Nuclei per fibre I 3.8 ± 0.3 3.8 ± 0.4 0.914 
 II 3.5 ± 0.3 3.8 ± 0.2 0.303 
Myonuclear domain (µm2) I 1763 ± 157 1621 ± 79 0.450 
 II 1848 ± 152 1576 ± 116 0.106 
Data are presented as means±SEM. CSA, cross-sectional area.  
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Supplemental Table 3 | Skeletal muscle lipid content and saturation 
 Pre Post P-value 
TAG    
Total (μmol·g dry weight-1) 142 ± 40 135 ± 25 0.750 
Saturation (%) 36 ± 1 36 ± 1 0.558 
MUFA (%) 51 ± 1 49 ± 1 0.275 
PUFA (%) 14 ± 1 14 ± 1 0.069 
DAG    
Total (μmol·g dry weight-1) 2.9 ± 0.3 3.4 ± 0.2 0.132 
Saturation (%) 41 ± 1 42 ± 1 0.752 
MUFA (%) 47 ± 1 45 ± 1 0.170 
PUFA (%) 12 ± 1 13 ± 1 0.020 
Ceramides    
Total (μmol·g dry weight-1) 0.6 ± 0.5 0.6 ± 0.2 0.574 
Saturation (%) 75 ± 0 74 ± 0 0.358 
MUFA (%) 17 ± 0 17 ± 0 0.950 
PUFA (%) 8 ± 0 8 ± 0 0.161 
PL    
Total (μmol·g dry weight-1) 77.5 ± 2.9 75.0 ± 3.0 0.259 
Saturation (%) 39 ± 0 40 ± 1 0.019 
MUFA (%) 10 ± 0 9 ± 0 0.707 
PUFA (%) 52 ± 1 51 ± 1 0.072 
FFA    
Total (μmol·g dry weight-1) 3.1 ± 0.4 4.0 ± 0.3 0.085 
Saturation (%) 51 ± 1 49 ± 1 0.231 
MUFA (%) 39 ± 1 39 ± 1 0.771 
PUFA (%) 10 ± 1 12 ± 1 0.045 
Values (means±SEM) represent skeletal muscle lipid content and degree of saturation of various lipid frac-
tions, prior to and following 7 days of strict bed rest. DAG, diacylglycerol; FFA, free fatty acid; MUFA, monoun-
saturated fatty acid; PL, phospholipid; PUFA, polyunsaturated fatty acid; TAG, triacylglycerol. 
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CHAPTER 11 
General Discussion 
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Various situations, such as the recovery from illness or rehabilitation after injury, often 
necessitate a period of physical inactivity in otherwise healthy individuals. This muscle 
disuse is initiated to enhance the recovery process, but is accompanied by the loss of 
muscle mass and muscle strength, as well as other negative health consequences. In 
this thesis, we studied the underlying physiological mechanisms responsible for muscle 
disuse atrophy, and assessed various nutritional and/or exercise interventional strate-
gies to prevent muscle atrophy during a period of disuse. In this final chapter we will 
address the implications of the presented findings, and discuss them in a broader per-
spective. At the end of this chapter we have defined important goals for future research 
in this area. 
The impact of short-term disuse 
Most work addressing the impact of disuse on muscle atrophy in humans has applied 
experimental disuse models, such as limb immobilization and bed rest, for several 
weeks (e.g. [1-10]). Fewer studies have tried to address the impact of short(er) periods 
of bed rest or limb immobilization on muscle mass loss (e.g. [11-14]). This is of particular 
relevance as the average hospital length of stay for patients of all ages and all reasons 
of admission is 7 days [15]. Previous studies have shown a decline in functional strength 
after 4 days of leg immobilization [16, 17], but the effect of such a short period of im-
mobilization on muscle mass had not been assessed before. Therefore, in Chapter 2, we 
assessed the loss of muscle mass and strength following 5 vs 14 days of leg immobiliza-
tion in healthy, young men. We demonstrate that merely 5 days of leg immobilization 
already leads to a substantial decline in muscle mass. Next to the 3.5% muscle loss that 
was observed, a concomitant 9% loss of muscle strength was seen (Chapter 2, [18]). 
Such short periods of disuse not only occur during hospitalization, but can also occur 
during recovery from illness or minor injury at home. These repeated ‘catabolic crises’ 
are now suggested to contribute to the persistent loss of muscle mass with ageing [19, 
20]. This is due to the fact that older individuals generally do not regain all muscle tissue 
that was lost during a period of disuse [10, 21, 22]. More specifically, Hvid and co-
workers have shown that elderly individuals experience more difficulties when trying to 
re-gain muscle lost after a period of disuse when compared to their younger counter-
parts [21]. The impact of multiple, successive short periods of disuse may largely, if not 
entirely, explain the 3-8% muscle loss that is observed per decade after the age of 30 
[19, 23]. This ‘accelerated ageing’ further stresses the importance of focussing on both 
the prevention of muscle loss during disuse, as well as regaining muscle loss during 
subsequent rehabilitation. 
Any net loss of muscle mass must be underpinned by an increase in muscle protein 
breakdown, a decrease in muscle protein synthesis, or a combination of both. Long-
term muscle disuse has been shown to be accompanied by declines in both basal [2, 4, 
6, 24-29] and postprandial muscle protein synthesis rates [26, 30, 31]. No studies have 
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measured basal or postprandial muscle protein synthesis rates following short-term 
muscle disuse. Therefore, in Chapter 3, we subjected twelve healthy, young males to 5 
days of one-legged knee immobilization. Following the immobilization period, we used 
stable isotope tracer infusions combined with the ingestion of intrinsically labelled pro-
tein to assess postabsorptive and postprandial muscle protein synthesis rates in the 
immobilized and control leg. This study showed that merely 5 days of immobilization 
reduces postabsorptive myofibrillar protein synthesis rates by 41±13% and postprandial 
myofibrillar protein synthesis rates by as much as 53±4% (Chapter 3, [32]). Additionally, 
indirect data from static markers suggested that the onset of disuse leads to an increase 
in muscle protein breakdown [33-36]. Therefore we suggested that muscle atrophy 
during short-term disuse is caused by a temporary increase in muscle protein break-
down and a large decrease in muscle protein synthesis (Figure 3). 
 
 
Figure 1 | Theoretical time course of the development of muscle disuse atrophy, combined with the associat-
ed changes in muscle protein synthesis and breakdown. Section A depicts the hypothesis obtained from
indirect data that the onset of disuse is accompanied by an increase in muscle protein breakdown and a
decrease in muscle protein synthesis, resulting in rapid muscle atrophy. Section B illustrates the data available 
that show that prolonged disuse (>10 days) results in a more modest rate of muscle atrophy when compared
with short-term disuse, which is primarily caused by a decline in muscle protein synthesis. Adapted from [42]. 
 
However, the relative contribution of the decline in basal muscle protein synthesis, the 
impaired muscle protein synthetic response to feeding, and the increase in muscle pro-
tein breakdown to muscle atrophy remains to be elucidated. As it is a technical chal-
lenge to measure muscle protein breakdown rates in vivo in humans, there is a lack of 
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studies investigating the role of muscle disuse on muscle protein breakdown. Conse-
quently, many researchers emphasize the contribution of muscle protein synthesis to 
muscle atrophy. However, it is important to consider whether interventional strategies 
should target muscle protein synthesis or muscle protein breakdown to maximize their 
effect. Interventions that can stimulate basal and postprandial muscle protein synthesis, 
as well as inhibit muscle protein breakdown in the first few days of disuse may be the 
most effective in preventing muscle loss during a (short) period of disuse. 
 
 
I N T E R V E N T I O N A L  S T R A T E G I E S  
Neuromuscular electrical stimulation 
Physical activity is one of the more potent stimuli that can increase muscle protein syn-
thesis [37]. The introduction of an exercise regimen during a period of bed rest has 
been shown to effectively maintain muscle protein synthesis rates [27]. Furthermore, it 
has been shown that muscle atrophy can be attenuated or even abolished when a rela-
tively low dose of exercise is applied [38-40]. While performing physical activity is un-
doubtedly the most effective intervention to preserve muscle mass, it is often impossi-
ble to maintain a certain level of physical activity during periods of muscle disuse. Im-
mobilized individuals, such as injured athletes, will be severely limited in their training 
possibilities due to the presence of a cast or brace that rigorously restricts range of 
motion. Additionally, individuals who are bedridden due to general weakness or illness 
are likely unable to perform any activities at all. In such situations, an exercise mimetic 
such as neuromuscular electrical stimulation (NMES) could be applied to induce electri-
cally evoked muscle contractions and, as such, stimulate muscle anabolism [41]. While 
the technique has been used in physical therapy practice over the past decades, it has 
recently gained a lot of attention from physiologists due to its influence on skeletal 
muscle mass during injury or rehabilitation. Previously, we performed a study in our 
laboratory in which subjects underwent 60 min of high-frequency, high-intensity NMES. 
We showed that NMES led to 27% greater muscle protein synthesis rates in the stimu-
lated leg when compared to the non-exercised contralateral control leg [42]. This posi-
tive effect of NMES on muscle protein synthesis translates to beneficial effects on mus-
cle mass: we showed a preservation of muscle mass following 5 days of leg immobiliza-
tion in healthy, young individuals (Chapter 4, [43]). This is in line with others who have 
demonstrated the efficacy of NMES in preventing muscle loss in various clinical condi-
tions [25, 44-49]. Moreover, we recently showed that NMES has the capacity to fully 
prevent the dramatic muscle wasting that is observed in critically ill, comatose, Inten-
sive Care Unit (ICU) patients (Chapter 5, [50]). Data obtained in these studies suggest 
that, in line with mechanistic data [42], the benefits of NMES are, at least partly, at-
tributed to an increase in postabsorptive muscle protein synthesis rates [25]. In support, 
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we showed an increase in mTOR phosphorylation following 7 consecutive days of 
NMES, suggesting a beneficial effect of repeated bouts of NMES on basal muscle pro-
tein synthesis rates (Chapter 5, [50]). However, of interest, some data also pointed to 
an attenuation of muscle protein breakdown. This was indicated by a reversal of skeletal 
muscle mRNA expression of intermediates in the ubiquitin proteasome pathway, follow-
ing multiple days with twice-daily NMES (Chapter 4, [43]). The increase in ubiquitin 
proteasome pathway activity during disuse without NMES is characteristic for the tran-
sient rise in muscle protein breakdown, which likely contributes to the observed muscle 
atrophy during short-term disuse. The parallel occurrence of an increase in muscle pro-
tein synthesis and a suppression of muscle protein breakdown in our studies is indica-
tive of a more positive muscle protein balance when NMES is applied on a regular basis. 
These data underline the effectiveness of NMES in a disuse setting, and the need for it 
to be applied directly following the onset of muscle disuse. 
While NMES is clearly an effective tool for attenuating muscle disuse atrophy, little 
information is available on how it can be (more) effectively applied. To specify its impact 
on skeletal muscle tissue, the long-term effect of high-frequency (>50 Hz) NMES has 
been investigated in a fibre-type specific manner. Increases in both type I and II muscle 
fibre size have been observed in free-living, non-immobilized healthy individuals [51-53] 
and patients [50, 54] following multiple sessions of NMES training. More specifically, 
this effect has been shown to be located mainly in the type IIa fibres [55, 56]. In situa-
tions of muscle disuse, we have shown that NMES leads to relatively greater changes in 
type II fibre size compared with type I fibre size [43, 50]. Specifically, NMES prevented 
the 16% decrease in type I and the 24% decrease in type II muscle fibre size in comatose 
patients [50]. Moreover, NMES applied during immobilization even led to specific type II 
muscle fibre hypertrophy [43]. The specific effect of NMES on type II fibres may be, at 
least partly, due to their more superficial location than type I fibres, as demonstrated by 
Sjöström and co-workers [57]. This makes NMES a highly relevant interventional strate-
gy in various situations where individuals suffer from predominant type II muscle fibre 
atrophy, such as following injury [58], during immobilization [1, 59] or critical illness 
[50], but also with ageing [60, 61]. Obviously, in our studies we have examined the effi-
cacy of NMES on one muscle group only. An important next step would be to target 
multiple muscle groups to maximize the relevance of applying NMES in clinical practice. 
Although the quadriceps femoris is one of the muscle groups most susceptible to atro-
phy [9], large muscle groups such as the hamstrings, calves, and (lower) back muscles, 
that also atrophy substantially [9], would likely benefit from treatment with NMES. 
Applying NMES to multiple muscle groups should be performed under guided supervi-
sion, given the importance of correct placement of electrodes and adjustment of the 
intensity to ensure full contractions throughout the session. Although newly developed 
products such as whole-body NMES suits have simplified the use of NMES in healthy 
individuals, further development of such products is essential to make their use feasible 
for more clinically compromised patients. Despite the demonstrated potential of NMES 
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as a training modality during disuse, normal voluntary contractions remain the first 
choice in clinical practice to alleviate or prevent muscle atrophy. Physical activity such 
as passive mobilisation or performing exercises in bed or at the bedside need to be 
applied more frequently in various clinical settings. Strategies to stimulate physical 
activity are required to change the current mindset in clinical practice, to motivate pa-
tients to remain (more) active rather than turning passive and inactive. Since there are 
many opportunities to implement physical activity or NMES during a period of disuse, it 
is crucial to define approaches suitable to the various patient groups. It is important not 
to focus on the effects of exercise (mimetics) on muscle mass only, but also investigate 
the impact on metabolic health, functional capacity, quality of life, and long-term out-
comes such as morbidity and mortality. 
Protein or amino acid supplementation 
Muscle protein synthesis can be strongly modulated by the intake of food, and specifi-
cally dietary protein [62-64]. Protein or essential amino acid ingestion acutely stimulates 
muscle protein synthesis rates in a dose-dependent manner [65, 66]. In healthy, young 
individuals, a dose of 15-20 g of a high-quality protein (or ~7.5-10 g crystalline essential 
amino acids) is sufficient to maximally stimulate muscle protein synthesis rates [65, 67, 
68]. However, as disuse is accompanied by anabolic resistance to protein intake [26, 30-
32] a larger bolus is necessary to stimulate postprandial muscle protein synthesis rates 
during muscle disuse. It has been shown that anabolic resistance in other situations 
(e.g. normal ageing) can be overcome by increasing the amount [69] or changing the 
type of protein [70]. Although it remains to be established if changing the amount or 
type of protein can augment the postprandial muscle protein synthetic response during 
muscle disuse, it certainly offers a promising strategy to attenuate disuse atrophy. 
In healthy individuals, dietary protein intake provides ~15 percent of total energy in-
take. For an 80 kg male, consuming 9 MJ per day [71], this would result in a daily habit-
ual protein intake of ~80 g. However, during situations of muscle disuse, total energy 
and protein intake are reduced due to the decline in energy requirement [72, 73] 
and/or a reduction in appetite [74, 75]. Individuals will therefore consume less dietary 
protein, which will compromise muscle mass preservation. As such, it has been pro-
posed that an overall increase in the protein or amino acid content of the diet could 
alleviate muscle loss during a period of disuse [19, 76, 77]. Despite a relative paucity of 
data, studies focusing on mimicking hospitalization have indeed shown that supplemen-
tation with high doses of crystalline amino acids attenuates the loss of muscle mass 
during disuse [7, 78, 79]. In contrast, we (Chapter 6, [71]) and others [80] have shown 
no beneficial effect of protein supplementation during a period of physical inactivity. 
This apparent discrepancy can potentially be explained by differences in the impact of 
free amino acids versus intact protein on muscle mass preservation [81]. However it is 
more likely that differences between studies are attributed to the level of amino acid or 
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protein provision applied in those studies. Beneficial effects of protein or amino acid 
supplementation were only observed in those studies in which the control group con-
sumed protein at a level no higher than the current Recommended Daily Allowance 
(RDA), i.e. 0.8 g·kg body weight-1·day-1 [82]. Consequently, this would mean that popula-
tions at risk for undernutrition during muscle disuse, such as institutionalized or hospi-
talized elderly [83, 84], are more likely to benefit from protein supplementation to 
maintain ample daily protein intake. Dietary protein intake is prerequisite to maintain 
muscle mass during disuse. However, increasing protein intake above habitual intake 
levels does not further attenuate muscle mass loss during a period of disuse (Chapter 6, 
[71]). Additional considerations that should be regarded when optimising protein intake 
in various groups are, besides determining the optimal quantity of protein, the timing of 
ingestion of the supplement and the type of protein that is given [85]. Protein supple-
mentation can be timed together with a relatively low-protein meal such as breakfast or 
lunch [86], to maximize the postprandial muscle protein synthetic response to meal 
ingestion. Although the threshold for the maximal postprandial stimulation of muscle 
protein synthesis during disuse remains to be elucidated, it is clear that proper meal 
distribution can play an important role in optimizing 24 h muscle protein balance. To 
date, it remains to be established how much protein is required to maximally stimulate 
muscle protein synthesis rates during periods of physical inactivity. Additionally, the 
type of protein that is consumed may also modulate the postprandial muscle protein 
synthetic response. Ingestion of more rapidly digestible whey protein has been shown 
to lead to greater increases in postprandial muscle protein synthesis rates when com-
pared with casein ingestion [70]. The greater anabolic properties of whey protein can 
be, at least partly, attributed to the greater leucine content [70]. Previous work from 
our group [87] and others [88-90] has shown that increasing the leucine content of a 
meal can augment postprandial muscle protein synthesis rates. Furthermore, leucine 
has also been shown to have anti-proteolytic properties [91-93]. Therefore, leucine 
supplementation may represent an effective strategy to preserve muscle mass during a 
period of disuse. In support, recent work demonstrates that leucine supplementation 
can preserve muscle mass during 7 days, but not 14 days, of bed rest [94]. Similar sug-
gestions have been made for supplementation with leucine’s metabolite β-Hydroxy β-
methylbutyric acid (HMB, [8]). Future studies will likely address the impact of free ami-
no acid supplementation to preserve muscle mass loss during short periods of disuse. 
Other nutritional compounds have been identified that may contribute to preserve 
muscle mass during a short period of disuse [76]. Such nutritional compounds that can 
be applied during muscle disuse or subsequent rehabilitation include creatine [95, 96], 
fish-oil-derived omega 3 fatty acids [97], green tea extract [98], and vitamin D [99, 100]. 
Another promising nutritional compound, ursolic acid, has been shown to reduce atro-
phy in mice via an inhibition of atrophy-associated skeletal muscle mRNA expression 
and a positive effect on insulin signalling [101, 102]. Whereas it remains to be estab-
lished if its effects are similar in humans, it could be suggested that ursolic acid can help 
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to preserve muscle quality as well as metabolic health during a period of disuse. Similar-
ly, the compound resveratrol has recently gained much attention for its proposed ability 
to inhibit muscle atrophy under cachectic and atrophic conditions. The effects of 
resveratrol during muscle disuse in animal models include the downregulation of pro-
inflammatory cytokines and an upregulation of the level of Akt, AMPK and SIRT1 [103, 
104]. However, the efficacy of resveratrol supplementation to exert these effects in an 
in vivo human model remains uninvestigated. 
Combined intervention of NMES and protein ingestion 
Neuromuscular electrical stimulation has been discussed previously as an effective 
method to stimulate muscle protein synthesis rates in an overnight fasted state [42]. 
However, people spend approximately half of their day under the influence of their last 
meal, i.e. in the postprandial state. Since disuse-induced anabolic resistance likely plays 
a key role in the process of muscle atrophy, we were looking for a strategy to optimize 
the postprandial response to the ingestion of a protein meal. A previous study from our 
laboratory showed that anabolic resistance to protein intake can be overcome by per-
forming physical activity prior to food ingestion [105]. Therefore, at present, the opti-
mal approach to attenuate muscle disuse atrophy likely lies in the parallel application of 
NMES and nutritional modulation. Up until recently, no data were available that as-
sessed the combined effect of NMES and dietary protein intake. We recently performed 
two studies to assess the surplus effects of NMES on the postprandial muscle protein 
synthetic response to protein ingestion. In contrast to what we hypothesized, we 
showed that a single bout of NMES performed immediately prior to intake of a meal-like 
amount of protein did not augment the postprandial muscle protein synthetic response 
(Chapter 7). In that study, conducted in healthy, active, older participants, NMES did not 
lead to additional stimulation of de novo muscle protein accretion after ingestion of 20 
g casein protein. In a second study, we used NMES to increase the postprandial muscle 
protein synthetic response prior to sleep. We created conditions simulating hospitaliza-
tion by subjecting participants to one day of bed rest before the NMES session (Chapter 
8). In contrast to the previous study, the use of NMES resulted in ~18% greater muscle 
protein synthesis rates when compared to the non-stimulated leg. These results show 
that although the surplus effect of NMES is not present in active individuals (Chapter 7), 
NMES can sensitize the muscle of older, physically less active, individuals to the anabolic 
properties of protein feeding (Chapter 8). Up until now, these combined strategies of 
protein feeding and NMES have not been extrapolated to a multiple-day model of dis-
use. However, we speculate that proper timing of NMES, immediately before a meal, 
will overcome anabolic resistance and therefore attenuate skeletal muscle loss during a 
period of muscle disuse. Of course this also requires new insights and technological 
developments to allow translation of these findings into to relevant interventions to 
support muscle mass preservation during disuse. 
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Bed rest as a model for muscle disuse atrophy 
In the scientific literature, muscle disuse in humans is generally studied using a limb 
immobilization or bed rest model. Although both models are used to investigate under-
lying mechanisms of muscle loss and to test the efficacy of interventional strategies, this 
may not be justified due to potential differences between models (i.e. systemic factors 
or the amount of muscle action possible). Whereas some researchers have tried to 
extrapolate results of limb immobilization studies to a whole-body disuse setting, this 
may lead to incorrect results based on different rates of atrophy between muscle 
groups [9]. Conceptually, it is possible that interventions to preserve muscle mass would 
need to differ when disuse either occurs locally (via limb immobilization) or on a whole-
body level (bed rest). Additionally, different rates of muscle atrophy could be accompa-
nied by a different impact on metabolic health. Although previous work, based on com-
bined results of separate studies, has suggested that immobilization leads to more pro-
nounced muscle loss than bed rest [106], no direct comparison of the rate and amount 
of muscle loss between leg immobilization and bed rest existed. In Chapter 9, we com-
pared twenty healthy males who participated in either a 7-day leg immobilization study 
or a 7-day bed rest study. We showed that both leg immobilization and bed rest led to 
considerable declines in muscle mass (-5.4±1.0 vs -3.2±0.9%, respectively) and strength 
(-6±3 vs -8±2%, respectively; Chapter 9). Although the rate of muscle atrophy was com-
parable between both models, the total muscle loss during bed rest clearly exceeded 
that during immobilization due to the total amount of inactive tissue. Indeed, we 
demonstrated that merely one week of bed rest leads to a 1.4 kg loss of muscle tissue in 
healthy, young individuals (Chapter 10). This muscle atrophy was accompanied by a 
severe metabolic decline, such that 7 days of strict bed rest led to a ~30% decline in 
insulin sensitivity (Chapter 10). This development of insulin resistance was accompanied 
by a decline in muscle oxidative capacity, without alterations in skeletal muscle lipid 
content or saturation level, markers of oxidative stress, or capillary density. Whereas 
the molecular mechanisms responsible remain to be elucidated, our findings clearly 
indicate that bed rest-induced insulin resistance is not associated with mechanisms 
implicated in high-fat diet-induced insulin resistance. This study demonstrates that 
interventional strategies should not only focus on preventing muscle loss during a peri-
od of disuse, but should also aim to attenuate the decline in metabolic health that oc-
curs during disuse in a bed rest model. 
In conclusion, both experimental models of disuse lead to comparable rates of mus-
cle atrophy and can therefore both be used to induce muscle loss in an experimental 
setting. However, the choice for which experimental model to use depends on the re-
search question. When specifically studying mechanisms underlying muscle disuse atro-
phy, the limb immobilization model is appropriate as it isolates inactivity without the 
need for altering habitual dietary intake. In contrast, in more clinically relevant situa-
tions the bed rest model is of utmost value to mimic a period of hospitalization. In a 
246 | CHAPTER 11 
clinical setting, the functional impairment that occurs with limb immobilization can be 
relatively easily attenuated or even prevented by the strategies described in this thesis. 
In contrast, the metabolic decline that is associated with bed rest is more problematic 
given the fact that not only skeletal muscle tissue is affected, but due to inter-organ 
crosstalk other organs such as liver and adipose tissue are involved. 
 
 
F U T U R E  R E S E A R C H  
Over the past years, the impact of protein supplementation during muscle disuse has 
hardly been investigated. Not only is it challenging to subject healthy individuals to 
muscle disuse, the fact that nutritional intake should be thoroughly controlled brings 
about an extra difficulty. It is crucial that in the near future work will be undertaken to 
establish the dose-responsiveness of protein intake and the subsequent muscle protein 
synthetic response to feeding, in order to assess how much protein should be ingested 
per meal in patients experiencing disuse. When the optimal protein dose to maximally 
stimulate muscle protein synthesis during disuse has been established in both young 
and elderly individuals, we should seek for ways to implement this knowledge in clinical 
practice. This can be done by distributing protein intake such that the required protein 
intake is achieved in every main meal, as well as prior to sleep. Alternatively, it is possi-
ble to accomplish adequate protein consumption via supplementing with protein or 
amino acids on top of a habitual diet. In parallel, other nutritional compounds such as 
leucine or HMB should be tested for their suggested effect on muscle protein synthesis 
and breakdown, and consequently on muscle mass, during short-term disuse. 
Neuromuscular electrical stimulation (NMES) is a feasible technique to re-introduce 
a certain level of physical activity. Whereas we demonstrated the proof of principle in 
an experimental setting, future studies should aim to apply NMES in a clinical setting by 
means of targeting multiple muscle groups. Not only its effect on muscle mass, but also 
the metabolic effects of NMES as well as long-term outcomes such as muscle function, 
morbidity, and mortality should be examined. Eventually, the combined strategy of 
NMES and protein feeding should be optimized and tested in a multiple-day model of 
disuse, in order to overcome anabolic resistance and limit muscle loss. 
The focus of this thesis was on the effect of various interventions to prevent or at-
tenuate muscle loss during muscle disuse. Although the results discussed are limited to 
the effect on muscle mass only, both NMES [51, 107-110] and the discussed nutritional 
interventions [6, 7, 111, 112] could have an important impact on muscle quality or met-
abolic health during disuse. Similarly, these interventions are very likely to have poten-
tial benefits during the recovery from muscle disuse [10, 96, 113, 114]. Therefore, it is 
important to keep in mind that a strategy that does not alleviate muscle atrophy during 
disuse might still be able to affect metabolic health or recovery. Finally, as an improve-
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ment in metabolic health could possibly lead to an attenuation of muscle atrophy and 
vice versa, it may be relevant to test the efficacy of an intervention on both muscle 
quantity and muscle quality simultaneously. 
 
 
C O N C L U S I O N S  
Various situations, such as the recovery from illness or rehabilitation after injury, often 
necessitate a period of skeletal muscle disuse and lead to muscle loss in otherwise 
healthy individuals. Even a few days of bed rest or immobilization can lead to substan-
tial declines in muscle mass and strength and are accompanied by a decline in metabol-
ic health. Re-introduction of some level of physical activity by the application of neuro-
muscular electrical stimulation (NMES) can augment postabsorptive and/or postprandi-
al muscle protein synthesis rates and can prevent muscle loss during short-term disuse 
in various clinical populations. Maintenance of habitual dietary protein consumption is 
prerequisite for muscle maintenance, but further increasing protein intake does not 
prevent muscle loss during disuse. Combining the anabolic properties of physical activi-
ty (surrogates) with nutritional support will have synergistic effects and both should, 
therefore, be applied in interventions aiming to prevent or alleviate muscle atrophy 
during short periods of disuse.   
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S U M M A R Y  
Various situations, such as the recovery from illness or rehabilitation after injury, may 
necessitate a period of physical inactivity in otherwise healthy individuals. This muscle 
disuse during a period of leg immobilization or bed rest leads to the loss of muscle mass 
and strength and can have numerous resultant negative health consequences. We need 
insight in the mechanism(s) responsible for disuse-related muscle atrophy to develop 
effective interventional strategies to preserve muscle mass and offset the negative 
health consequences of muscle disuse. In this thesis we examine the various aspects of 
skeletal muscle disuse atrophy and investigate the efficacy of various interventional 
strategies to combat disuse atrophy. 
 
The effects of prolonged (two weeks or longer) muscle disuse have been extensively 
studied in the past. However, given that the average hospital length of stay is currently 
seven days, it is of importance to focus on the effects of short-term disuse. Therefore, 
we first assessed the impact of short (five days) versus long (fourteen days) term impact 
of leg immobilization on muscle mass and muscle strength in healthy, young volunteers 
(Chapter 2). As expected, we observed a substantial decline in muscle mass and 
strength following fourteen days of leg immobilization. However, even a mere five days 
of leg immobilization resulted in a 3.5% decrease in muscle mass and a 9% decline in 
muscle strength. This underlines the impact of short periods of muscle disuse, and em-
phasizes the need to prevent or attenuate muscle loss during short periods of muscle 
disuse. The loss of muscle mass is caused by a decline in muscle protein synthesis, a 
decline in muscle protein breakdown, or a combination of both. Therefore, we studied 
the impact of 5 days of leg immobilization on muscle protein synthesis in a fasted state 
and following ingestion of a protein-rich drink in Chapter 3. In that chapter we showed 
that muscle protein synthesis rates in the immobilized leg were considerably lower in 
both the postabsorptive as well as the postprandial state when compared with the non-
immobilized control leg. This work shows that merely five days of disuse lowers fasting 
muscle protein synthesis and decreases the sensitivity of the muscle to dietary protein 
intake, a phenomenon called ‘anabolic resistance’. Therefore, strategies to prevent or 
attenuate muscle loss during disuse should focus on stimulating muscle protein synthe-
sis, as well as overcoming anabolic resistance. 
Physical activity is one of the main anabolic stimuli required to maintain skeletal 
muscle mass. However, during muscle disuse it is often impossible to perform physical 
activity due to weakness or restriction of movement imposed by a cast. In Chapter 4 and 
5, we applied neuromuscular electrical stimulation (NMES) to maintain some level of 
physical activity during short-term muscle disuse. We demonstrate that in healthy, 
young adults, NMES is effective to prevent muscle loss during five days of one-legged 
immobilization (Chapter 4). In a follow-up study, we showed that NMES applied in criti-
cally ill, comatose patients in the Intensive Care Unit (ICU) fully prevented the large 
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amount of muscle that is typically lost in these patients (Chapter 5). These two studies 
emphasize the importance of some level of muscle contraction to preserve muscle mass 
during a period of muscle disuse. 
We started this thesis by describing the impact of short-term disuse on muscle mass 
and muscle protein synthesis. Such short periods are of particular relevance to the age-
ing society, as the accumulation of successive periods of disuse is thought to contribute 
to the muscle loss observed with ageing, termed sarcopenia. In Chapter 6, we assessed 
the impact of protein supplementation on muscle mass and strength during five days of 
immobilization in healthy, elderly volunteers. We show that twice-daily intake of a pro-
tein supplement does not prevent the loss of muscle mass and strength. Based on this 
we concluded that protein supplementation is not of additional value when an individu-
al’s habitual dietary protein intake is maintained at a supraoptimal level. To overcome 
the disuse-induced anabolic resistance we applied NMES as a strategy to increase the 
postprandial muscle protein synthetic response to protein ingestion in the older popula-
tion. We applied the combined approach of using NMES together with protein ingestion 
in Chapter 7 and 8. By using intrinsically labelled protein we were able to analyse how 
much of the ingested protein was eventually built into contractile muscle proteins. In 
Chapter 7 we show that NMES does not augment muscle protein accretion in healthy, 
recreationally active men. In Chapter 8, a comparable group of healthy elderly remained 
bed-rested for a full day at the University. In the evening we applied NMES after which 
we provided participants with a protein drink. From this study we concluded that, in 
contrast to what we showed in Chapter 7, NMES represents an effective strategy to 
stimulate muscle protein accretion following protein ingestion in a setting of reduced 
physical activity. 
Muscle disuse can be localized to a limb (e.g. when an arm or leg is immobilized due 
to a bone fracture) or to the whole body (e.g. when a patient undergoes bed rest during 
illness or following surgery). Until now, both models are used interchangeably when 
studying muscle disuse, without knowing the extent of muscle atrophy that they cause. 
Therefore, we directly compared the loss of muscle mass and strength during seven 
days of leg immobilization versus seven days of bed rest in Chapter 9. We demonstrate 
that both models of muscle disuse lead to substantial declines in muscle mass and 
strength. Although no differences in leg muscle loss were observed, total muscle loss 
during bed rest exceeded that during leg immobilization only due to the total amount of 
muscle tissue involved in the disuse. The considerable amount of muscle loss following 
bed rest inevitably has an impact on muscle function and metabolic health. To investi-
gate this, we subjected ten healthy, young males to seven days of strict bed rest (Chap-
ter 10). We showed substantial declines in muscle mass, muscle function, and metabolic 
health. Effective strategies should therefore not only focus on maintaining muscle mass 
and function during short periods of bed rest, but should also aim to preserve metabolic 
health. 
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The final chapter of this thesis (Chapter 11) encompasses a broad discussion on the 
implications of the work described. This thesis demonstrates that effective interven-
tional strategies are warranted to prevent or attenuate the loss of muscle mass, 
strength, and metabolic health during short-term muscle disuse. Promising strategies 
include NMES plus pre-sleep protein feeding. Given the considerable muscle loss during 
merely five to seven days of muscle disuse, it is of paramount importance to apply ef-
fective intervention strategies before, during, and after a period of muscle disuse. 
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S A M E N V A T T I N G  
Korte perioden van fysieke inactiviteit zijn vaak nodig voor het herstel tijdens ziekte of 
na een blessure, en vinden bijvoorbeeld plaats wanneer een patiënt bedrust dient te 
houden of een been in het gips gezet wordt. Zulke perioden van inactiviteit leiden tot 
het verlies van spiermassa (ook wel spieratrofie genoemd), een afname in spierkracht 
en vele andere negatieve gevolgen. Gezien de negatieve gevolgen van fysieke inactivi-
teit, is het van belang om te begrijpen waarom het verlies van spiermassa en –kracht 
plaatsvindt. Op deze manier is het mogelijk om interventiestrategieën te kunnen ont-
wikkelen die effectief zijn in het afremmen of voorkomen van spieratrofie. 
 
De effecten van langdurige fysieke inactiviteit (langer dan twee weken) zijn in het verle-
den uitgebreid in kaart gebracht. Het is echter ook van belang om te kijken naar kortere 
perioden van fysieke inactiviteit, omdat de gemiddelde ziekenhuisopname voor patiën-
ten tegenwoordig slechts zeven dagen duurt. Daarom hebben we in Hoofdstuk 2 geke-
ken naar de impact van kortdurende versus langdurende fysieke inactiviteit op spier-
massa en -kracht. Hierbij hebben we gezonde, jonge mannen met een been in het gips 
gezet gedurende vijf of veertien dagen. Zoals verwacht zagen we dat er na veertien 
dagen immobilisatie een sterke daling in spiermassa en –kracht te zien was. Echter, zelfs 
na vijf dagen immobilisatie was er al een afname van 3,5% in spiermassa en van 9% in 
spierkracht zichtbaar. Dit illustreert de invloed van slechts enkele dagen fysieke inactivi-
teit, en toont bovendien het belang om te begrijpen waarom deze spieratrofie optreedt. 
Verlies van spiermassa wordt veroorzaakt door een vermindering van de spiereiwitop-
bouw, een verhoging van de spiereiwitafbraak, of een combinatie van beide factoren. 
Daarom hebben we in Hoofdstuk 3 onderzocht wat het effect van vijf dagen immobilisa-
tie van één been op de spiereiwitopbouw is, in zowel nuchtere toestand als ook na 
inname van een eiwitrijke drank. In dat hoofdstuk hebben we laten zien dat in zowel de 
nuchtere als de gevoede toestand de snelheid van de spiereiwitopbouw sterk verlaagd 
was, wanneer we dit vergeleken met de waarden in het niet-geïmmobiliseerde contro-
lebeen. Fysieke inactiviteit leidt dus niet alleen tot een verlaging van de spiereiwitop-
bouw in nuchtere toestand maar zorgt ook voor een verminderde gevoeligheid van de 
spier voor de anabole werking van eiwit ingenomen via de voeding. Dit fenomeen wordt 
‘anabole resistentie’ genoemd. Het is daarom nodig om ons bij het ontwikkelen van 
interventiestrategieën ter vermindering van atrofie zowel te richten op het stimuleren 
van de spiereiwitopbouw, als het tegengaan van anabole resistentie. 
Een van de belangrijkste stimuli voor de opbouw van spieren is fysieke activiteit. Het 
is echter tijdens een periode van fysieke inactiviteit vaak niet mogelijk om te trainen of 
oefeningen te doen, omdat patiënten zich zwak voelen of omdat hun bewegingen wor-
den beperkt door een gipskoker. In Hoofdstuk 4 en 5 hebben we daarom neuromuscu-
laire electrostimulatie (NMES) toegepast om een beperkte mate van spieractiviteit te 
behouden tijdens een periode van inactiviteit. We hebben laten zien dat NMES effectief 
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is in het volledig voorkomen van spieratrofie tijdens vijf dagen immobilisatie in gezonde, 
jonge mannen (Hoofdstuk 4). Daarnaast hebben we NMES toegepast in ernstig zieke, 
comateuze patiënten op de Intensive Care. Niet alleen hebben we laten zien dat deze 
patiënten ongeveer vijf keer zo snel spiermassa verliezen als gezonde personen tijdens 
inactiviteit, maar ook dat NMES in staat is om deze atrofie volledig tegen te gaan 
(Hoofdstuk 5). Deze twee studies laten zien dat spiercontracties essentieel zijn om 
spierverlies tijdens kortdurende fysieke inactiviteit te verminderen. 
We zijn dit proefschrift begonnen met het beschrijven van de impact van kortduren-
de fysieke inactiviteit op spiermassa, -kracht, en –eiwitopbouw. Zulke perioden zijn 
voornamelijk van belang voor ouderen omdat gedacht wordt dat het herhaaldelijk voor-
komen van zulke perioden bijdraagt aan sarcopenie, het spierverlies dat we zien met 
veroudering. Naast fysieke activiteit is voeding, en vooral de hoeveelheid eiwit in de 
voeding, een belangrijke stimulus voor spieropbouw. Om die reden hebben we in 
Hoofdstuk 6 gekeken of we met eiwitsuppletie het verlies van spiermassa en spierkracht 
kunnen afremmen bij gezonde ouderen die gedurende vijf dagen geïmmobiliseerd wer-
den. We tonen aan dat het tweemaal daags innemen van een eiwitsupplement de 
spieratrofie en het verlies van spierkracht niet kan voorkomen. Op basis hiervan nemen 
we aan dat eiwitsuppletie geen meerwaarde heeft wanneer de habituele eiwitinname 
voldoende is. Hierna zijn we gaan kijken hoe we de spiereiwitopbouw na eiwitinname 
verder kunnen stimuleren bij oudere mensen. We hebben hiervoor NMES toegepast, 
omdat een eerdere studie uit onze onderzoeksgroep heeft laten zien dat NMES de spie-
reiwitopbouw kan stimuleren. De gecombineerde aanpak van het uitvoeren van NMES 
en de inname van eiwit hebben we toegepast in Hoofdstuk 7 en 8. Hierbij hebben we 
NMES toegepast op een van beide benen, terwijl het andere been als controlebeen 
gold. Door het gebruik van intrinsiek gelabeld eiwit waren we in staat om te analyseren 
hoeveel van het ingenomen eiwit uiteindelijk in contractiele spiereiwitten in de spier 
was ingebouwd. Uit Hoofdstuk 7 blijkt dat het toepassen van NMES voorafgaand aan 
inname van een eiwitdrank niet zorgt voor een meetbare toename in spiereiwitopbouw 
in actieve, gezonde ouderen. Parallel hieraan heeft in Hoofdstuk 8 een vergelijkbare 
groep gezonde ouderen een hele dag bedrust gehouden, waarna we ’s avonds voor het 
slapen NMES hebben toegepast en een eiwitdrank hebben gegeven. De conclusie van 
dit onderzoek was dat, in tegenstelling tot de resultaten in Hoofdstuk 7, NMES wél ef-
fectief is in het stimuleren van de spiereiwitopbouw na inname van een eiwitdrank in 
een situatie van verminderde fysieke activiteit. 
Fysieke inactiviteit kan lokaal geïnduceerd worden (bijvoorbeeld door een gipskoker 
om een arm of been na een botbreuk) of op heel-lichaamsniveau plaatsvinden (zoals 
wanneer een patiënt bedrust dient te houden tijdens ziekte of na een operatie). Tot op 
heden worden beide modellen naast elkaar gebruikt voor het bestuderen van fysieke 
inactiviteit, zonder daarbij te weten wat de snelheid van spieratrofie is in beide situa-
ties. Om die reden hebben we in Hoofdstuk 9 een directe vergelijking gemaakt van de 
snelheid van zowel spierverlies als spierkrachtafname tussen zeven dagen beenimmobi-
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lisatie en zeven dagen bedrust. Uit deze vergelijking blijkt dat er geen verschil was in de 
snelheid van atrofie, maar dat bedrust wel leidt tot een groter totaal spiermassaverlies 
vanwege de grotere hoeveelheid spierweefsel die verminderd actief is. Het is onvermij-
delijk dat spierverlies een substantiële invloed heeft op het functioneren van de spier en 
de hormoonhuishouding. Om dit te onderzoeken hebben in Hoofdstuk 10 tien gezonde, 
jonge mannen gedurende zeven dagen volledige bedrust gehouden. Dit resulteerde in 
een substantiële afname in spiermassa, spierfunctie, en metabole gezondheid. Deze 
resultaten laten zien dat interventiestrategieën tijdens fysieke inactiviteit zich niet al-
leen moeten richten op het voorkomen van spieratrofie, maar ook op het behouden 
van metabole gezondheid. 
Dit proefschrift sluit af met een discussie van de onderzoeksresultaten (Hoofdstuk 
11) en de implicaties hiervan. De bevindingen van dit proefschrift demonstreren dat we 
effectieve interventies nodig hebben om spieratrofie, het verlies van spierkracht en de 
metabole achteruitgang tijdens een periode van fysieke inactiviteit te verminderen of 
zelfs te voorkomen. Veelbelovende strategieën hiervoor zijn het toepassen van NMES 
en het geven van eiwitrijke voeding, waarbij rekening gehouden moet worden met het 
tijdstip van eiwitinname. Gezien het substantiële spierverlies dat al optreedt tijdens vijf 
tot zeven dagen fysieke inactiviteit, is het van groot belang om effectieve interventies 
zowel voor, tijdens als na een periode van inactiviteit toe te passen. 
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V A L O R I Z A T I O N  
Relevance 
Hospitalization, often required during illness or following surgery, is associated with 
high health care costs. To illustrate this, the costs for one hospital bed per day in the 
Netherlands is 200 euro (based on primary, secondary and tertiary hospitals, [1]). At 
present, individuals who are admitted to the hospital have an average length of stay of 
less than 7 days [2]. During such periods of muscle disuse, patients suffer from muscle 
loss, which has been shown to be predictive of mortality [3]. Periods of hospitalization 
have been shown to be of particular relevance to the elderly population. Currently, the 
length of hospital stay has been demonstrated to increase with advancing age from the 
age of 40 [2]. Periods of muscle disuse not only occur during hospital admission, but 
also when an individual is struck with illness at home. While younger individuals demon-
strate a full natural recovery after a period of disuse, recovery from disuse in elderly has 
been shown to be impaired [4]. More specifically, a 4-week progressive resistance-type 
exercise program was insufficient to fully regain lost muscle mass in the elderly [4]. The 
accumulation of such short periods of muscle disuse has been thought to contribute to 
the loss of muscle mass and strength with ageing, termed sarcopenia [5, 6]. Due to the 
greater longevity, the subpopulation of elderly individuals aged 80 year and older is 
currently the fastest growing subpopulation in the developed world [7]. In the Nether-
lands, it has been estimated that in 2040 the number of people aged 65 and over will 
have increased to 4.8 million [8]. Together with the fact that life expectancy keeps on 
increasing [8], there will be more elderly people who are at risk for the negative conse-
quences of muscle disuse in the next decades. 
Nowadays, the Netherlands have more day care patients than in-patients [2], which 
demonstrates that we are able to minimize hospital stay. Moreover, in-patients are 
dismissed earlier, which is demonstrated by a reduction in average hospital length of 
stay from 7.5 days in 2003 to 5.2 days in 2013 [2]. However, a possible hazard could be 
that in the eyes of our physicians and health care workers, it is no longer worth to focus 
on preventing muscle loss during this decreased length of stay. 
Target groups 
In the present thesis, we have investigated strategies to combat muscle atrophy during 
short-term muscle disuse in a controlled laboratory setting. Even though within the 
scientific community there is consensus that merely a few days of muscle disuse already 
leads to various negative health consequences, our findings have not yet been translat-
ed to the general public. Firstly, amongst patients awareness should be created of the 
impact of even short-term muscle disuse. Obviously, it should be emphasized that such 
periods should be avoided or shortened as much as possible. It is the task of physicians 
and health care workers to educate patients in this. During hospital stay, patients are 
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currently not encouraged to be active: their food is served at the bed side and an ap-
pointment with their physician takes places in the patients’ room. As a result, elderly 
hospitalized patients spend 83% of their entire time in bed [9]. Of their time out of bed, 
they spend a mere 43 minutes per day standing or walking [9]. There is a clear role for 
policy makers here, as the mindset and logistics in hospitals need to be altered to 
change the current situation. Examples of minimizing physical inactivity in hospitals 
could entail serving meals in a shared dining room, assuring that patients visit their 
physician in her/his consulting room, and implementing digital (e.g. via television or 
internet) or real life physical activity or exercise (e.g. guided by a physical therapist). In 
order to achieve this, policy makers have to provide financial and (infra)structural sup-
port. Lastly, in the future insurance companies can benefit from the beneficial effects of 
NMES, applied with or without (more) protein rich nutrition. However, they will likely 
wait with implementing such a technique until the long-term effects are demonstrated 
in a large multicentre trial. 
The results of this thesis are of great relevance for people who undergo a (short) pe-
riod of disuse, and consequently lose a substantial amount of muscle mass. Muscle 
disuse is associated with specific type II muscle fibre atrophy [10]. Such fibre-type spe-
cific atrophy is not only seen in situations of muscle disuse, but also occurs in patients 
with cancer cachexia and chronic obstructive pulmonary disease. There is limited 
knowledge on the efficacy of NMES and protein ingestion in these patient groups. How-
ever, based on the results of this thesis, these interventional strategies are promising to 
have a beneficial effect in other situations of selective type II muscle fibre atrophy. 
Products and activities 
The current thesis demonstrates the efficacy of NMES to evoke muscle contractions and 
prevent muscle disuse atrophy. However, NMES is not a new technique: already in 1987 
its value was demonstrated in a patient cohort by Gibson and co-workers [11]. The 
studies in the present thesis have advanced our knowledge on the applicability of NMES 
by confirming its efficacy during short-term disuse in healthy individuals (Chapter 4) and 
comatose patients (Chapter 5). Moreover, we have applied NMES in combination with 
nutritional intake (Chapter 7 and 8) to optimize the treatment of patients undergoing a 
period of disuse. Future large, multicentre trials should be conducted to assess the 
long-term impact of NMES. Obviously, it is important to focus on outcomes such as 
hospital length of stay, morbidity, and mortality rates in such large clinical trials. Addi-
tionally, it is relevant to also assess the long-term effect of NMES during hospitalization 
(e.g. 1-year following hospital discharge) on muscle function, metabolic health, and 
quality of life. In parallel, NMES can theoretically be safely used by individuals who un-
dergo a period of muscle disuse. However, before NMES can be used in an unsupervised 
manner, technological developments are necessary to improve user friendliness. Devic-
es should be able to adjust the stimulation intensity based on feedback on the extent of 
266 | Valorization 
muscle contraction, so that throughout the session a full muscle contraction can be 
guaranteed without any input from the user. Currently, NMES devices are not yet able 
to perform in this way. This implies that if hospitals want to introduce the technique as 
it stands now, all sessions will have to be guided by a physical therapist or nurse. Given 
the time commitment of the procedure, this will decrease the cost-effectiveness. It is 
therefore necessary to re-design these devices. 
As part of this thesis we tested the efficacy of protein supplementation to attenuate 
muscle atrophy during short-term immobilization in elderly volunteers (Chapter 6). 
There we showed that twice-daily protein supplementation did not affect muscle atro-
phy, suggesting protein supplementation is not of additional value when an individual’s 
habitual protein intake is maintained at a sufficient level. This is line with previous work, 
which suggested that protein supplementation is of surplus value in individuals consum-
ing no more than 0.8 g per kg bodyweight per day [12], which is the current Recom-
mended Dietary Allowance (RDA) for protein intake. Nutrition companies should con-
tinue their work in optimizing food products that are suitable for stimulating muscle 
protein synthesis and thereby minimizing muscle loss in undernourished patients. It is 
crucial that food intake is monitored thoroughly at hospital admission and during hospi-
tal stay, in order to tailor dietary intake plans to individual patient’s needs. In healthy 
individuals, it is possible that not total daily intake, but distribution of intake (i.e. feeding 
pattern) and type of protein are more important. More knowledge on the effect of 
dietary feeding pattern and type of protein on muscle atrophy is necessary to develop 
more specific clinical nutrition products. 
Personal perspective 
Throughout the years of my PhD trajectory, it became clear to me that scientists tend to 
focus on a small topic while sometimes losing overview of the other processes that are 
possibly implicated. In muscle disuse research, many advances in the field of muscle 
protein metabolism have been made over the past years. However, as demonstrated in 
Chapter 10, muscle disuse not only leads to muscle atrophy but also leads to a disturb-
ance in metabolic health, demonstrated by a marked reduction in insulin sensitivity. To 
date, there are few data available on the interaction between muscle disuse atrophy 
and the disuse-induced decline in metabolic health. I look forward to continue working 
on this topic in the future, to unravel the impact of muscle disuse on both muscle quan-
tity and quality. 
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D A N K W O O R D  
Een totaal van 665 dagen inactiviteit, 81 paar krukken, 406 spierbiopten en 10.820 
minuten electrostimulatie. Niet alleen dat, maar ook de hulp van anderen was hard 
nodig voor het afronden van dit proefschrift. Daarom is het nu de hoogste tijd om de 
mensen om me heen te bedanken! 
 
Luc, als Luyksgestelse was het gelukkig niet moeilijk om een stageplek bij M3 te be-
machtigen. Ik ben, na dik 9 jaar onderdeel van deze groep te zijn geweest, nog steeds 
blij dat ik destijds als stagiaire ben begonnen met de paraplegenstudie. Sindsdien zijn de 
mogelijkheden eindeloos geweest, heb je me altijd gesteund in wat ik wilde doen en 
ben ik je enorm dankbaar voor de hoeveelheid ‘wat minder voor de hand liggende’ 
studies die ik in de afgelopen jaren heb kunnen doen. Naast het feit dat je hebt gezorgd 
voor een stevige wetenschappelijke basis, ben ik je zeer erkentelijk dat je me basic life 
skills zoals het gebruik van koffiecreamer op een kampvuur hebt bijgebracht. Bedankt 
voor alles, ge komt de schoai mèr es terug hoale hè! 
 
Lex, er is heel wat veranderd vanaf het moment dat je in je oranje hoodie achter je pc 
zat en ik je kwam storen met vragen over T1 en T2, tot het moment dat je nu als mijn 
co-promotor fungeert. Ik was je destijds al dankbaar voor je hulp bij mijn stage terwijl je 
zelf in de afrondende fase van je proefschrift zat, maar ben dat nu des temeer. Bedankt 
dat de deur altijd open stond wanneer dat nodig was! 
 
Ben, aka BWBW, I don’t really know where to start! Ever since the beginning of my PhD 
trajectory, we have been working together on a mutual topic of interest, i.e. muscle 
disuse atrophy. We formed a great team and were very productive over the past years, 
but more importantly, we also became good friends. Friday afternoon wasn’t complete 
without Belgian ‘office beers’ on ice in a styrofoam box, which we combined with any-
thing worthy of discussing in a social scientific event we called ‘Beer & Data’. I am sur-
prised how we could find something interesting to chat about week after week. Thank 
you so much for everything, and thank you for being there as my co-promotor now. It’s 
been epic so far, and I am looking forward to working together again in Exeter! 
 
Graag zou ik deze mogelijkheid ook aangrijpen om de gipsmeesters (John, Chris, Marie-
Louise, Danielle, Mario, Anniek) te bedanken voor de fijne samenwerking en gezellige 
sfeer. Bedankt ook alle collega’s van HB/BW sectie A, met name Anja, Dorien, Gijs, Hasi-
be, Jasper, Jos, Loek en Wendy, voor de hulp met studies en analyses alsook de goeie 
sfeer en leuke vrijdagmiddagborrels. A special thanks to the co-authors on the papers in 
this thesis: Adrian, Bart, Bas, Graham, Rinske, and Tanya. Aimé, Dominique, Pascal en 
Paul, hartelijk dank voor jullie betrokkenheid en vertrouwen tijdens de studie in het 
Virga Jessa. 
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Cleo, Desiree B en Desiree M; hartelijk dank voor jullie administratieve hulp, mentale 
steun, en onontbeerlijke relativeringsvermogen. 
 
M3’ers, wat vind ik het fijn dat jullie mijn collega’s waren! Bedankt Andy, Annemie, 
Astrid, Bart P, Cas, Cindy, Evelien, Fleur, Gabriel, Henrike, Jean, Jorn, Joy, Jan-Willem, 
Kristin, Milou, Naomi, Nick, Letty, Sofie, Stefan, en Tim voor de fijne samenwerking in de 
afgelopen jaren. Jno, bedankt voor je inzet bij analyses en de onvergetelijke fontein-
/zee-momenten op congressen. Joan, je hulp als clamp-koning bij de tweede bedrust-
studie, compleet met boeiende verhalen, was super. Joey en Philippe, wat knap dat 
jullie het (bijna tot het einde) hebben uitgehouden met mij als roomie. Marika, super-
bedankt voor je praktische hulp en broodnodige mentale steun bij uitvoer van de coma-
studie. Rachel, M3 en ikzelf gaan je verfrissende nuchterheid en ImageJ skills nog mis-
sen. Twannie, bedankt voor al die Westerns, PCRs, en gepeuterde vezels van de afgelo-
pen jaren. Tyler, thanks for your ‘support’ at Thembi when we deserved a Westie after 
acceptance of a paper. 
 
Im, een speciaal woord van dank voor jou. Ondanks dat we in het begin nogal sceptisch 
waren over elkaar (‘wie is in hemelsnaam toch die Imre waar iedereen het over 
heeft?!’), ben ik ontzettend blij dat we in de jaren erna zulke goede vriendinnen zijn 
geworden. Met jou is er altijd iets te beleven, is niks te gek, en ik vind je dan ook een 
van de gaafste mensen die ik ken. Jarenlang huisgenoten met jou zijn betekende veel 
wijn en kaas, rotondeschoenen passen, tandenpoetsen op de badrand, veel ‘bomen’ 
over het leven en kort-maar-krachtige teksten op de spiegel; ik had het voor geen goud 
willen missen! Homies 4 life! 
Amb, wat was het fijn om de afgelopen jaren met jou te kunnen spuien over onze 
promotietrajecten. Hoewel er altijd wel iets tegen zat, was dat vaak na een avond wijn-
proeven tot ‘behapbaar’ teruggebracht zodat we er weer tegenaan konden. Ik vind het 
gaaf om te zien dat je je ambities met duizelingwekkende efficiëntie najaagt, zonder 
daarbij die relaxte houding te verliezen (‘alles is relatief’). Fijn dat je erbij bent tijdens 
mijn promotie, al kon je er misschien niet meer onderuit nadat je mij tot zowel ceremo-
niemeester bij jullie bruiloft als paranimf bij je eigen promotie had gebombardeerd… 
Dat jullie een goed team vormen hebben jullie al laten zien, al was dat in een iets 
andere setting in de kroeg in Gerlos. Bedankt dat jullie naast me staan! 
 
Vrienden en familie zijn absoluut onmisbaar tijdens een promotietraject. Zonder de 
aanwezigheid van de mensen hieronder was het traject ongetwijfeld een stuk minder 
aangenaam en waarschijnlijk ook minder succesvol geweest! 
Emma, Hanneke en Joke; wat een toffe tijd hebben we gehad op 4B in Wageningen! 
Samen eten, spelletjes doen, en niet te vergeten avonden lang strijden met Singstar 
voordat we naar de Bunker gingen. De skills die ik daarbij heb opgedaan zijn tijdens de 
bedruststudies flink van pas gekomen! Tegenwoordig is Singstar bij ons minder populair 
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(tijd voor nieuwe DVD’s?!), maar daarvoor in de plaats kwamen lekker eten en drinken. 
Geen vervelende verandering! 
Britt, wij gaan al waaaaay back, vanaf de tijd dat de burritos van de Pijp nog de talk 
of the town waren, men in de kleine pauze petitfourtjes föhnde en je twee kauwgums 
op Freedent-achtige wijze in je mond stopte na een klein ongelukje. Sindsdien zijn we 
allebei onze eigen weg gegaan, maar wel wetende dat het ‘toch wel goed zit’. Ik vind 
het vet om te zien dat je altijd vol ideeën zit, je eindeloze energie hebt, en je het beste 
voorbeeld bent van dat je tegelijkertijd moeder én gaaf kunt zijn! 
Suus, Veertje, Carlala en Marije; de afgelopen jaren waren onze weekendjes (Lon-
don baby, een of andere ‘k*tstad’, Keulen, enzovoort) een heerlijke afleiding van het 
normale leven. Met jullie is het altijd goed, ligt de veritas in de vino, en kun je ook ge-
woon eten bestellen als je geen honger hebt maar als het alweer twee uur geleden is 
sinds je voor het laatst wat hebt gegeten. Ons bezoek aan Oktoberfest in München zal ik 
niet snel vergeten, en ik hoop dat we dat in de komende jaren nog eens dunnetjes over 
gaan doen! 
Loes, we zijn inmiddels al ongeveer 25 jaar vriendinnen, uit de tijd van Biek en Poer-
tel. Ik vind het tof dat je altijd enthousiast en betrokken bent, en altijd in bent om iets 
leuks te gaan doen! Ook al mag je mij daarbij (iets met een oranje jurkje op vakantie) 
soms wel wat meer terug fluiten… ;) Fijn dat we elkaar de laatste tijd vaker zien! 
 
Eef, Iris en Amb; tijdens de eerste maanden van onze opleiding kwamen we elkaar te-
gen, ergens in de collegebanken tussen de rijen met appeltjes en Spa Blauw flesjes. 
Daarna volgden veel etentjes, drankjes, en weekendjes (met etentjes en drankjes). 
Ondanks diezelfde basis zijn we allemaal toch compleet anders terecht gekomen, leuk 
om te zien! 
Eef, in 2008 hebben we samen voor de eerste keer de Vierdaagse gelopen, en daar-
na heb je me nog twee keer weten over te halen. Ik heb het daarbij gelaten… Maar dat 
jij sinds die eerste keer ieder jaar bent geweest, laat zien wat voor doorzetter je bent. Ik 
heb ontzettend veel respect voor je! 
Iris, het is ongelofelijk hoe alles bij jou altijd op z’n pootjes terecht komt. Voor een 
(internationale) verhuizing of het krijgen van een kind draai jij je hand niet om. Daar-
naast ben je ook nog eens ontzettend goed in het onderhouden van je Nederlandse 
vrienden en het bijhouden van alles wat er in Nederland gebeurt (beter dan dat wij in 
Nederland dat doen!). Fijn dat jullie je weer in Nederland kunnen gaan settelen, maar 
mocht je de UK missen ben je altijd welkom in Exeter! 
Amb, wat hebben we de afgelopen jaren veel kunnen genieten van onze gezamenlij-
ke hobby´s eten en wijn. Fijn dat we altijd tijd konden vrijmaken hiervoor! En ik zal het 
hier nog maar eens bevestigen voordat we het vergeten: die Vinologenopleiding komt 
er! 
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Frans, Tonnie, Wilco, Marloes en Frank; bedankt voor jullie interesse in mijn proefschrift 
en toekomstplannen in de afgelopen tijd. Fijn dat de koffie (en een biertje) altijd klaar 
staat! 
 
Jo, Miep, Willem en Marie; heel erg bedankt voor alle luisterende oren, avonden met 
bier en geouwehoer in Luyksgestel of Antwerpen, meedenken met de lay-out van dit 
proefschrift, ‘geleende’ stoelen en droge Dirks-humor (bedankt, Jo!) die alles gemakke-
lijk alsook hilarisch maakt. Jo, bedankt voor alle relativerende woorden van de afgelo-
pen jaren. Miep, gaaf dat je zo betrokken bent geweest bij het hele proces. Willem, fijn 
om te merken dat we altijd zo op dezelfde lijn zitten, ook al zien we elkaar niet vaak. 
Marie, tof (op z’n Antwerps!) dat je m’n broertje zo gelukkig maakt! 
 
Rinus, de laatste woorden van dit dankwoord zijn voor jou. Bedankt voor de rust en 
liefde die je me geeft, en voor je soms hilarische maar altijd onmisbare relativerings-
vermogen. Dat we elkaar hebben leren kennen tijdens de laatste fase van mijn promotie 
heeft ervoor gezorgd dat je me op goede en minder goede momenten hebt meege-
maakt en daardoor heb ik extra veel zin en vertrouwen in wat er komen gaat. Gaaf dat 
je vanaf het begin enthousiast bent geweest om mee naar het buitenland te gaan, dus: 
op naar de pints! 
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Marlou Dirks was born on September 8, 1985 in Luyksgestel, the Netherlands. She com-
pleted secondary school at the Rythovius College in Eersel in 2004. In the same year, 
she started her Bachelor program of Nutrition and Health at Wageningen University. In 
2007 she obtained her BSc diploma after writing her BSc thesis entitled ‘Skeletal muscle 
atrophy’. Immediately after that, she started her Master’s degree with a yearlong in-
ternship in the research group of Prof Luc van Loon at the department of Human 
Movement Sciences at Maastricht University. There she performed a human volunteer 
intervention study in paraplegic individuals, and gained analytical experience in per-
forming immunohistochemical muscle analyses.  
After obtaining her MSc degree in 2009, she started working as a research assistant 
on the ProMuscle project at the division of Human Nutrition at Wageningen University. 
There, she worked on a large randomized controlled trial to investigate the impact of 
protein supplementation with and without resistance-type exercise training on muscle 
mass and physical performance in frail elderly participants. In 2011, Marlou returned 
back to Maastricht and started her PhD project under the supervision of Prof Luc van 
Loon at Maastricht University. In the years that followed, she performed numerous 
human intervention studies to assess the impact of short-term muscle disuse and test 
interventional strategies that may alleviate muscle loss during a period of inactivity. 
Throughout the years, Marlou was awarded the Charles M. Tipton Student Research 
Award from the American College of Sports Medicine (ACSM) and the ECSS Young Inves-
tigators Award from the European College of Sport Sciences (ECSS) in 2014, as well as 
the International Early Career Physiologist Travel Award from the American Physiologi-
cal Society (APS) in 2015. In January 2016, Marlou started working as a postdoctoral 
fellow on a large project investigating the effect of dietary feeding pattern on muscle 
mass and metabolic health during short-term bed rest under the supervision of Prof Luc 
van Loon. Currently, Marlou is working as a postdoctoral fellow at the University of 
Exeter under the supervision of Dr Francis Stephens. There she is continuing her re-
search on the impact of (in-)activity and nutrition on skeletal muscle metabolism. 
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